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Thesis summary 
Green tea and its active constituents possess numerous health promoting properties, including 
regulation of glucose homoeostasis and anti-cancerous effects. However, the molecular mechanisms 
underpinning these properties are poorly understood. This study investigated the effects of green tea 
extracts on glucose metabolism in insulin-sensitive and breast cancer cells, and C57/BL mice. Glucose 
uptake in the presence and absence of protein kinase B (Akt) and adenosine 5’-monophosphate-activated 
protein kinase (AMPK) inhibitors, hepatic glycogenesis, triglyceride content, the rate of lipolysis, 
metabolic gene expression, and Akt and AMPK phosphorylations were assessed in mouse skeletal 
myotubes, adipocytes and hepatocytes. Epigallocatechin gallate (EGCG), epicatechin (EC), epicatechin 
gallate (ECG), quercetin, and combinations of these compounds selectively increased glucose uptake in 
these cell lines, and specific dose and time points of ECG and quercetin stimulated AML12 
glycogenesis. EGCG, EC, and ECG suppressed adipocyte adipogenesis and lipolysis. These effects were 
mediated via AMPK in myotubes and Akt in adipocytes/hepatocytes cells. In mice fed a normal or 
glucose rich diet alongside decaffeinated green tea extract (DGTE), EGCG, and commercial green tea 
extract (GTE), markers related to glucose and lipid metabolism, body and tissues mass, and ingestion 
behaviour were assessed. DGTE and EGCG significantly reduced fasting glucose by 45.5% and 33.9% 
in a glucose fed mice. EGCG increased insulin level and accordingly increased measured of insulin 
resistance and beta cell function in normal fed mice, whilst, EGCG and GTE significantly increased 
insulin levels only in glucose-fed mice. Interestingly, selected extracts of green tea raised all adipose 
tissue masses. The significant increase in triglyceride contents were seen in mice fed a normal diet with 
DGTE and EGCG, and only EGCG with glucose diet. In breast cancer cells, cell viability, apoptosis, 2-
NBDG uptake, lactate production, cellular migration, and phosphorylation of Akt and AMPK markers 
were explored. EGCG, experiment catechins, and quercetin significantly decreased cell viability, and 
induced apoptosis, whilst EGCG and quercetin showed reduced cell migration. EGCG and quercetin 
significantly decreased MCF7 and MDA-MB-231 glucose uptake associated with marked decrease in 
lactate production. To conclude, selected green tea compounds have significant potential anti-
glycaemic, anti-diabetic, and anti-tumour properties, and exert their effects at least in part through Akt 
and AMPK signalling pathways. 
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1 Introduction 
The understanding of the molecular and genetic basis of human biology has developed rapidly to 
improve our knowledge of many life-threatening diseases. The evolution of biomedical science has 
contributed to significant improvements in human life through more efficient diagnosis and treatment 
of the main human diseases. Despite this, there remain numerous fatal diseases which act to limit human 
lifespan and quality of life. The mechanisms of these diseases are as yet not well understood, and a 
fundamental understanding of them through continuous research is necessary. 
 
The human body consists of some interconnected, complex physiological systems which work 
together to maintain homoeostasis throughout life. Fundamentally, the human body develops from a 
single fused cell which undergoes proliferation, development, and differentiation to form many 
differentiated cells, tissues, and organs. The total number of cells in the human body is thought to be 
between 1012 and 1016. However, the estimated number could be 3.72 x 1013 (Bianconi, et al., 2013). All 
physiological processes are controlled by the protein coding genes of the human genome, the total 
number of which is still under debate. Estimations of the total number of genes are varied with ranges 
of 26,000 and 30,000 (Lander, et al., 2001), 20,000-25,000 (Collins, et al., 2004). It is likely, however, 
that 19,000 might be an accurate number of genes that exist in the human body (Ezkurdia, et al., 2014).  
 
Many eukaryotic cells undergo mitotic cell division in which a single cell produces two daughter 
cells holding the same genetic components as the progenitor. All cells are systematically organised 
through a cell cycle which consists of two gap phases (G1 and G2), a synthesis phase (S), and a mitotic 
phase (M) (Figure 1.1) (Krafts, 2010). Cells actively start their journey from a G1 phase in which the 
cells are growing and metabolically active, subsequently passing to S phase to completely replicate 
DNA. These cells then pass on to G2 phase to complete protein synthesis and prepare for mitosis, 
followed by mitotic division in the M phase, however, some cells become quiescent but still 
metabolically active when they moved from G1 to G0 (Kumar, et al., 2010). 
 
The cells, tissues, and organs in the human body exhibit homoeostasis process which enable the 
maintenance of a constant internal environment. Cell, tissue, and organ homoeostasis, therefore, 
contribute to the various systems that support homoeostasis at the level of the whole body (Guyton and 
and Hall, 2006). Clearly, disruption of the main cellular functions in the body due to illness or injury 
may affect tissue, organ, and whole body function and essentially leads to disorder and disease. Of vital 
importance to the present study is dysregulated glucose metabolism, which can contribute to many 
disorders including hyperglycaemia, hyperinsulinemia, insulin resistance, and increase the risk of type 
2 diabetes (T2D) (Bano, 2013). Furthermore, disruption in the balance of cellular homoeostasis between 
proliferation and apoptosis can cause either development of cancer due to the free rate of proliferation 
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or degeneration due to a counter state (Elmore, 2007). As the rapid growth of cancer cells requires high 
energy to maintain proliferation, survival and biosynthesis, this energy can be obtained from 
accelerating aerobic glucose metabolism (Vander Heiden, et al., 2009). Therefore, targeting cancer cell 
glucose metabolism may provide possible therapeutic resolution.   
  
 
Figure 1.1 The cell cycle. 
 
1.1 Glucose homoeostasis 
Glucose is a common metabolic substrate and necessary form of energy which provides cells and 
organs with a substrate from which they can produce vital energy to perform their normal functions. 
Under normal physiological circumstances, cellular glucose is metabolised throughout the body to 
generate adenosine triphosphate (ATP), a coenzyme that acts as a key mediator of cellular energy in 
many cells including the brain and nervous system (Thorens and Mueckler, 2010). Almost all living 
cells continuously utilise glucose as a primary source of energy for performing their regular functions. 
The main sources of glucose in the body are from ingested food, as well as glucose released into the 
blood from stores of glycogen in the liver (referred to as glycogenolysis) and glucose converted from 
amino acids and lactate (gluconeogenesis) (Gong and Muzumdar, 2012).  The levels of circulating 
glucose, therefore, depend on the amount of glucose entering and leaving the blood (Gerich, 2000). 
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After a meal or prolonged fasting the levels of glucose may either rise or fall and the body, therefore, 
needs to respond to maintain glucose at its physiological set point of 4 and 6 mmol/l (Saltiel and Kahn, 
2001). The sharp decrease in blood glucose levels may lead to seizures, unconsciousness, and death 
while chronically high concentrations may result in blindness, vascular diseases, and renal damage 
(Szablewski, 2011). Thus, maintaining constant levels of blood glucose concentration is a fundamental 
process known as glucose homoeostasis (DeFronzo, 1988). 
 
Insulin and glucagon are the major hormones that control the levels of glucose in the circulation and 
therefore regulate glucose homoeostasis. Insulin is an essential anabolic hormone which regulates 
energy and glucose metabolism (Pessin and Saltiel, 2000;Szablewski, 2011). It is synthesised and 
released directly into the bloodstream from pancreatic beta-cells in response to stimuli including 
increased glucose and amino acid concentrations in the blood after a meal. The major function of insulin 
is suppression of glucagon secretion and hepatic glucose production (Sesti, 2006). Furthermore, insulin 
can facilitate glucose uptake in skeletal muscle and adipose tissue via translocation of glucose 
transporters through activating insulin receptor (Bano, 2013). Glucagon is secreted from pancreatic 
alpha-cells in response to decreased blood glucose levels and can restore normoglycaemia by targeting 
glycogen in the liver and increasing glucose release by glycogenolysis (Mayo, et al., 2003), and 
increasing gluconeogenesis (Landau, et al., 1996). Therefore, glucagon counteracts the glucoregulatory 
function of insulin (Drucker, 2005). Thus, insulin and glucagon in addition to insulin-sensitive tissues 
are essential in maintaining normal glucose homoeostasis (Figure 1.2). 
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Figure 1.2 Glucose homoeostasis process. 
High blood glucose stimulates pancreatic beta-cells to secrete insulin which targets insulin-sensitive 
tissues including adipose, hepatic, and skeletal muscle to maintain normal glucose level through 
increasing glucose uptake, glycogenesis, lipogenesis, and suppression of lipolysis, glycolysis and 
hepatic glucose production. Whereas, low blood glucose stimulates pancreatic alpha-cells to secrete 
glucagon which acts to increase hepatic glucose production, lipolysis and glycolysis to restore normal 
blood glucose levels. 
 
1.1.1 The role of liver in glucose homoeostasis 
The liver has a crucial role in maintaining blood glucose levels by providing a balance between 
glucose production and uptake. In the normal physiological state, after a meal, the level of blood glucose 
is increased, and accordingly insulin secretion is increased. In this circumstance, the liver acts to 
neutralise blood glucose levels through minor changes in glucose uptake and glycogen storage in 
hepatocytes (Figure 1.2) (Edgerton, et al., 2009). Furthermore, the liver can convert glucose into lipids 
in the form of very low-density lipoprotein (VLDL) after glycogen deposits are full, and this lipid is 
transported to adipose tissue (Vidal-Alabró, et al., 2012). In the prolonged fasting state, the level of 
blood glucose is low, and this stimulates glucagon release.  The following acts directly on the liver to 
release glucose and compensate low level of glucose.  This glucose is released firstly by breaking down 
the stored glycogen into glucose via glycogenolysis and secondly, through gluconeogenesis after 
27 
 
glycogen levels are depleted in an extended period of fasting (Edgerton, et al., 2009).The liver is 
responsible for releasing 80% of glucose into the blood circulating in fasting condition (Cano, 2002). 
Therefore, insulin resistance and prevalence of T2D can impair hepatic glucose metabolism and increase 
hepatic glucose production.  
 
1.1.2 The role of skeletal muscle in glucose homoeostasis 
Skeletal muscle is the major tissue for post-prandial glucose disposal in the body and as such plays 
a pivotal role in maintaining glucose metabolism. The normal function (contraction and relaxation) of 
skeletal muscle required energy which is continuously obtained; the principle sources of energy in 
skeletal muscle are glucose and lipids (Frayn, 2003). In the fed state, blood glucose and insulin levels 
are increased, and therefore insulin stimulates the skeletal muscle to increase glucose uptake through 
insulin receptor-mediated glucose transporter translocation (Figure 1.3) (Tremblay, et al., 2003). 
Furthermore, glucose that is absorbed by muscle can be converted into glycogen and stores within the 
skeletal muscle tissue (Saltiel and Kahn, 2001). Whereas, in the fasted state, the levels of glucose and 
insulin are reduced, and therefore skeletal muscle uses non-esterified fatty acids (NEFA) as a source of 
energy.  
 
1.1.3 The role of adipose tissue in glucose homoeostasis 
Adipose tissue is a connective tissue that plays a major role in the regulation of energy homoeostasis 
including glucose and lipid homoeostasis. Two main types of adipose tissue are distributed in the body; 
the most abundant is white adipose tissue (WAT), and the second is brown adipose tissue (BAT). WAT 
is comprised of 35-75% adipocytes with the remainder comprising cell types including pericytes, blood 
cells, endothelial cells and others (Cinti, 2009). Interestingly, WAT has dual functions.  First, it assists 
in maintaining blood glucose by storing glucose and lipids within adipocytes as triglyceride in the fed 
state and releasing glycerol and lipids in the fasted state. Secondly, it secretes adipokines which are 
known to be heavily involved in glucose and lipid metabolism ((Bays, et al., 2008;Gaidhu, et al., 2011). 
In the fed state, insulin promotes glucose uptake and inhibits lipolysis in adipocytes, and increases 
NEFA uptake by activating lipoprotein lipase (Campbell, et al., 1992).  
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Figure 1.3 Skeletal muscle glucose uptake. 
Insulin stimulates the skeletal muscle to increase glucose uptake based on insulin signalling that 
promotes activation of PI3K/Akt which eventually causes Glut4 translocation and expression leading to 
increased glucose uptake.  
 
 
1.2 Glucose metabolism 
Metabolism is a multi-chemical process that leads to production or consumption of energy during 
various physiological states. Glucose is a basic and important molecule which is considered the largest 
source of energy fuels to most organisms. The glucose is transported into the cells by facilitating 
diffusion through glucose transporters proteins (Gluts) that are expressed on cell surface membranes 
(Thorens and Mueckler, 2010). Based on physiological status, the entering glucose molecules undergo 
either anabolic processes to form glycogen and triglycerides by glycogenesis and lipogenesis 
respectively or catabolic processes to generate energy by glycolysis. Glycolysis is a series of chemical 
reactions of glucose molecule metabolism that liberates chemical energy. This process is composed of 
10 enzymatic reactions classified into two stages (Figure 1.4). The energy investment phase is the first 
of five reactions, and the next five reactions are called the energy generation phase (Harvey and Ferrier, 
2011). 
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In the first stage, glucose is phosphorylated by the enzyme hexokinase to form glucose-6-phosphate 
which is unable to be transported out of cells. Isomerization of this molecule by phosphoglucose 
isomerase leads to the formation of fructose-6-phosphate which undergoes phosphorylation to form 
fructose 1,6-bisphosphate by the action of the enzyme phosphofructokinase. Subsequently, aldolase acts 
to split 1,6-bisphosphate molecule into glyceraldehyde 3-phosphate and dihydroxyacetone phosphate; 
the latter is then isomerised by triosephosphate isomerase to form two molecules of glyceraldehyde 3-
phosphate. This stage is accomplished by consuming two molecules of ATP rather than generating 
energy whereas the end products of the second stage are two molecules of pyruvate and four of ATP 
(Harvey and Ferrier, 2011). The second stage starts with oxidative-reduction of glyceraldehyde 3-
phosphate by an enzyme called glyceraldehyde 3-phosphate dehydrogenase to form 1,3-bisphospho-
glycerate which is catalysed by phosphoglycerate kinase to synthesis 3-phosphoglycerate. The 
phosphate group in the latter molecule is switched to the 2nd position by phosphoglycerate mutase to 
produce 2-phosphoglycerate which undergoes dehydration by enolase to form phosphoenolpyruvate that 
is subsequently catalysed to liberate pyruvate by the function of pyruvate kinase enzyme (Mckee and 
Mckee, 2013).  
 
Fundamentally, the end product of glycolysis, pyruvate, could be used to generate more energy 
through the process of oxidative phosphorylation or be converted to lactate or ethanol by lactic acid and 
alcoholic fermentation (Figure 1.5). In anaerobic conditions, lactate dehydrogenase stimulates the 
process of pyruvate reduction by NADH to produce lactate or pyruvate decarboxylase converts pyruvate 
to acetaldehyde which is subsequently converted to ethanol by alcohol dehydrogenase without 
producing any additional ATP from both fates and this pathway is called anaerobic glycolysis (Gatenby 
and Gillies, 2004). In aerobic conditions, pyruvate dehydrogenase stimulates oxidative decarboxylation 
of pyruvate to form acetyl-Coenzyme A in mitochondria which subsequently enters the tricarboxylic 
acid (TCA) cycle. This process is called aerobic glycolysis (oxidative respiration), and the end products 
of this process are CO2, H2O, and 32 ATP molecules (Harvey and Ferrier, 2011). 
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Figure 1.4 Steps involve in glycolysis.  
The investment stage (A) starts with the first phase through oxidation of entering glucose by 
hexokinase and ends with the fifth step, the formation of glyceraldehyde-3-phosphate and 
dihydroxyacetone phosphate. This stage consumes two molecules of ATP and is promoted by the action 
of 5 enzymes. The energy generating stage (B) which starts with oxidative-reduction of glyceraldehyde 
3-phosphate by the enzyme glyceraldehyde 3-phosphate dehydrogenase and produces two molecules of 
pyruvate and four molecules of ATP at the end. This stage is mediated by the action of 5 enzymes.  
 
31 
 
 
Figure 1.5 Fates of pyruvate. 
Pyruvate can undergo anaerobic fermentation to form lactate by the action of lactate dehydrogenase, 
or ethanol-mediated by pyruvate decarboxylase and alcohol dehydrogenase enzymes. Whereas, in the 
presence of oxygen, pyruvate undergoes oxidative phosphorylation to acetyl CoA and the latter enters 
TCA and electron transport system to produce carbon dioxide, water, and ATPs.  
 
1.3 Signalling pathways involved in glucose metabolism 
Multiple signalling pathways are thought to participate in the regulation of glucose homoeostasis. 
Insulin-dependent phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) is one of the main pathways 
which plays a critical role in maintaining glucose metabolism. This role occurs by increasing glucose 
uptake, glycogen and triglyceride formation, and suppressing hepatic glucose production in response to 
insulin (DeFronzo and Tripathy, 2009;Lanner, et al., 2006;Sesti, 2006).  Adenosine 5’-monophosphate-
activated protein kinase (AMPK) is another metabolic regulator which is believed to be a major insulin-
independent signalling pathway that is responsible for maintaining glucose homoeostasis (Carling, 
2004;Kemp, et al., 2003). 
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1.3.1 The PI3K/Akt molecular pathway 
PI3K/Akt is a major and classical molecular pathway of metabolic actions of insulin (Figure 1.6) 
(Cho, et al., 2001). PI3K class I is a member of three categories (I-III) of lipid kinase family based on 
lipid affinity substrate and structure domain (Engelman, et al., 2006;Vanhaesebroeck, et al., 2010). This 
class is well characterised and plays a vital role in insulin signalling to mediate glucose homoeostasis 
(Rameh and Cantley, 1999). PI3K is heterodimer protein which is composed of the regulatory subunits 
P85, and P110 a catalytic subunit (Foster, et al., 2003). 
 
The activation of this signalling pathway depends on the ability of insulin to bind to its receptor. The 
binding occurs at the level of extracellular α-subunit of the insulin receptor that is located on the surface 
of many cell types including hepatocytes, myocytes, and adipocytes (Khan and Pessin, 2002). 
Furthermore, tyrosine residue auto-phosphorylation at the level of intracellular β-subunit leads to 
phosphorylation of the insulin receptor substrate (IRS) (Sesti, et al., 2001). Subsequently, IRS 1 and 2 
binds with PI3K at the P85 regulatory subunit causing activation of the P110 catalytic subunit (Schultze, 
et al., 2012). Once PI3K is activated, the phosphorylation of ptdlns (4,5) p2 on the cell surface membrane 
leads to the formation of ptdlns (3,4,5) p3, subsequently activating 3-phosphoinositide dependent protein 
kinase (PDK) which is responsible for activation of Akt and atypical protein kinase C (aPKC).  
 
Akt is a Ser/Thr protein kinase which is responsible for regulating a wide variety of cellular functions, 
including regulation of glucose metabolism (Whiteman, 2002). Akt consists of an N-terminal PH 
domain, a C-terminal tail PH domain, and a kinase domain located between them. Three types of 
encoding Akt are expressed in mammalian tissues, Akt1/PKBα, Akt2/PKBβ, and Akt3/PKBγ (Manning 
and Cantley, 2007;Schultze, et al., 2011). Insulin sensitive tissues expressed Akt isoforms 1 and 2, 
whereas isoform 3 is only expressed in the brain, testes, pancreatic islets, and adipose tissue (Buzzi, et 
al., 2010;Yang, et al., 2003). Phosphorylation of PKB on Thr 308 and Ser 437 leads to activate Akt to 
enhance insulin action via translocation of glucose transporters to increase glucose uptake in insulin-
sensitive cells (Leney and Tavare, 2009). In addition to inactivation of glycogen synthase kinase-3 
(GSK-3) and activation of glycogen synthase gene to promote glycogen synthesis, and fatty acid 
synthase gene to enhance lipogenesis (Lanner, et al., 2006;Schultze, et al., 2012). This pathway 
regulates suppression of hepatic glucose production through downregulating phosphoenolpyruvate 
carboxykinase (PEPCK) and glucose 6 phosphatase (G6Pase) transcriptional genes by inhibiting the 
activity of forkhead box O1 (FOXO1) factor (Figure 1.6) (O-Sullivan, et al., 2015).  
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Figure 1.6 Insulin signalling pathway (PI3K/Akt). 
The signalling pathway is initiated by binding insulin with the extracellular α-subunit of its receptor 
which leads to activating PI3K and then Akt. This activation leads to increased glucose uptake through 
Gluts translocation, increased glycogenesis through phosphorylation of GSK-3, and increased 
lipogenesis through increased transcriptional genes of SREBP-c and PPARγ. Furthermore, the pathway 
suppresses hepatic glucose production by inhibiting FOXO1 which decreases the expression of PEPCK 
and G6Pase, and activation mTORC1 through inhibiting TSC1, 2. 
 
 
1.3.2 The AMPK signalling pathway 
AMPK is a major energy sensor which plays a central role in lipid and glucose metabolism to regulate 
the balance between energy generation and expenditure at both cellular and whole organism levels 
(Carling, 2004;Hardie, 2004;Kemp, et al., 2003). AMPK is a serine/threonine kinase heterotrimeric 
protein composed of three encoding subunits. One catalytic α-subunit which displays two isoforms α1 
and α2 as well as two regulatory (β and γ) subunits in two and three isoforms (β1, β2 and γ1, γ2, and γ3) 
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respectively. These isoforms are expressed in specific tissues and could form 12 heterotrimeric 
combinations (Mahlapuu, et al., 2004). Isoform one from each of three subunits (α1, β1, and γ1) is 
expressed in most cells while the other isoforms are expressed specifically in skeletal muscles and 
myocardium (Carling, 2005;Wong and Lodish, 2006). 
 
Activation of AMPK is controlled and mediated by three distinct upstream kinases. Stimulation of 
these kinases leads to the phosphorylation of a threonine residue (Thr-172) on the current T-loop of the 
α-subunit (Birnbaum, 2005). An energy depleted state in response to an increase in AMP/ATP ratio 
causes activation of first upstream kinase tumour suppressor liver kinase B1 (LKB1) to induce AMPK 
activation through an AMP-dependent pathway (Kahn, et al., 2005;Lizcano, et al., 2004;Woods, et al., 
2003). Calcium/calmodulin-dependent protein kinase kinase B (CaMKKB) is another upstream 
regulator which is stimulated by increasing intracellular Ca+2 to mediate phosphorylation of Thr-172 
and activation of AMPK (Birnbaum, 2005;Hawley, et al., 2005;Woods, et al., 2005). A third regulator 
is transforming growth factor-B activated protein kinase 1 (TAK1) which when upregulated leads to the 
activation of AMPK (Hawley, et al., 2005) and increases cellular protection against apoptosis by TNF 
(Herrero-Martin, et al., 2009). Once AMPK activation occurs, many cellular processes can be activated 
in various metabolic tissues to regulate glucose and lipid metabolism through stimulation of multiple 
downstream pathways (Figure 1.7). 
 
 In skeletal muscle, activation of AMPK through physiological or pharmacological signals enhances 
glucose uptake by increasing translocation of Glut4 (Mu, et al., 2003;Wright, et al., 2005). The proposed 
molecular mechanism of this action is phosphorylation of phospho-Akt substrate (PAS, AS160)/ 
(TBC1D1) tre-2/USP6, BUB2, cdc16 domain family member 1 (Frosig, et al., 2010;Funai and Cartee, 
2009). Also, AMPK increases fatty acid oxidation in muscles and liver through inhibition of Malonyl-
CoA (fatty acid uptake inhibitor). This inhibition is mediated by phosphorylation and inactivation of 
acetyl-CoA carboxylase 2 (ACC2) (Melony-CoA creator) and regulation of carnitine-palmitoyl 
transferase1 (CPT1) (Dean, et al., 2000;Zhou, et al., 2001). Alternatively, direct inactivation of acetyl-
CoA carboxylase 1 (ACC1) suppresses fatty acid synthesis (Saha and Ruderman, 2003). Furthermore, 
decreased cholesterol synthesis is also seen through inhibition of 3-hydroxy-3-methylglutaryl coenzyme 
A (HMG-CoA) which is main cholesterol synthesis regulator (Pallottini, et al., 2004). 
 
In the hepatocytes, activation of AMPK can directly phosphorylate and inhibit glycogen synthase 2 
and 1 (GS) in the hepatocytes and myocytes respectively, causing decreased glycogen synthesis (Bultot, 
et al., 2012;Jorgensen, et al., 2004). However, there is a suggestion that AMPK activity could be 
inhibited by glycogen due to the binding site between them on the β-subunit (McBride, et al., 2009). 
Moreover, activation of AMPK has been implicated in the regulation of gluconeogenesis by inhibiting 
hepatic glucose production through downregulation of PEPCK and G6Pase gene (Cool, et al., 2006). 
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The molecular mechanisms that may be involved in the suppression of hepatic glucose output are 
inactivation of c-AMP response element (CRE)-binding protein regulated transcription coactivator2 
(CRTC2) and FOXO1 (Liu, et al., 2008b). Also decrease transcriptional activity of c-AMP response 
elements (CRE) by inhibiting GSK-3B (Horike, et al., 2008).  
  
In adipocytes, AMPK and its specific downstream pathways can regulate lipid metabolism. In 
addition to decreased fatty acid synthesis and increased oxidation, AMPK phosphorylation inactivates 
hormone sensitive lipase (HSL) and suppresses its translocation to lipid droplets as well as inhibiting its 
action on isoproterenol leading to inhibition of lipolysis (Daval, et al., 2005). Furthermore, AMPK 
inhibits lipogenesis and triglyceride formation through decreasing the activity of glycerol acyl 
transferase (triglyceride synthesis) (Daval, et al., 2006). Also inhibiting the expression of transcriptional 
lipogenesis factors including sterol regulatory element binding protein 1c (SREBP-1c) (Zhou, et al., 
2001), carbohydrate response element binding protein (ChREBP), and FOXO1 (Orci, et al., 2004). 
 
 
Figure 1.7 AMPK signalling pathway. 
Phosphorylation of Thr 172 and activation of AMPK is mediated by three signals included LKB1, 
CaCMKKB, and TAK-1 associated with increased AMP: ATP ratio. Once activation is promoted, 
AMPK acts to regulate glucose metabolism in hepatic, muscular, and adipose tissues. These are 
increased glucose and fatty acid uptake through increasing expression of Gluts, increase mitochondrial 
biogenesis, and inhibits fatty acid and cholesterol synthesis, increasing fatty acid oxidation and 
inhibiting lipogenesis, and decrease hepatic glucose production.  
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1.4 Diabetes mellitus 
Diabetes is a common metabolic disorder characterised by elevating blood glucose levels due to 
defects in carbohydrate metabolism associated with absent or insufficient insulin and decreased insulin 
sensitivity. According to IDF (2015), there are currently 415 million people who suffer from diabetes 
mellitus worldwide. Of these there 153.2 million in the Western Pacific, 78.3 million in South East Asia, 
59.8 million in Europe, 44.3 million in North America and the Caribbean, 35.4 million in the Middle 
East and North Africa, 29.6 million in South and Central America, and finally 14.2 million in Africa. 
The incidence of this disease will likely increase, and the global incidence is expected to reach 642 
million by 2040. Despite global efforts, the prevalence of diabetes is increasing due to some factors 
including obesity, poor diet, sedentary behaviour and also genetic predispositions (Muoio and Newgard, 
2008). There are several classifications of diabetes mellitus including type 1, type 2, gestational diabetes 
and maturity onset diabetes of the young (MODY). Type 2 diabetes (T2D) is by far the most prevalent 
form of these categories and has historically been associated with increasing age and adiposity. 
 
1.4.1 Type 2 diabetes mellitus 
T2D is the most common form of diabetes and occurs primarily due to a dual defect of insulin resistance 
and beta cell dysfunction. Despite hyperinsulinaemia due to the pancreatic beta-cells produced insulin, 
plasma glucose concentrations still rise due to decreased insulin sensitivity, and when the pancreas can 
no longer counteract this insulin resistance, a diagnosis of diabetes is usually made (Bano, 2013;Kahn, 
et al., 2006). The prevalence of T2D is increased in older people, therefore; it is a major health problem 
(IDF, 2015). 
 
1.4.2 Aetiology of type 2 diabetes mellitus 
Despite the global efforts to elucidate the causes and predisposing factors so that T2D may be better 
prevented and treated, the morbidity and mortality rates are still increasing (IDF, 2015). A complex 
combination of factors exists which enhances the risk of T2D, and these causes are either related to 
insufficient insulin secretion and/or insulin action. 
 
1.4.2.1 Pancreatic beta-cell dysfunction 
Recently, it has been suggested that the key aetiology involved in the onset of T2D is a failure of 
pancreatic beta-cells to produce sufficient insulin to overcome peripheral insulin resistance (Dunmore 
and Brown, 2013). The pancreas is a mixed gland which contains two main portions; an exocrine portion 
which forms the majority of the pancreas, while the smaller element is the endocrine portion which 
secretes hormones directly into the bloodstream (Persaud, et al., 2012). Islets of Langerhans have 
exhibited at least five different endocrine cells including alpha, beta, delta, gama, and epsilon cells (Int 
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Veld and Marichal, 2010). The beta-cell secretes insulin as a result of elevated blood glucose levels 
through glucose-stimulated insulin secretion (GSIS), whereby glucose is transported into the beta-cell 
by Glut2 and oxidised by glucokinase to produce ATP. The ATP/ADP ratio is altered and induces ATP-
sensitive K (KATP) channel closure at the cell membrane. The latter leads to depolarization of the 
plasma membrane which facilitates the influx of extracellular Ca+2  stimulating insulin exocytosis 
(Figure 1.8) (Gong and Muzumdar, 2012). Even in the face of constant high plasma glucose 
concentration, the beta-cell can rapidly act to compensate the demand of insulin to maintain glucose 
homoeostasis in the body. Therefore, prolonging the action of beta-cells can lead to an eventual loss of 
their sensation and function to produce insulin through impairment of GSIS, which finally leads to the 
development of diabetes (Hou, et al., 2009;Ohtsubo, et al., 2005). 
 
 
Figure 1.8 Glucose stimulates insulin secretion. 
Diagram of insulin release from pancreatic beta-cells. Insulin is secreted in response to elevates 
glucose concentration. The process initiation by transporting glucose into beta-cell through Glut2 and 
oxidised by glucokinase to produce ATP. Increase ATP/ADP ratio and induced ATP-sensitive K 
(KATP) channel closure the cell surface. As a result of that, depolarization of plasma membrane is take 
placed which facilitate the extracellular Ca+2 influxes into beta-cell which subsequently triggers 
cytosolic insulin granules and release it by exocytosis.  
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1.4.2.2 Insulin resistance 
Insulin resistance is an abnormal condition which leads to loss of sensitivity of metabolic cells 
(hepatocytes, adipocytes, and myocytes) to insulin while beta cells still produce insulin to neutralise the 
hyperglycaemia. It is often associated therefore with hyperinsulinaemia and increases the risk of 
developing T2D (IDF, 2006). Failure of insulin to activate the signalling pathways through binding with 
its receptor leads to the development of insulin resistance (Pessin and Saltiel, 2000). Furthermore, 
inhibition of tyrosine phosphorylation of IRS-1 concomitant with decreased activity of PI3K can cause 
impairment of insulin function in peripheral tissues and insulin resistance (Figure 1.9) (Petersen and 
Shulman, 2006). Over the past decade, the research in this field has developed rapidly and focused on 
mechanisms of insulin resistance to create a therapeutic agent targeting this mechanism to increase 
insulin sensitivity. However, progress has been slow (Savage, et al., 2005).  
 
1.4.2.2.1 Obesity  
Obesity is one of the major public health concerns worldwide due to implications and consequences 
accompanied it. Simply, it can be defined as an abnormal excessive accumulation of adipose tissue. 
More specifically, it is a term which describes an imbalance between energy consumption and 
expenditure (WHO, 1998). Those who are obese and/or overweight are assessed by using body mass 
index (BMI) which is individual body weight in kilograms divided by the square of the height in meters 
(kg/m²). The WHO (2003) has set the parameters of this phenotypic measurement with overweight 
individuals having a BMI greater than 25kg/m² BMI and obese individuals greater than 30kg/m² BMI. 
Other methods exist, including skinfold thickness and waist circumference (Bano, 2013). Globally, there 
are more than one billion overweight adults and approximately 300 million individuals described as 
being clinically obese (WHO, 2003), whereas the global overweight or obese children are estimated 42 
million in 2013 and by 2025 could reach to 70 million between infants and young children (WHO, 
2014a).  
 
Obesity has been well studied and is known to play a fundamental role in the pathogenesis of insulin 
resistance and development of T2D (Figure 1.9) (Item and Konrad, 2012;Kahn, et al., 2006). Adipose 
tissue has a significant endocrine function in addition to its distinct storage role, where secreted 
molecules including adipokines have been shown to be strongly linked to glucose homoeostasis (Ginter 
and Simko, 2010). Dysfunction of adipose tissue in obesity and overweightedness can include abnormal 
accumulation of lipid as well as adipocyte hypertrophy (Castro, et al., 2014). This adipose tissue tends 
to release a relatively high amount of non-esterified fatty acid (NEFA) due to increased lipolysis, in 
addition to adipokines and inflammatory cytokines (Abel, 2010;Makki, et al., 2013). Circulating NEFA 
can target skeletal muscle tissue and promote insulin resistance through impairment of insulin-
stimulated glucose uptake by increasing long-chain fatty acetyl-CoA (LC-CoA) accumulation and 
39 
 
formation of diacylglycerol (DAG) and ceramide. The latter caused activation of protein kinase C 
(PKC), I-kappa-B kinase (IKB-kinase-B), and Jun N-terminal kinase (JNK) and causes serine 
phosphorylation of IRS-1 (Morino, et al., 2006). The phosphorylation reduces the ability of IRS-1 to 
activate PI3K and downstream pathways (Snel, et al., 2012). Similarly, NEFA promotes insulin 
resistance in the liver and therefore prevents glucose uptake and glycogen synthesis (Snel, et al., 2012). 
 
Some of the adipokines that are released by adipose tissue are strongly linked to obesity, insulin 
resistance, and development of T2D. A wide array of adipokines, chemokines, and cytokines are 
released from adipose tissue, and their levels can change with progression towards obesity (Fain, 
2010;Fain, 2012;Fantuzzi, 2005;Trayhurn, et al., 2006). Dysfunction of adipose tissue can lead to 
dysregulated fatty acid metabolism due to excess energy, which in turn can cause alteration of 
adipokines secretion and development of inflammation (McArdle, et al., 2013). Adipokines related to 
obesity and insulin resistance including pro-inflammatory interleukin-1α and β (IL-1α, β), inflammatory 
interleukin 6 (IL-6), tumour necrosis factor alpha (TNFα), monocyte chemoattractant protein (MCP-1), 
plasminogen activator inhibitor 1 (PAI-1). In addition to leptin, resistin, and adiponectin (Fain, 
2012;Rasouli and Kern, 2008). Increased circulating levels of IL-1β and IL-1receptor 1 (IL-1R1) are 
also associated with obesity and insulin resistance (Juge-Aubry, et al., 2003). These cytokines can impair 
insulin signalling through serine phosphorylation of IRS-1 due to activation of many serine kinases like 
JNK and IκB kinase (IKK) (Gual, et al., 2005). The impaired insulin signalling reduced the activation 
of PI3K and thereafter decreased the expression of Gluts and glucose uptake (Juge-Aubry, et al., 
2003;McArdle, et al., 2013;Schenk, et al., 2008). 
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Figure 1.9 Insulin resistance. 
Several factors contributed to the development of insulin resistance, these are predisposing factors 
related to obesity and ageing. Impairment of adipocytes function, inheritance, and modern lifestyle 
including consumption of high caloric diet associated with lack of physical activity lead to development 
of obesity. Obesity associated with increased oxidative stress, ageing, mitochondrial dysfunction, 
reduced activity of enzymes defence system lead to develop insulin resistance. All these factors can 
interact with insulin signalling including impaired insulin/insulin receptor binding and blocked 
downstream signalling pathway to regulate glucose homoeostasis including glucose and lipid 
metabolism in insulin-sensitive cells. At this stage, pancreatic beta cells still secret insulin to overcome 
hyperglycaemia, however insulin sensitivity is reduced and can no longer mediate proper effect to 
regulate glucose and lipid metabolism in insulin-sensitive cells. Development of insulin resistance 
concomitant with or without pancreatic beta-cell dysfunction leads to the development of T2D, which 
is main public health concerned.  
 
1.4.2.2.1.1 Obesity and the role of genetics, diet, and lifestyle 
Obesity is a multifactorial disorder which is determined by the interaction of multiple factors 
including genetic, neuroendocrine, and lifestyle which can interact to lead to dysregulated glucose and 
lipid metabolism (Aronne, et al., 2009). It is believed that genetic predisposition is the first factor 
implicated in obesity (Walley, et al., 2006). Several twin, adoption and family studies have been 
conducted to investigate the contribution of genetic factors in the prevalence of obesity. With regards to 
other factors, the genetic predisposition in twin studies is estimated 40-77% (Farooqi, 2005;Llewellyn, 
et al., 2008).  
 
41 
 
The hypothalamus plays a central role in maintaining the balance between energy intake and 
expenditure in the body as it contains several nuclei which receive regulatory information through 
hormonal and neuronal signals (Xu, et al., 2003). The arcuate nucleus plays a key role in the regulation 
of energy balance; it contains two sets of neurones. The first set is orexigenic and the second 
anorexigenic. Stimulation of orexigenic neurones leads to increased food intake and decreased energy 
expenditure, while activation of anorexigenic neurones induces energy expenditure and inhibits food 
intake (Barsh and Schwartz, 2002). Insulin is responsible for glucose and lipid homoeostasis that has 
an anorexigenic impact (Air, et al., 2002). In addition, a primary adiposity indicator leptin has a similar 
effect to insulin (Friedman and Halaas, 1998). Furthermore, ghrelin secreted as a result of an empty 
stomach acts to regulate energy balance by stimulating orexigenic set (Kohno, et al., 2003). Moreover, 
the distal part of the gastrointestinal tract secretes peptide YY (PYY) which suppresses orexigenic 
neurones set (Calle, et al., 2003). 
 
The lifestyle factors that interact with the other factors are essential for progression of individual 
obesity. According to WHO (2003), the prevalence of obesity is increased due to high consumption of 
low nutrient food with high energy associated with a lack of physical activity. Obviously, sedentary 
behaviour, eating habits, and increased consumption of high-calorie food due to low price and 
availability is highly associated with the prevalence of obesity and weight gain (Kelly, et al., 
2008;Maffeis, 2000). There is a strong relationship between lifestyle with physical activity and weight 
gain (Swinburn, et al., 2004). Recently, several studies have evidenced a strong link between energy 
intake and sedentary behaviour in the prevalence of obesity and weight gain (Papas, et al., 2007). 
Gortmaker, et al. (1996) and Robinson (2001) identified the effects of watching TV on child obesity, 
and the results showed a strong relationship between watching television and the onset of obesity in 
children. 
 
1.4.2.2.2 Mitochondrial dysfunction 
Dysregulation of normal mitochondrial function has been associated with the development of insulin 
resistance and the increased onset of obesity and T2D. Mitochondria are a key cellular organelle that 
regulates cellular energy balance through facilitating the production of ATP from glucose and lipid 
metabolism (Turner and Heilbronn, 2008). Mitochondrial oxidative phosphorylation produces ATP 
which in turn is consumed by cells based on need. However, the process is considered efficient when 
high levels of ATP are produced (Mogensen and Sahlin, 2005). High energy demand stimulates 
mitochondrial biogenesis so that mitochondrial numbers can adapt to match this requirement (Alam and 
Rahman, 2014). Mitochondrial dysfunction is mediated by alteration of several markers including levels 
of protein, mRNA, and oxidation activity of mitochondrial enzymes (Heilbronn, et al., 2007). Also 
alteration in the number, size, shape, content and oxidative phosphorylation activity (Montgomery and 
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Turner, 2015;Ritov, et al., 2005). Mitochondrial function can be impaired with reduced biogenesis, 
oxidative protein content and activity, and fatty acid oxidation (Montgomery and Turner, 2015).  
 
1.5 Cancer 
Cancer is a common and potentially fatal disease which is considered as the second greatest cause of 
death globally after cardiovascular diseases. It is believed that the disruption of the balance of normal 
cellular proliferation/apoptosis is responsible for cancer initiation (Elmore, 2007). Globally there were 
14.1 million new cases diagnosed and 8.2 million deaths in 2012 (WHO, 2014b). The prevalence of 
cancer is expected to increase by 2030 to up to 22.2 million new cases annually (Bray, et al., 2012) and 
the mortality rate is also projected to increase from 8.2 million to 12.6 million cases (WHO, 2014b). 
The term ‘cancer’ was first used by Hippocrates, the great Greek physician in around 460-370BC, and 
the terms cancerous, and carcinoma has been used from that time to describe non-ulcer and ulcer-
forming tumours (American Cancer Society, 2014). However, cancer has been discovered in ancient 
Egypt mummies when the evidence of bone cancer was displayed (Sudhakar, 2009). The first recorded 
case that described cancer is detected in ancient Egyptian manuscripts which back to 1600BC and called 
Edwin Smith papyrus which referred to an American Egyptologist Edwin Smith (ACS, 2014).  
 
At the cellular level, cancer is a multi-step process initiated from one single cell or a small number 
of cells. These steps were proposed in 1947 as pre-carcinogenic, epi-carcinogenic, and meta-
carcinogenic (Berenblum and Shubik, 1947). However, many studies have since been carried out to 
investigate these cancer development stages. The process of tumorigenesis is thought to consist of three 
major phases (Figure 1.10) which are an initiation, promotion, and progression (Cooper, 2000). In the 
first step, a normal cell is transformed into a neoplastic cell which is subsequently stimulated to enter 
the promotion phase via an increased rate of proliferation as well as increases in the size of the tumour 
followed by excess mutations to promote progression (Devi, 2004). Several categorizations are applied 
to recognise the type of cancer. Based on the cell type in which the tumour originated, three groups are 
identified, and these are carcinomas, sarcomas, and leukaemias or lymphomas which could be either 
benign or malignant according to their behaviour and response to treatment (Cooper, 2000). 
Furthermore, a widely used classification is based on the type of tissue in which cancer was developed 
for instance: breast, lung, pancreatic, liver, prostate,  and more (Cooper, 2000). 
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Figure 1.10 Tumour development stages.  
Three stages can be recognised in tumour development; these are an initiation, promotion, and 
progression. In these stages, single or cluster of cells acquired genetic mutation and altered their 
proliferation behaviour, the cells then increased their proliferation rate leading to excessive 
accumulation of genetic mutation. The cells then entered promotion stage followed by progression stage.   
This figure reproduced from(Hardin, et al., 2012). 
 
1.6 Breast cancer 
Breast cancer (BC) is a term that describes heterogeneous tumours formed from breast tissue that is 
commonly diagnosed in females. Globally, BC is considered the leading cause of women cancer death 
and is the second leading cause of overall cancer death after lung cancer (Steward and Wild, 2014). 
According to IARC (2013), there were 1.7 million new cases of BC  recorded in 2012 worldwide which 
represented 25% of all cases of female cancer diagnosis, the mortality rate was 14.7% of all female 
cancer death cases, with about 521,907 death cases being recorded. In the UK, the recorded new cases 
of female BC in 2011 were 50,285 with 11,643 death cases in 2012 (Cancer Research UK, 2012). In the 
USA,  there were 232,670 new female diagnosed with BC which account 29% from all diagnosis types 
of cancer in woman whereas mortality rate was 15% about 40.000 death cases  (Siegel, et al., 2014). 
Therefore, BC in the UK and USA is considered the second most common cause of female death.  
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Cancer, including breast cancer (BC), is a multifactorial disease and several predisposing factors are 
thought to be involved in its initiation. These are genetics, lifestyle, related diseases, and other factors 
including ageing, ethnicity, menarche and menopause, the density of breast tissue, radiation, previous 
cancer or BC. Also birth control, hormonal replacement therapy, breastfeeding, in addition to 
controversial factors like bras, induced abortion, breast implants, and antiperspirants (American Cancer 
Society, 2014). In the UK, statistics have shown that modification of poor lifestyle including cessation 
of smoking, eating healthy food, decreased consumption of alcohol, reduced hormonal replacement 
therapy associated with increased breastfeeding. Also increased physical activity and reduction in body 
mass, decreased exposure to sunlight and radiation can be involved in prevention of 174,200 general 
cancer cases and 15,000 BC cases each year (Cancer Research UK, 2014). 
 
1.6.1 Classification of breast cancer 
During puberty, lactation, and pregnancies the breast epithelial stem cells undergo rapid proliferation 
and morphogenesis to develop breast tissue (Visvader, 2009). These stem cells may be exposed to 
carcinogenic agents which can cause genetic mutation leading to uncontrolled proliferation to form 
atypical hyperplasia which then develops to in situ carcinoma and is followed by invasive carcinoma 
(Allred, et al., 2001). Atypical hyperplasia is considered to be a pre-invasive lesion which contains some 
abnormal mutant cells without displaying invasive properties and which is known as atypical ductal 
hyperplasia (ADH) when located in the ductal portion or atypical lobular hyperplasia (ALH) when 
located in a lobular portion (Allred, et al., 2001). Further proliferation of abnormal cells in ADH and 
ALH leads to the development of non-invasive ductal carcinoma in situ (DCIS) and lobular carcinoma 
in situ (LCIS). The risk of development invasive BC is increased in patients diagnosed with DCIS and 
LCIS (Li, et al., 2006a). 
 
To date, several classifications of BC have been used and developed to improve treatment and 
predicting clinical outcomes. The first classification is based on tumour size, lymph node and metastatic 
status in addition to histological type and grade (Elston and Ellis, 1991;Schnitt, 2010). BC can also be 
classified into biological and clinical subtypes (Taherian-Fard, et al., 2015). In the late 1980s, a new 
classification landed which depends on an expression of molecular biomarkers including oestrogen 
receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) 
(Leong and Zhuang, 2011). Based on this BC can be categorised into eight subtypes including 
ER+/PR+/HER2+, ER+/PR+/HER2-, ER+/PR-/HER2+, ER+/PR-/HER2-, ER-/PR+/HER2-, ER-/PR-
/HER2+, ER-/PR+/HER2+, and ER-/PR-/HER2- or triple-negative (Parise and Caggiano, 2014). 
Molecular gene expression profiles identified four major molecular subtypes including; luminal-like, 
basal-like, HER2+, and normal like (Perou, et al., 2000), and then became five categories including 
luminal A, luminal B, HER2+, basal-like, and normal like (Sorlie, et al., 2003).  These subtypes were 
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correlated with biomarkers (ER, PR, HER2, Ki-67, and cytokeratin) to identify broad categories of BC 
(Joensuu, et al., 2013;Parise and Caggiano, 2014). These are luminal A (ER+/PR+/HER2-/lowKi-67), 
luminal B (ER weaker+/PR+ or -/HER2+ or -/Ki-67+ high), HER2 enriched (ER-/PR-/HER2+), basal-
like (ER-/PR-/HER2-/CK5/6+/EGFR+), and normal like (ER- or +/PR unknown/HER2-
/CK5/6+/EGFR+) (Rosa, 2015;Weigelt, et al., 2010). 
 
1.6.2 Metastasis  
Metastasis is a series of complex biological steps in which cancerous cells are transported from their 
origin site to a new secondary organ in the body. Due to heterogeneity, BC cells have the ability to 
develop metastatic behaviour and invade distant organs through the lymphatic and vascular systems 
(Weigelt, et al., 2005). The major metastatic sites of BC are bone, liver, lung, brain, and distant nodal 
(Kennecke, et al., 2010). In general, approximately 90% of all cancer mortality is related to metastatic 
behaviour (Spanoa, et al., 2012), whereas metastasis is responsible for around 25%-50% of death in 
patients diagnosed with BC (Kozlowski, et al., 2015). Furthermore, the poor survival outcomes of some 
BC subtypes like a triple negative (ER-/PR-/HER2-) are strongly associated with rapid tumour 
development and metastasis (Lorusso and Ruegg, 2012). 
 
The increase in research into metastasis of tumourigenic cells has seen the development of several 
theories on the mechanisms underpinning metastasis. The relationship between metastasis and target 
tissue was first mentioned in “Das sarkomdes Uvealtradus” by the Austrian ophthalmologist Ernst Fuchs 
in 1882 (Piris and Mihm, 2007). This observation inspired English surgeon Stephen Paget, and after 
seven years he published a paper with the title ‘The distribution of secondary growths in cancer of the 
breast’ which held the first concept on cancer metastasis. This theory referred to ‘seed and soil’ which 
proposed that primary cancer cells with metastatic behaviour (seed) have the ability to spread to the 
other organs which provided an appropriate environment for these ‘seeds’ to grow (Paget, 1989). Since 
published, this theory was debated by other researchers for several years and was finally accepted as the 
main theory contributing to the field of cancer and which was subsequently supported by many studies 
later on. 
 
There exist two different spatial-temporal models responsible for tumour cell dissemination to other 
organs and tissues (Klein, 2009;Pantel and Brakenhoff, 2004). The first states that metastasis is time 
dependent and that its development occurs with continuous time (Kozlowski, et al., 2015). Due to the 
rapid accumulation of mutant genes, primary cancer cells progressively proliferate and expand during 
the time, and some of these cells acquire metastatic capability and escape from the primary lesion and 
invade distant organs (Fidler, 2003;Pantel and Brakenhoff, 2004). This type of metastasis is called the 
linear model of cancer (Kozlowski, et al., 2015). The second model is known as the parallel model and 
46 
 
opposes the linear model and suggests that tumour cells, especially breast carcinomas, have the ability 
to spread from a pre-malignancy primary site to other organs in the early stages of progression (Klein, 
2009). 
 
Simply put, BC metastasis is a multi-step biological event that occurs as a result of excessive genomic 
modification leading to increased cellular proliferation and alteration of behaviour during tumour 
progression. These complex steps include angiogenesis, local migratory and systemic invasion, and 
specific organ cloning (Figure 1.11) (Kozlowski, et al., 2015). All tumour cells including BC cells have 
the ability to create new blood vessels from pre-existing vasculature via angiogenesis through an 
angiogenic factor called hypoxia-inducible factor 1 (HIF-1) as a result of hypoxia which is a proper 
condition for survival and growth of tumour cells (Harris, 2002). This factor targets several key genes 
responsible for survival and induces organ-specific metastasis like vascular endothelial growth factor 
(VEGF) and chemokine receptor (CXCR4) (Kozlowski, et al., 2015). Furthermore, increased expression 
of a collagen remodelling factor called lysyl oxidase (LOX) in BC has been involved in increase 
metastasis (Erler, et al., 2006).  
 
After the formation of new blood vessels, cancer cells migrate from the primary tumour in the form 
of single or grouped cells through disruption of cell-to-cell adhesion by attenuating the expression of E-
Cadherin and increasing epithelial-to-mesenchymal transition (EMT) (Hennessy, et al., 2009). These 
detached cells are motile and locally intravasate newly formed blood vessels through the actions of 
markers including TGFB, notch and hedgehog, transcription regulators Twist and Snail (SNA, SNA11), 
MAP-Kinases, and Wnt which stimulate cells to undergo EMT (Tse and Kalluri, 2007). In the 
circulation, the cells adapt to their new environment and increase their survival through interacting with 
blood platelets and using them as a protective shield whilst in the circulation (Gupta and Massague, 
2006). Once again, these migratory cells at some point in the circulation act to break down the 
vasculature wall and escape out by extravasation facilitated by L or P-selectins, expression of NAGPTL4 
gene, and targeting tissue chemokines (Kozlowski, et al., 2015). The cells in new tumour site either 
enter the dormancy state and lose their ability to colonise the target organ while remaining viable and 
invasive, or they adapt to the new environment and promote growth and survival (Gupta and Massague, 
2006).  
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Figure 1.11 Cancer cells metastasis mechanism. 
This figure illustrates the mechanism of cancer cell metastasis started from excess mutation of 
proliferating cells to invade distinct organs. This figure reproduced from (Gupta and Massague, 2006).   
 
1.7 The association between obesity, T2D and breast cancer 
Obesity, insulin resistance, and T2D are the major factors which have been confirmed to have a 
positive correlation with the incidence of most types of cancer including BC (Cohen and LeRoith, 
2012;Ghose, et al., 2015;Lipscombe, et al., 2015). It is believed that individuals who are overweight or 
obese are more likely to develop cancer (Park, et al., 2014). Furthermore, the mortality rate of cancer is 
increased by 52% and 62% in obese men and women with BMIs > 40kg/m2 which suggests a strong 
relationship between obesity and the prevalence of cancer (Calle, et al., 2003). A recent meta-analysis 
of large cohort studies identified that increased BMI is associated with increased incidence of breast and 
other types of cancer (Reeves, et al., 2007). Pre-menopausal BC has been found to have an inverse 
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relationship with obesity (Stephenson and Rose, 2003). This effect is thought to be due to relatively low 
concentrations of oestrogen in an obese pre-menopausal woman (Abrahamson, et al., 2006). Despite 
obese pre-menopausal woman exhibiting a relatively reduced risk of BC, many observations have 
suggested that they express high levels of oestrogen receptors which can lead to malignancy (Daling, et 
al., 2001). 
 
Several meta-analyses including case-control and cohort studies have been conducted to determine 
the relative risk factors for BC in patients who were diagnosed with T2D. Indeed evidence appears to 
show that the prevalence of T2D increases the development of many types of cancer including liver, 
pancreatic, and endometrial cancers with about 200% relative risk. Whereas relative risks for colon, 
rectum, breast, and bladder cancers were 120% - 150% (Giovannucci, et al., 2010). Furthermore, 
diabetic patients are more likely to develop cancer at any site with approximately 74% higher risk 
compared with non-diabetic patients (Tsilidis, et al., 2015). Specifically, several studies confirmed that 
BC is increased in diabetic patients by 20%, 22%, and 23% higher risk compared to non-diabetic patients 
(Hardefeldt, et al., 2012;Larsson, et al., 2007;Liao, et al., 2011). A cohort study showed that diabetes 
increases the risk of developing stages II, III, IV of BC by 14%, 21%, and 33% respectively compared 
to stage I (Lipscombe, et al., 2015). Due to the different status of pre- and post-menopausal risk, a meta-
analysis has shown that diabetes increases the risk of developing post-menopausal BC compared to non-
diabetic, whereas no association with premenopausal BC was seen (Bowker, et al., 2011;Boyle, et al., 
2012).   
 
Molecularly and biologically, several mechanisms are thought to be involved in the association 
between obesity, insulin resistance, T2D and increased incidence of cancer, including BC. These 
mechanisms may include oestrogen bioavailability, insulin and insulin-like growth factors (IGFS), and 
chronic inflammatory cytokines alteration (Figure 1.12) (Joung, et al., 2015). 
  
1.7.1 Insulin/ insulin growth factors (IGFs) connection 
Increased circulation of endogenous insulin and IGFs have been identified to be involved in 
tumorigenesis processes in BC (Cohen and LeRoith, 2012). High levels of these peptides are related to 
different metabolic disorders including hyperinsulinemia, obesity, insulin resistance, and T2D. IGFs are 
insulin related peptides consisting of IGF-1 and IGF-2 isoforms which are secreted mainly by the liver 
in response to growth hormone (Lann and LeRoith, 2008). Most circulating IGFs are bounded to IGFBPs 
which act to regulate IGF bioavailability (Laron, 2001). It has been reported that the metabolic syndrome 
is strongly associated with high levels of free IGF-1 due to inhibition of IGFBP production (van 
Kruijsdijk, et al., 2009). Both insulin and IGF-1 receptors are heterotetrameric structures that exhibit 
high homology to each other (Lann and LeRoith, 2008). The function of both is mediated by binding to 
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their receptors leading to the activation of signalling pathways including PI3K/Akt/mTOR, Ras/MAPK 
and NF-κB nuclear translocation (Rose and Vona-Davis, 2012). Therefore, high circulating levels of 
insulin and IGF-1 target cellular homoeostasis and can promote cellular proliferation concomitant with 
suppression of apoptosis which leads to increased prevalence of cancer. 
  
 
Figure 1.12 Association between obesity, T2D and initiation of cancer.  
Three mechanisms may be involved in the development of cancer in obese and diabetic patients. 
These are insulin/IGFs, oestrogen/SHBG, chronic inflammation/cytokines, and adipokines connections. 
Obesity and diabetes cause insulin resistance which increases Insulin and IGF-1 availability and 
decreases GFBP1/2 and SHBG. In addition to increased inflammatory cytokines (TNFα, IL-6, IL-1β), 
and dysregulated adipokines secretion (increased leptin, decreased adiponectin and resistin). 
Furthermore, increased bioavailability of oestrogen due to the high activity of the aromatase enzyme 
may also occur. All these factors together target cellular homoeostasis and dysregulate the balance 
between cellular proliferation and apoptosis which leads to cancer initiation. Figure adapted from 
(Gallagher and LeRoith, 2015).    
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1.8 Glucose metabolism in cancer cells 
The process of cellular metabolism consists of a vast number of chemical reactions regulated by a 
network of specific enzymes and detectors that can sense nutrients in the surrounding microenvironment 
to produce the chemical energy required for proliferation and survival. As mentioned earlier, the 
pyruvate produced from glycolysis undergoes oxidative decarboxylation in the presence of oxygen to 
form acetyl coenzyme A (acetyl-CoA) which enters the TCA cycle and is completely oxidised by the 
respiratory chain to generate 36 ATP molecules (Seo, et al., 2014). The other fate of pyruvate is to be 
converted to lactate through a fermentation process by the activity of lactate dehydrogenase during 
anaerobic conditions without generating any additional ATP molecules (Lunt and Vander Heiden, 
2011). Glucose can be metabolised to produce a high quantity of lactate even in the presence of oxygen, 
and this process is referred to as ‘aerobic glycolysis’ or the ‘Warburg effect’ (Lunt and Vander Heiden, 
2011;Vander Heiden, et al., 2009).  Due to the inefficiency of this process to generate ATP, the process 
of aerobic glycolysis occurs rapidly to produce more energy to meet the cellular demand for proliferation 
(Ganapathy-Kanniappan and Geschwind, 2013). This rapid proliferation rate under hypoxic and less 
vascularised conditions which is associated with massive consumption of glucose as a source of energy 
are recognised in cancer cells.  The accelerated metabolism via the aerobic glycolysis pathway provides 
energy for survival, proliferation, and biosynthesis (Li, et al., 2011a). This metabolism is a fundamental 
discovery presented in the 1920s by German physiologist and medical doctor Otto Heinrich Warburg, 
awarded medical Nobel Prize in 1931 for this discovery and later on supported works. The second 
process provides glucose as a source of energy consumed by cancer cells for proliferation and survival 
is Cori cycle (Goodwin, et al., 2014). This gluconeogenesis process is provided energy required by 
cancer cells through converting lactate to glucose in the liver (Tisdale, 2009). The hypothesis behind the 
alteration of metabolism of the cancer cells from oxidative phosphorylation (more efficient) to aerobic 
glycolysis (less efficient) is disruption of cancer cells mitochondria which cause switching of the 
metabolic pathway (Koppenol, et al., 2011). 
 
Despite the uncertain origin of tumour cell metabolic change which is proposed by many studies that 
investigated Warburg phenomenon, aerobic glycolysis is considered one of the main hallmarks of cancer 
cells (Hsu and Sabatini, 2008). Previous studies have investigated the precise mechanisms which could 
be responsible for metabolic modification of cancer cells that are present in Warburg effect. As 
previously mentioned, the Warburg effect is thought to be due to a mitochondrial defect; however 
research has identified that the mitochondrial disruption may be an incorrect hypothesis to explain the 
alteration of metabolism from oxidative phosphorylation to aerobic glycolysis (Weinhouse, 1976). 
Furthermore, studies have shown that cancer cell metabolism is a complex process and many factors 
could be involved in shifting metabolism including the availability of nutrients and microenvironmental 
hypoxia, mitochondrial DNA (mtDNA) mutations, tumour suppressor genes, and oncogenes (Figure 
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1.13) (Jang, et al., 2013b). Moreover, it has been suggested that genetic mutations leading to alterations 
in some signalling molecule pathways and enzymes which are involved in glucose utilisation and uptake 
as well as in cellular proliferation and survival may also be involved in metabolism (Cairns, et al., 
2011;Vander Heiden, et al., 2009).  
  
The first of these potential factors is the tumour microenvironment (Hsu and Sabatini, 2008). Tumour 
hypoxia conditions promote activation of HIF-1 which subsequently regulates many genes and enzymes 
responsible for angiogenesis, glycolysis, and pyruvate converted to lactate including increased 
expression of VEGF, Glut1, and lactate dehydrogenase A (LDHA) (Semenza, 2010). Furthermore, 
activation of HIF-1 leads to a reduction in oxidative phosphorylation via prevention of pyruvate entering 
the TCA cycle through increased activation of (PDKs) concomitant with inhibition of pyruvate 
dehydrogenase (Kim, et al., 2006a;Papandreou, et al., 2006). In addition to hypoxia, normoxia 
conditions can promote stabilisation of HIF-1 through various mechanisms like the oncogenic 
PI3K/Akt/mTOR pathway (Cairns, et al., 2011). 
 
Increased mtDNA mutation is another marker potentially responsible for reducing oxidative 
phosphorylation in cancer cells which increase aerobic glycolysis to compensate for the energy required 
for proliferation (Kroemer, 2006). These mutations can directly dysregulate enzymes implicated in the 
oxidative process including succinate dehydrogenase (SDH), isocitrate dehydrogenase (IDH), and 
fumarate dehydrogenase (FDH) (Wallace, 2012). Accumulation of succinate, fumarate, 2-
hydroxyglutrate and other oncometabolite in cancer cell mitochondria can lead to modification of 
cellular metabolism (Adam, et al., 2014). Obviously, generation of mitochondrial ROS is constantly 
responsible for mediating mtDNA mutation in tumour cells (Li, et al., 2011a). 
 
Additionally, oxidative stress and generation of cellular ROS can lead to genomic instability, 
dysregulated tumour suppressor gene function (including P53) which interacts with cellular metabolism 
of tumour cells (Liu, et al., 2008a;Vousden and Ryan, 2009). The main functions of transcriptional 
factor P53 are regulating cell cycle, promoting DNA repair, and regulating apoptosis process (Vousden 
and Ryan, 2009). However, it is believed that the P53 plays an important role in cellular metabolism 
through upregulation of TP53-induced glycolysis and apoptosis regulator (TIGAR) which in turn 
dephosphorylates fructose-2,6-bisphosphatase (Fru-2,6-P2) and directly suppresses glycolysis 
(Bensaad, et al., 2006). Also, P53 promotes the expression of cytochrome C oxidase (SCO2) which is 
an essential assembly gene in the mitochondrial electron transport chain that leads to the activation of 
glucose metabolism through oxidative phosphorylation (Matoba, et al., 2006). Furthermore, P53 
cooperates with transcriptional factor OCT1 to regulate metabolism and provide a balance between 
oxidative phosphorylation and glycolysis (Shakya, et al., 2009). Therefore, dysfunction of P53 leads to 
altered cellular metabolism from oxidative respiration to a high glycolysis rate and lactate production.  
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Alteration of oncogenic signalling pathways including PI3K/Akt/mTOR and LKB1/AMPK are 
involved in tumour cell proliferation, survival, and metabolic modification. The activity of PI3K in 
tumour cells is controlled by tumour suppressor gene PTEN which is subsequently regulated by P53 
gene (Stambolic, et al., 2001). Activation of PI3K leads to activation of the downstream pathway Akt 
which in turn activates glycolysis through increasing the activity of glycolytic enzymes such as 
phosphofructokinase 2 and hexokinase (Elstrom, et al., 2004;Robey and Hay, 2009). Furthermore, Akt 
promotes activation of mTOR through inhibiting tuberous sclerosis 2 (TSC2) (Robey and Hay, 2009), 
and increasing expression of HIF-1 in both hypoxic and normoxic conditions (Cairns, et al., 2011). 
Thus, dysfunction of P53 leads to deregulated PTEN which promotes PI3K activation and subsequently 
stimulate glycolysis. Similarly, activation of the energy sensor AMPK through the expression of the 
upstream LKB1 promotes activation of AMPK which in turn activates mTOR and switches cancer cell 
metabolism towards aerobic glycolysis. 
 
Dysregulation of the Ras/Raf/MAPK pathway has been identified in tumourigenesis as an oncogenic 
alteration which occurs due to Ras and Raf mutations (Dhillon, et al., 2007). Activation of mutant Ras 
is mediated through stimulating receptor tyrosine kinases (RtKs) as a result of binding of growth factors 
to generate specific binding sites called growth factor receptor-bound protein 2 (GRB2) which induce 
the nucleated exchange factor son of sevenless (SOS) (Santarpia, et al., 2012). Once Ras is activated, 
the further activation of downstream pathways takes place including Raf, MEK1 and 2, and ERK1 and 
2 that leads to increased cellular proliferation and survival in cancer cells (Kim and Choi, 2010). 
 
MYC is pro-oncogene transcriptional factor acting as a regulator of cell proliferation and 
metabolism. Activation and overexpression of MYC have been confirmed to be involved in the 
alteration of many factors including glucose and glutamine metabolism, lipid synthesis, mitochondrial 
biogenesis, and cell-cycle progression, which increase tumorigenesis and alter metabolism (Dang, 
2013). Decreased expression of MYC in T-cells causes inhibition of cellular glycolysis and 
glutaminolysis (Wang, et al., 2011). Furthermore, dysregulated MYC has been shown to cooperate with 
HIF-1 to mediate glycolysis through activation of several factors including hexokinase 2, pyruvate 
dehydrogenase kinase 1, and VEGF, as well as activation of Glut1 and lactate dehydrogenase A (Dang, 
et al., 2008;Kim, et al., 2007). Finally, alteration of all these markers promotes modification of cancer 
cell metabolism to glycolysis instead of oxidative phosphorylation.   
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Figure 1.13 Factors involved in the alteration of cancer cells metabolism. 
Several factors involved in aerobic glycolysis of cancer cells. Hypoxia stimulates glycolysis by 
increasing expression of HIF-1, Glut, VEGF, LDHA and PDK associated with inhibition of PDH. 
Secondly, mtDNA mutation and accumulation of succinate, fumarate, and 2-hydroxyglutaratein 
mitochondrion. Dysfunction of P53 causes deregulation of TIGAR, SCO2, OCT1 and PTEN which 
activates PI3K/Akt/mTOR to increased glycolysis. Mutant LKB1 mediated deactivate of AMPK which 
activates mTOR and interacts with glycolysis. Activation of Ras/Raf/MEK1,2/ERK1,2 or 
Ras/PI3K/Akt/mTOR due to mutant Ras or/and Raf increases cellular proliferation and cancer initiation. 
Overexpression of MYC is increased glycolysis and glutaminolysis by cooperating with HIF-1 to 
promote glycolysis.  
 
1.9 Tea 
Tea is an ancient natural beverage which is believed to be the second most consumed drink in the 
world after water (Cheng, 2004;Jian, et al., 2004;Peres, et al., 2011;Vuong, et al., 2010). The different 
types of tea originate from the leaves that grow in a superior bud above the shoots of the plant which 
belong to the Aceae family of the Camellia Sinensis plant (Gutman and Ryu, 1996). There are three 
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different types of tea based on fermentation status which are; black fully fermented, oolong partially 
fermented, and green unfermented tea (Cheng, 2004). However, more types of tea have been identified 
additionally including yellow, white, and Pu-Erh (Cheng, 2006;Vuong, 2014). The consumption of these 
types of tea varies based on some factors including country and culture. The global consumption of 
black, green, and oolong teas is estimated at 75%, 23%, and 2% respectively (McKay and Blumberg, 
2002). Another study suggested similar findings, reporting that the world consumption of a black, green, 
and another type of teas are 78%, 20%, and 2% respectively (Vuong, 2014). The most popular tea 
consumed in India, Europe, and many other countries is black tea (Chung, et al., 2003;McKay and 
Blumberg, 2002) whilst Asian countries, especially China and Japan prefer green tea as well as oolong 
tea (Cheng, 2004;Koo and Cho, 2004). 
 
1.9.1  Green tea 
Green tea is considered the second most popular tea consumed around the world after black tea 
(Vuong, 2014). Green tea is thought to contain more ingredients potentially responsible for health 
benefits compared with black tea due to its unfermented production through direct steaming of tea leaves 
which allow the enzymes responsible for changing colour to break down and preserve active compounds 
(Chacko, et al., 2010;Senanayake, 2013). Historically, this popular type of tea is mainly produced in 
China and Japan (Willson, 1999;Zuo, et al., 2002). The bitter taste of green tea is assigned to high 
contents of polyphenol (Willson, 1999). 
 
1.9.1.1 Composition of green tea 
The composition of tea varies due to several factors including the type of tea, geographic origin, 
harvested season, the age of the leaves, environmental conditions, and the level of fermentation or 
manufacturing method  (Chacko, et al., 2010;Fraser, et al., 2013). The unfermented production process 
of tea leaves produces a green tea that preserves active compounds due to this process. Polyphenols are 
a major constituent of phytochemicals which are present in many fruits and vegetables including green 
tea which makes up between 45-90% (w/w) (Chacko, et al., 2010). Green tea polyphenols can be divided 
into phenolic acid (not polyphenol), non-flavonoid polyphenol, and flavonoids and these subclasses are 
further divided into many subcategories (Ganguly, 2003). Flavonoids are an interesting subclass because 
they exhibit some compounds that have been reported to have health benefits. The backbone of this 
family contains two aromatic rings (A and B) which are connected by C ring. This family can be 
subdivided depending on the position of attachment between B and C ring, the position of hydroxyl 
groups on the rings, and general structure into flavan-3-ols, flavanones, flavonols, anthocyanidins, 
flavones and isoflavones (Beecher, 2003). 
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 Most common effects of green tea are assigned to catechins which are the most abundant members 
of the flavan-3-ol subfamily and represent around 25-35% of the dry weight (w/w) of green tea extract 
(Abdel-Rahman, et al., 2011). Green tea catechins contain several active ingredients possessing different 
chemical structures (Figure 1.14). These are catechin (C) which represents around 6% (w/w), 
epicatechin (EC; 11%, w/w), epicatechin gallate (ECG; 14%, w/w), epigallocatechin (EGC; 23%, w/w), 
and epigallocatechin gallate (EGCG; 41`%, w/w). In addition to caffeine which represents around 5% 
(w/w) (El-Shahawi, et al., 2012). Furthermore, gallocatechin (GC), catechin gallate (CG), and 
gallocatechin gallate (GCG) are types of catechins that have been identified in green tea (Dalluge and 
Nelson, 2000). While the flavonols are thought to be less potent than catechins and contain mainly 
quercetin, myricetin, and kaempferol which represent 2-3% (v/v) of the water soluble solids (Wang and 
Helliwell, 2000). Chemically, green tea extract consists of  (w/w) 15-20% protein, 4% amino acid, 26% 
fibre. Also 7% carbohydrate, 7% lipid, 2% pigment, 5% minerals, and 30% phenolic compounds (mainly 
EC, EGC, ECG, and EGCG) (Chacko, et al., 2010).  
 
1.9.1.2 Bioactivity of green tea 
In recent decades, several in vivo and in vitro studies have been carried out to investigate the role of 
green tea in a broad range of common diseases. The potentially powerful positive impact of green tea is 
typically assigned to one of the phenol groups in its content. Nevertheless, the underlying mechanism 
behind any health benefits of consuming green tea or its active compounds is still poorly understood. 
Importantly, green tea extract is thought to have the ability to scavenge oxygen and nitrogen free radicals 
that result from cell and tissue oxidative stress. This ability occurs by utilising the radicals through its 
phenol group, suggesting that consumption of green tea may prevent some pathological processes 
(Cabrera, et al., 2006;Mak, 2012;Zhang, et al., 2013b).  
 
The health benefits of consuming green tea have been demonstrated in different fields including 
oxidation (Koo and Cho, 2004) and inflammation (Cavet, et al., 2011). Also in reducing the onset and 
ameliorating the effect of cardiovascular disease (Chacko, et al., 2010;Zheng, et al., 2011). In addition, 
green tea has been reported to have a positive effect on weight loss and regulation of adipose tissue 
accumulation in the body (Park, et al., 2011;Rains, et al., 2011;Richard, et al., 2009). Also benefits in 
neurodegenerative diseases (Mandel, et al., 2004). Furthermore, green tea and its polyphenolic active 
compounds have been shown to have the ability to regulate glucose homoeostasis and improve diabetic 
condition (Babu, et al., 2013;Hininger-Favier, et al., 2009;Roghani and Baluchnejadmojarad, 2010). 
These effects are mediated by increasing cellular glucose uptake of insulin-sensitive cells through 
increasing expression of Gluts and decreasing hepatic glucose output through suppressing 
gluconeogenesis genes (PEPCK and G6Pase). These effects are thought to be achievable by different 
signalling pathway including activation of AMPK and/or PI3K/Akt (Babu, et al., 2013;Collins, et al., 
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2007;Hininger-Favier, et al., 2009;Zhang, et al., 2010). Moreover, green tea and several of its active 
ingredients possess anti-tumourigenic effects including reduced cell viability via increasing apoptosis, 
inhibition of cell growth and cell cycle arrest (Adhami, et al., 2003;Baliga, et al., 2005;Carvalho, et al., 
2010). Many molecular pathways are potentially implicated in green tea’s anti-cancer activity including 
targeting cell signalling and metabolic enzymes like PI3K/Akt, MAPK, JAK/STAT, Wnt and Notch, 
COX, and NFκB (Singh, et al., 2011). 
 
Figure 1.14 Chemical structure of active constitutes in green tea.  
Chemical structures of the main active ingredients in green tea, epicatechin EC (A), epigallocatechin 
gallate EGCG (B), epicatechin gallate ECG (C), quercetin (D), and myricetin (E). 
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1.10  Aims and hypotheses 
The comprehensive purpose of this study was to identify the effect of green tea extract on glucose 
homoeostasis and metabolism using in vitro and in vivo models, as well as to investigate the impact of 
green tea on breast cancer (BC) cells in vitro. Bearing in mind the well-defined dysregulation of glucose 
homoeostasis including glucose and lipid metabolism and related progression of diseases including T2D 
and BC, the hypotheses of this study were: 
• The active compounds of green tea extract have the ability to maintain glucose homoeostasis 
through regulating glucose and lipid metabolism by increasing glucose uptake in insulin-
sensitive cells and stimulated glycogenesis and lipogenesis associated with decreased 
lipolysis by activation of AMPK or Akt pathway. 
• These compounds play a major role in decreasing progression of breast cancer through 
reducing viable cells and induced apoptosis by alteration of cellular glucose metabolism 
through a direct effect on AMPK or Akt pathway. 
• Whole green tea extract and EGCG act to prevent obesity, increase insulin sensitivity, and 
prevent diabetes in mice either consuming high glucose solution or normal drinking water 
through regulating glucose and lipid metabolism. 
• Activation of AMPK and/or Akt and downstream signalling pathways could be the potential 
mechanism of these compounds to promote anti-obesity and anti-diabetic effects through 
expression markers related to glucose and lipid metabolism in essential mouse insulin-
sensitive tissues.  
As a result of these hypotheses the defined aims of this study were stated as follow: 
• To investigate the impact of most abundant active ingredients of green tea extract on 
regulation glucose and lipid metabolism in insulin-sensitive cells through assessing 
several metabolic markers like glucose uptake, glycogenesis, lipogenesis, lipolysis, and 
metabolic genes expression. 
• To identify the role of these compounds on Akt and AMPK signalling pathways. 
• To determine the ability of these active compounds to mediate toxic effect on BC cells 
to reduce cell viability through promoting apoptosis. 
• To investigate the role of these compounds on BC glucose metabolism and their 
relationship with Akt and AMPK signalling pathways.  
• To demonstrate the potential effect of whole green tea extract and EGCG on maintaining 
glucose homoeostasis, weight gain, adiposity and lipid metabolism, and insulin 
sensitivity in mice consuming normal water or challenging with high glucose water to 
induce obesity and insulin resistance. 
• To elucidate the mechanisms underlying the effect of these naturally occurring 
compounds as glucose homoeostasis regulators, anti-obesity and anti-diabetic agents. 
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2.1 Cell line studies 
2.1.1 Cell culture 
2.1.1.1 Mouse hepatocyte (AML12) cell line 
Mouse hepatocytes (AML12) cell were purchased from American Type Culture Collection (ATCC® 
CRL2254™), the vial containing cells was thawed at 37°C by using a water bath, and this process was 
carried out for one to two minutes until only a small piece of ice remained in the vial. The vial was 
moved to tissue culture cabinet after rinsing it with 70% ethanol. Total vial contents were transferred to 
a 25 cm² Corning tissue culture flask (TC) (Appleton Woods, UK) containing 6 ml of complete growth 
medium (1:1 Dulbecco's Modified Eagle's Medium and Ham's F12, Gibco®, Life Technologies, UK). 
The medium supplemented with 0.005 mg/ml insulin, 0.005 mg/ml transferrin, 5 ng/ml selenium (ITS) 
(Gibco®, Life Technologies, UK),  and 40 ng/ml dexamethasone (Sigma Aldrich, UK), in addition to 
50:500ml (v/v) Foetal Bovine Serum (FBS) (Gibco®, Life Technologies, UK) and 2mM/ml L-
Glutamine (LG) 5:500ml (v/v) (Gibco®, Life Technologies, UK), and 100 unit/ml penicillin and 
0.1mg/ml streptomycin (P/S) 5:500ml (v/v) (Sigma Aldrich, UK). The flask was transferred to a tissue 
culture incubator and incubated at 37°C and 5% CO2 humidified air atmosphere. Cells were subcultured 
when 80-90% confluent. Briefly, flasks containing cells were removed from the incubator and placed 
inside a tissue culture cabinet, media were removed and cells were washed once with 5ml of 1x 
Phosphate Buffer Saline pH 7.4 (PBS) (Gibco®, Life Technologies, UK). The washing buffer was 
aspirated, and the cells were exposed to 1ml of 1x 0.5% trypsin, 0.2% EDTA (Sigma Aldrich, UK) and 
placed in the incubator for 5 minutes to allow all cells to detach. 1ml of complete media was added to 
the cell suspension to neutralise the action of trypsin. The cell suspension was then transferred to a 
centrifuge tube, and cell pellets were collected after five minutes of centrifugation at 500 RCF. The cells 
were resuspended in 2ml complete cell culture medium and subsequently transferred to a 75 cm² TC 
flask containing 15ml complete medium and placed in a tissue culture incubator under the standard 
condition. The cell culture was maintained through replenishing the cell culture media every 2 to 3 days. 
 
2.1.1.2 Mouse myoblast (C2C12) cell line 
Mus Musculus (mouse) myoblast (C2C12) cell was obtained from American Type Culture Collection 
(ATCC® CRL1772™). The cells were cultured in 25 cm² TC flask containing 6ml of completed growth 
media a Dulbecco's Modified Eagle's Medium (DMEM) containing 4.5 g/L glucose and 4mM LG with 
phenol red (Gibco®, Life Technologies, UK). The media supplemented with 50:500ml (v/v) FBS in 
addition to 5:500ml (v/v) penicillin/streptomycin equal 100 unit/ml penicillin and 0.1mg/ml 
streptomycin. The cells were then incubated in the same incubation conditions mentioned previously. 
The subculturing procedure was similar to the method stated above, and the media were replenished 
every 2 to 3 days to maintain culture. 
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2.1.1.2.1 C2C12 cell line differentiation 
Mouse myoblasts are primary myocyte characterised by specific a morphology that is distinct from 
mature myocyte morphology. The myoblasts cells were exposed to a specific differentiation medium 
for a limited time, and the cells become fully differentiated (myocytes). The differentiation media is 
mostly similar to the proliferation and maintaining media (PM) except the supplementation of serum, 
where instead of using 50:500ml (v/v) of FBS a 10:500ml (v/v) horse serum (Gibco, Life Technologies, 
UK) is used to induce differentiation. The differentiation process is variable but normally takes around 
4-5 days in early passage cells and 7-9 days from passage 15 and over. Clear morphological alteration 
could be seen after two days of the differentiation process. The clearest morphological changes after full 
differentiation include that the cells became tubular, elongated, and multinuclear. 
 
2.1.1.3 Mouse embryonic fibroblast (3T3-L1) cells 
3T3-L1 cell was obtained from Zenbio Inc., Cambridge Bioscience, UK (Zenbio® SP-L1-F). Cells 
were cultured to proliferate in 25 cm² TC flask containing 6ml of completed proliferation media (BM), 
a Dulbecco's Modified Eagle's Medium (DMEM) containing 4.5 g/L glucose and 4mM LG with phenol 
red and without sodium pyruvate (Corning®, 10-017-CV, Appleton Woods, UK). The media 
supplemented with 50:500ml (v/v) FBS in addition to 100 unit/ml penicillin and 0.1mg/ml streptomycin 
5:500ml (v/v). The cells were then incubated in the same incubation conditions mentioned previously 
for culturing AML12 and C2C12 cells. Cells were then subcultured into 75 cm² TC flask containing 
complete proliferation media described above by using the same procedure for sub-culturing AML12 
and C2C12 cell lines. Finally, the cells were incubated in 5% carbon dioxide humidified atmosphere at 
37°C temperature. The culture media was replenished every 2-3 days to maintain healthy proliferating 
conditions. 
 
2.1.1.3.1 3T3-L1 cell differentiation 
3T3-L1 cells are pre-adipocytes originating from clonal murine Swiss mouse fibroblasts. This cell 
line is commonly used in basic science research focussed on obesity and metabolism due to its ability 
to readily differentiate into mature adipocytes when exposed to a special cocktail to stimulate 
adipogenesis and lipid droplet formation. Pre-adipocyte cells were cultured into TC flask or in microwell 
plates containing complete proliferation media and incubated at 37°C temperature in a humidified 
atmosphere with 5% CO2. Culture medium was replaced every 2-3 days with fresh proliferation medium 
until the cells reached confluency. Before induced differentiation, the cells were incubated for additional 
48 hours in proliferation media. Differentiation was initiated by removing proliferating media and 
replacing it with differentiation media (DM), Dulbecco's Modified Eagle's Medium/Ham’s F12 (50:50) 
mixture with L-glutamine and phenol red and without sodium pyruvate. The media supplemented with 
50ml FBS, 100 unit/ml Penicillin and 0.1mg/ml Streptomycin which equivalent 5ml and several 
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differentiation agents. These agents including 1µg/ml insulin, 0.25µM of dexamethasone, 0.5mM of 3-
isobutyl-1-methylxanthine (IBMX, Sigma Aldrich, UK), 3.3µM of biotin (Sigma Aldrich, UK), 2µM of 
rosiglitazone (Santa Cruz Biotechnology, USA), and 0.17µM of pantothenate (Sigma Aldrich, UK). The 
cells were then incubated for three days in the conditions mentioned previously to induce differentiation 
by stimulating adipogenesis and lipid droplets formation which increased in number and size with time. 
Differentiation media was aspirated after three days of incubation, and the cells were then exposed to 
maintaining media (MM) which consisted of Dulbecco's Modified Eagle's Medium/Ham’s F12 (50:50) 
mixture with L-glutamine. Complemented with 50ml FBS, 5ml penicillin/streptomycin, and many 
important agents for stimulating and maintaining the cells and lipid droplets formation which included 
1µg/ml insulin, 0.25µM of dexamethasone, 3.3µM of biotin, and 0.17µM of pantothenate. The 
maintaining media was replenished on days 6, 9, and 12. The differentiating cells displayed varying 
numbers and sizes of lipid droplets in day 15 when they were considered fully differentiated. A detailed 
description of media used in 3T3-L1 cells differentiation is summarised in (Figure 2.1).  
 
 
Figure 2.1 3T3-L1 cell line differentiation medium. 
 
2.1.1.4 Breast adenocarcinoma (MCF7) cell line 
The MCF7 cell line was obtained from American Type Culture Collection (ATCC® HTB-22™). 
Cells were grown and maintained in Dulbecco's Modified Eagle's Medium (DMEM) containing 4.5 g/L 
glucose and 4 mM LG with phenol red and without sodium pyruvate supplemented with 50:500ml (v/v) 
FBS and 100 unit/ml penicillin and 0.1mg/ml streptomycin, 5:500ml (v/v). Cells were incubated at 37°C 
in a humidified atmosphere containing 5% CO2 and media was replenished every 2-3 days. The cells 
were subcultured after reaching confluence by using a similar process for sub-culturing described earlier.  
 
Basic media
• DMEM high 
glucose with L-
Glutamine 
• 50ml FBS
• 5ml P/S
Differentiated media
• DMEM Ham's F12 
(50:50) with LG
• 50ml FBS
• 5mlP/S
• 1µg/ml Insulin
• 0.25µM Dexamethasone
• 0.5mM IBMX
• 3.3µM Biotin
• 2µM Rosiglitazone
• 0.17µM of 
Panthothenate 
Maintaining media
• DMEM Ham's F12 
(50:50) with LG
• 50ml FBS
• 5ml P/S
• 1µg/ml Insulin
• 0.25µM Dexamethasone
• 3.3µM Biotin
• 0.17µM of 
Panthothenate
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2.1.1.5 Breast adenocarcinoma (MDA-MB-231) cell line 
The MDA-MB-231 cells were purchased from American Type Culture Collection (ATCC® HTB-
26™). The cells were grown in RPMI 1640 containing phenol red, LG and 100 unit/ml penicillin and 
0.1mg/ml streptomycin which is equivalent to 5:500ml (v/v), and supplemented with 50:500ml (v/v) 
FBS. The culture was incubated at 37°C in a 5% CO2 humidified atmosphere. Subculturing was 
performed when the cells reach confluence by using the same protocol mentioned earlier.  
 
2.1.2 Green tea compound preparation 
All green tea compounds were purchased from Sigma Aldrich, UK unless otherwise stated. 
Epigallocatechin gallate (EGCG), epicatechin gallate (ECG), epicatechin (EC) were dissolved in sterile 
deionized water at 1mM concentration whereas, myricetin and quercetin were dissolved in dimethyl 
sulfoxide (DMSO) at 1mM concentration. The stock solution was aliquot and stored at -20ᵒC until used. 
 
2.1.3 Cell line cryopreservation 
All cell lines used in this study were cryopreserved in liquid nitrogen in-between uses and therefore 
required freezing and thawing procedures. Briefly, media was aspirated from 75 cm² TC flask containing 
cell culture and subsequently washed with 10ml of PBS. The PBS was removed and cells were detached 
using trypsin as detailed earlier. Detached cells were subsequently centrifuged at 500 RFC to form a cell 
pellet. Pellets were resuspended in cryopreserving solution which is 10% (v/v) of cryoprotectant DMSO 
in complete cell culture media, and then 1ml of the cell suspension was transferred into a cryovial. The 
vial was stored for 24 hours at -80°C in cell freezing box and then moved into liquid nitrogen bank. 
 
2.1.4 Cell counting 
Trypan blue dye is widely used regarding counting cells by using haemocytometer to identify living 
and dying cells. The assay is based on living cells excluding uptake of the dye and non-viable cells then 
being stained dark blue. The assay was performed to count cells of all cell lines that have been used in 
this study.  The cells were routinely trypsinized and neutralised with complete medium, and cell 
suspensions were then transferred to centrifuge tubes and spun down for 5 minutes at 500 RFC followed 
by discarding the supernatant and resuspension of the cell pellet with 1ml of complete medium. 
Subsequently, 100µl of cell suspension was transferred to new Eppendorf tube, and an equal volume of 
0.4% (v/v) trypan blue was added, followed by pipetting up and down to enhance mixing. A 10µl of the 
mixture was loaded on one side of haemocytometer chamber, and the cells were examined under a 
microscope. The living unstained cells were counted, whereas stained dying cells were excluded in 4 
squares located at the corner and one big central square in the middle of haemocytometer field (Figure 
2.2). The equation display to calculate the number of the live cells in one millilitre was [(living cell 
numbers in 5 squares/ 5) x diluent factor (2) x 104]. 
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Figure 2.2 Cells counted using haemocytometer. 
Haemocytometer field is showing counting area which is represented by four squares at the corners 
of the field and one square located in the middle (A). Haemocytometer counting area. (B). One square 
calculated area is showing counting process. 
 
2.1.5 Determination of glucose in culture media of insulin-sensitive cell lines 
Measuring glucose concentration in cell supernatant is a widely used indirect technique to estimate 
cellular glucose uptake (Drira and Sakamoto, 2013). However, this method is less accurate as it measures 
the concentration of glucose remain in the medium which could contain glucose resulting from 
gluconeogenesis and glycogenolysis. Insulin-sensitive cell lines including C2C12, 3T3-L1, and AML12 
cells were seeded into 24 well plates at density of 2x105 and maintained in the standard conditions 
mentioned previously until reach confluency. C2C12 and 3T3-L1 were routinely differentiated 
following the differentiation protocol described earlier. All cells were starved in serum-free medium for 
2h and then treated with 0.1, 1, and 10µM active compounds of green tea (EGCG, EC, ECG, myricetin, 
quercetin, and combinations of these compounds) in various time points including 24, 48, 72 hours. The 
20µM concentration of all compounds was tested only in AML12 in addition to other doses. The cells 
were treated with and without 10µM of selective AMPK (Dorsomorphin dihydrochloride, Tocris, UK) 
and selective Akt (10-[4'-(N, N-Diethylamino)butyl]-2-chlorophenoxazine hydrochloride, Tocris, UK) 
inhibitor molecules. These treatments were in addition to green tea active compounds in concentration 
and time points where significant results had previously been established when the cells were treated 
only with green tea compounds. The medium was collected at each time point, centrifuged and the 
amount of glucose in the medium was measured using a commercially available glucose 
oxidase/peroxidase assay kit (GAGO20, Sigma Aldrich, UK) with an amendment for use in 96 well 
plates.  This kit depends on an enzymatic reaction in which glucose is oxidised to gluconic acid and 
A B 
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hydrogen peroxide by the action of glucose oxidase. The existence of peroxidase generates a brown 
colour of oxidised o-dianisidine that resulted from the reaction between hydrogen peroxide and 
colourless o-dianisidine. This colour will then be converted to a solid pink colour by the reaction 
between oxidised o-dianisidine and sulfuric acid. The assay was performed in all treated metabolic cell 
line culture medium using 96 well plates. Briefly, the glucose standard was prepared in 5 points 
including 0, 10, 20, 30, and 40µg/ml respectively by using glucose standard supplied with the kit 
(1mg/ml). All metabolic cells culture media were diluted between 1/100 and 1/150 by using deionized 
water. A 50µl/well of standard and sample were transferred into 96 well plates in duplicated followed 
by adding 100µl/ well of glucose assay reagent. The plate was protected from light by using aluminium 
foil, and the reaction was initiated by placing the plate in an incubator at 37°C for 30 minutes. After 
completed incubation period, a 100µl/well of 12N H2SO4 was added to stop the reaction. The intensity 
absorbance was measured at 540nm using Multiscan (Thermo Scientific®) plate reader. 
 
2.1.6 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose (2-NBDG) uptake 
2.1.6.1 Insulin-sensitive cell 2-NBDG uptake 
AML12, myoblast (C2C12), and preadipocytes (3T3-L1) cells were seeded into 96 well plates at a 
density of 104 cells/well in 100µl complete media and incubated overnight. C2C12 and 3T3-L1 cells 
were differentiated before measuring 2-NBDG uptake. All cells were supplemented with low glucose 
serum free medium up to 2h before treatment, and subsequently, the cells (C2C12 and 3T3-L1) were 
treated with 1 and 10µM of EGCG, EC, and ECG. Whereas AML12 treated with 1 and 10µM of EC, 
ECG, combination, and 1, 10, 20µM of quercetin in addition to the 100µM final concentration of 2-
NBDG in 100µl/well completed low glucose media in triplicated. The cells were then incubated for 6h 
followed by washing 3x with pre-cold HBSS and leaving the last wash solution. Subsequently, 
fluorescence intensity was measured at 465/540 Excitation/Emission (Ex/Em) using fluorescence 
microplate reader SpectraMAX GeminiXS (Molecular Devices, UK) and SoftMaxPro software. 
 
2.1.6.2 Breast cancer cell 2-NBDG uptake 
  MCF7 and MDA-MB-231 BC cells were plated in 96 well plates at a density of 104 cells/well in 
100µl completed media and incubated overnight. Subsequently, cells were serum starved in DMEM low 
glucose medium for 2h, followed by treatment with green tea compounds that caused reduced lactate 
concentration in previous experiments in addition to the 100µM final concentration of 2-NBDG in 
100µl/well complete low glucose media in triplicate. MCF7 cells were treated with 100µM and 150µM 
of EGCG in addition to 150µM quercetin, whereas MDA-MB-231 cells are treated same as MCF7 in 
addition to 100µM and 150µM of combination catechins (EGCG, EC, and ECG). The cells of both cell 
lines were incubated 4h in the incubator, and 2-NBDG uptake was measured following the method 
mentioned previously. 
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2.1.7 Cell viability assays 
2.1.7.1 PrestoBlue® cell viability assay 
The proliferative/cytotoxic effects of various compounds of green tea at specific used concentrations 
and incubation times were investigated in all insulin-sensitive and BC cell lines used. PrestoBlue® cell 
viability reagent (Life Technologies, UK) was used to measure proliferation/viability of cells. The assay 
is based on the conversion of blue resazurin to red resorufin by the metabolic activity of viable cells. 
Briefly, all cell lines were seeded in 96 well plates at a cell density of 5x10³ in 100µl/well final volume 
of complete medium and incubated overnight to allow cells to attach. Insulin-sensitive cell lines were 
differentiated prior to treatment with various concentrations of green tea compounds over a range of 
times. 1 and 10µM of EGCG, EC, ECG, myricetin, quercetin, and the combination of all compounds 
were used to treat C2C12 and 3T3-L1 cells, whereas AML12 cells were treated with same doses and 
compounds in addition to 20µM for 24, 48, and 72h. Both BC cell lines were treated with 1, 10, 50, 100, 
and 150µM of EGCG, EC, ECG, a combination of these compounds, myricetin, and quercetin for 24, 
48, and 72h. After desired treatment periods had been complete, cell culture medium was aspirated, and 
the cells were rinsed in 90µl of completed fresh medium.  Subsequently, 10µl of PrestoBlue was added 
to cell culture in addition to control wells that did not contain any cells in triplicate; then the plate was 
incubated for 4 hours at 37ᵒC and 5% CO2 incubator. When the incubation period was finished, the cell 
culture medium containing PrestoBlue was transferred to 96 fluorescence microplate, and the 
fluorescence was measured at 353/615nm (Ex/Em) by using fluorescence microplate reader 
SpectraMAX GeminiXS (Molecular Devices, UK) and SoftMaxPro software. 
 
2.1.7.2 Neutral red cell viability assay 
Neutral red (NR) is another reagent widely used to measure cell viability. The assay was used to 
determine live cells in both BC cell lines in addition to PrestoBlue® in order to confirm the effect of 
test compounds. NR solution (0.33% in DPBS) was purchased from Sigma Aldrich, UK. The principle 
action of NR is based on dye incorporation and liberation, in other words, live cells in culture will absorb 
the vital dye by active transport, and it is incorporated in lysosomes then this dye will liberate from 
lysosomes in the presence of an acidophilic solution. 5x10³ cells were seeded in clear 96 well plates and 
incubated in the standard conditions overnight, then the test compounds were applied for the desired 
period, and cell viability was measured after the complete treatment time in triplicate wells. Briefly, the 
treated medium was removed and 10µl of NR reagent in 90µl fresh completed medium was added to 
cell culture. The plate was incubated for 4 hours at 37°C temperature and humidified atmosphere 
containing 5% CO2 to allow the vital dye to incorporate. After that, the dye solution was aspirated 
carefully, and the cells were quickly fixed by using neutral red fixative solution (0.1% CaCl2 in 0.5% 
formaldehyde, w/v) for two minutes, extended fixation time will lead to bleach the dye. The fixative 
was removed after two minutes, and 100µl of solubilization solution (1% acetic acid in 50% ethanol, 
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v/v) was added and incubated at room temperature for 10 minutes to allow dye liberation. The plate was 
then placed on a horizontal shaker for 1 minute to enhance dye mixing. The absorbance was measured 
at 540nm and 690nm using Multiscan (Thermo Scientific®) plate reader. 
 
2.1.8 Analysis of glycogen content in AML12 cells 
To determine the concentration of glycogen in AML12 cells a proprietary glycogen assay kit was 
obtained from BioAssay Systems, UK (EnzyChrom™Glycogen Assay Kit, Cat#E2GN-100). The assay 
is enzymatic based that measures glucose which results in the final step from the breakdown of glycogen. 
Cells were cultured in 24 well plates in 1ml complete media and allowed to be 80-90% confluent, 
followed by serum starvation for up to 2h before being exposed to the treatment. Cells were 
supplemented with green tea compounds that previously showed increased glucose uptake (1µM EC, 1 
and 10µM ECG, 1, 10, 20µM quercetin, and 1 and 10µM combination for 72h, in addition to 10µM 
ECG for 24h). Then the cells were subsequently harvested, and the glycogen assay was performed 
following the manufacturer's protocol. Briefly, cells were homogenised in an ice bath by adding 25µl of 
homogenization solution which is a mixture of 25mM citrate and 2.5g/L NaF with pH= 4.2. The samples 
were centrifuged for 5 minutes at 14000 RFC, and the clear supernatant was collected and diluted 1/100 
for assay. A glycogen standard was prepared in 4 concentrations in addition to the blank (200, 150, 100, 
50, and 0µg/ml) by using the standard solution supplied with this kit. 10µl of standards and samples 
were transferred to clear 96 well plates in duplicated. Subsequently, 90µl of assay reagent (90µl assay 
buffer, 1µl enzyme A, 1µl enzyme B, and 1µl dye) was added, the plate was tapped to enhance mixing 
and incubated for 30 minutes at room temperature. The intensity of the colour that results from the 
reaction was measured at 570nm using Multiscan (Thermo Scientific®) plate reader. 
 
2.1.9 Estimation of free glycerol release from mature 3T3-L1 cells 
Measurement of the amount of glycerol produced from adipose tissue is indicative of the rate of 
lipolysis which is the process of breakdown of triglyceride into free fatty acid and glycerol due to energy 
demand. Pre-adipocytes cells were plated into 24 well plates in full proliferation media mentioned earlier 
and incubated in a CO2 incubator at 37°C until the cells were become 100% confluent, followed by 
incubation for an additional two days before initiating differentiation. Differentiation was induced as 
described previously. Mature adipocytes were serum starved for 2h and subsequently treated with test 
compounds in dose and time points that increased glucose uptake previously (1 and 10µM of EGCG, 
EC, and ECG) for 48 and 72h. Cell culture supernatant was collected and glycerol content was detected 
using a commercial free glycerol reagent kit from Sigma Aldrich, the UK based on the protocol provided 
with the kit with minor modification to use it with 96 well plates instead of a cuvette. The detection of 
glycerol in this methodology depends on several enzymatic reactions, first adenosine-5’-triphosphate 
(ATP) phosphorylation of glycerol to form glycerol-1-phosphate (G-1-P) and adenosine-5’-diphosphate 
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(ADP) by the catalysed action of glycerol kinase (GK). Then glycerol phosphate oxidase subsequently 
oxidises glycerol-1-phosphate to produce dihydroxyacetone phosphate (DHAP) and hydrogen peroxide 
(H2O2), and the latter reacts with sodium N-ethyl-N-(3-sulfopropyl)-anisidine (ESPA) and 4-
aminoantipyrine (4-AAP) to produce quinonimine dye by the effect of peroxidase (POD). Finally, dye 
absorbance is measured. Briefly, glycerol standard was prepared in 8 points serial dilution from 
260µg/ml to 0µg/ml, then the standard and samples were plated in duplicate well of 96 clear well plates 
in a volume of 2.5µl/ well followed by adding 200µl/ well free glycerol reagent to initiate the reaction. 
Subsequently, the plate was incubated at room temperature and protected from light by aluminium foil 
for 10-15 minutes. The dye absorbance was measured at 540nm using Multiscan (Thermo Scientific®) 
plate reader. 
 
2.1.10 Mature 3T3-L1 Triglyceride Oil red O staining  
Pre-adipocytes (3T3-L1) cells were seeded into 24 well plates in completed media and incubated in 
CO2 incubator till they reached 100% confluence. Differentiation was induced following the protocol 
mentioned previously. Cells were washed twice with PBS and subsequently fixed by adding 10% (v/v) 
isotonic formaldehyde solution for 30 minutes at 37°C. The fixative solution was discarded and cells 
were again washed twice with dH2O followed by a five-minute room temperature incubation in 60% 
(v/v) isopropanol. This solution was aspirated, and the cells were rinsed with an appropriate volume of 
oil red O working solution (Sigma Aldrich, UK) for 15 minutes at 37°C. Oil red O solution was removed 
carefully, and then the cells were washed several times with dH2O and subsequently examined and 
photographed under a fluorescence microscope (Leica DMI4000 B inverted microscope).  
 
2.1.11 Estimation of cellular triglyceride content in mature 3T3-L1 cells 
3T3-L1 cells were seeded into 24 well plates and differentiated following the protocol mentioned 
previously. Mature adipocytes were then treated with green tea compounds (1 and 10µM of EGCG, EC, 
and ECG for 48 and 72h). Cellular triglycerides were extracted directly by using 5% (v/v) of 100x triton 
(Fisher Scientific, UK). Briefly, media were removed, and the cells were washed with PBS followed by 
addition of 100µl/well of 5% (v/v) of 100x triton solution. Cells were then scraped from the surface of 
their well plates. The suspensions were collected and slowly heated from 80°C-100°C for 5 minutes and 
subsequently slowly cooled down to room temperature. The heating and cooling were repeated once 
again, and samples were then centrifuged at 14,000 RCF for 10 minutes. The supernatant was transferred 
to new tubes for assay. A proprietary triglyceride assay kit was obtained from BioAssay Systems, UK 
(EnzyChrom™Triglyceride Assay Kit, Cat#ETGA-200). This assay is based on measuring colour 
intensity that resulted from dye oxidation during triglyceride hydrolysis and glycerol capture. The assay 
was performed according to the manufacturer's protocol. Briefly, a triglyceride standard was prepared 
in 4 points started from 1-0 mmol/L (1, 0.6, 0.3, 0 mmol/L) using the standard reagent supplied with the 
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kit. A 10 µl/well of standard and diluted samples (1:10) were placed in 96 well plates in duplicate, 
followed by the addition of 100µl/well of working reagent which included 100µl assay buffer, 2µl 
enzyme mix, 5µl lipase, 1µl ATP, and 1µl dye reagent. Then the plate was tapped and incubated for 30 
minutes at room temperature, and subsequently, the absorbance was measured at 570nm using Multiscan 
(Thermo Scientific®) plate reader.  
     
2.1.12 Cellular lactate assay 
Amplite™ Fluorimetric L-Lactate Assay Kit was purchased from AAT Bioquest® (Cat# 13814). 
This assay depends on coupled enzymatic activity to detect the amount of lactate by measuring the 
amount of fluorogenic NADH that is formed in the final step which is related to the amount of lactate, 
and the assay was performed following the manufacturer protocol. Briefly, MCF7 and MDA-MB-231 
BC cell lines were seeded into 24 well plates at a cell density of 3x104 /well in 1ml complete media. The 
cells were cultured overnight and subsequently serum starved for 2h with serum free media before being 
exposed to active compounds of green tea in 1ml complete media for 6 and 24h with and without 1mM 
sodium pyruvate. The cell culture medium was collected and stored directly at -80°C or immediately 
underwent deproteinization to inactivate all enzymes especially lactate dehydrogenase. To perform 
deproteinization cell culture medium was heated up for 15 minutes at 80°C and subsequently centrifuged 
at 8000 RCF for 10 minutes. The supernatant was collected for assay and stored at -20°C. Before the 
start of the test, the L-lactate standard that was supplied with the assay kit was prepared in 8 
concentrations starting from 1mM - 0µM. The assay was initiated by adding 50µl/well of standard and 
samples into black 96 well plates in duplicate. 50µl of lactate assay mixture solution was added to each 
well. The reaction was completed by incubating the plate for 2h at room temperature away from light. 
Fluorescence intensity was measured at 540/590 Ex/Em with 570 cut off point using fluorescence 
microplate reader SpectraMAX GeminiXS (Molecular Devices, UK) and SoftMaxPro software.     
 
2.1.13  Caspase 3/7 apoptosis assay  
The CellEvent® Caspase-3/7 Green Ready Probes® Reagent (cat no R 37111) was purchased from 
Thermofisher Scientific, UK. This assay is based on detection of the activation of caspase 3/7 during 
apoptosis which promotes DEVD cleavage allowing a nucleic acid dye to bind with DNA and generate 
a fluorescent signal. The assay was performed following the manufacturer’s protocol. Briefly, MCF7 
and MDA-MB-231 cells were plated into 96 well plates at a cell density of 5x103 cells/well and 
incubated for 24h at standard incubation environment. MCF7 cells were treated with 100, 150µM EGCG 
and 150µM quercetin with and without 1mM sodium pyruvate for 24h in 100µl complete media. MDA-
MB-231 cells were treated with 100 and 150µM of EGCG and combination of green tea catechin in 
addition to 150µM quercetin with and without 1mM sodium pyruvate for 24h. Cell culture medium was 
aspirated, and cells were exposed to 100µl/well of fresh medium containing CellEvent reagent (2 
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drops/1ml media). The cells were incubated for 60 minutes in a standard cell culture incubator, and 
subsequently, emission of fluorescence was measured at 502/530 Ex/Em using fluorescence microplate 
reader SpectraMAX GeminiXS (Molecular Devices, UK).    
 
2.1.14 Cellular migration assays 
Scratch assay is conventional, well developed, and economical method which has been used widely 
to track in vitro cell migration, matrix remodelling, and cellular polarisation (Liang, et al., 2007). 
Simply, the assay is based on monitoring cellular movement from both edges of artificial scratch that is 
made in confluent monolayer cell toward the gap until newly cellular contact is established (Liang, et 
al., 2007). The disruption of the cell to cell contact during scratch assay causes increased growth factors 
concentration at the margins which stimulate wound healing through proliferation and migration 
(Yarrow, et al., 2004). Cellular migrations of both BC cell lines (MCF7 and MDA-MB-231) have been 
assessed using wound scratch healing assay. A classic microscopic imaging and automated cell-IQ® 
were used to determine migration process based on the ability of cells to migrate and close the artificial 
gap. 
 
2.1.14.1 Wound scratch classic microscopic imaging assay 
Cellular migration of MCF7 and MDA-MB-231 was investigated using traditional standard wound 
scratch assay. Briefly, cells were seeded into 24 well plates in 1ml complete media and were incubated 
at 37°C and 5% CO2 atmosphere until they became 100% confluent. Cells were then exposed to 5µg/ml 
of mitomycin C in serum-free media for 2h before treatment and initiation of the assay to inhibit cellular 
proliferation (Carretero, et al., 2008). A cross shape scratch was performed in each well of monolayer 
cell using a sterile 20µl pipette tip, and subsequently, cells were washed with HBSS to remove all 
detachable cells. The MCF7 cells were then treated with 50µM of EGCG and quercetin, whereas MDA-
MB-231 cells were treated with  EGCG, a combination of green tea catechin (GTC), and quercetin in 
1ml complete media and wound healing was monitored at two-time points (0 and 24h).   Images were 
captured at 0, and 24h using Leica DMI4000 B inversion microscope and % of wound closure was 
analysed using free TScratch software developed by Koumoutsakos’s group (CSE Lab, ETH, Zurich) 
(Geback, et al., 2009). 
 
2.1.14.2 Wound scratch cell IQ® migratory assay 
Confirmation of MCF7 and MDA-MB-231 cell migration in response to green tea treatments was 
determined using an automated image capture system called Cell IQ® (CM Technologies, Finland). 
Cells were cultured in 24 well plates in 1ml complete media and incubated in standard condition until 
they reached 100% confluence. Prior to introduction to the Cell-IQ system, the cellular proliferation was 
inhibited by exposing both cultured cell lines to 5µg/ml of mitomycin C in serum-free media for 2h. The 
70 
 
cell monolayer was scratched along the vertical axis using a sterile 20µl pipette tip, and washing was 
applied to remove any free cells using HBSS. The MCF7 and MDA-MB-231cells were then treated with 
treatments mentioned above, and plates were placed in the Cell IQ® system, and two interested regions 
were chosen for each well of both cell lines. The captured images were selected every six hours over 24 
hour treatment. A percent of wound closure was calculated by analysing images using Cell-IQ® 
analyser™ software based on comparing initially scratched area and new closure area during time points 
that were selected previously. 
 
2.1.15 Total RNA extraction and reverse transcription  
Total RNA of both metabolic and cancer cell lines was isolated using Ambion/RNA Trizol® Reagent 
(Life Technologies, UK). Briefly, all cell lines were seeded into 12 well plates and incubated at standard 
conditions for 24h. The metabolic cells including C2C12 and 3T3-L1 were differentiated before 
treatment as mentioned previously. C2C12 and 3T3-L1 cells were treated with 10µM EGCG, EC, and 
ECG; whereas AML12 has been processed with 10µM of EC, ECG, quercetin, whole experiment green 
tea compounds, also, to control containing 0.1% (v/v) DMSO as a vehicle for 24h. While, MCF7 and 
MDA-MB-231 were treated with 100µM of EGCG and quercetin, and EGCG, GTC, quercetin 
respectively in addition to 1% (v/v) DMSO control as a vehicle for 24h. The cells were then lysed 
directly using 1ml of Trizol® reagent per 10 cm2, which means 1ml/3 wells of 12 well plates and the 
total RNA was isolated following the manufacturer’s protocol. Subsequently, purified RNAs were 
quantified using NanoDrop1000 spectrophotometer (Thermofisher Scientific, UK), and RNA 
concentration was recorded by measuring absorbance at 260/280nm. 1µg of total RNA from each sample 
of all cell lines was reverse transcribed using cDNA synthesis kit containing oligo dT primer (Primer 
design, UK) except 3T3-L1 cells in which total RNA was used at a concentration of 100ng in 20µl final 
volume. Synthesis of cDNA was performed following manufacturer’s instruction by initiation reaction 
for 20 minutes at 55°C and then heat inactivation for 15 minutes at 75°C using a programmed 
thermocycler. The cDNAs obtained from this synthesis were diluted one in10 using PCR water and 
stored at -20ᵒC until required for amplification. 
 
2.1.16 Real-time Polymerase Chain Reaction (qPCR) 
Specific mouse metabolic genes and human cancer apoptotic genes were amplified using 5µl diluted 
cDNA in 20µl final volume reaction by performing SYBR® Green qPCR. Specific mouse metabolic and 
human apoptotic primers were purchased from Thermofisher Scientific as well as selected housekeeping 
primers (Invitrogen, UK). These primers are insulin receptor (IR), hexokinase 1 (HK1), Glut2, Glut4, 
Gys1, pyruvate dehydrogenase kinase 4 (PDK4), Peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha (PGC1α), G6Pase, PEPCK, carnitine palmitoyltransferase 1alpha (CPT1α), Acyl-
CoA Synthase (Long-Chain) (ACSL), C/EBPα, SREBP1c. Furthermore, lipoprotein lipase (LPL), fatty 
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acid synthase (FASN), fatty acid binding protein 4 (FABP4), peroxisome proliferator-activated receptor 
gamma (PPARγ), B-cell lymphoma 2 (BCL2), apoptosis regulator Bax (Bax), oncogene Myc (Myc), 
and tumour suppressor p53 (P53). The forward and reverse sequence of primers and normalising 
housekeeping gene primers that have been used for each cell line of mouse metabolic and human cancer 
apoptosis are listed in Table 2.1.  20µl of final volume reaction (5µl diluted sample and 15µl master mix 
containing SYBR green with forward and reverse interested primers) were placed in each well of 96 
PCR well plates in duplicated and subsequently sealed. The plate was transferred to Stratagene 
MX3000P™ thermal cycler (Stratagene, UK). The thermocycling conditions were one activation cycle 
of 95°C for 10 minutes, 40 cycles of 95°C for 15 seconds and 60°C for one minute, and one cycle of 
95°C for 30 seconds followed by 60°C for one minute and the 95°C for 30 seconds. The cycle threshold 
(Ct) value is the point at which fluorescence in each well begins to increase exponentially, and this was 
obtained for housekeeping genes and interesting genes.  The average value of Ct was used to calculate 
the value of ∆C t by subtracting average Ct value of housekeeping gene from average Ct value of 
responsive genes. The relative level of gene expression was calculated using equation 2ˆ∆∆Ct whereas 
∆∆Ct is the average ∆Ct value of control reference subtracted from the ∆Ct value of the interested gene.   
 
Table 2.1 Primer sequences of metabolic and BC cell lines. 
No Cell lines Primer Forward and Reverse sequences 
 
 
 
 
 
 
1 
 
 
 
 
 
 
C2C12 
 
 
 
 
 
mActin F/ CCTCCCTGGAGAAGAGCTATG 
R/ TTACGGATGTCAACGTCACAC 
mIR F/ AATGGCAACATCACACACTACC 
R/ CAGCCCTTTGAGACAATAATCC 
mHK1 F/ GACCGAGGCATCTTCGA 
R/ AGCAGCGGTAATCGGTCACT 
mGLUT4 F/ ACATACCTGACAGGGCAAGG 
R/ CGCCCTTAGTTGGTCAGAAG 
mGys1 F/ TATCGCTGGCCGCTATGAGTT 
R/ CACTAAAAGGGATTCATAGAG 
mPDK4 F/ GATTGACATCCTGCCTGACC 
R/ CATGGAACTCCACCAAATCC 
mPGC1α F/ GAGTCTGAAAGGGCCAAGC 
R/ GTAAATCACACGGCGCTCTT 
 
 
 
 
 
 
 
 
2 
 
 
 
 
 
 
 
 
AML12 
 
 
mActin F/ CCTCCCTGGAGAAGAGCTATG 
R/ TTACGGATGTCAACGTCACAC 
mIR F/ AATGGCAACATCACACACTACC 
R/ CAGCCCTTTGAGACAATAATCC 
mHK1 F/ GACCGAGGCATCTTCGA 
R/ AGCAGCGGTAATCGGTCACT 
mGLUT2  F/ TGTGCTGCTGGATAAATTCGCCTG 
R/ AACCATGAACCAAGGGATTGGACC 
mGys1 F/ TATCGCTGGCCGCTATGAGTT 
R/ CACTAAAAGGGATTCATAGAG 
mG6Pase F/ AACGCCTTCTATGTCCTCTTTC 
R/ GTTGCTGTAGTAGTCGGTGTCC 
mPEPCK F/ CTTCTCTGCCAAGGTCATCC 
R/ TTTTGGGGATGGGCAC 
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mCPT1α F/ ACGGAGTCCTGCAACTTTGT 
R/ GTACAGGTGCTGGTGCTTTTC 
mACSL F/ CAGAACATGTGGGTGTCCAG 
R/ GTTACCAACATGGGCTGCTT 
 
 
 
 
 
 
 
 
 
 
 
3 
 
 
 
 
 
 
 
 
 
 
 
3T3L1 
mActin F/ CCTCCCTGGAGAAGAGCTATG 
R/ TTACGGATGTCAACGTCACAC 
mIR F/ AATGGCAACATCACACACTACC 
R/ CAGCCCTTTGAGACAATAATCC 
mHK1 F/ GACCGAGGCATCTTCGA 
R/ AGCAGCGGTAATCGGTCACT 
mGLUT4 F/ ACATACCTGACAGGGCAAGG 
R/ CGCCCTTAGTTGGTCAGAAG 
mCEBPα F/ TGGATAAGAACAGCAACGAG 
R/ TCACTGGTCAACTCCAACAC 
mSREBP1c F/ CAACGCTGGCCGAGATCTAT 
R/ TCCCCATCCACGAAGAAACG 
mPPARγ F/ GTCACGTTCTGACAGGACTGTGTGAC 
R/ TATCACTGGAGATCTCCGCCAACAGC 
mLPL F/ TGGATGAGCGACTCCTACTTCA 
R/ CGGATCCTCTCGATGACGAA 
mFASN F/ GGCTCTATGGATTACCCAAGC 
R/ CCAGTGTTCGTTCCTCGGA 
mFABP4 F/ TCACCATCCGGTCAGAGAGTA 
R/ GCCATCTAGGGTTATGATGCTC 
 
 
 
 
 
4 
 
 
 
 
MCF7 & 
MDA-MB-231 
hYWHAZ F/ ACTTTTGGTACATTGTGGCTTCAA 
R/ CCGCCAGGACAAACCAGTAT 
hBCl2 F/ AGGAAGTGAACATTTCGGTGAC 
R/ GCTCAGTTCCAGGACCAGGC 
hBax F/ TGCTTCAGGGTTTCATCCAG 
R/ GGCGGCAATCATCCTCTG 
hMyc F/GGCAAAAGGTCAGAGTCTGG 
R/ GTGCATTTTCGGTTGTTGC 
hP53 F/ CTGGCCCCTGTCATCTTCTG 
R/ CCGTCATGTGCTGTGACTGC 
 
2.1.17 Analysis of cell signalling 
2.1.17.1 Protein isolation 
Cells were lysed using 1x Radio-Immunoprecipitation Assay (RIPA) buffer (Millipore, Watford, 
UK) containing phosphatase and complete protease inhibitor cocktail C (Santa Cruz Biotechnology, 
Germany). Briefly, treated cells were washed two times with 1x cold Tris-buffered saline (TBS) (20mM 
Tris and 150mM NaCl), and an appropriate volume of complete RIPA buffer was added. Subsequently, 
the cell layer was scraped and all content was transferred into a microcentrifuge tube and incubated in 
an ice bath for 15 minutes to complete cell lysis. The content was centrifuged at 10,000RCF for 10 
minutes at 4ºC to remove all debris followed by collecting supernatant into the new microcentrifuge 
tube and storing at -80ºC.   
 
2.1.17.2 Protein quantification 
The concentration of the total protein in the samples was quantified using Bio-Rad DC™ Protein 
Assay (Bio-Rad, UK). The principle of this assay is similar to Lowry assay with only reducing 
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measurement time. The assay is based on reduced folin reagent by copper-treated protein that resulted 
from reaction between protein and copper in an alkaline medium. The absorbance of the final generated 
blue colour is then measured at 750nm. Briefly, bovine serum albumin was dissolved in 1x RIPA buffer 
as standard ranging from (0.25-1.5mg/ml) in addition to diluent buffer RIPA as a 0ng/ml. Samples were 
diluted in 1x RIPA buffer (1:4). 5µl of standard and samples were transferred to each well of 96 well 
plates in triplicate. 25µl of working reagents A and B (50:1) were added to each well followed by adding 
200µl/well reagent B. The plate was incubated 15 minutes at room temperature, and subsequently, 
absorbance was read at 750nm using a Multiscan (Thermo Scientific®) plate reader. Protein 
concentration was calculated from plotting a standard curve from the data obtained and using the 
equation of the line. 
 
2.1.17.3 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Samples were denatured in 5x Laemmli sample buffer (deionized water, 60mM Tris-HCl pH 6.8, 
10% (v/v) glycerol, 2% (v/v) SDS, 0.01% (v/v) bromophenol blue and 5% (v/v) β-mercaptoethanol) for 
5 minutes at 95°C. Gels were prepared according to standard manufacturer recipes using 1mm thick 
glass plates. 4% (v/v) protogel stacking buffer and 12% (v/v) of 4x protogel resolving buffer (National 
Diagnostics, Geneflow, UK) were prepared and casted, and a comb was inserted on the top of stacking 
gel to make wells for loading samples. 20µg of total protein from 3T3-L1, AML12, MCF7, and MDA-
MB-231, and 25µg of total protein from C2C12 were loaded into each well in addition to 5µl molecular 
weight marker as a protein ladder PageRuler™ Plus (Fisher Scientific, UK). Samples then underwent 
electrophoresis in 1x running buffer Novex® Tris-Glycine SDS running buffer (Life Technologies, UK) 
to separate protein by size and charge using SDS-PAGE which performed by using Mini Protean® 3 
Cell (Bio-Rad Laboratories Ltd., UK). Gels were run at 40mA for more than 1 hour or until the stain 
reached the bottom of the gel. 
 
2.1.17.4 Western blotting 
The tank and all equipment required to perform transfer were prepared, and foam pads, filter papers, 
and nitrocellulose hybond ECL membranes (Amersham GE Healthcare, UK) were soaked into 1x Novex 
Tris-Glycine Transfer Buffer (Life Technologies, UK) for 15 minutes prior to transfer cassette assembly. 
After protein being separated by SDS-PAGE, the gel containing separated protein was removed 
carefully from the glass plate and placed into 1x transfer buffer for 5 minutes. The transfer sandwich 
was built from negative to positive charge. The foam pad has been put on a first layer followed by two 
pieces of Whatman chromatography filter paper, the SDS-PAGE gel was then placed and subsequently, 
nitrocellulose membrane positioned above, two pieces of Whatman chromatography filter paper formed 
the 5th layer, and foam pad formed the 6th layer. The cassette was closed and placed in mini trans-blot 
electrophoretic transfer cell (Bio-Rad Laboratories Ltd, UK) with an ice pack to keep transfer process 
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cool. The tank was filled with transfer buffer and run at 100V for one hour. After protein had been 
moved to nitrocellulose membrane, the latter was washed with 1x TBS and blocked overnight with 3% 
(v/v) BSA in Tris Buffered Saline Tween 20 (0.1% (v/v) Tween) (TBST) at 4ºC. The membrane was 
then washed three times with 1x TBS for 5 minutes each and subsequently incubated with primary 
antibody diluted in TBST containing 0.5% (v/v) BSA for 1.5 hours at room temperature. The primary 
antibodies used are Akt 1/2/3 mouse monoclonal (1:500), AMPKα 1/2 mouse monoclonal (1:500), pAkt 
1/2/3 mouse monoclonal (1:250), and pAMPKα 1/2 Thr172 rabbit polyclonal (1:250) (Santa Cruz 
Biotechnology Inc., Germany). Following that the membrane was washed five times with TBST 5 
minutes each and one time with TBS for 5 minutes. Incubation with secondary antibody was performed 
for one hour at room temperature using goat anti-mouse IgG-HRP (1:5000) for all mouse monoclonal 
primary antibodies, and goat anti-rabbit IgG-HRP (1:5000) for rabbit polyclonal primary antibody (all 
purchased from Santa Cruz Biotechnology Inc., Germany). After incubation with the secondary 
antibody, the membrane was washed with TBST five time for five minutes each and one time with TBS 
for five minutes. The excess wash solution was removed and an equal volume of reagent A and B of 
Enhanced Chemiluminescence substrate (ECL) (Geneflow, UK) were mixed and applied to cover the 
membrane (0.1ml/cm2) for 5 minutes in a dark room. The excess ECL substrate was drained and the 
membrane was developed and visualised using a G-box transilluminator (Syngene). Protein bands 
intensity were quantified using Image J software (ImageJ, NIH). The analysed data were normalised to 
total Akt 1/2/3 and total AMPKα 1/2 band intensity.     
    
2.2 Analysis of green tea consumption in mice 
2.2.1 Animal care and housing 
48 male C57BL/6J mice aged 6-8 weeks were purchased from Charles River, UK, and housed in an 
animal unit of Aston University, School of Life and Health Sciences. All experiments were conducted 
under research ethics regulations and approved by Aston University Ethics Committee, Birmingham, 
UK, and the project licence reference is PPL30/3253. Mice were maintained under standard conditions 
12:12 h light/dark cycle, 20ºC ± 1ºC temperature, and 50% ±10% humidity. Mice were allowed to adapt 
to the new environment for five days before any treatment with free access to tap water and chow (Rat 
and Mouse No 3 Breeding (RM3), Special Dietary Services (SDS), UK).  
 
2.2.2 Experimental design and treatment   
After five days of acclimatisation, mice were separated into two main groups of 24 for experiments 
one and two. Following that, mice of each main group were then randomly divided into four groups with 
each group containing six mice housed in two separate cages. For experiment one (1), all four groups 
had free access to standard chow and controlled access to water containing the treatment compounds for 
four weeks. The groups were control group (C) which received only vehicle (1% (v/v) DMSO, Fisher 
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Scientific, UK) with drinking water, decaffeinated green tea extract group (DGTE) received 50mg/kg/ 
day decaffeinated green tea extract (Sigma Aldrich, UK originally from U.S. Pharmacopeial 
Convention, USA) with drinking water. EGCG group received 10mg/kg/day EGCG (Tocris Bioscience, 
UK), and green tea extract (GTE) group received 100mg/kg/day commercial green tea extract 
(Blackburn distributions, UK). For experiment two (2), all four groups had similarly free access to chow 
and controlled access to glucose supplemented water containing treatment for four weeks. The groups 
of experiment 2 were treated the same as treatment provided to groups of experiment 1 except the 
drinking water in experiment 2 containing 30% (w/v) D-glucose (Sigma Aldrich, UK) to produce a 
hypercaloric diet. Mice distribution and treatment for this work appears in Figure 2.3.      
 
2.2.3 Blood sampling and tissue harvesting 
At the end of the experiment, mice were fasted overnight and sacrificed by cervical dislocation. 
Blood was collected for all groups and subjected to clot, centrifuge and serum obtained for measuring 
insulin and total cholesterol. Organs and tissues including liver, heart, brain, kidneys, skeletal muscle, 
visceral adipose tissue, subcutaneous adipose tissue, and intra-scapular adipose tissue were dissected 
carefully by Adam Watkins. All organs and tissues weight were measured and stored at -80ºC. 
 
2.2.4 Glucose tolerance test (GTT) 
A glucose tolerance test (GTT) was performed for all mice at days 0 and 28 days. Briefly, mice were 
fasted overnight (16h) before a bolus of 2g/kg of D-glucose solution was injected intraperitoneally (IP). 
The blood glucose levels were measured using GlucoRx nexus blood glucose monitor kit TD 4277 
(pharmacy link, UK) at time 0 before glucose injected (fasting blood glucose) and at 15, 30, 60, and 120 
minutes after glucose solution injection by sampling blood from the tip of the tail of all mice. Fasting 
blood glucose (FBG), glucose area under the curve (gAUC), and the level of blood glucose after 2h of 
GTT were recorded, calculated, and analysed for all mice groups. The test was performed by Adam 
Watkins. 
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Figure 2.3 Mice experimental design. 
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2.2.5 Measurement of circulating insulin  
This study was designed to investigate circulating insulin levels alongside the level of glucose during 
GTT at day 0 and 28 days after treatment for all mice groups. However, it was difficult to obtain a 
sufficient volume of blood from the tip of the tail for both glucose and insulin (Bowe, et al., 2014). 
Thus, the level of insulin was measured for all groups only at the end of the experiment. Mice fasted 
overnight, and blood was collected from them after sacrifice. Blood samples were allowed to clot and 
quickly centrifuged at 2000 RCF for 10 minutes at 4ºC. A clear serum supernatant was aspirated and 
stored at -80ºC. Subsequently, the concentration of fasting serum insulin was assayed in the samples 
using a mouse insulin ELISA kit (Mercodia, Sweden) according to the manufacturer’s protocol. This 
sandwich enzymatic immunoassay is a colorimetric-based assay which detects insulin molecules in the 
samples through direct sandwich ELISA technique. Briefly, the insulin in the sample reacts with 
peroxidase conjugated mouse monoclonal anti-insulin enzyme which is conjugated with anti-insulin 
antibodies that bounded to wells surfaces. An unbounded enzyme that labelled antibodies was removed 
by washing followed by initiating the reaction to detect bounded conjugate through additional 3,3’5,5’-
tetramethylbenzidine (TMB) substrate. Acid was used to stop this reaction followed by optical density 
measurement at 450nm. Briefly, 1x of enzyme conjugate reagent was prepared by mixing one part of 
enzyme conjugate 11x with ten parts of enzyme conjugate buffer, which were all supplied with the kit. 
1x of washing buffer was also prepared through diluted 21x wash solution that was supplied with the 
kit using doubled distilled water. The standard reagents supplied with the kit are ready to use, and the 
concentrations are 0, 0.2, 0.5, 1.5, 3, and 6.5µg/l. 10µl/well of standards and samples were transferred 
to a special plate coated with mouse monoclonal anti-insulin in duplicate. 100µl/well of 1x enzyme 
conjugate solution was added, and the plate was sealed and incubated for 2h at room temperature on 
plate shaker 800 rpm. After incubation, the plate was washed six times using 350µl/well washing buffer, 
then 200µl/well of TMB substrate was added, and the plate was incubated for 15 minutes at room 
temperature. The reaction was stopped after 15 minutes through applying 50µl/well of 0.5M of H2SO4 
stopping solution followed by shaking the plate for 5 seconds to enhance mixing, and the optical density 
was read at 450nm using Multiscan (Thermo Scientific®) plate reader. 
 
2.2.6   Calculation of homoeostasis model assessment (HOMA) 
Homeostatic modelling including homoeostasis model assessment-insulin resistance (HOMA-IR), 
homoeostasis model assessment-beta cell function (HOMA-B), and homoeostasis model assessment-
insulin sensitivity (HOMA-S) were calculated from data obtained from fasting glucose and insulin for 
all mice after 28 days of treatment. These homeostatic models have been calculated using computerised 
HOMA calculator two software version 2.2.3 (Oxford University, Diabetes Trial Unit, Oxford Centre 
for Diabetes, Endocrinology and Metabolism, UK). HOMA is a simple, inexpensive, and reduced time 
consuming model compared to euglycemic clamp test. The model is developed by Matthews in 1985 to 
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measure insulin sensitivity in human clinical cases based on strong correlation between the levels of 
insulin and glucose in fasting status. Several studies validated this model to measure insulin sensitivity 
and beta cell function in human (Chang, et al., 2006), with limited study showed accurate using this 
model to calculate insulin sensitivity in rodent, however the limitation is due to the metabolic differences 
between human and rodent (Antunes, et al., 2016).   
 
2.2.7 Measurements of weight gain, food and water consumption 
The body weight of mice in all eight groups was measured before intervention (week 0), and every 
week during the experiment. Total body weight gain of each group (control and treated) was calculated 
at the end of the experiment by subtracting body weight at week 0 from body weight at week 4. Similarly, 
consumption of chow and water containing treatment were measured and recorded each week during 
the intervention for all groups. The average mouse chow and water consumption were calculated each 
week for each group. As treatments were administrated with drinking water, and due to the inherent lack 
of control on the water volume consumed, the proposed treatments concentration that has been used 
were inaccurate. Therefore, the actual average concentration of treatments (DGTE, EGCG, and GTE) 
for each mouse was calculated based on the mean volume of water consumed by mouse per day. 
 
2.2.8 Circulating lipid profile 
The original design of the experiment was proposed to determine lipid profile of all mouse groups 
before treatment and 28 days after administrated treatment. However, due to the limited blood volume 
obtainable from the tip of the tail of each mouse, the measurement of lipid profile was assessed only 
after 28 days of treatment. Mice fasted overnight, the level of triglyceride (TG) and high-density 
lipoprotein (HDL) were determined in obtained blood using CardioChek® P.A analyser and lipid PTS 
panels (RedMed™, Poland). Briefly, the panel chip and lipid panel test strips were attached to their 
places on the analyser. A 50µl blood sample was loaded onto the test strip, and after 2 minutes the 
measurements were displayed. Total cholesterol (TC) in mice serum samples was detected separately 
by using the EnzyChrom™ Cholesterol Assay Kit (BioAssay System, Universal Biologicals Ltd., UK). 
This colorimetric assay is based on measurement the density of reduced form of Nicotinamide adenine 
dinucleotide (NAD) which is NADH. First, cholesterol esters are hydrolyzed to free cholesterol by 
cholesterol esterase; then cholesterol dehydrogenase catalysed free cholesterol to cholest-4-ene-3-one 
which reduced NDA to form NADH which is proportional to total cholesterol in the sample. Finally, 
the calculated Low-Density Lipoprotein (cLDL) was calculated from the existing data obtained (total 
cholesterol, TG, and HDL) using Friedewald formula (FF) which is cLDL= TC-HDL-TG/5 LDL 
(Friedewald, et al., 1972;Knopfholz, et al., 2014).  
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2.2.9 Total RNA extraction and reverse transcription 
Total RNA of mouse liver, adipose tissue, and skeletal muscle was extracted using Ambion/RNA 
Trizol® Reagent (Life Technologies, UK) following the manufacturer’s protocol. Briefly, more than 
100mg of tissue (liver, adipose tissue, and skeletal muscle) were homogenised in 1ml Trizol reagent in 
an ice bath using IKA® T10 basic homogenizer (IKA® WERKE GMBH &CO. KG., Germany). The 
homogenised samples were centrifuged at 12,000RCF for 10 minutes at 4ºC to remove all insoluble 
materials. The supernatant which contains RNA was aspirated and placed in 1.5ml PCR microcentrifuge 
tube, and RNA was isolated following the procedure mentioned previously in section 2.1.15. RNA was 
then quantified, all samples were treated with RNase-free DNase (Qiagen, UK) to remove genomic 
contamination. Reverse transcription was performed as mentioned previously and 500ng for liver and 
skeletal muscle, and 100ng for adipose tissue RNA samples were used for cDNA synthesis. 
 
2.2.10  Real-time polymerase chain reaction (PCR) 
SYBR® Green qPCR was performed for liver, skeletal muscle, and adipose tissue cDNA samples 
following the protocol mentioned in section 2.1.16. The specific target genes are mouse IR, Gys1, Glut2, 
G6Pase, PEPCK, CPT1α, and FASN for the liver. Also IR, Glut4, Gys1, PDK4, and PGC1α for skeletal 
muscle, and IR, Glut4, SREBP1c, C/EBPα, PPARγ, FABP4, FASN, and LPL, in addition to Actin. The 
sequences of these primers are mentioned in Table 2.1. 
  
2.3 Statistical analysis 
Statistical analysis was performed using Graph Pad Prism version 6 software (Inc., USA). All data 
were presented as means ± standard error of the mean (SEM) in triplicate of 3 independent experiments. 
The statistical analysis between experimental statuses of all presented data was determined by one-way 
analysis of variance (ANOVA) followed by Tukey’s post-hoc test for multiple comparisons unless 
otherwise states. The differences were considered significant at p values< 0.05 as specified by *, p 
values< 0.01 are specified by **, p values< 0.001 are specified by ***, and p values <0.0001 are 
specified by ****. 
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3.1 Introduction 
The human body can maintain blood glucose within the normal physiological levels through 
balancing glucose entering the circulation and removing excess glucose from the circulation during 
various conditions including fed and fast states. This homeostatic process is under tight hormonal control 
under normal circumstances, specifically relying on insulin and glucagon in addition to insulin and 
glucagon sensitive tissues including hepatic, skeletal muscles, and adipose tissue, as well as insulin 
insensitive tissues like stomach, gut, brain, and pancreas (Aronoff, et al., 2004). After a meal, elevated 
circulatory blood glucose levels stimulate pancreatic beta-cells to secrete insulin into the bloodstream 
through a process called GSIS (Gong and Muzumdar, 2012). Once insulin is released, the metabolically 
sensitive tissues accelerate glucose uptake and reduce endogenous glucose output to restore the normal 
blood glucose level. This cellular glucose can be converted to glycogen which is stored in hepatic tissue 
and consumed in skeletal, muscular tissue due to daily energy requirements, whereas adipose tissue 
metabolises glucose and stores it in the form of triglyceride (Aronoff, et al., 2004;Saltiel and Kahn, 
2001). 
 
Disruption of glucose homoeostasis either due to inadequate insulin secretion and/or insulin 
insensitivity leads to metabolic disturbance and eventually T2D. It is well known that this disease is 
characterised by hyperglycaemia associated with or without hyperinsulinaemia due to insulin resistance 
and continuous glucose released from the liver and adipose tissue (Gerich, 2000;Zhang, et al., 2013a). 
Although significant research into the fundamental biology of T2D has been performed in recent 
decades, it is still poorly understood and ‘incurable’ and considered a common and major health concern.  
 
There exist several different types of anti-diabetic drug that have been developed and approved to 
managed hyperglycaemia in diabetic conditions. These include sulfonylureas, biguanides, α-glucosidase 
inhibitors, thiazolidinediones,  meglitinides,  amylin analogues, and dipeptidyl peptidase 4 (DPP4) 
inhibitors (Distefano and Watanabe, 2010). However, metformin is the most commonly prescribed drug 
which has been used to manage high blood glucose levels primarily via suppression of hepatic glucose 
output in diabetic patients (Zhou, et al., 2001). Green tea and its active compounds have been reported 
to have a broad range of health benefits, including claims of anti-diabetic properties (Babu, et al., 2013). 
Like agents that sensitise to insulin, green tea and its ingredients appear to possibly regulate glucose 
homoeostasis through increasing glucose uptake that is enhanced by expression of Glut2 and 4 in 
insulin-sensitive tissues (Hanhineva, et al., 2010). Furthermore, they regulate glucose utilisation in 
hepatic tissue by inhibiting glucose production through a direct effect on PEPCK and G6Pase, as well 
as increased insulin sensitivity (Babu, et al., 2013). This anti-diabetic action of green tea could be 
promoted by activation of the AMPK or/and PI3K signalling pathways (Zhang, et al., 2010).   
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The aims of the research described in this chapter are 
• To investigate the effect of individual active compounds of green tea including EGCG, EC, 
ECG, myricetin, quercetin, and combination of all these compounds together on glucose and 
lipid metabolism in vitro. 
• To investigate the regulation of metabolic gene expression by active compounds of green tea 
including EGCG, EC, ECG, myricetin, quercetin, and combination of all these compounds 
together 
• To identify the potential role of the AMPK and Akt signalling pathways in any effects that 
are caused by exposure to active compounds of green tea.  
 
 
3.2 Materials and methods 
All materials and methods of three insulin-sensitive cell lines included AML12, C2C12, and 3T3L1 
related to in vitro study were mentioned in detail in chapter two (Materials and Methods). These are 
glucose assay, cellular fluorescence glucose analogue uptake (2-NBDG), Rt. PCR, SDS-PAGE, and cell 
viability assay for all cell lines, in addition to glycogen assay of AML12 cell line only, free glycerol 
released, Oil red O staining, triglyceride assay for mature 3T3-L1.  
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3.3 Results 
Both C2C12 and 3T3-L1 are undifferentiated cell lines and therefore require differentiation before 
they are suitable to study glucose metabolism. Thus, these cells were differentiated before any 
experimental work commenced. The process of differentiation of C2C12 may take four to eight (or nine) 
days, following the process described in chapter two. This process was observed under a light 
microscope and was based on morphological changes including cellular elongation and tubular 
formation (Figure 3.1). Alternatively, 3T3-L1 pre-adipocyte differentiation takes approximately 15 
days, the process of which is also described in chapter two.  Accumulation of lipid droplets was observed 
during the differentiation process until the cells expressed increased in number and size of lipid droplets 
(Figure 3.2).  
  
   
   
Figure 3.1 Mouse myoblast (C2C12) cell line differentiation. 
Differentiation of C2C12 cells was performed as mentioned previously in tissue culture materials 
and methods before any experiment to study the effect of green tea active compounds on glucose 
metabolism. (A) C2C12 cells at day 0. (B) Day 3 of differentiation. (C) Day 5 of differentiation. (D) 
Day 8 of differentiation. The images were captured using Leica DMI4000 B inversion microscope at 
100x magnification. 
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Figure 3.2  Mouse pre-adipocyte (3T3-L1) cell line differentiation. 
Differentiation process of 3T3-L1 cells was performed as mentioned previously in tissue culture 
materials and methods before any experiment to study the effect of green tea active compounds on 
glucose and lipid metabolism. (A) Day 0 of differentiation. (B) Day 3 of differentiation, some cells show 
visible small lipid droplets. (C) Day 6 of differentiation, the numbers and sizes of lipid droplet is 
increased. (D) Day 9 of differentiation, the cells showed an increase in the size of lipid droplets. (E, F) 
Day 12, 15 of the differentiation process. The images were captured using Leica DMI4000 B inversion 
microscope at 100x magnification. 
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3.3.1 Selected compounds of green tea increased glucose uptake in C2C12 cells 
Measurement of glucose concentration in cell supernatant is indirect technique used to estimate 
cellular glucose uptake, with decreased glucose concentration in supernatant being indicative of an 
increase in cellular glucose uptake (Drira and Sakamoto, 2013). Regulation of glucose uptake in 
differentiated C2C12 cells was investigated. Cells were treated with several active compounds of green 
tea including EGCG, EC, ECG, myricetin, quercetin, and the combination of (EGCG, EC, ECG, 
myricetin, and quercetin) at various concentrations (0.1, 1, and10µM) at specified time points (24, 48, 
and 72h). The results showed that EGCG, EC, and ECG at 1 and 10µM induced significant increases of 
glucose uptake by 36.47%±4.3% (p=0.0191), 37.30%±2. 2% (p=0.0150), 38.33%±4.5% (p<0.0001), 
41%±3.58% (p<0.0001), 47.26%±5.16% (p<0.0001), 47.58%±5.17% (p<0.0001) respectively after 48h 
(Figure 3.4) and 45.14%±8.81% (p<0.0001), 55.70%±13.93% (p<0.0001), 56.77%±6.57% (p<0.0001), 
46.12%±2.38% (p<0.0001), 51.74%±5.66% (p<0.0001), 48.76%±6.37% (p<0.0001) respectively after 
72h (Figure 3.5) compared to control. Cellular glucose uptake was unaffected by myricetin, quercetin, 
and combination of green tea compounds at all concentrations and time points. Neither green tea 
compounds nor concentrations caused any significant effect on glucose uptake after 24h of intervention 
(Figure 3.3). 
 
3.3.2 Selected compounds of green tea increased glucose uptake in 3T3-L1 cells 
The impact of several active compounds of green tea on glucose uptake in adipose cells was 
investigated by exposing the differentiated 3T3-L1 cells to 0.1, 1, and 10µM of EGCG, EC, ECG, 
myricetin, quercetin, and the combination of these compounds for 24, 48, 72h.  Cells showed significant 
response and increased glucose uptake by 38.2%±3.46% (p=0.0001), 37.7%±6.81% (p=0.0002), 
37.86%±6.1% (p=0.0002), 34%±6.95% (p=0.0013), 49.72%±16% (p<0.0001), 41.57%±6.5% when 
treated with only 1 and 10µM of EGCG, EC, and ECG after 48h respectively (Figure 3.7) and by 
57.9%±13.43% (p<0.0001), 54.7%±13.16% (p<0.0001), 55.4%±13% (p<0.0001), 51.76%±10.63% 
(p<0.0001), 56.87%±11.6% (p<0.0001), 48.41%±10% (p<0.0001) after 72h respectively compared to 
control (Figure 3.8). No effects were mediated by myricetin, quercetin, and the combination of green 
tea compounds at all concentrations during the same incubation periods. Similarly, no effect of all green 
tea compounds on glucose uptake was observed after 24h incubation (Figure 3.6).   
 
3.3.3 Selected compounds of green tea increased glucose uptake in AML12 cells 
The role of green tea active ingredients on indirect cellular glucose uptake in AML12 was determined 
by treating the cells with 0.1, 1, 10, 20µM of EGCG, EC, ECG, myricetin, quercetin, and the 
combination of these compounds for 24, 48, 72h. After 24h incubation only, insulin and ECG at 10µM 
significantly increased glucose uptake by 23.4%±2.7% (p<0.0001) and 23.3%±4% (p<0.0001) (Figure 
3.9). Whilst no effect of all green tea compounds on glucose uptake was observed after 48h, except 
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insulin increased glucose uptake by 29.7%±1% (p=0.0078) compared to control and 30.2%±2.1% 
(p=0.0055) compared to DMSO (Figure 3.10). Significant effects were exhibited after 72h intervention, 
ECG and combination of green tea compounds at 1 and 10µM elevated glucose uptake by 35%±1.1% 
(p<0.0001), 33.4%±3.55% (p<0.0001), 33.6%±0.9% (p<0.0001), and 37.7%±1.25% (p<0.0001) 
respectively. Similar effects were mediated by quercetin at 1, 10, and 20µM which caused 62.8%±6% 
(p<0.0001), 44.3%±3.5% (p<0.0001), and 43.2%±5.55% (p<0.0001) increases in glucose uptake 
respectively compared to control. EC at only 1µM increased glucose uptake by 34.4%±5.6% (p<0.0001) 
compared to control (Figure 3.11).  
 
 
Figure 3.3 Green tea compounds and glucose uptake in C2C12 cells. 
C2C12 cells were seeded in 24 well plate at density 2x105 and incubated in standard conditions until 
reached 80% confluency. Differentiation was induced, and the cellular glucose uptake was assessed by 
measuring amount of glucose remained in culture media after treated cells with different concentrations 
and compounds of green tea for 24h. No effect of these compounds on glucose uptake was observed 
compared to control. Data presented mean ± SEM, ***p<0.001, ****p<0.0001, n=3. 
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Figure 3.4 Selected green tea compounds increase glucose uptake in C2C12 cells. 
C2C12 cells were seeded in 24 well plate at density 2x105 and incubated in standard conditions until 
reached 80% confluency. Differentiation was induced, and cellular glucose uptake was assessed by 
measuring amount of glucose remained in culture media after cells treated with different concentrations 
and compounds of green tea for 48h. EGCG, EC, and ECG significantly increased cellular glucose 
uptake compared to control. Data presented mean ± SEM, ***p<0.001, ****p<0.0001, n=3. 
 
Figure 3.5 Selected green tea compounds increase glucose uptake in C2C12 cells. 
C2C12 cells were seeded in 24 well plate at density 2x105 and incubated in standard conditions until 
reached 80% confluency. Differentiation was induced, and cellular glucose uptake was assessed by 
measuring amount of glucose remained in culture media after treated cells with different concentrations 
and compounds of green tea for 72h. EGCG, EC, and ECG significantly increased cellular glucose 
uptake compared to control. Data presented mean ± SEM, ***p<0.001, ****p<0.0001, n=3.  
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Figure 3.6 Green tea compounds and glucose uptake in 3T3-L1 cells. 
3T3L1 cells were seeded in 24 well plate at density 1.5x104 and incubated in standard conditions 
until completed confluency. Differentiation was induced, and cellular glucose uptake was assessed by 
measuring amount of glucose remained in culture media after exposed cells to different concentrations 
and compounds of green tea for 24h. No effect of these compounds on glucose uptake was observed 
compared to control. Data presented mean ± SEM, **p<0.01, ****p<0.0001, n=3. 
 
Figure 3.7 Selected green tea compounds increase glucose uptake in 3T3-L1 cells. 
3T3L1 cells were seeded in 24 well plate at density 1.5x104 and incubated in standard conditions 
until completed confluency. Differentiation was induced, and cellular glucose uptake was assessed by 
measuring amount of glucose remained in culture media after exposed cells to different concentrations 
and compounds of green tea for 48h. EGCG, EC, and ECG significantly increased cellular glucose 
uptake compared to control. Data presented mean ± SEM, ***p<0.001, ****p<0.0001, n=3. 
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Figure 3.8 Selected green tea compounds increase glucose uptake in 3T3-L1 cells. 
3T3L1 cells were seeded in 24 well plate at density 1.5x104 and incubated in standard conditions 
until completed confluency. Differentiation was induced, and cellular glucose uptake was investigated 
by measuring amount of glucose remained in culture media after exposed cells to different 
concentrations and compounds of green tea for 72h. EGCG, EC, and ECG significantly increased 
cellular glucose uptake compared to control. Data presented mean ± SEM, **p<0.01***p<0.001, 
****p<0.0001, n=3. 
 
Figure 3.9 Selected green tea compounds increase glucose uptake in AML12 cells. 
AML12 cells were seeded in 24 well plate at density 2x105 and incubated in standard conditions until 
completed confluency. Cellular glucose uptake was investigated by measuring the amount of glucose 
remained in culture media after exposed cells to different concentrations and compounds of green tea 
for 24h. Only ECG at 10µM significant increased cellular glucose uptake compared to control. Data 
presented mean ± SEM, ****p<0.0001, n=3. 
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Figure 3.10 Green tea compounds and glucose uptake in AML12 cells. 
AML12 cells were seeded in 24 well plate at density 2x105 and incubated in standard conditions until 
completed confluency. Cellular glucose uptake was assessed by measuring amount of glucose remained 
in culture media after exposed cells to different concentrations and compounds of green tea for 48h. No 
effect of these compounds on glucose uptake was observed compared to control. Data presented mean 
± SEM, **p<0.01, n=3. 
 
Figure 3.11 Selected green tea compounds increase glucose uptake in AML12 cells. 
AML12 cells were seeded in 24 well plate at density 2x105 and incubated in standard conditions until 
completed confluency. Cellular glucose uptake was investigated by measuring the amount of glucose 
remained in culture media after exposed cells to different concentrations and compounds of green tea 
for 72h. The result showed a significant increase of cellular glucose uptake responding to EC, ECG, 
quercetin, and combination compared to control. Data presented mean ± SEM, ****p<0.0001, n=3. 
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3.3.4 The role of AMPK and Akt in enhanced glucose uptake in C2C12 cells by green 
tea compounds  
The role of the AMPK and Akt signalling pathways in the glucoregulatory effects of selected green 
tea compounds that increased glucose uptake in C2C12 cells were investigated by co-incubating cells 
with specific AMPK or Akt inhibitor molecules in addition to green tea compounds. Differentiated 
C2C12 cells were treated with 1 and 10µM of EGCG, EC, and ECG with and without AMPK or Akt 
inhibitor molecules for 48 and 72h. 1 and 10µM EGCG increased glucose uptake by 36.5%±4.3% 
(p=0.0069), 37.3%±2.2% (p=0.0051) after 48h and 45.14%±4.8% (p<0.0001), 55.7%±14% (p<0.0001) 
after 72h. Co-incubation with AMPK or Akt inhibitors alongside 1 and 10µM EGCG for 48h produced 
significant reductions of glucose uptake compared to EGCG alone, in response to AMPK inhibition. 
The recorded reductions were: 48.6%±13% (p<0.0001) and 73%±11.7% (p=0.0002) (Figure 3.12 A). 
Both AMPK and Akt inhibitors incubated alongside 1 and 10µM EGCG significantly decreased glucose 
uptake after 72h incubation. These decreases were: 65.9%±5.3% (p <0.0001) and 124.2%±5.1% 
(p<0.0001) by AMPK inhibitor, 40.6%±3.4% (p=0.0242) and 49.7%±4.7% (p=0.0273) by Akt (Figure 
3.12 B). EC at 1 and 10µM significantly elevated glucose uptake by 38.33%±6.5% (p<0.0001) and 
41%±3.6% respectively (p<0.0001) after 48h, and by 56.8%±6.6% (p<0.0001) and 46.1%±2.4% 
(p<0.0001) after 72h. These increases were inhibited by 74.3%±12.6% (p<0.0001) and 56.5%±2.6% 
(p=0.0003) through inhibition AMPK for 48h (Figure 3.13 A), whereas both AMPK and Akt inhibitors 
significantly suppressed glucose uptake by 123.8%±6.4% (p<0.0001) and 100.4%±6.5% (p<0.0001), 
60.9%±5.2% (p=0.0031), and 39.3%±1.9% (p=0.0413) after 72h respectively (Figure 3.13 B). Similarly, 
1 and 10µM ECG mediated 47.3%±5.2% (p<0.0001), 47.6%±5.2% (p <0.0001), 51.7%±5.7% 
(p<0.0001), and 48.8%±6.4% (p<0.0001) increases in glucose uptake after 48 and 72h. Inhibition of 
AMPK suppressed these increases in glucose uptake by 103.3%±9.7% (p<0.0001) and 63.8%±3.2% 
(p<0.0001) after 48h (Figure 3.14 A), while both AMPK and Akt inhibitors caused 87%±6.2% 
(p<0.0001), 122.8%±5.4% (p<0.0001), 59.8%±15.5% (p=0.0171), and 55%±2.4% (p=0.00224) 
decrease in glucose uptake compared to treatment alone after 72h intervention (Figure 3.14 B).   
 
3.3.5 The role of AMPK and Akt in enhanced glucose uptake in 3T3-L1 cells by green 
tea compounds   
The role of AMPK and Akt was also examined in adipocyte glucose uptake in response to selected 
green tea active compounds. Mature 3T3-L1 cells were co-cultured with 10µM of AMPK or Akt 
selective inhibitor molecules alongside 1 and 10µM of EGCG, EC, and ECG that increased glucose 
uptake previously for 48 and 72h. EGCG at 1 and 10µM caused 38.2%±3.5% (p<0.0001), 37.8%±6.8% 
(p<0.0001), 57.9%±13.4% (p<0.0001), and 54.7%±13.2% (p<0.0001) increases in glucose uptake 
compared to control after 48 and 72h respectively. These increases were significantly inhibited by the 
Akt inhibitor only and estimated reductions were 45.5%±5.9% (p=0041), 49.5%±1.5% (p=0.0010), 
92 
 
117.8%±13.5% (p<0.0001), and 90.5%±8.4% (p=0.0022) after 48 and 72h incubation respectively 
(Figure 3.15). A similar effect was observed when the cells were treated with 1 and 10µM of EC. This 
compounds caused 37.9%±6.1% (p<0.0001), 34%±7% (p=0.0012), 55.4%±13% (p<0.0001), and 
51.8%±10.6% (p<0.0001) increases in glucose uptake after 48 and 72h incubation. These increases in 
glucose uptake were suppressed by 57.5%±6.7% (p=0.0005), 57.6%±7.2% (p=0.0002), 102.2%±11% 
(p<0.0001), and 72.9%±7.9% (p=0.0032) when the cells were exposed to the Akt inhibitor after 48 and 
72h incubation respectively (Figure 3.16). Furthermore, 1 and 10µM ECG significantly increased 
glucose uptake by 49.7%±15.9% (p<0.0001), 41.6%±6.5% (p<0.0001), 59.2%±12.4% (p<0.0001), and 
60.6%±10.3% (p<0.0001) after 48 and 72h incubation compared to control. Co-incubation with the Akt 
inhibitor significantly reduced glucose uptake compared to treatment alone, with reductions of 
59.6%±7.5% (p=0.0104), 49%±6.3% (p=0.0179), 86.6%±7.3% (p=0.0084), and 95%±8.4% (p=0.0039) 
after 48 and 72h respectively being recorded (Figure 3.17). Alternately, co-incubation with an AMPK 
inhibitor alongside green tea treatments for 48 and 72h did not significantly change glucose uptake rates. 
 
3.3.6 The role of AMPK and Akt in enhanced glucose uptake in AML12 cells by green 
tea compounds  
The role of AMPK and Akt signalling pathways on selected compounds of green tea that enhanced 
glucose uptake in AML12 cells were explored through co-incubating cells with 10µM of selective 
AMPK or Akt inhibitor molecules in the presence of green tea compounds that previously produced 
significant increases glucose uptake. The impact of EC, ECG, quercetin, and combination of 
experimental green tea compounds in AML12 cells was only apparent after 72h treatment with no 
significant effect displayed before that, except ECG at 10µM after 24h. The latter compound 
significantly increased glucose uptake by 16.8%±1.95% (p=0.0009), and this amount was suppressed 
by adding an Akt inhibitor, which reduced glucose uptake by 16.4%±4% (p=0.0135) (Figure 3.18). EC 
at 1µM for 72h significantly increased glucose uptake by 32.4%±7.4% (p=0.0086), which was reduced 
by 48.5%±9.5% by the action of the Akt inhibitor molecule (p=0.0076, Figure 3.19). Also, 1 and 10µM 
of ECG increased glucose uptake by 30.2%±7.3% (p=0.0011) and 29.9%±5.6% (p=0.0021) respectively 
after 72h, and Akt inhibition suppressed this by 37%±5.3% (p=0.0087) and 42%±6.6% (p=0.0027) 
respectively (Figure 3.20). A combination of green tea compounds increased glucose uptake at 1 and 
10µM up to 38.2%±4.8% (p=0.0002) and 35.75%±3.6% (p=0.0005) after 72h incubation respectively. 
Again the Akt pathway seemed to be involved in this effect by suppressing glucose uptake by 
45.8%±9.8% (p=0.0040) and 52.8%±9.8 (p=0.0011) respectively, compared to treatment alone (Figure 
3.21). Furthermore, quercetin at 1, 10, and 20µM caused 34.3%±5.6% (p=0.0005), 41.8%±2.8% 
(p=0.0008), and 34.2%±5.6 (p=0.0008) increases in glucose uptake after 72h incubation respectively, 
whilst Akt inhibition significantly decreased this by 45.8%±7.9% (p=0.0033), 67%±12.6% (p=0.0022), 
and 53.4%±7.3% (p=0.0004) respectively (Figure 3.22 and Figure 3.23). 
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Figure 3.12 AMPK and Akt inhibitors reduce EGCG induced glucose uptake in C2C12 cells. 
C2C12 cells were seeded in 24 well plate at density 2x105 and incubated in standard conditions until 
reached 80% confluency. Differentiation was induced, and cells were treated with EGCG in presence 
and absence AMPK or Akt inhibitor, followed by estimating glucose uptake through measuring glucose 
remained in the media. (A) EGCG significantly increased glucose uptake compared to control, and this 
effect was significantly inhibited by AMPK inhibitor after 48h. (B) EGCG significantly increased 
glucose uptake compared to control, and this effect was significantly inhibited by AMPK and Akt 
inhibitors after 72h, and strongest effect mediated by AMPK inhibitor. Data presented mean ± SEM, 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, n=3. 
94 
 
 
 
Figure 3.13 AMPK and Akt inhibitors reduce EC induced glucose uptake in C2C12 cells. 
C2C12 cells were seeded in 24 well plate at density 2x105 and incubated in standard conditions until 
reached 80% confluency. Differentiation was induced, and cells were treated with EC in presence and 
absence AMPK or Akt inhibitor, followed by estimating glucose uptake through measuring glucose 
remained in the media. (A) EC significantly increased glucose uptake compared to control, and this 
effect was significantly inhibited by AMPK inhibitor after 48h. (B) EC significantly increased glucose 
uptake compared to control, and this effect was significantly inhibited by AMPK and Akt inhibitors 
after 72h, and strongest effect mediated by AMPK inhibitor. Data presented mean ± SEM, *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001, n=3. 
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Figure 3.14 AMPK and Akt inhibitors reduce ECG induced glucose uptake in C2C12 cells.  
C2C12 cells were seeded in 24 well plate at density 2x105 and incubated in standard conditions until 
reached 80% confluency. Differentiation was induced, and cells were treated with ECG in presence and 
absence AMPK or Akt inhibitor, followed by estimating glucose uptake through measuring glucose 
remained in the media. (A) ECG significantly increased glucose uptake compared to control, and this 
effect was significantly inhibited by AMPK inhibitor after 48h. (B) ECG significantly increased glucose 
uptake compared to control, and this effect was significantly inhibited by AMPK and Akt inhibitors 
after 72h, and strongest effect mediated by AMPK inhibitor. Data presented mean ± SEM, *p<0.05, 
****p<0.0001, n=3. 
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Figure 3.15 Akt inhibitor reduces EGCG induced glucose uptake in 3T3-L1 cells.  
3T3L1 cells were seeded in 24 well plate at density 1.5x104 and incubated in standard conditions 
until completed confluency. Differentiation was induced, and cells were treated with EGCG in presence 
and absence AMPK or Akt inhibitor, followed by estimating glucose uptake through measuring glucose 
remained in the media. (A) EGCG significantly increased glucose uptake compared to control, and this 
effect was significantly inhibited by AMPK inhibitor after 48h. (B) EGCG significantly increased 
glucose uptake compared to control, and this effect was significantly inhibited by AMPK inhibitor after 
72h. Data presented mean ± SEM, **p<0.01, ***p<0.001, ****p<0.0001, n=3.  
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Figure 3.16 Akt inhibitor reduces EC induced glucose uptake in 3T3-L1 cells.  
3T3L1 cells were seeded in 24 well plate at density 1.5x104 and incubated in standard conditions 
until completed confluency. Differentiation was induced, and cells were treated with EC in presence and 
absence AMPK or Akt inhibitor, followed by estimating glucose uptake through measuring glucose 
remained in the media. (A) EC significantly increased glucose uptake compared to control, and this 
effect was significantly inhibited by AMPK inhibitor after 48h. (B) EC significantly increased glucose 
uptake compared to control, and this effect was significantly inhibited by AMPK inhibitor after 72h. 
Data presented mean ± SEM, **p<0.01, ***p<0.001, ****p<0.0001, n=3.  
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Figure 3.17 Akt inhibitor reduces ECG induced glucose uptake in 3T3-L1 cells.  
3T3L1 cells were seeded in 24 well plate at density 1.5x104 and incubated in standard conditions 
until completed confluency. Differentiation was induced, and cells were treated with ECG in presence 
and absence AMPK or Akt inhibitor, followed by estimating glucose uptake through measuring glucose 
remained in the media. (A) ECG significantly increased glucose uptake compared to control, and this 
effect was significantly inhibited by AMPK inhibitor after 48h. (B) ECG significantly increased glucose 
uptake compared to control, and this effect was significantly inhibited by AMPK inhibitor after 72h. 
Data presented mean ± SEM, *p<0.05, **p<0.01, ****p<0.0001, n=3.  
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Figure 3.18 Akt inhibitor reduces ECG induced glucose uptake in AML12 cells. 
AML12 cells were seeded in 24 well plate at density 2x105 and incubated in standard conditions until 
completed confluency. Cells were treated with ECG in presence and absence AMPK or Akt inhibitor, 
followed by estimating glucose uptake through measuring glucose remained in the media. ECG 
significantly increased glucose uptake after 24h compared to control, and this increase was significantly 
suppresed by Akt inhibitor. Data presented mean ± SEM, *p<0.05, ***p<0.001, ****p<0.0001, n=3. 
 
Figure 3.19 Akt inhibitor reduces EC induced glucose uptake in AML12 cells. 
AML12 cells were seeded in 24 well plate at density 2x105 and incubated in standard conditions until 
completed confluency. Cells were treated with EC in presence and absence AMPK or Akt inhibitor, 
followed by estimating glucose uptake through measuring glucose remained in the media. EC 
significantly increased glucose uptake after 72h compared to control, and this increase was significantly 
suppresed by Akt inhibitor. Data presented mean ± SEM, **p<0.01, ****p<0.0001, n=3. 
100 
 
 
 
Figure 3.20 Akt inhibitor reduces ECG induced glucose uptake in AML12 cells. 
AML12 cells were seeded in 24 well plate at density 2x105 and incubated in standard conditions until 
completed confluency. Cells were treated with ECG in presence and absence AMPK or Akt inhibitor, 
followed by estimating glucose uptake through measuring glucose remained in the media. (A, B) ECG 
at 1 and 10µM significantly increased glucose uptake after 72h compared to control, and this increase 
was significantly suppresed by Akt inhibitor. Data presented mean ± SEM, **p<0.01, ****p<0.0001, 
n=3. 
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Figure 3.21 Akt inhibitor reduces green tea combination induced glucose uptake in AML12 cells. 
AML12 cells were seeded in 24 well plate at density 2x105 and incubated in standard conditions until 
completed confluency. Cells were treated with combination of green tea compounds in presence and 
absence AMPK or Akt inhibitor, followed by estimating glucose uptake through measuring glucose 
remained in the media. (A, B) Green tea combination at 1 and 10µM significantly increased glucose 
uptake after 72h compared to control, and this increase was significantly suppresed by Akt inhibitor. 
Data presented mean ± SEM, **p<0.01, ****p<0.0001, n=3. 
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Figure 3.22 Akt inhibitor reduces quercetin induced glucose uptake in AML12 cells. 
AML12 cells were seeded in 24 well plate at density 2x105 and incubated in standard conditions until 
completed confluency. Cells were treated with quercetin in presence and absence AMPK or Akt 
inhibitor, followed by estimating glucose uptake through measuring glucose remained in the media. (A, 
B) Quercetin at 1 and 10µM significantly increased glucose uptake after 72h compared to control, and 
this increase was significantly suppresed by Akt inhibitor. Data presented mean ± SEM, **p<0.01, 
***p<0.001, ****p<0.0001, n=3. 
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Figure 3.23 Akt inhibitor reduces quercetin induced glucose uptake in AML12 cells. 
AML12 cells were seeded in 24 well plate at density 2x105 and incubated in standard conditions until 
completed confluency. Cells were treated with 20µM of quercetin in presence and absence AMPK or 
Akt inhibitor, followed by estimating glucose uptake through measuring glucose remained in the media. 
Quercetin significantly increased glucose uptake after 72h compared to control, and this increase was 
significantly suppresed by Akt inhibitor. Data presented mean ± SEM, ***p<0.001, ****p<0.0001, n=3. 
 
3.3.7 Green tea compounds increased 2-NBDG uptake in C2C12 cells 
2-NBDG is a fluorescent glucose analogue which has been successfully used to determine the rate 
of cellular glucose uptake in various cell lines (O'Neil, et al., 2005). The 2-NBDG uptake was assessed 
in differentiated C2C12 cells after incubation with selected compounds of green tea that had previously 
shown a significant increase in glucose uptake. Treatment was performed for 6h to provide a shorter-
term analysis of glucose movement. Results showed that 1 and 10µM EGCG, EC, and ECG significantly 
increased cellular 2-NBDG uptake in treated cells compared to control, however the increases are very 
small which contrast with glucose uptake measured by estimating amount of glucose remain in the media 
(Figure 3.24). The increases in the amount of fluorescence related to 2-NBDG uptake were recorded as: 
16.7%±2.4% (p=0.0001), 17.6%±2% (p<0.0001), 17.15±1.9% (p<0.0001), 18.28%±1.7% (p<0.0001), 
17.18%±1.8% (p<0.0001), and 19.06%±2.2% (p<0.0001) compared to control respectively.  
 
3.3.8 Green tea compounds increased 2-NBDG uptake in 3T3-L1 cells 
The 2-NBDG uptake was investigated in mature 3T3-L1 cells in response to selected compounds of 
green tea that showed a significant increase in glucose uptake previously for 6h. The results showed that 
1 and 10µM EGCG, EC, and ECG significantly boosted cellular 2-NBDG uptake in treated cells 
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compared to control (Figure 3.25). Increases in fluorescence of 21.15%±1.77% (p<0.0001), 
25.46%±1.76% (p<0.0001), 24.12%±2% (p<0.0001), 26.75±2% (p<0.0001), 22.14%±1.85% 
(p<0.0001), and 26.30%±1.45% (p<0.0001) respectively were observed. These modest but significant 
glucose uptake are difference from amount of glucose uptake that measured by indirect estimated level 
of glucose remain in the media. 
 
3.3.9 Green tea compounds increased 2-NBDG uptake in AML12 cells 
 Similarly, 2-NBDG uptake was investigated in AML12 when cultured with selected compounds of 
green tea that previously showed a significant increase in cellular glucose uptake. 1 and 10µM of EC, 
ECG, and combination of green tea compounds, in addition to 1, 10, 20µM of quercetin significantly 
increased 2-NBDG uptake (Figure 3.26). Percentage increases were: 14.60%±1.33% (p<0.0001), 
17.23%±2% (p<0.0001), 18.62%±1.64% (p<0.0001), 18.96%±1.75% (p<0.0001), 22.29%±1.43% 
(p<0.0001), 25.44%±0.95% (p<0.0001), 33.56%±0.87% (p<0.0001), 25.63%±1.83% (p<0.0001), and 
23.89%±1.79% (p<0.0001) for EC, ECG, quercetin, and combination of green tea compared to control 
respectively. As previously mentioned, these little but significant elevated in glucose uptake are 
contradict from the indirect uptake that measured level of glucose remain in the media.  
 
 
Figure 3.24 Selected green tea compounds increase 2-NBDG uptake in C2C12 cells. 
C2C12 cells were seeded in 96 well plate at density 104 and incubated in standard conditions for 24h. 
Differentiation was induced, and the cells were then serum starved for 2h followed by treating with 
EGCG, EC, and ECG in low glucose media containing 100µM 2-NBDG for 6h. Cellular fluorescence 
was measured, and the result showed that green tea compounds significantly increased 2-NBDG uptake 
compared to control. Data presented mean ± SEM, ***p<0.001, ****p<0.0001, n=3. 
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Figure 3.25 Selected green tea compounds increase 2-NBDG uptake in 3T3-L1 cells. 
3T3L1 cells were seeded in 96 well plate at density 104 and incubated in standard conditions until 
reach confluency. Differentiation was induced, and the cells were serum starved for 2h followed by 
treating with EGCG, EC, and ECG in  low glucose media containing 100µM 2-NBDG for 6h. Cellular 
fluorescence was measured, and the result showed that green tea compounds significantly increased 2-
NBDG uptake compared to control. Data presented mean ± SEM, ****p<0.0001, n=3. 
 
Figure 3.26 Selected green tea compounds increase 2-NBDG uptake in AML12 cells. 
AML12 cells were seeded in 96 well plate at density 104 and incubated in standard conditions for 
24h. Cells were then serum starved for 2h followed by treating with EC, ECG, quercetin, and 
combbination in low glucose media containing 100µM 2-NBDG for 6h. Cellular fluorescence was 
measured, and the result showed that green tea compounds significantly increased 2-NBDG uptake 
compared to control. Data presented mean ± SEM, ****p<0.0001, n=3. 
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3.3.10 Role of AMPK and Akt on green tea induced 2-NBDG uptake in C2C12 cells  
The impact of AMPK and Akt inhibitors on the cellular 2-NBDG uptake in C2C12 cells was 
investigated. Cells were exposed to these compounds at 10µM in addition to 1µM of EGCG, EC, and 
ECG that previously showed a significant increase in 2-NBDG uptake for 6 and 12h. A significant 
increase of 2-NBDG uptake was observed after 6h in response to green tea compounds, and this uptake 
was unaffected by AMPK or Akt inhibitors (Figure 3.27A). In contrast, after 12h of treatment, the cells 
showed significant elevation in 2-NBDG uptake by 21.2%±0.9% (p<0.0001), 20.3%±0.3% (p<0.0001), 
and 20.4%±0.7% (p<0.0001) respectively, which significantly decreased by 11%±0.8% (p<0.0001), 
10.3%±0.75% (p<0.0001), and 10.2%±0.8% (p<0.0001) respectively when the cells were co-incubated 
with selective AMPK inhibitor molecules alongside these green tea compounds (Figure 3.27 B). 
 
3.3.11  Role of AMPK and Akt on green tea induced 2-NBDG uptake in 3T3-L1 cells 
To identify the effect of AMPK and Akt on increased 2-NBDG uptake that was mediated by selected 
compounds of green tea in 3T3-L1 cells, mature cells were co-incubated with selective 10µM AMPK 
or Akt inhibitors alongside 1µM of EGCG, EC, and ECG for 6 and 12h. Green tea compounds caused 
increases in 2-NBDG uptake after 6h without any effect of AMPK or Akt inhibitors on this uptake 
(Figure 3.28 A). After 12h, however, green tea compounds increased 2-NBDG uptake by 22.3%±0.8% 
(p<0.0001), 20.2%±1.3% (p<0.0001), and 19.5%±1.6% (p<0.0001) respectively, and this increases was 
reduced by 13.9%±1.1% (p<0.0001), 14.5%±1.3% (p<0.0001), and 13.7%±1.1% (p<0.0001) in 
response to the Akt inhibitor only (Figure 3.28 B).  
 
3.3.12  Role of AMPK and Akt on green tea induced 2-NBDG uptake in AML12 cells 
The role of AMPK and Akt inhibitor molecules were examined on the cellular 2-NBDG uptake in 
AML12 cells through supplementing the culture cells to these inhibitors in addition to green tea 
compounds that had previously shown significant increases in 2-NBDG uptake (EC, ECG, quercetin, 
and catechins combination) for 6 and 12h. Cells showed a significant increase in 2-NBDG uptake after 
6h in response to green tea compounds with no effect of Akt or AMPK inhibitors in reducing 2-NBDG 
uptake (Figure 3.29 A). Cells after 12h of exposure to selected green tea compounds exhibited 
significant increases of 2-NBDG uptake by 26.6%±1.5% (p<0.0001), 29.6%±3.15% (p<0.0001), 
27.2%±1.7% (p<0.0001), and 25.7%±1.1% (p<0.0001) respectively, and these increases were reduced 
markedly by 18.4%±1.1% (p<0.0001), 13.7%±1.6% (p<0.0001), 16.8%±1% (p<0.0001), and 
16.8%±1.1% (p<0.0001) respectively in response to the Akt inhibitor (Figure 3.29 B).    
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Figure 3.27 AMPK inhibition reduces green tea compounds induced C2C12 2-NBDG uptake.  
C2C12 cells were seeded in 96 well plate at density 104 and incubated in standard conditions for 24h. 
Differentiation was induced, and the cells were then serum starved for 2h followed by treating with 
EGCG, EC, and ECG with and without AMPK or Akt inhibitor in low glucose media containing 100µM 
2-NBDG. (A) Six hours co-incubation, green tea compounds increased 2-NBDG uptake without any 
effect of both inhibitors. (B)  12h co-incubation, green tea compounds increased 2-NBDG uptake, and 
the increases were significantly reduced by AMPK inhibition. Data presented mean ± SEM, 
****p<0.0001, n=3. 
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Figure 3.28 Akt inhibition reduces green tea compounds induced 3T3L-1 2-NBDG uptake.  
3T3L1 cells were seeded in 96 well plate at density 104 and incubated in standard conditions until 
reach confluency. Differentiation was induced, and the cells were then serum starved for 2h followed 
by treating with EGCG, EC, and ECG with and without AMPK or Akt inhibitor in low glucose media 
containing 100µM 2-NBDG. (A) Six hours co-incubation, green tea compounds increased 2-NBDG 
uptake without any effect of both inhibitors. (B)  12h co-incubation, green tea compounds increased 2-
NBDG uptake, and the increases were significantly reduced by Akt inhibition. Data presented mean ± 
SEM, ****p<0.0001, n=3. 
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Figure 3.29 Akt inhibition reduces green tea compounds induced AML12 2-NBDG uptake.  
AML12 cells were seeded in 96 well plate at density 104 and incubated in standard conditions for 
24h. Cells were serum starved for 2h followed by treating with EC, ECG, quercetin, and combination 
with and without AMPK or Akt inhibitor in low glucose media containing 100µM 2-NBDG. (A) Six 
hours co-incubation, green tea compounds increased 2-NBDG uptake without any effect of both 
inhibitors. (B)  12h co-incubation, green tea compounds increased 2-NBDG uptake, and the increases 
were significantly reduced by Akt inhibition. Data presented mean ± SEM, ****p<0.0001, n=3. 
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3.3.13  The effect of green tea compounds on cell viability  
The cell viability of insulin-sensitive cell lines including AML12, differentiated C2C12, and 3T3-L1 
was assessed to ensure that changes in nutrient utilisation were not due to changes in cell viability. Also 
to fully clarify the understanding of the link between the effects of active constitutes of green tea and 
the significant increases of cellular glucose and 2-NBDG uptake that had previously been displayed. 
The assay was performed as described in chapter two. Differentiated C2C12 cells were exposed to 1 and 
10µM EGCG, EC, ECG, myricetin, quercetin, and the combination of these compounds for 24, 48, and 
72h. Neither concentrations nor different time points affected cell viability (data not shown). Similarly, 
mature 3T3-L1 treated with the same compounds at the same incubation times revealed cell viability 
was unchanged in response to treatment at any time points (data not shown). AML12 cells were cultured 
with the same compounds above, but at 1, 10, and 20µM, and again all compounds at all concentrations 
did not affect cell viability (data not shown). 
 
3.3.14  Selected green tea compounds increased glycogen formation in AML12 cells 
Glycogen content was determined in AML12 cells that had exhibited significant increases in glucose 
and 2-NBDG uptake previously in response to selected green tea compounds. Cells were exposed to 
10µM ECG for 24h, 1 and 10µM of ECG and combination of green tea compounds, 1µM EC, and 1, 
10, and 20µM quercetin for 72h followed by measuring the amount of glycogen stored in the cells. No 
significant differences in glycogen content were observed in cells treated with 1µM EC, 1µM and 10µM 
ECG for 72h compared to control (Error! Reference source not found.). Whereas, exposure to 10µM 
ECG for 24h caused a significant increase in cellular glycogen content (59.24%±12%, p=0.0284), as 
shown in Figure 3.30. Quercetin treatment at 1 and 10µM for 72h did not elicit any significant change 
in cellular glycogen content, whilst  20µM significantly increased cellular glycogen content to 
157.4%±13.9% (p=0.0245) compared to control group (Figure 3.31). Combined green tea compounds 
did not significantly alter glycogen content, with measurements of up to 94.1%±12.1% (p=0.0875) and 
142.7%±15.94% (p=0.0531) for 1 and 10µM compared to control respectively (Figure 3.31). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
111 
 
 
Figure 3.30 ECG increases glycogen content in AML12 cells. 
AML12 cells were seeded in 24 well plate at density 2x105 and incubated in standard conditions until 
completed confluency. Cells were serum starved for 2h, and treated with 10µM ECG for 24h, then cells 
were homogenised, and glycogen content was investigated. The result showed ECG significantly 
increased glycogen content compared to control. Data presented mean ± SEM,*p<0.05, n=3. 
 
Figure 3.31 Quercetin increases glycogen contents in AML12 cells. 
AML12 cells were seeded in 24 well plate at density 2x105 and incubated in standard conditions until 
completed confluency. Cells were serum starved for 2h, and treated with indicated concentration of  EC, 
ECG, quercetin, and green tea compounds combination for 72h, then cells were homogenised, and 
glycogen content was investigated. Only 20µM quercetin increased glycogen content compared to 
DMSO. Data presented mean ± SEM, *p<0.05, n=3. 
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3.3.15  Lipid accumulation in differentiated 3T3-L1 cells 
Oil red O staining was used to assess lipid accumulation in differentiating 3T3-L1 cells during 
various time points of differentiation. The cells accumulated noticeable lipid droplets at days 6, 9, 12 
and 15 from initiation of differentiation, and both the size and number of lipid droplets increased with 
advances in time (Figure 3.32). 
 
 
   
   
Figure 3.32 Oil red O triglyceride staining of 3T3-L1 cells during differentiation. 
3T3L1 cells were seeded in 6 well plate at density 6x105 and incubated in standard conditions until 
completed confluency. Differentation was induced as mentioned in materials and methods, and the cells 
were stained with oil red O during differentiation process. (A) Cells were stained at day 6 of 
differentiation demonstrating small and numerous lipid droplets appearing red in colour. (B) Staining at 
day 9 shows an increased number and size of lipid droplets. (C) Lipid droplets become larger than before 
at day 12 of differentiation. (D) Red stained larger lipid droplets formed by day 15 of differentiation. 
The images were captured using Leica DMI4000 B inversion microscope and Ceti Inverso TC100 
inverted microscope at 100x magnification. 
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3.3.16  Selected green tea compounds decreased triglyceride contents in 3T3-L1 cells 
The effect of green tea compounds on lipid homoeostasis in adipocytes was investigated by 
measuring triglyceride content of mature 3T3-L1 after exposed to selected compounds of green tea at 
concentrations and time points that had previously shown significant increases in glucose and 2-NBDG 
uptake. Cells were treated with EGCG, EC, and ECG at 1 and 10µM for 48 and 72h and subsequently 
assayed triglyceride content as described in chapter two. The results showed significant reduction of 
cellular triglyceride content in cells treated with selected compounds of green tea after 48 and 72h 
compared to control (Figure 3.33). Reductions of 74.11%±4% (p<0.0001), 77%±10.8% (p<0.0001), 
39.91%±19.7% (p=0.0170), 51.9%±16.8% (p=0.0014), 43.5%±21.25% (p=0.0081), and 48%±1.5% 
(p=0.0031) respectively were observed after 48h, in addition to 95%±26.2% (p<0.0001) and 
36.8%±0.6% (p= 0.0173) decreases of triglyceride level caused by 10µM isoprenaline and 100nM 
insulin respectively compared to control. After 72h the reductions in triglyceride levels were 
62.75%±20.62% (p<0.0001), 52%±13.56% (p=0.0001), 32.8%±4.4% (p=0.0178), 60.24%±13.43% 
(p<0.0001), 50.86%±7% (p=0.0002), and 53.17%±20.76% (p=0.0001) respectively, whereas 
isoprenaline and insulin caused a 61.7%±12.6% (p<0.0001) and 28.6%±4.6% (p= 0.0496) reduction in 
triglyceride compared to control (Figure 3.33). Surprisingly, the cells exposed to insulin for 48 and 72h 
show significant reduction in triglyceride which is a unique and unlikely effect as the proper effect is to 
stimulate lipogenesis.   
 
3.3.17  Selected green tea compounds reduced lipolysis in 3T3-L1 cells 
The amount of glycerol released from differentiated 3T3-L1 cells is an indirect measure of cellular 
lipolysis. Glycerol release was measured for treatment concentrations that had previously shown an 
increase in glucose and 2-NBDG uptake associated with a decrease in triglyceride content. Cells were 
incubated with 1 and 10µM EGCG, EC, and ECG for 48 and 72h, and glycerol release was measured in 
the cell culture media. The results showed that treatment with EGCG, EC, and ECG for 48 and 72h 
significantly reduced the amount of glycerol released from 3T3-L1 cells compared to control (Figure 
3.34). Reductions in glycerol release in compared to control were: 38.8%±9.5% (p=0.0003), 
38.9%±10.1% (p=0.0002), 29.4%±7.6% (p=0.0110), 41.3%±7.4% (p<0.0001), 36.3%±9.1% 
(p=0.0007), and 39.1%±7.9% (p=0.0002) for 48h respectively, whereas 10µM isoprenaline as a positive 
control increased glycerol release by 37.6%±1.2% (p=0.0002) compared to control. After 72h, decreases 
of glycerol release were 36.5%±8.7% (p=0.0002), 32.4%±10% (p=0.0012), 42.5%±8.8% (p<0.0001), 
45%±9.7% (p<0.0001), 42.7%±10.3% (p<0.0001), and 37.7%±5.8% (p=0.0001) respectively, whilst 
isoprenaline elevated glycerol release by 28.6%±1.5% (p=0.0033) compared to control. 
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Figure 3.33 Selected green tea compounds decrease triglyceride level in 3T3-L1 cells. 
3T3L1 cells were seeded in 24 well plate at density 1.5x104 and incubated in standard conditions 
until completed confluency. Differentiation was induced, and the cells were serum starved for 2h, and 
treated with EGCG, EC, and ECG for 48 and 72h. Triglyceride was extracted and quantified. (A) 
Significant decreases of cellular triglyceride were observed in treated cells compared to control after 
48h. (B). Treated cells exhibited significant reductions in triglyceride content after 72h incubation 
compared to control. Data presented mean ± SEM, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, 
n=3. 
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Figure 3.34 Selected green tea compounds reduce glycerol release from 3T3-L1 cells. 
3T3L1 cells were seeded in 24 well plate at density 1.5x104 and incubated in standard conditions 
until completed confluency. Differentiation was induced, and the cells were serum starved for 2h, and 
treated with EGCG, EC, and ECG for 48 and 72h. The level of glycerol releases from cells was 
quantified in culture media. (A) Significant reduction of glycerol concentration was observed in treated 
cell culture media compared to control after 48h. (B). Treated cells culture media exhibited significant 
reduce in glycerol levels after 72h incubation compared to control. Data presented mean ± SEM, 
**p<0.01, ***p<0.001, ****p<0.0001, n=3. 
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3.3.18  Effect of green tea compounds on the level of glucose and lipid metabolism gene 
expression  
The effects of active green tea compounds that previously showed significant effects on nutrient 
homoeostasis on gene expression of metabolic genes were investigated using qRT-PCR. The genes 
tested were IR, HK1, Glut4, PDK4, PGC1a, and Gys1 for C2C12 cells. Also IR, HK1, Glut2, Gys1, 
G6Pase, PEPCK, ACSL, CPTα1 in AML12 cells and  IR, HK1, Glut4, C/EBPα, LPL, FASN, FABP4, 
SREBP1c, and PPARγ in 3T3-L1 cells. The relative mRNA expression of these genes was calculated 
using equation 2-∆∆Ct (Livak and Schmittgen, 2001)  after gene expression was normalised to a 
housekeeping gene (Actin). The result showed that the level of mRNA expression of metabolic genes 
in C2C12 was not significantly altered by any of the treatments (Table 3.1). Similarly, EGCG, EC, and 
ECG did not alter the level of metabolic gene expression in 3T3L1 cells compared to control (Table 
3.2). Furthermore, no significant change in metabolic genes expression were observed in treated AML12 
cells compared to control (Table 3.3).  
 
Table 3.1 Effect of green tea compounds on glucose metabolism mRNA expression in C2C12 cells. 
C2C12 cells were seeded in 12 well plate at density 4x105 and incubated in standard conditions until 
reached 80% confluency. Differentiation was induced, cells were starved for 2h and then were treated 
with 10µM of EGCG, EC, and ECG for 24h. RNA was isolated and reverse transcriptased, followed by 
quantifing amplification of selected glucose metabolism mRNA by using qPCR. No significant 
differences between green tea treatments and control of all tested gene were seen. Data displayed as 
relative fold of gene expression normalised to housekeeping gene. Data presented mean ± SEM, n=3. 
 
mRNA Treatment ↑↓ Fold of control P value 
 
IR 
Insulin 0.7225 ± 0.1607 0.8968 
EGCG 0.9104 ± 0.1584 0.9980 
EC 1.296 ± 0.4067  0.8873 
ECG 0.7591 ± 0.1858 0.9340 
 
HK1 
Insulin 0.9279 ± 0.2694 0.9952 
EGCG 1.600 ± 0.4044 0.9014 
EC 0.9197 ± 0.5066 0.9944 
ECG 0.8396 ± 0.3577 0.9812 
 
Glut4 
Insulin 1.369 ± 0.09037 0.8790 
EGCG 1.450 ± 0.2536 0.7845 
EC 1.504 ± 0.3905 0.7120 
ECG 1.374 ± 0.3988 0.8739 
 
PDK4 
Insulin 1.052 ± 0.2113  > 0.9999 
EGCG 1.194 ± 0.08041 > 0.9999 
EC 1.389 ± 0.4891 0.9908 
ECG 1.687 ± 0.7814 0.8850 
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PGC1α 
Insulin 1.049 ± 0.09195 > 0.9999 
EGCG 0.6439 ± 0.1376 0.3476 
EC 0.5368 ± 0.1943 0.1656 
ECG 0.4297 ± 0.01285 0.0733 
 
Gys1 
Insulin 1.229 ± 0.3843 0.9929 
EGCG 1.212 ± 0.5074 0.9948 
EC 0.8237 ± 0.3283 0.9956 
ECG 0.8745 ± 0.3953 0.9987 
 
Table 3.2 Effect of green tea compounds on glucose and lipid metabolism mRNA expression in 
3T3-L1 cells. 
3T3-L1cells were seeded in 12 well plate at density 3x105 and incubated in standard conditions until 
completed confluency. Differentiation was induced, cells were starved for 2h and then were treated with 
10µM of EGCG, EC, and ECG for 24h. RNA was isolated and reverse transcriptased, followed by 
quantifing amplification of selected glucose and lipid metabolism mRNA by using qPCR. No significant 
differences between green tea treatments and control of all tested gene were seen. Data displayed as 
relative fold of gene expression which normalised to housekeeping gene. The data presented mean ± 
SEM, n=3. 
 
mRNA Treatment ↑↓ Fold of control P value 
 
IR 
Insulin 0.8526 ± 0.1703 0.9642 
EGCG 0.7121 ± 0.1036 0.7805 
EC 1.012 ± 0.3244 > 0.9999 
ECG 0.6547 ± 0.1224 0.6695 
 
HK1 
Insulin 1.144 ± 0.4587 > 0.9999 
EGCG 2.529 ± 1.562 > 0.9999 
EC 3.860 ± 2.633 > 0.9999 
ECG 34.31 ± 31.40 0.4966 
 
Glut4 
Insulin 0.5101 ± 0.08767 0.9548 
EGCG 1.261 ± 0.4688 0.9987 
EC 0.6888 ± 0.1649 0.9893 
ECG 1.857 ± 1.115 0.8416 
 
C/EBPα 
Insulin 0.8030 ± 0.1598 0.9913 
EGCG 1.076 ± 0.08899 0.9998 
EC 1.296 ± 0.1898 0.9669 
ECG 2.434 ± 0.6798 0.0687 
 
LPL 
Insulin 0.5314 ± 0.1204 0.9997 
EGCG 4.989 ± 1.468 0.6566 
EC 1.155 ± 0.5874 > 0.9999 
ECG 6.559 ± 4.238 0.3665 
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FASN 
Insulin 0.6635 ± 0.1479 0.9590 
EGCG 1.885 ± 0.1188 0.9103 
EC 1.580 ± 0.3627 0.9887 
ECG 2.883 ± 1.129 0.2983 
 
FABP4 
Insulin 0.6989 ± 0.1674 0.9919 
EGCG 3.245 ± 0.9062 0.2867 
EC 1.660 ± 0.6312 0.9820 
ECG 3.257 ± 1.063 0.2823 
 
SREBP1c 
Insulin 0.7561 ± 0.06438 0.9662 
EGCG 0.7484 ± 0.1120 0.9628 
EC 1.385 ± 0.1669 0.9304 
ECG 2.090 ± 0.6413 0.2021 
 
PPARγ 
Insulin 0.4943 ± 0.08012 0.6540 
EGCG 1.117 ± 0.2819 0.9977 
EC 1.853 ± 0.1615 0.2217 
ECG 1.795 ± 0.4757 0.2755 
 
 
 
Table 3.3 Effect of green tea compounds on glucose metabolism mRNA expression in AML12 cells. 
AML12cells were seeded in 12 well plate at density 4x105 and incubated in standard conditions until 
completed confluency. Cells were starved for 2h and then were treated with 10µM of EC, ECG, 
quercetin, and combination for 24h. RNA was isolated and reverse transcriptased, followed by 
quantifing amplification of selected glucose metabolism mRNA by using qPCR. No significant 
differences between green tea treatments and control of all tested gene were seen. Data displayed as 
relative fold of gene expression which normalised to housekeeping gene. The data presented mean ± 
SEM, n=3. 
 
mRNA Treatment ↑↓ Fold of control P value 
 
 
IR 
Insulin 1.675 ± 0.9192 >0.9999 
EC 8.615 ± 3.918 0.1498 
ECG 2.897 ± 0.1303 0.9914 
Quercetin 2.359 ± 0.8495 0.9997 
Combination of GT 4.113 ± 2.961 0.9400 
 
 
HK1 
Insulin 4.158 ± 3.087 0.5755 
EC 1.606 ± 0.1642 0.9998 
ECG 2.28 ± 0.2419 0.9888 
Quercetin 2.482 ± 0.8616 0.9940 
Combination of GT 1.364 ± 0.2924 >0.9999 
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Glut2 
Insulin 3.354 ± 1.906 0.9568 
EC 6.011 ± 2.345 0.4419 
ECG 4.719 ± 1.572 0.7393 
Quercetin 2.168 ± 0.6923 0.9997 
Combination of GT 3.921 ± 3.003 0.9221 
 
 
Gys1 
Insulin 3.071 ± 1.473 0.5464 
EC 2.143 ± 0.4149 0.9442 
ECG 3.276 ± 0.5819 0.4437 
Quercetin 3.266 ± 1.007 0.4649 
Combination of GT 2.31 ± 0.7633 0.9096 
 
 
G6Pase 
Insulin 4.371 ± 4.069 0.9036 
EC 3.146 ± 0.6884 0.9897 
ECG 1.759 ± 0.4488 >0.9999 
Quercetin 2.207 ± 1.379 0.9996 
Combination of GT 4.26 ± 2.916 0.9092 
 
 
PEPCK 
Insulin 6.897 ± 5.82 0.6857 
EC 6.43 ± 2.543 0.7564 
ECG 4.097 ± 0.7925 0.9766 
Quercetin 1.92 ± 0.6199 >0.9999 
Combination of GT 3.577 ± 2.361 0.9940 
 
 
CPTα 
Insulin 3.455 ± 2.244 0.5044 
EC 2.611 ± 0.427 0.8623 
ECG 2.665 ± 0.1158 0.8439 
Quercetin 1.378 ± 0.5809 >0.9999 
Combination of GT 1.44 ± 0.2106 >0.9999 
 
 
ACSL 
Insulin 3.537 ± 2.387 0.9845 
EC 8.671 ± 4.06 0.2773 
ECG 3.8 ± 0.6926 0.9744 
Quercetin 3.293 ± 1.033 0.9958 
Combination of GT 5.089 ± 3.368 0.8976 
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3.3.19 Effect of green tea compounds on AMPK phosphorylation in C2C12 cells  
Previous results showed the inhibitory effect of selective AMPK inhibitor molecule on glucose 
uptake in C2C12 cells mediated by selective green tea compounds including EGCG, EC, and ECG. 
Based on that, the AMPK pathway is likely implicated in the effect of selected green tea compounds in 
glucose homoeostasis regulation. Phosphor-specific Western blotting was used to detect the levels of 
phosphorylated AMPK (pAMPK) protein expression in C2C12 cell lysate after exposed cells to green 
tea compounds for 15 and 30 minutes. As this experiment was performed on two occasions only, which 
cannot be taken as a final result, the data did not show statistically significant differences between green 
tea treatments and control (Figure 3.35). 
 
3.3.20  Effect of green tea compounds on phosphorylation of Akt in 3T3-L1 cells 
Based on the result shown previously that co-incubating mature 3T3-L1 cells with selective Akt 
inhibitor molecule alongside selected green tea compounds significantly suppresses glucose and 2-
NBDG uptake, Akt could be involved in the effect of these selected compounds of green tea in regulating 
glucose homoeostasis. This signalling pathway was determined in 3T3-L1 cells through measuring of 
expression of specific Akt protein in cell lysate by phosphor-specific Western blotting after 15 and 30 
minutes post-treatment with selected compounds of green tea. This experiment was also only performed 
twice and therefore cannot be considered in drawing final conclusions. However, the analysed data 
displayed no significant differences in phosphorylation of Akt protein between treatments and control 
(Figure 3.36).   
 
3.3.21  Effect of green tea compounds on phosphorylation of Akt in AML12 cells 
Looking at Akt expression in AML12, based on the result expressed previously, showed that Akt 
inhibition significantly reduced cellular glucose and 2-NBDG uptake in AML12 when the cells were 
co-cultured with selected green tea compounds in addition to selective Akt inhibitor molecules. 
Accordingly, Akt could be a potential pathway of the effect of selected green tea compounds to regulate 
glucose homoeostasis. Phosphor-specific Western blotting was performed to identify the levels of 
phosphorylated Akt (pAkt) proteins in AML12 cell lysate post-treatment with EC, ECG, and quercetin 
for 15 and 30 minutes. Similarly, this experiment was conducted twice which therefore cannot use to 
make any final conclusion. However, the result showed no significant differences between treatments 
and control in the expression level of pAkt (Figure 3.37).    
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Figure 3.35 Effect of selected green tea compounds on pAMPK expression in C2C12 cells. 
C2C12 cells were seeded in 6 well plate at density 8x105 and incubated in standard conditions until 
reached 80% confluency. Differentiation was induced, and the cells were serum starved for 2h, and then 
were treated with 10µM of EGCG, EC, and ECG for 15 and 30 minutes. Total protein was isolated and 
quantified, and phosphor western blotting was performed to identify the leve of pAMPK. (A). Total and 
phosphorylation levels of AMPK protein bands represented one experiment. (B) Analysed band 
intensity of pAMPK expression. Due to the experiment was performed in two occasion, therefore, no 
final conclusion can be drawn and more independent experiment is needed. The data displayed as a % 
of control which normalised to total AMPK expression. Bands intensity were quantified using Image J 
software. Data presented as n=2.   
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Figure 3.36 Effect of selected green tea compounds on pAkt expression in 3T3-L1 cells. 
3T3-L1 cells were seeded in 6 well plate at density 6x105 and incubated in standard conditions until 
completed confluency. Differentiation was induced, and the cells were serum starved for 2h, and then 
were treated with 10µM of EGCG, EC, and ECG for 15 and 30 minutes. Total protein was isolated and 
quantified, and phosphor western blotting was performed to identify the leve of pAkt. (A). Total and 
phosphorylation levels of Akt protein bands represented one experiment. (B) Analysed band intensity 
of pAkt expression. Due to the experiment was performed in two occasion, therefore, no final conclusion 
can be drawn and more independent experiment is needed. The data displayed as a % of control which 
normalised to total Akt expression. Bands intensity were quantified using Image J software. Data 
presented as n=2.  
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Figure 3.37 Effect of selected green tea compounds on pAkt expression in AML12 cells. 
AML12 cells were seeded in 6 well plate at density 8x105 and incubated in standard conditions 
until completed confluency. The cells were serum starved for 2h, and then were treated with 10µM 
of EC, ECG, and quercetin for 15 and 30 minutes. Total protein was isolated and quantified, phosphor 
western blotting was performed to identify the leve of pAkt. (A). Total and phosphorylation levels 
of Akt protein bands represented one experiment. (B) Analysed band intensity of pAkt expression. 
Due to the experiment was performed in two occasion, therefore, no final conclusion can be drawn 
and more independent experiment is needed. The data displayed as a % of control which normalised 
to total Akt expression. Bands intensity were quantified using Image J software. Data presented as 
n=2. 
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3.4 Discussion 
Normal cellular glucose homoeostasis contributes significantly towards the maintenance of normal 
blood glucose levels between 4 and 6mmol/L in the circulation (DeFronzo, 1988;Saltiel and Kahn, 2001) 
and therefore to regular metabolic health. During ageing, or changes in diet or physical inactivity, this 
process can be disrupted, causing unsustainably high amounts of glucose in the circulation. Prolonged 
hyperglycaemia together with elevated secretion of insulin eventually leads to decreased insulin 
sensitivity and a reduction in the ability of metabolic cells to respond to insulin action; a phenomenon 
referred to as insulin resistance which leads to an increased risk of developing T2D. Therefore, seeking 
a natural compound that possesses robust properties is essential and can be successfully involved in 
prevention and/or improving impaired glucose homoeostasis including glucose and lipid metabolism. 
As alternative herbal medicine has been excessively used to protect and cure some diseases, green tea 
has shown potent properties against wide pathogenic processes, including dysregulation of glucose and 
lipid metabolism, although the signalling pathway of this impact is not yet completely understood. 
Therefore, this study was designated to determine the ability of several active compounds of green tea 
to regulate glucose metabolism and the possible pathway of this effect in vitro.     
  
The glucose uptake data presented in this study shows that insulin-sensitive cell lines selectively 
respond to some compounds of green tea and thus increases cellular glucose and 2-NBDG uptake 
(Figure 3.3 to Figure 3.11 and Figure 3.24 to Figure 3.26). These increases were produced by different 
green tea compounds that varied in their effect according to cell type and time of exposure, however 
small but significant uptake was seen when glucose uptake was measured directly using 2-NBDG 
compared to amount of glucose uptake that measured by estimating the level of glucose remained in the 
media. These effect of green tea compounds on glucose uptake in both methods of measuring were not 
dose dependent, and the effect of some compounds particularly in AML12 cells (Figure 3.9 and Figure 
3.11) showed U-shaped doses response. This phenomenon is widely seen, as the low dose promoted 
effect without affected biological system until the high dose reached threshold which inhibited 
compounds effect due to saturation (Reynolds, 2010) Therefore, the study suggests that some of these 
effective compounds produce their effects specific to metabolic cell type. As the green tea compounds 
can boost glucose uptake in some metabolic cells (Yan, et al., 2012), this is often enhanced through the 
function of Gluts, particularly class I (Zhao and Keating, 2007). The present study result is partially 
consistent with recent work which showed green tea, and some of its compounds can increase glucose 
uptake in hepatocytes (Cordero-Herrera, et al., 2014), myocytes (Deng, et al., 2012), and in adipocytes 
(Ueda, et al., 2010) through Gluts translocation. However, the current study presents some unique data 
in AML12 cells. Despite previous contradictory data regarding the level of Glut2 and 4 mRNA 
expression (Table 3.1 to Table 3.3), the results are suggestive of the effects being mediated via 
translation regulation of Gluts. Although the results were statistically insignificant, increasing the 
125 
 
number of independent observations might clarify any effect of green tea on Gluts expression. 
Additionally, due to limitations in budget, it was not possible to investigate protein expression or 
trafficking of Gluts, so the possibility of green tea compounds regulating glucose homoeostasis via 
translation or post-translational regulation of Gluts exists. Collectively, the study suggests that 
consumption of some compounds of the green tea could manage high levels of circulating glucose and 
therefore might be supported pre-diabetic and existing diabetic conditions.   
 
Cellular glucose uptake and metabolism are mainly regulated through the major molecular pathways 
PI3K and AMPK. Due to the accumulation evidence that identified the green tea compounds can 
increase glucose uptake and regulate metabolism through activation of the AMPK pathway, the present 
study considered the role of both Akt and AMPK in the effect of selected green tea compounds that had 
induced glucose uptake previously. Firstly, this was performed through inhibiting either Akt or AMPK 
in the insulin-sensitive cell lines that were exposed to selected green tea compounds. The result showed 
that inhibiting AMPK in C2C12 cells suppressed glucose uptake in response to selected green tea 
compounds, whilst inhibiting Akt suppressed green tea compounds from inducing glucose uptake in 
3T3-L1 and AML12 cells (Figure 3.12 to Figure 3.23). Secondly, based on these results, the activity of 
pAkt and pAMPK proteins was assessed in insulin-sensitive cell lines in response to green tea 
compounds to confirm signalling pathway. As this experiment was repeated only twice, the displayed 
results (Figure 3.35 to Figure 3.37) cannot be used to build a conclusion and therefore further 
independent experiments are required. These results, however, do not fully correspond with the majority 
of previous work that has identified several compounds of green tea capable of increasing skeletal 
muscle cell glucose uptake. This uptake occurs through activating AMPK, which was confirmed by 
increasing expression of the pAMPK protein (Deng, et al., 2012;Ding, et al., 2012;Li, et al., 
2011b;Zhang, et al., 2010). However, Akt could be responsible for this uptake (Jung, et al., 2008). 
Regulation of glucose uptake and metabolism in adipocyte and hepatocyte using green tea compounds 
is believed to be through increasing activation of pAMPK (Collins, et al., 2007;Hwang, et al., 
2005;Murase, et al., 2009). However, Akt might be involved in this effect of green tea (Ueda, et al., 
2010). Regardless of the previously published results, the current study presents some unique data that 
describes the regulatory effect of some specific compounds of green tea in 3T3-L1 and AML12 through 
activating Akt signalling. The study, therefore, suggesting that selected green tea compound-induced 
glucose uptake may selectively activate either PI3K/Akt and/or AMPK pathways depending on insulin-
sensitive cell type. A further study encompassing this aspect is, however, needed to understand this 
further. 
    
The hepatic tissue is play crucial role in maintaining glucose homoeostasis under different 
physiological conditions. Hepatic cellular glucose is usually converted to glycogen in an insulin-
dependent manner, together with the activity of specific genes related to glycogen synthesis. In T2D this 
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is often impaired, which leads to reducing glycogen formation due to decreased glucose uptake, 
secondary to insulin insensitivity and decreased activity of glycogenic genes. This impairment occurs 
alongside increased hepatic glucose production through glycogenolysis and gluconeogenesis. The 
present study attempted to identify the level of glycogen, the activity of glycogen synthesis gene, and 
activity of genes that directly regulate glucose production in response to selected compounds of green 
tea. Whilst some green tea compounds failed to induce a significant change in glycogen concentration, 
ECG after 24h and quercetin after 72h did cause an increase in glycogen storage (Figure 3.30 and Figure 
3.31). Alongside this data, analysis of mRNA expression of the glycogen synthase (GS) gene, G6Pase 
and PEPCK showed no significant changes in expression (Table 3.3). The effect of green tea compounds 
on glycogen activity and hepatic glucose production have been recently investigated with contradictory 
findings being reported. Supplementing green tea to diabetic rats caused an increase in activity of the 
GS gene and, therefore, increased hepatic glycogen formation compared with non-treated rats, whilst no 
effect of green tea was found on hepatic glycogen content in rats fed on a high-fat diet (Sundaram, et 
al., 2013). Furthermore, green tea active constituents play a critical role in the liver gluconeogenic 
process through regulating key genes, including G6Pase and PEPCK, and eventually leading to 
suppressed hepatic glucose production (Collins, et al., 2007;Waltner-Law, et al., 2002;Yasui, et al., 
2011). The data regarding gene expression, however, did not support the previous positive effect of 
green tea compounds, as measuring mRNA does not always provide a proper indication. The amount of 
protein phosphorylation, which was not considered in this study due to the cost, is therefore required to 
understand this further. A possible reason for the data on mRNA expression could be due to the poor 
performance of the primers used to detect the expression of these genes (Figure 8.18 to Figure 8.26), or 
methodological error due to insuffiecient independent experiment. While a possible reason for the 
glycogen result is that the cells did not express an increase in glycogen storage which may have exhibited 
an increase in glucose oxidation; the cells are removing more glucose from their environment but not 
storing any extra glycogen. As the insulin also did not induced any significant effect on glycogen 
content, the possible reason for that could be insensitive assay kit or methodology error and more 
independent experiment is required. Despite the present study results and previously published results, 
the study identified the metabolic effect of some green tea compounds on the AML12 cell line for the 
first time. Therefore any data presented is considered unique. 
 
 Adipose tissue is a major site of energy storage which can metabolise glucose into triglycerides 
through the multistep process of lipogenesis in an insulin-dependent manner. Also, lipolysis, a process 
of catabolism of triglyceride into glycerol and free fatty acid, is inhibited by insulin (Duncan, et al., 
2007). Insulin resistance and diabetes cause an increase in lipolysis rate which increases glycerol and 
free fatty acid release from adipose tissue stores. It is widely accepted that the green tea extracts can 
regulate glucose metabolism in adipose tissue importantly through suppressed lipolysis and therein FFA 
releases. The present study investigates these impacts in mature 3T3-L1 cells. As the results show, the 
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selected green tea compounds reduced triglyceride levels (Figure 3.33) and glycerol release (Figure 
3.34). The study did not, however, detect any significant differences in mRNA levels of adipogenic and 
lipolytic genes (Table 3.2). These insignificant expressions of mRNA could be due to insufficient 
independent experiment, or unspecific primer binding (Figure 8.8 to Figure 8.17). This data fits with 
previous study results which have demonstrated the ability of green tea extracts to prevent fat formation 
(Cunha, et al., 2013;Lee, et al., 2009a;Mochizuki and Hasegawa, 2004), and to reduce lipolysis by 
decreasing the amount of glycerol released (Kim, 2014). These effects are enhanced through alteration 
of some adipogenic and lipolytic key genes including C/EBP-α, PPAR-γ, SREBP-1c, FABP4, LPL and 
FAS by downregulating expression levels of their mRNA (Lee, et al., 2009b).  Based on all of these 
results together, the study suggests that EGCG, EC, and ECG possess anti-obesity effects by altering 
the levels of lipogenesis/lipolysis through an as yet unexplored mechanism. As only the levels of mRNA 
were measured with no significant result, it was difficult to draw a mechanism and measurement of 
protein activities are therefore needed to explore this further. Despite the previously published results, 
the data presented here is very pertinent as the study used mature cells that closely exhibited the normal 
physiological functions seen in the human body. Accordingly, early and regular consumption of green 
tea compounds could prevent more triglyceride accumulation and suppress FFA release, which might 
protect from developing obesity and T2D, or could manage them if they already exist.   
 
Ultimately, the study has identified that several active compounds of green tea including EGCG, EC, 
ECG, quercetin, and a combination of these compounds, could regulate cellular glucose and lipid 
metabolism in insulin-sensitive cell lines. The regulatory effects of these compounds are firstly through 
increasing cellular glucose uptake, which induced selectively based on compounds and cell type. Some 
of these compounds in addition to increased glucose uptake, stimulated firstly used AML12. 
Furthermore, in addition to well-known regulatory effect of EGCG in adipose cells, EC and ECG 
showed potent effect to regulate lipogenesis/lipolysis including suppressed more triglyceride 
accumulation and FFA release, this observation is important as obesity is encompassed releases of FFA 
which both involved in development insulin resistance. All these effects are in part mediated by selective 
activation of either AMPK in skeletal muscle cells or Akt hepatic and adipose cells, and this result 
suggests selective effect of green tea compounds according to cell type. However, the signalling pathway 
of these effects are not yet confirmed and specific studies to investigate this further are required. These 
compounds could, however, potentially be therapeutic agents to regulate glucose and lipid metabolism 
in individuals with metabolic disease or disorders like obesity and T2D. 
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Chapter Four 
 
The effect of green tea extract on 
glucose homoeostasis in high 
glucose fed mice  
 
4 The effect of green tea extract on glucose homoeostasis in high glucose fed mice  
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4.1 Introduction 
A cluster of risk factors has been shown to have a critical role in dysregulation body glucose 
homoeostasis and increase the incidence of several disorders and diseases related to impairment glucose 
and lipid metabolism (Lebovitz, 2006;Martín-Timón, et al., 2014;Rossner, 2002). Obesity associated 
with insulin resistance, dyslipidaemia, and glucose intolerance are the major metabolic dysfunction 
referred to as ‘metabolic syndrome’ that increases the risk of type 2 diabetes (T2D) (Batsis, et al., 
2007;Flier, 2004;Kahn, et al., 2006). Excessive caloric intake is the main factor involved in the 
development of individual obesity which is linked to insulin resistance that precedes to T2D (Hill, et al., 
2012;Pang, et al., 2014). In this case, there is an increased glucose influx concomitant with elevated 
hepatic glucose production that causes continuous hyperglycaemia which is a characteristic feature of 
T2D (Inzucchi, et al., 2012;Nathan, et al., 2009).   
 
Rodents, particularly mice and rats, are widely used as a model to study dysregulated of glucose and 
lipid metabolism including conditions such as obesity, insulin resistance, and T2D. The diet-induced 
obesity and insulin resistance in rodents is gaining attention as a tool to investigate the role and 
composition of the diet in the induction of obesity (Barbosa-da-Silva, et al., 2014;Islam and Loots du, 
2009). In addition to impairment of glucose metabolism (Bowe, et al., 2014), and development of novel 
anti-diabetic treatments (King, 2012).  The effect of high-fat diet on C57BL/6 mice was firstly reported 
in 1988 (Surwit, et al., 1988).  Mice that consumed a high-fat diet developed obesity, impaired of glucose 
tolerance, dysregulated of glucose homoeostasis and insulin resistance (Ahren, 1999;Winzell and Ahren, 
2004). Furthermore, this impairment can be achieved by inducing a positive energy balance via 
supplementing other nutrients. These nutrients could be the carbohydrates sucrose and fructose either in 
diet or drinking water (Lim, et al., 2010;Schultz, et al., 2013;Sumiyoshi, et al., 2006;Tran, et al., 
2009;Wagoner, et al., 2015).    
 
The beneficial effects of green tea extract and/or some of its main active constituents on the 
regulation of glucose and lipid metabolism has previously been studied in animal models (Chen, et al., 
2011;Haidari, et al., 2012), and in human trials (Mackenzie, et al., 2007;Suliburska, et al., 
2012;Venables, et al., 2008;Zhang, et al., 2012). The green tea extract or EGCG can improve glucose 
tolerance in rodent fed high fat, high fructose and sucrose diet induced obesity, and in induced diabetes 
(Chen, et al., 2009;Tang, et al., 2013;Wolfram, et al., 2005;Wu, et al., 2004b). Secondly, consumption 
of these compounds caused reduction of high fasting blood glucose that resulted from dysregulation of 
glucose and lipid metabolism in obesity and diabetes (Alam, et al., 2014;Bose, et al., 2008;Tsuneki, et 
al., 2004;Wu, et al., 2004a). In addition, green tea compounds can reduce accumulation of fat in various 
body regions, as well as reduce body weight and weight gain (Chen, et al., 2009;Cunha, et al., 
2013;Klaus, et al., 2005;Park, et al., 2011).  Furthermore, decreased the level of circulating insulin, 
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ameliorated insulin resistance and increased insulin sensitivity in obese and pre-diabetic subjects (Bose, 
et al., 2008;Nomura, et al., 2015;Tang, et al., 2013;Wu, et al., 2004a;Wu, et al., 2004b). Moreover, 
these compounds show the ability to regulate impaired lipid metabolism by decreasing the levels of 
circulating cholesterol and triglyceride (Axling, et al., 2012;Bose, et al., 2008;Sugiura, et al., 2012).     
 
The aims of the research described in this chapter are: 
• To explore the impact of green tea extract and its abundant active compound (EGCG) on 
body weight and weight gain, subcutaneous, visceral, and intra-scapular fat weight, 
feeding and drinking behaviour in mice fed normal chow and drinking either water or high 
glucose supplemented water. 
• To investigate the effect of these natural compounds on measures of glucose metabolism 
including fasting glucose, glucose tolerance, insulin sensitivity, beta-cell function, and 
markers of lipid metabolism including measurement of total cholesterol (TC), triglyceride 
(TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) in both normal 
and glucose fed mice. 
• To determine the role of these compounds to regulate genes expression related to glucose 
and lipid metabolism in the main metabolic insulin-senstive tissues (hepatic, skeletal 
muscle, and adipose tissues). 
 
4.2 Materials and methods 
All material and methods that have been used to investigate the effects of green tea extracts and its 
main compound EGCG on glucose homoeostasis in vivo were mentioned in details in chapter two. These 
methods including measurment the level of glucose during tolerance test (GTT), fasting blood glucose 
(FBG) using glucose meter, calculated glucose area under the curve (gAUC). In addition to estimate the 
level of fasting serum insulin through ELISA kit, and calculating homoeostasis model assessment 
including insulin resistance, beta cell function, and insulin sensitivity (HOMA-IR, B, and S) based on 
FBG and insulin data in fasting state using computerised HOMA calculator two software. Furthermore, 
food and water consumption, total weight gain, fat pads mass (visceral, subcutaneous, intra-scapular), 
and organs weight, as well as lipid profile including TC, HDL, TG, and cLDL. TG and HDL were 
measured by using CardioChek® P.A analyser, and the level of TC was estimated by colorimetric assay, 
whereas, cLDL was calculated by using Friedewald equation based on the levels of TC, TG, and HDL. 
Moreover, expressions of some genes that involved in regulation of glucose and lipid metabolism in 
insulin-sensitive tissue were measured by using qPCR. All data were analysed using one way ANOVA 
followed by Tukey’s post-hoc test for multiple comparisons unless otherwise stated. 
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4.3 Results 
4.3.1 Effect of green tea extracts and EGCG on total weight and weight gain 
Total body weight and therefore weight gain were monitored weekly in the control and three 
treatment groups decaffeinated green tea extract (DGTE), EGCG, and commercial green tea extract 
(GTE) of mice that had water supplemented with or without glucose. Whole body weight of mice 
showed no significant differences between treatment and control in all groups, except GTE fed mice, 
which displayed a significant increase body weight of 11% (p=0.0392) and 12.25% (p=0.0247) at week 
one only in both main groups respectively (Figure 4.1). Mice that received treatments without glucose 
showed significantly less weight gain compared to control, with DGTE fed mice having 40.8%±8% less 
weight gain (p=0.0070), and EGCG fed mice having 31%±4.5% less weight gain (p=0.0471) (Figure 
4.2 A). However, GTE fed mice did not show a significant decrease in weight gain. No significant effect 
of green tea extracts on weight gain were seen in mice receiving treatment with a high glucose diet 
compared to control mice (Figure 4.2 B).  
 
4.3.2 Effect of green tea extracts and EGCG on food and water intake 
Diet and water consumption were measured weekly during the treatment period. The average food 
consumed (mouse/day) in mice treated without glucose was: 3.79g (control), 3.39g (DGTE), 3.57g 
(EGCG), and 3.88g (GTE). From this, only DGTE caused a significant decrease food intake by 
10.4%±3.2% (p=0.0007) compared to control (Figure 4.3 A), whereas no significant differences in food 
intake were recorded between treatment and control groups that received 30% (w/v) of glucose alongside 
green tea extracts. The average food intake (mouse/day) of these groups were: 2.041g (control), 1.863g 
(DGTE), 2.32g (EGCG), and 1.9g (GTE) (Figure 4.3 B). These data do however show that 
supplementation of water with glucose reduced the amount of food consumed in all groups. Water intake 
(mouse/day) was calculated in (control, DGTE, EGCG, and GTE) groups fed normal and a glucose diet, 
and the average intakes were; 5.776mls, 4.149mls, 4.797mls, and 6.252mls and 8.155mls, 9.578mls, 
8.79mls, and 9.037mls respectively. Based on analysed data, there were no significant differences 
between treatment and control of all groups except DGTE, which caused a significant decrease water 
intake by 28.2%±4% (p=0.0382) in mice fed a normal diet (Figure 4.4). According to water consumption 
data, the actual doses of treatment were calculated for each group. These doses were 39.555, 13.943, 
and 89.036mg/kg/day for groups receiving DGTE, EGCG, and GTE without glucose respectively, and 
for those fed with high glucose, the doses were 56.628, 11.748, and 83.759 mg/kg/day respectively.  
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Figure 4.1 GTE increases body weight at week one in mice fed normal or glucose-rich diet. 
Mice fed DGTE, EGCG, and GTE for 28 days in drinking water supplemented with or without 30% 
(w/v) of glucose. Mice weight was measured weekly and average weight was then calculated every week 
during experiment. (A) Body weight of mice fed green tea compounds without glucose diet, only GTE 
at week one increased body weight compared to control. (B) Body weight of mice fed green tea 
compounds alongside glucose diet, only GTE at week one increased body weight compared to control. 
Data presented mean ± SEM, *p<0.05, n=6. 
 
W e e k  0 W e e k  1 W e e k  2 W e e k  3 W e e k  4
2 4
2 5
2 6
2 7
2 8
2 9
3 0
3 1
3 2
M
ou
se
 b
od
y 
w
ei
gh
t 
(g
ra
m
s)
C o n tr o l
D G T E
E G C G
G T E
*
A
W e e k  0 W e e k  1 W e e k  2 W e e k  3 W e e k  4
2 4
2 5
2 6
2 7
2 8
2 9
3 0
3 1
3 2
3 3
3 4
3 5
M
ou
se
 b
od
y 
w
ei
gh
t 
(g
ra
m
s)
C o n tr o l
D G T E
E G C G
G T E
*
B
133 
 
 
 
Figure 4.2 Selected green tea extracts reduce weight gain in mice fed normal diet. 
Mice fed DGTE, EGCG, and GTE for 28 days in drinking water supplemented with or without 30% 
(w/v) of glucose. Mice weight was measured weekly and average weight gain was then calculated at the 
end of experiment. Mice body weight gain was calculated based on the differences between the recorded 
weight of mice at day 0 and day 28 post treatment with green tea extracts. (A) DGTE and EGCG 
significantly decreased weight gain in mice fed normal diet compared to control. (B) All treatments 
showed no significant effect to reduce weight gain in mice supplemented with glucose diet. Data 
presented mean ± SEM, *p<0.05, and **p<0.01, n=6. 
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Figure 4.3 DGTE reduces diet intake in mice fed normal diet. 
Mice fed DGTE, EGCG, and GTE for 28 days in drinking water supplemented with or without 30% 
(w/v) of glucose. Mice food intake was measured twice a week and average chow intake was then 
calculated at the end of experiment. (A). Diet consumption of mice received treatments without glucose 
diet; only DGTE decreased diet intake compared to control. (B). Diet consumption of mice received 
treatments with glucose diet, no effect of all treatments on food intake compared to control. However, 
mice received 30% (w/v) of glucose in drinking water showed decreases diet intake compared to mice 
received normal water. Data presented mean ± SEM, ***p<0.001, n=6. 
135 
 
 
 
Figure 4.4 DGTE reduces water intake in mice fed normal diet. 
Mice fed DGTE, EGCG, and GTE for 28 days in drinking water supplemented with or without 30% 
(w/v) of glucose. Mice water intake was measured twice a week and average water intake was then 
calculated at the end of experiment. (A). Average water consumptions of mice received treatments 
without glucose water; only DGTE decreased water intake compared to control. (B). Water consumption 
of mice received treatments with glucose-rich diet, no effect of all treatments on water intake compared 
to control. However, mice fed 30% (w/v) of glucose water showed increases water intake compared to 
mice fed normal water. Data presented mean ± SEM, *p<0.05, n=6. 
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4.3.3 Effect of green tea extract on insulin-sensitive tissue mass 
Liver, skeletal muscle, subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT), and intra-
scapular brown adipose tissue (BAT) were harvested and weighted after 28 days of treatment with 
DGTE, EGCG, and GTE supplementation with or without high glucose diet. Only EGCG significantly 
increased liver mass (32.6%± 4.1%, p=0.0004) compared to control in mice fed a normal diet (Figure 
4.5 A). All green tea treatments supplemented with a high glucose diet did not alter liver mass compared 
to control (Figure 4.5 B). All green tea extracts provided to mice without and with a glucose diet did not 
affect skeletal muscle mass compared to control (Figure 4.6).  
 
Mice supplemented with 30% (w/v) of glucose in their drinking water for 28 days showed no 
significant changes in fat depots mass compared to mice received only water except SAT weight was 
significantly increase (p=0.0375).  SAT mass was significantly increased in mice receiving DGTE and 
EGCG without glucose supplementation compared to control. These increases in mass were 
88.7%±14% (p=0.0186) and 192.2%±8.1% (p<0.0001) (Figure 4.7 A). SAT mass in mice supplemented 
with green tea extracts alongside glucose diet appeared to be higher than control, however only DGTE 
and GTE promoted significant increases. The recorded increases of SAT mass were 88.6%± 12% 
(p=0.0116) and 82.5%±13.7% (p=0.0197) respectively (Figure 4.7 B). Only EGCG treatment 
significantly altered VAT mass with an increase of 121.6%±7.8% (p<0.0001) being recorded in mice 
fed a normal diet compared to control (Figure 4.8 A). DGTE and GTE significantly increased VAT mass 
by 91.5%±12.7% (p=0.0145) and 85.4%±14% (p=0.0237) compared to control in mice fed a glucose-
rich diet (Figure 4.8 B). In mice fed a normal diet only, EGCG caused a significant increase in BAT 
mass by 76.5%±6.9% (p<0.0001) compared to control (Figure 4.9 A). Mice supplemented with a high 
glucose diet alongside green tea treatments DGTE, and GTE increased BAT mass by 79.7%±6.4% 
(p=0.0082) and 101%±8.8% (p=0.0009) compared to control (Figure 4.9 B). 
 
4.3.4 Effect of green tea extracts on glucose tolerance test (GTT) 
The GTT was performed before and after treatment with DGTE, EGCG, and GTE with and without 
glucose supplementation for 28 days. The level of blood glucose was monitored at set time points (0 – 
2h) during GTT (Figure 4.10). From obtained data, glucose area under the curve (gAUC) was calculated, 
and the result showed no differences between green tea extract treatments and control in all groups 
(Figure 4.11). The level of glucose after 2h was recorded to identify the ability of the body to dispose 
of glucose. In all groups, those who administrated green tea extracts without or with a glucose diet 
showed no significant differences in blood glucose concentration between treatment and control which 
indicated that green tea extract did not increase glucose clearance (Figure 4.12). Furthermore, Glucose 
supplemented to mice for 28 days did not significantly impaired glucose tolerance compared to glucose 
tolerance at day 0 as the gAUC and glucose clearance were not significantly changed. 
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Figure 4.5 EGCG increases liver mass in mice fed normal diet. 
Mice fed DGTE, EGCG, and GTE for 28 days in drinking water supplemented with or without 30% 
(w/v) of glucose. At the end of experiment, fasted mice were sacrificed, and the liver was dissected and 
weighted, and then average weight was calculated. (A). Liver mass of mice fed a normal diet with green 
tea extracts; only EGCG increased liver weight compared to control. (B). Liver mass of mice fed glucose 
rich diet with green tea extracts; all treatments did not change liver mass compared to control. Data 
presented mean ± SEM, ***p<0.001, n=6.  
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Figure 4.6 Green tea extracts do not alter skeletal muscle mass in all mice groups.  
Mice fed DGTE, EGCG, and GTE for 28 days in drinking water supplemented with or without 30% 
(w/v) of glucose. At the end of experiment, fasted mice were sacrificed, and the skeletal muscles were 
dissected and weighted, and then average weight was calculated. (A). The skeletal muscle mass of mice 
fed a normal diet with green tea extracts showed no differences between treated and control group. (B). 
The skeletal muscle mass of mice fed glucose rich diet with green tea extracts showed no differences 
between treated and control group. Data presented mean ± SEM, n=6. 
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Figure 4.7 Selected green tea extracts increase SAT mass in mice fed normal or glucose-rich diet. 
Mice fed DGTE, EGCG, and GTE for 28 days in drinking water supplemented with or without 30% 
(w/v) of glucose. At the end of experiment, fasted mice were sacrificed, and the SAT was dissected, 
weighted, and the average weight was calculated. Mice fed glucose diet showed significant increased 
SAT weight compared to normal mice. (A). SAT mass of mice fed a normal diet with green tea extracts, 
DGTE and EGCG increased SAT mass compared to control. (B). SAT mass of mice fed glucose diet 
with green tea extracts, DGTE and GTE increased SAT mass compared to control. Data presented mean 
± SEM, *p<0.05 and ****p<0.0001, n=6. 
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Figure 4.8 Selected green tea extracts increase VAT mass in mice fed normal or glucose-rich diet. 
Mice fed DGTE, EGCG, and GTE for 28 days in drinking water supplemented with or without 30% 
(w/v) of glucose. At the end of experiment, fasted mice were sacrificed, and the VAT was dissected, 
weighted, and the average weight was calculated. Mice fed glucose diet showed no significant of VAT 
weight compared to normal mice. (A). VAT mass of mice fed a normal diet with green tea extract, 
EGCG increased VAT mass compared to control. (B). VAT mass of mice fed glucose rich diet with 
green tea extracts, DGTE and GTE increased VAT mass compared to control. Data presented mean ± 
SEM, *p<0.05, ****p<0.0001, n=6. 
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Figure 4.9 Selected green tea extracts increase BAT mass in mice fed normal or glucose-rich diet. 
Mice fed DGTE, EGCG, and GTE for 28 days in drinking water supplemented with or without 30% 
(w/v) of glucose. At the end of experiment, fasted mice were sacrificed, and the BAT was dissected, 
weighted, and the average weight was calculated. Mice fed glucose diet showed no significant of VAT 
weight compared to normal mice. (A). BAT mass of mice fed a normal diet with green tea extracts, 
EGCG increased BAT mass compared to control. (B). BAT mass of mice fed glucose rich diet with 
green tea extracts,  DGTE and GTE increased BAT mass compared to controls. Data presented mean ± 
SEM, **p<0.01, ***p<0.001, ****p<0.0001, n=6. 
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 Figure 4.10 Glucose levels during GTT in all mice received green tea extracts.  
Mice fed DGTE, EGCG, and GTE for 28 days in drinking water supplemented with or without 30% 
(w/v) of glucose. Glucose tolerance test was performed at day 0 and 28 days through monitoring level 
of glucose at 15, 30, 60, and 120 minutes after intra peritoneal injected of fasting mice with 2g/kg D-
glucose solution. (A). Tolerance curves of mice fed a normal diet with green tea extracts. (B). Tolerance 
curves of mice fed glucose rich diet with green tea extracts. The data presented mean ± SEM, n=6. 
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Figure 4.11 Green tea extracts do not reduce gAUC in mice fed normal or glucose-rich diet. 
Mice fed DGTE, EGCG, and GTE for 28 days in drinking water supplemented with or without 30% 
(w/v) of glucose. Glucose levels were measured during GTT at day 0 and 28, and glucose area under 
the curve was calculated. Mice fed glucose diet for 28 days showed no significant reduction of gAUC 
compared to gAUC in mice at day 0. (A). The gAUC of mice fed a normal diet with green tea extracts, 
no effect of treatments to reduce gAUC compared to control. (B). The gAUC of mice fed glucose rich 
diet with green tea extracts; all treatments did not reduce gAUC compared to control. The data presented 
mean ± SEM, n=6. 
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Figure 4.12 Green tea extracts do not increase glucose clearance during GTT in all mice. 
Mice fed DGTE, EGCG, and GTE for 28 days in drinking water supplemented with or without 30% 
(w/v) of glucose. Glucose levels at 120 minutes during GTT at 0 and 28 days was obtained and glucose 
clearance was then analysed. Mice fed glucose diet showed no significant effect to reduce glucose 
clearance compared to mice at day 0. (A). A glucose level of mice fed a normal diet with green tea 
extracts, no effect of all treatments to dispose of glucose compared to control. (B). A glucose level of 
mice fed glucose rich diet with green tea extracts, no effect of all treatments to increase disposal blood 
glucose compared to control. Data presented mean ± SEM, n=6. 
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4.3.5 Selected green tea extracts reduced mice fasting blood glucose (FBG) 
FBG was measured before GTT was performed as a baseline of glucose concentration for mice that 
received treatments without and with glucose rich diet. The FBG levels in mice fed a normal diet with 
DGTE, EGCG, and GTE were unchanged compared to control (Figure 4.13 A, p>0.9999, 0.9939, and 
0.5797 respectively). Alternatively, supplementation of glucose to the control group for 28 days 
significantly increased FBG level (277.6%±10.4% (p<0.0001) compared to the control group at day 0. 
Only DGTE and EGCG reduced the high level of FBG by 45.5%±19.7% (p=0.0011) and 33.9%±10% 
(p=0.0296) compared to control (Figure 4.13 B). 
 
4.3.6 Selected green tea extracts increased the levels of fasting insulin in serum  
The levels of fasting insulin were determined in serum of all mice groups after 28 days of treatment 
with DGTE, EGCG, and GTE either without or with a glucose supplemented diet. Mice treated with 
green tea only, DGTE, and GTE showed no significant effect on the level of insulin (77.3%±34.2%, 
p=0.8707 and 49%±57.3%, p=0.9434). EGCG, however, caused a significant elevation in the level of 
insulin by 443.8%±20.7% (p=0.0009) compared to control (Figure 4.14 A). Mice treated with these 
extracts in addition to a glucose diet expressed high levels of insulin compared to control, with only 
EGCG and GTE significantly increased insulin concentrations by 194.5±17.3% (p=0.0022) and 
149.8%±13.9% (p=0.0175) (Figure 4.14 B).  
 
4.3.7 Homoeostasis model assessment (HOMA) 
HOMA including IR, B, and S were calculated based on the glucose and insulin levels in fasting 
condition. HOMA-IR and B were measured in all mice groups, whereas HOMA-S was determined only 
in mice receiving green tea extracts with a high glucose diet. The latter was due to the levels of insulin 
in groups receiving treatments without a glucose-rich diet being low. Therefore, ineligible for use in 
calculating HOMA S. DGTE and GTE did not cause any significant effect on insulin resistance 
(p=0.5255 and p=0.9684), while EGCG significantly increased insulin resistance by 411.3%±13.7% 
(p<0.0001) compared to control in mice fed a normal diet (Figure 4.15 A). All treatments in mice 
supplemented with a glucose diet did not show any differences in insulin resistance compared to control 
(Figure 4.15 B, p=0.2836), p=0.4398, and p=0.3955). In mice fed a normal diet alongside green tea 
extracts, only EGCG significantly increased pancreatic beta-cell function by 548.4%±27.9% (p=0.0066) 
(Figure 4.16 A). No statistically significant increases in beta-cells function were seen in mice 
supplemented with green tea extracts alongside a glucose-rich diet, with values of 653%±38%, 
p=0.0629, 511%±24.2%, p=0.1815, and 375%±20.4%, p=0.4202 compared to control (Figure 4.16 B). 
Moreover, unchanged levels of insulin sensitivity were observed between all treatment and control mice 
that had consumed a high glucose diet (Figure 4.17, p=0.1593, 0.9859, and 0.9998). 
146 
 
 
 
Figure 4.13 Selected green tea extracts decrease FBG levels in mice fed glucose-rich diet. 
Mice fed DGTE, EGCG, and GTE for 28 days in drinking water supplemented with or without 30% 
(w/v) of glucose. Fasting blood glucose level was measured at day 0 and 28 after treatment with selected 
green tea extract using glucose meter. Mice fed glucose diet for 28 days showed impairment of FBG 
which was significantly increased compared to its level at day 0. (A). FBG levels of mice fed a normal 
diet with green tea extracts,  no effect of all treatments to reduce FBG compared to control. (B). FBG 
levels of mice fed glucose rich diet with green tea extracts,  DGTE and EGCG significantly reduced 
high level of FBG compared to control. Data presented mean ± SEM, *p<0.05 **p<0.01, and 
****p<0.0001, n=6. 
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Figure 4.14 Selected green tea extracts increase insulin levels in mice fed normal or glucose-rich 
diet. 
Mice fed DGTE, EGCG, and GTE for 28 days in drinking water supplemented with or without 30% 
(w/v) of glucose. At the end of experiment, blood was collected from fasted mice and subjected to serum 
process. Fasting serum insulin levels were measured specific ELISA kit. (A). Insulin level of mice fed 
a normal diet with green tea extracts; only EGCG increased insulin level compared to control. (B). 
Insulin level of mice fed glucose rich diet with green tea extracts,  EGCG and GTE increased insulin 
level compared to control. Data presented mean ± SEM, *p<0.05 **p<0.01, ***p<0.001, n=5. 
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Figure 4.15 EGCG increases HOMA-IR value in mice fed normal diet. 
Mice fed DGTE, EGCG, and GTE for 28 days in drinking water supplemented with or without 30% 
(w/v) of glucose. At the end of experiment, fasting glucose and insulin were measured, and then HOMA-
IR was calculated. (A). HOMA-IR of mice fed a normal diet with green tea extracts; only EGCG 
increased insulin resistance compared to control. (B) HOMA-IR of mice fed glucose rich diet with green 
tea extracts, no significant effect of all treatments on insulin resistance compared to control. Data 
analysed by using computerised HOMA calculator 2 software (Oxford University, Diabetes Trial Unit, 
UK). Data presented mean ± SEM, ****p<0.0001, n=5. 
149 
 
 
 
Figure 4.16 EGCG increases HOMA-B value in mice fed normal diet. 
Mice fed DGTE, EGCG, and GTE for 28 days in drinking water supplemented with or without 30% 
(w/v) of glucose. At the end of experiment, fasting glucose and insulin were measured, and then HOMA-
B was calculated. (A). HOMA-B of mice fed a normal diet with green tea extracts; only EGCG increased 
of beta-cell function compared to control. (B) HOMA-B of mice fed glucose rich diet with green tea 
extracts, no significant effect of all treatments on beta-cell function compared to control. Data analysed 
by using computerised HOMA calculator 2 software (Oxford University, Diabetes Trial Unit, UK). Data 
presented mean ± SEM, **p<0.01, n=5. 
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Figure 4.17 Green tea extracts do not alter HOMA-S in mice fed glucose-rich diet. 
Mice fed DGTE, EGCG, and GTE for 28 days in drinking water supplemented with or without 30% 
(w/v) of glucose. At the end of experiment, fasting glucose and insulin were measured, and then HOMA-
S was calculated only in mice fed glucose diet. No significant effect of all treatments on insulin 
sensitivity compared to control. Data analysed by using computerised HOMA calculator 2 software 
(Oxford University, Diabetes Trial Unit, UK). Data presented mean ± SEM, n=5. 
 
 
4.3.8 Selected green tea extracts reduced circulating total cholesterol (TC)  
The levels of TC were investigated in mice after 28 days of treatment with DGTE, EGCG, and GTE 
with or without glucose supplementation. Mice treated with EGCG and GTE compounds without high 
glucose showed no significant reduction in the levels of TC (p=0.0656 and p=0.4653) compared to 
control, however only DGTE significantly decreased the level of TC by 44.4%±3.7% (p=0.0014) 
(Figure 4.18 A). All green tea extract treatments in mice supplemented with glucose caused significant 
decreases in the level of TC compared to control (Figure 4.18 B). The recorded percentage of these 
reductions were: 52.2%±10% (p<0.0001), 51.5%±3.3% (p<0.0001), and 53.2%±6.9% (p<0.0001) 
respectively. 
 
4.3.9 Selected green tea extract increased circulating triglyceride (TG) levels 
The concentration of TG was measured in all groups after 28 days of treatment with DGTE, EGCG, 
and GTE with or without glucose supplementation. The result showed that the level of TG was 
significantly increased by 123.2%±4.7% (p<0.0001) and 64%±8.3% (p=0.0004) in mice that received 
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DGTE and EGCG without a high glucose diet compared to control, with no significant effect of GTE 
(p=0.9968) (Figure 4.19 A). EGCG treatment alongside a glucose supplemented diet caused a 
62.2%±6.9% (p<0.0001) increase of TG compared to control without significant effect of DGTE 
(p=0.4630) and GTE (p=0.9010) (Figure 4.19 B).  
 
4.3.10 Effect of green tea extract on the level of high-density lipoprotein (HDL) 
The level of HDL was determined in mice after 28 days post-treatment with DGTE, EGCG, and GTE 
that were supplemented with or without a glucose diet. The result showed that there were no significant 
differences between treatments and control regarding HDL concentration in mice fed a normal diet 
(Figure 4.20 A, p=0.8699, 0.2460, and 0.7694 respectively). Similarly, mice given green tea extracts 
alongside a glucose-rich diet did not express statistically significant increases in HDL level compared 
to control (Figure 4.20 B, p=0.1414, 0.0541, and  0.7863 respectively). 
 
4.3.11 Selected green tea extracts decreased the level of calculated low-density 
lipoprotein (cLDL) 
The level of cLDL was measured in mice after 28 days of treatment with DGTE, EGCG, and GTE 
that received treatment alone or with a high glucose diet based on obtained lipid profile data, including 
TC, TG, and HDL. The levels of cLDL were significantly decreased by 72.5%±10.5% (p=0.0008) and 
53.5%±35.9% (p=0.0126) when mice were treated with DGTE and EGCG alone compared to control, 
whereas GTE statistically failed to decrease cLDL level (p=0.3541) (Figure 4.21 A). Mice were given 
DGTE, EGCG, and GTE alongside a glucose rich diet expressed significant reduction in the level of 
cLDL compared to control. These decreases were: 81.8%±46.8% (p<0.0001), 86.3%±20% (p<0.0001), 
and 76.8%±12.7% (p<0.0001) respectively (Figure 4.21 B). 
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Figure 4.18 Selected green tea extracts decrease TC levels in mice fed normal or glucose-rich diet. 
Mice fed DGTE, EGCG, and GTE for 28 days in drinking water supplemented with or without 30% 
(w/v) of glucose. At the end of experiment, fasted mice were sacrificed, and blood was collected and 
subjected to serum process. The level of circulating total cholesterol was measured by using colorimetric 
assay kit. (A). TC levels of mice fed a normal diet with green tea extracts, DGTE decreased the level of 
TC compared to control (B). TC level of mice fed glucose rich diet with green tea extracts, all treatments 
decreased TC level compared to controls. Data presented mean ± SEM, **p<0.01, ****p<0.0001 n=6. 
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Figure 4.19 Selected green tea extracts increase TG levels in mice fed normal or glucose-rich diet. 
Mice fed DGTE, EGCG, and GTE for 28 days in drinking water supplemented with or without 30% 
(w/v) of glucose. At the end of experiment, the level of circulating triglyceride was measured in fasted 
mice by using CardioChek® P.A analyser with lipid PTS panels. (A). TG levels of mice fed a normal 
diet with green tea extracts, DGTE and EGCG increased of TG level compared to control. (B). TG levels 
of mice fed glucose rich diet with green tea extracts, only EGCG increased the level of TG compared to 
control. Data presented mean ± SEM, ***p<0.001, ****p<0.0001, n=6. 
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Figure 4.20 Green tea extracts do not alter HDL levels in mice fed normal or glucose-rich diet. 
Mice fed DGTE, EGCG, and GTE for 28 days in drinking water supplemented with or without 30% 
(w/v) of glucose. At the end of experiment, the level of circulating high density lipoprotein was 
measured in fasted mice by using CardioChek® P.A analyser with lipid PTS panels. (A). HDL levels of 
mice fed a normal diet with green tea extracts, no effect of all treatments on the level of HDL was 
observed compared to control. (B). HDL levels of mice fed glucose rich diet with green tea extract, no 
effect of all treatments on the level of HDL was observed compared to control. Data presented mean ± 
SEM, n=6. 
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Figure 4.21 Selected green tea extracts decrease cLDL levels in mice fed normal or glucose-rich 
diet. 
Mice fed DGTE, EGCG, and GTE for 28 days in drinking water supplemented with or without 30% 
(w/v) of glucose. At the end of experiment, the level of circulating low density lipoprotein was calculated 
by using Friedewald formula based on obtained lipid profile data row (A). The cLDL levels of mice fed 
a normal diet with green tea extracts, DGTE and EGCG decreased the level of cLDL compared to 
control. (B). The cLDL levels of mice fed glucose rich diet with green tea extracts, all treatments 
decreased the level of cLDL compared to control. Data presented mean ± SEM, *p<0.05, ***p<0.001, 
****p<0.0001, n=6. 
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4.3.12 Effect of green tea extract on glucose metabolism gene expression in liver 
Expression of mRNA related to glucose regulation and metabolism were examined in the liver of 
mice supplemented with DGTE, EGCG, and GTE with or without a rich glucose diet after 28 days of 
treatment. Expression of IR, Glut2, Gys1, G6Pase, PEPCK, CPT1α and FASN were assessed. The 
results of both main groups revealed that mice treated without and with a glucose diet showed no 
differences in expression of those genes between treatments and control, except EGCG in the high 
glucose diet group, which significantly downregulated expression of PEPCK mRNA, and all gene 
expression data can be seen in Table 4.1. 
 
4.3.13 Effect of green tea extract on glucose metabolism gene expression in skeletal 
muscle 
The mRNA expression of glucose metabolism genes including IR, Glut4, Gys1, PDK4, and PGC1α 
were determined in skeletal muscle of mice that received green tea extracts with or without a high 
glucose diet after 28 days of treatment. Green tea extracts did not mediate any differences in expression 
of these genes in all groups. Only EGCG and GTE gave to mice with a high glucose diet caused 
significant downregulation of PDK4 mRNA by 92%±34.25%, p=0.0131 and 93%±7.4%, p=0.0122 
compared to control, and all gene expression data can be seen Table 4.2. 
 
4.3.14 Effect of green tea extract on glucose and lipid metabolism gene expression in 
adipose tissue 
The level of mRNA expression of glucose and lipid metabolism genes expression including IR, 
Glut4, SREBP1c, C/EBPα, PPARγ, FASN, FABP4, and LPL were investigated in mice adipose tissue. 
Green tea extracts did not alter the expression of IR, SREBP1c, PPARγ, and FASN mRNA in all mice 
(Table 4.3). Green tea extracts supplemented to mice fed a normal diet did not change the level of Glut4 
expression (Table 4.3). DGTE and GTE significantly downregulated Gult4 mRNA expression by 
68.4%±40.75%, p=0.0124 and 65.9%±17.2%, p=0.0153 in mice fed a glucose-rich diet. (Table 4.3). 
DGTE and GTE combined with a calorie-rich diet significantly downregulated C/EBPα mRNA by 
87.6%±38.9%, p=0.0282 and 79%±44.75%, p=0.0459 compared to control. (Table 4.3). No differences 
in expression level of C/EBPα mRNA between treatments and control in mice fed a normal diet were 
seen. Furthermore, DGTE, EGCG, and GTE significantly decreased expression of FABP4 by 
77.6%±46.9%, p=0.0032, 85.9%±20.8%, p=0.0017, and 49.6%±30.3%, p=0.0386 in mice fed a normal 
diet, and by 89.3%±62%, p=0.0098, 75%±24.1%, p=0.0252, and 67.2%±32.4%, p=0.0427 in mice fed 
a high glucose (Table 4.3). LPL mRNA was significantly downregulated by 81%±31.2%, p=0.0016, 
78.7±47.9%, p=0.0019, and 46.2%±7%, p=0.0427 in response to DGTE, EGCG, and GTE in mice fed 
a normal diet. Whereas no statistically significant differences in LPL expression in response to DGTE 
were seen in mice fed a glucose-rich diet (Table 4.3).    
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Table 4.1 Effect of green tea extracts on glucose metabolism mRNA expression in the liver of mice 
fed normal or glucose-rich diet. 
Mice fed DGTE, EGCG, and GTE for 28 days in drinking water supplemented with or without 30% 
(w/v) of glucose. At the end of experiment, fasted mice were sacrificed and the liver was dissected. RNA 
was isolated and reverse transcriptased, followed by quantifing amplification of selected glucose 
metabolism mRNA by using qPCR. No significant differences between green tea treatments and control 
of all tested genes were seen except EGCG supplemented to mice with glucose significantly 
downregulated PEPCK mRNA leve compared to control. Data displayed as relative fold of gene 
expression which normalised to housekeeping gene. The data presented mean ± SEM, n=3. 
 
mRNA Mice treatment ↑↓ Fold of control ± SEM P value 
 
 
IR 
DGTE 
DGTE with glucose 
1.488 ± 0.8094 
6.007 ± 3.402 
0.9639 
0.2486 
EGCG 
EGCG with glucose 
1.411 ± 1.17 
0.3412 ± 0.04296 
0.9779 
0.9907 
GTE 
GTE with glucose 
0.8031 ± 0.1628 
0.8626 ± 0.3526 
0.9969 
0.9998 
 
 
Glut2 
DGTE 
DGTE with glucose 
1.245 ± 0.7747 
7.954 ± 4.692 
0.9954 
0.2709 
EGCG 
EGCG with glucose 
1.792 ± 1.068 
2.555 ± 1.591 
0.8503 
0.9696 
GTE 
GTE with glucose 
1.305 ± 0.1774 
1.541 ± 0.2099 
0.9907 
0.9987 
 
 
Gys1 
DGTE 
DGTE with glucose 
0.8558 ± 0.3334 
54.24 ± 26.84 
>0.9999 
0.0883 
EGCG 
EGCG with glucose 
15.18 ± 14.91 
0.7416 ± 0.2109 
0.5635 
>0.9999 
GTE 
GTE with glucose 
0.7586 ± 0.1532 
0.7472 ± 0.08106 
>0.9999 
>0.9999 
 
 
G6Pase 
DGTE 
DGTE with glucose 
0.5731 ± 0.3303 
1.145 ± 0.1539 
0.8303 
0.8855 
EGCG 
EGCG with glucose 
0.9426 ± 0.6006 
 0.6194 ± 0.07095 
0.9992 
0.2640 
GTE 
GTE with glucose 
0.6069 ± 0.105 
1.154 ± 0.2 
0.8603 
0.8661 
 
 
PEPCK 
DGTE 
DGTE with glucose 
0.716 ± 0.3643 
0.6626 ± 0.2196 
0.9229 
0.2962 
EGCG 
EGCG with glucose 
0.2242 ± 0.1087 
0.2402 ± 0.05387 
0.4014 
   0.0113*    
GTE 
GTE with glucose 
1.456 ± 0.4756 
0.537 ± 0.1013 
0.7818 
0.1139 
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CPT1α 
DGTE 
DGTE with glucose 
0.3487 ± 0.2785 
11.09 ± 7.078 
0.8249 
0.2637 
EGCG 
EGCG with glucose 
1.106 ± 1.003 
0.303 ± 0.1073 
0.9989 
0.9988 
GTE 
GTE with glucose 
0.6815 ± 0.08612 
0.9237 ± 0.6349 
0.9735 
>0.9999 
 
 
FASN 
DGTE 
DGTE with glucose 
0.2884 ± 0.2178 
3.955 ± 1.707 
0.9511 
0.4262 
EGCG 
EGCG with glucose 
3.045 ± 1.957 
3.358 ± 1.126 
0.5186 
0.5973 
GTE 
GTE with glucose 
0.5641 ± 0.1129 
4.225 ± 1.603 
0.9869 
0.3589 
 
Table 4.2 Effect of green tea extracts on glucose metabolism mRNA expression in the skeletal 
muscle of mice fed normal or glucose-rich diet. 
Mice fed DGTE, EGCG, and GTE for 28 days in drinking water supplemented with or without 30% 
(w/v) of glucose. At the end of experiment, fasted mice were sacrificed and the skeletal muscle was 
dissected. RNA was isolated and reverse transcriptased, followed by quantifing amplification of selected 
glucose metabolism mRNA by using qPCR. No significant differences between green tea treatments 
and control of all tested genes were seen except EGCG and GTE supplemented to mice with glucose 
significantly downregulated PDK4 mRNA leve compared to control. Data displayed as relative fold of 
gene expression which normalised to housekeeping gene. The data presented mean ± SEM, n=3. 
 
 
mRNA Mice treatment ↑↓ Fold of control ± SEM P value 
 
 
IR 
DGTE 
DGTE with glucose 
3.766 ± 1.891 
0.9502 ± 0.1348 
0.3789 
0.9923 
EGCG 
EGCG with glucose 
0.5352 ± 0.1317 
0.5171 ± 0.09557 
0.9905 
0.1347 
GTE 
GTE with glucose 
2.881 ± 1.266 
0.3921 ± 0.05978 
0.6656 
0.0546 
 
 
Glut4 
DGTE 
DGTE with glucose 
2.158 ± 0.8696 
2.423 ± 1.192 
0.9387 
0.4119 
EGCG 
EGCG with glucose 
0.9123 ± 0.2169 
0.6245 ± 0.033 
>0.9999 
0.9650 
GTE 
GTE with glucose 
3.345 ± 2.71 
0.4442 ± 0.1525 
0.6681 
0.9039 
 
 
Gys1 
DGTE 
DGTE with glucose 
8.396 ± 7.428 
1.077 ± 0.3249 
0.5331 
0.9984 
EGCG 
EGCG with glucose 
0.9202 ± 0.08099 
1.928 ± 0.5771 
>0.9999 
0.2889 
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GTE 
GTE with glucose 
1.403 ± 0.1515 
0.636 ± 0.1486 
0.9999 
0.8703 
 
 
PDK4 
DGTE 
DGTE with glucose 
2.738 ± 1.16 
0.4075 ± 0.1715 
0.3970 
0.0995 
EGCG 
EGCG with glucose 
0.03981 ± 0.01105 
0.08186 ± 0.02804 
0.7800 
0.0131* 
GTE 
GTE with glucose 
2.197 ± 0.8704 
0.07029 ± 0.005224 
0.6747 
0.0122* 
 
 
PGC1α 
DGTE 
DGTE with glucose 
5.76 ± 4.181 
1.354 ± 0.3336 
0.5067 
0.6709 
EGCG 
EGCG with glucose 
1.674 ± 0.6686 
0.6666 ± 0.1058 
0.9967 
0.6963 
GTE 
GTE with glucose 
3.12 ± 1.9 
0.5895 ± 0.1989 
0.9146 
0.5552 
 
Table 4.3 Effect of green tea extracts on glucose metabolism mRNA expression in the adipose 
tissue of mice fed normal or glucose-rich diet. 
Mice fed DGTE, EGCG, and GTE for 28 days in drinking water supplemented with or without 30% 
(w/v) of glucose. At the end of experiment, fasted mice were sacrificed and the adipose tissue was 
dissected. RNA was isolated and reverse transcriptased, followed by quantifing amplification of selected 
glucose and lipid metabolism mRNA by using qPCR. No significant differences between green tea 
treatments and control regarding to IR, SREBP1c, PPARγ, and FASN genes expression were seen 
compared to control. Glut4 and C/EBPα mRNAs were significantly downregulated in mice fed DGTE 
and GTE supplemented with glucose compared to control. FABP4 mRNA was significantly 
downregulated in response to all green tea treatments in mice fed normal and glucose rich diet compared 
to control. Whereas, LPL mRNA was significantly downregulated inresponse to all green tea treatments 
in mice fed normal diet only compared to control. Data displayed as relative fold of gene expression 
which normalised to housekeeping gene. The data presented mean ± SEM, n=3. 
 
mRNA Mice treatment ↑↓ Fold of control ± SEM P value 
 
 
IR 
DGTE 
DGTE with glucose 
0.8659 ± 0.5984 
0.8246 ± 0.3728 
>0.9999 
0.9417 
EGCG 
EGCG with glucose 
9.158 ± 9.032  
0.1766 ± 0.04989 
0.6063 
0.1252 
GTE 
GTE with glucose 
0.5749 ± 0.2741 
0.327 ± 0.08967 
0.9998 
0.2353 
 
 
Glut4 
DGTE 
DGTE with glucose 
0.3061 ± 0.1698 
0.3158 ± 0.1287 
0.3003 
0.0124* 
EGCG 
EGCG with glucose 
0.7082 ± 0.4522 
0.5444 ± 0.05545 
0.8529 
0.0869 
GTE 
GTE with glucose 
0.3038 ± 0.07783 
0.3415 ± 0.05862 
0.2980 
0.0153* 
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SREBP1c 
DGTE 
DGTE with glucose 
0.5726 ± 0.2813 
0.8144 ± 0.5851 
>0.9999 
0.9811 
EGCG 
EGCG with glucose 
30.77 ± 30.5 
0.548 ± 0.3507 
0.5436 
0.8087 
GTE 
GTE with glucose 
0.7828 ± 0.4521 
0.194 ± 0.1003 
>0.9999 
0.4372 
 
 
C/EBPα 
DGTE 
DGTE with glucose 
0.2149 ± 0.05607 
0.131 ± 0.05096 
>0.9999 
0.0282* 
EGCG 
EGCG with glucose 
20.8 ± 20.4 
0.3115 ± 0.1681 
0.5483 
0.0800 
GTE 
GTE with glucose 
0.4596 ± 0.1479 
0.216 ± 0.09666 
>0.9999 
0.0459* 
 
 
PPARγ 
DGTE 
DGTE with glucose 
2.618 ± 2.458 
1.586 ± 0.9036 
0.9997 
0.8152 
EGCG 
EGCG with glucose 
24.73 ± 24.48 
0.3629 ± 0.1292 
0.5541 
0.7666 
GTE 
GTE with glucose 
1.019 ± 0.8179 
0.2375 ± 0.08463 
>0.9999 
0.6626 
 
 
FASN 
DGTE 
DGTE with glucose 
0.145 ± 0.0922 
0.4961 ± 0.3787 
0.7984 
0.9987 
EGCG 
EGCG with glucose 
2.775 ± 1.284 
7.457 ± 4.841 
0.3020 
0.3146 
GTE 
GTE with glucose 
0.3585 ± 0.1559 
0.6914 ± 0.444 
0.8996 
0.9997 
 
 
FABP4 
DGTE 
DGTE with glucose 
0.2308 ± 0.1077 
0.116 ± 0.07188 
0.0032* 
0.0098** 
EGCG 
EGCG with glucose 
0.1476 ± 0.03068 
0.2595 ± 0.06262 
0.0017* 
0.0252* 
GTE 
GTE with glucose 
0.5105 ± 0.1549 
0.3369 ± 0.1093 
0.0386* 
0.0427* 
 
LPL 
 
DGTE 
DGTE with glucose 
0.1905 ± 0.05939 
0.3443 ± 0.1871 
0.0016** 
0.1033 
EGCG 
EGCG with glucose 
0.2129 ± 0.1019 
0.6763 ± 0.1683 
0.0019** 
0.5679 
GTE 
GTE with glucose 
0.538 ± 0.03811 
0.7196 ± 0.116 
0.0384* 
0.6662 
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4.4 Discussion  
Western society’s dietary behaviour and increasing consumption of calorie-rich diets are directly 
involved in dysregulation of glucose and lipid metabolism and thereafter in the global burden of obesity 
and diabetes, and their related consequences. Using natural compounds could be an additional tool to 
prevent and ameliorate some disorders related to the impairment of glucose homoeostasis.  The data 
presented here suggests that green tea and its active compounds exhibit several beneficial effects in 
mice; either those fed a normal diet or those fed a high glucose diet. Some previous studies have 
investigated and confirmed the positive effect of these compounds to regulate glucose homoeostasis. In 
addition to manage body weight and diabetic conditions in rodents (Babu, et al., 2013;Chen, et al., 
2011;Roghani and Baluchnejadmojarad, 2010;Snoussi, et al., 2014;Tang, et al., 2013). Therefore, the 
original plan for this section of the study was to use all of the compounds that had shown any 
glucoregulatory effects in metabolic cell models in a mouse study. However, due to significant practical 
and financial issues, this was not possible. An example of this was the insolubility of quercetin, which 
on the morning of the first set of mouse treatments was discovered to be wholly insoluble in drinking 
water of mice, even when first dissolved in DMSO or ethanol. Instead DGTE, GTE and EGCG were 
used because of their solubility. Based on this, the present study attempted to investigate the specific 
effects of DGTE, EGCG, and whole GTE on several parameters regarding glucose and lipid metabolism, 
body composition and mass in C57BL/6 mice fed a normal or glucose rich diet (30% glucose) for four 
weeks.   
 
In this study, the impacts of green tea extracts on glucose regulation during glucose tolerance testing 
were determined after 28 days in mice fed a normal or glucose-rich diet. Supplemented glucose diet to 
mice for 28 days did not impaired glucose tolerance as it failed to increase gAUC and reduce glucose 
disposal compared the data in day 0. Feeding DGTE, EGCG, and GTE to mice either with or without a 
high glucose supplementation showed no differences in glucose tolerance, as gAUC and glucose 
clearance after 2h of GTT were not affected (Figure 4.11 andFigure 4.12). These results are consistent 
with the study of Moreno, et al. (2014) in mice fed high fat diet and supplemented with EGCG for 30 
days, and the study of Nomura, et al. (2015) in diabetic mice. These findings are inconsistent with the 
results of several studies which have identified that green tea compounds can improve glucose tolerance. 
This improvement is through reducing the time of glucose clearance, and decreasing gAUC in diabetic 
and high calorie fed mice (Nishiumi, et al., 2010;Ortsater, et al., 2012;Snoussi, et al., 2014;Tang, et al., 
2013;Yan, et al., 2012). These unexpected effects may be due to the difference in treatment or could be 
related to the route of administration (drinking water), which affects the concentration of treatments 
based on either individual drinking behaviour or absorption rate. Interestingly, in the present study, 
administration of glucose solution for 28 days did cause a significant elevation of FBG level compared 
to day 0 (Figure 4.13 B). Thus, the study suggesting that animals that had consumed high levels of 
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glucose had impaired fasting glucose, a form of ‘pre-diabetes’ that in humans significantly increases the 
risk of developing T2D. This result is in agreement with previously published results that showed 
consumption of a high-glucose diet can increase FBG (Barros, et al., 2007;Hininger-Favier, et al., 
2009;la Fleur, et al., 2011). These increases in the levels of FBG were significantly decreased by the 
effect of green tea extract and EGCG (Bose, et al., 2008;Ortsater, et al., 2012;Santamarina, et al., 
2015;Yan, et al., 2012). These results are in agreement with the present study result that showed DGTE 
and EGCG significantly reduced FBG (Figure 4.13). This result was associated with an impressive 
increase in insulin secretion (Figure 4.14 B) and downregulation of expression of Glut4 in adipose tissue 
(Table 4.3) in response to DGTE and GTE supplementation. High glucose intake could be responsible 
for impairment of Glut4 expression, as appeared in the present study and as previously reported 
(Atkinson, et al., 2013;Ritze, et al., 2014). Collectively, the results presented in the present study showed 
positive effects of selected green tea extracts on FBG in mice fed a glucose-rich diet, therefore 
suggesting the use of green compounds could be of benefit for individuals who have pre-existing 
impaired fasting glucose or who are at risk of developing such a condition. 
 
High-energy diet intake can increase body mass and weight gain (Ritze, et al., 2014;Wagoner, et al., 
2015;Williams, et al., 2014). Therefore in the present study, the water supply of some groups of mice 
was supplemented with a 30% (w/v) of glucose solution to challenge energy homoeostasis and increase 
body mass. Alongside that, the effect of DGTE, EGCG, and GTE on body weight and weight gain was 
investigated. Analysis showed that there were no significant differences in body weight between 
treatments and control in all groups during the experiment, except GTE fed mice at week one only, 
which significantly increased body weight in both normal and glucose fed groups (Figure 4.1). This 
result could be possibly due to individual differences of ingestion behaviour, primary differences in 
body mass at the start point, and low green tea treatment concentrations associated with limited exposure 
time. The result is supported by a study which identified that GTE did not change mice body weight 
(Ortsater, et al., 2012;Tang, et al., 2013). Conversely, several studies have identified that green tea 
compounds can reduce body mass and weight gain in high calorie fed and diabetic animals (Bose, et al., 
2008;Chen, et al., 2011;Santamarina, et al., 2015;Snoussi, et al., 2014). Additionally, weight gain 
analysis showed no change in weight gain in mice fed a glucose-rich diet and supplemented with green 
tea extracts (Figure 4.2 B). Significant reductions in weight gain were observed in mice fed a normal 
diet with DGTE and EGCG (Figure 4.2 A). This result contradicts with some previous findings (Moreno, 
et al., 2014;Richard, et al., 2009), and partially corresponds with the result of Snoussi, et al. (2014). 
While there is clearly still a lack of clarity regarding the actions of green tea compounds in the 
management of body mass and weight gain,  the present data suggests that consumption of green tea 
may be a useful tool in the prevention of weight gain in individuals who consume a diet that is not 
excessively rich in sugar. The observation that this effect is lost in animals that consume excess glucose 
concerns, as it suggests that in the Western world, where glucose-rich diets are more common (Manzel, 
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et al., 2014), green tea may not have any impact on the rising incidence of obesity. However, further 
studies considering treatment concentration, experiment time, and route of administration are needed to 
clarify this aspect. 
 
Average chow and water intake were measured in all groups. Mice supplied with glucose solution 
showed decreased food intake and increased water consumption (Figure 4.3 and Figure 4.4). These 
differences most likely occurred due to the glucose solution stimulating mice to drink more water and 
decreasing hunger signals which led to reduced consumption of dry food (Bergheim, et al., 2008;Pang, 
et al., 2014;Ritze, et al., 2014). Administration of DGTE, EGCG, and GTE, in addition to glucose 
supplementation, did not alter the amount of food and water intake (Figure 4.3 and Figure 4.4 B). This 
result is possibly due to the sweetened taste of the water which would have masked the taste of green 
tea compounds. This finding is consistent with several studies that reported unchanged diet and water 
consumption when experimental animals received green tea extracts (Bose, et al., 2008;Chen, et al., 
2011;Li, et al., 2010). In groups that received their treatments without glucose supplemented water, 
DGTE significantly reduced food and water intake compared to control (Figure 4.3 and Figure 4.4 A). 
This result may be due to direct interaction with hunger signals, whilst the reduction in water 
consumption may be attributable to the taste of the water that contained DGTE. This interesting finding 
suggests that consumption of green tea can regulate feeding behaviour, possibly either by increasing 
satiety or reducing hunger signals. This observation is in contradiction of several studies that showed 
green tea compounds have no effect on food consumption in different animal models (Chen, et al., 
2011;Li, et al., 2010;Ortsater, et al., 2012). There is, however, some supporting data, where green tea 
extract reduced food and water intake in diabetic rats (Sundaram, et al., 2013). Similarly, Chen, et al. 
(2009)provided evidence that water intake in rats was decreased in response to GTE and EGCG. The 
possibility exists therefore that green tea compounds may have a regulatory role in food intake, but 
further research is needed to clarify the extent of this role. 
 
It has been previously reported that high a calorie diet induces obesity through alteration of adipose 
tissue mass, particular WAT mass, while green tea extracts have an anti-obesity effect via reduction of 
body weight and WAT mass (Nishiumi, et al., 2010). In this study, the effect of supplementing DGTE, 
EGCG, and GTE on body composition mass was determined in mice fed a normal or glucose-rich diet. 
No significant differences in skeletal muscle mass were seen in all treatment groups (Figure 4.6). 
Similarly, the hepatic mass was unchanged between most treatment and control groups, and only mice 
that received EGCG without glucose supplementation showed increased liver mass (Figure 4.5). 
Supplemented glucose diet to mice for 28 days did not significantly affected fat depots mass except SAT 
mass was significantly increased compared to day 0 SAT mass.  Interestingly, however, mouse adipose 
tissue depots including WAT and BAT showed marked responses to green tea treatments. DGTE and 
EGCG consumption significantly increased SAT mass, whilst only EGCG increased VAT mass in mice 
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that received treatments without glucose (Figure 4.7 and Figure 4.8 A). Significant increases in the mass 
of these adipose tissue depots were seen in mice fed a glucose diet with DGTE and GTE (Figure 4.7 and 
Figure 4.8 B). These data suggest that exposure to selected green tea extracts increase the capacity of 
the body to store nutrients in adipose tissue stores, and is therefore potentially obesogenic agents. 
Additionally, interesting increases in BAT mass were observed in mice fed a normal diet with EGCG 
only, while mice supplemented with DGTE and GTE alongside a glucose rich diet significantly 
increased BAT mass (Figure 4.9). These data are noticeably inconsistent with previously published 
studies that have investigated the effect of green tea compounds on body anthropometry, particularly 
concerning WAT and BAT depots (Bose, et al., 2008;Chen, et al., 2009;Li, et al., 2006b). Previous 
research has shown that mice fed a high-fat diet expressed increases in VAT and BAT mass which were 
reversed by EGCG (Chen, et al., 2011). A clear difference between these studies and the present study 
are the methods of introducing a glucos rich diet. The approach taken here to supplement glucose 
provides a different challenge than increasing lipid deposition. It is, therefore, possible that green tea 
compounds have cellular and molecular effects that could counteract the challenge of a high-fat diet, 
but not a high carbohydrate diet. This observation is important as Western diets often include 
consumption of excess carbohydrates and sugars (Manzel, et al., 2014), and therefore might provide an 
environment in which green tea is less able to have any anti-obesity effects. Further research in this area 
might compare the different forms of obesity induction directly to investigate this discrepancy. 
 
The level of circulating insulin is directly related to the level of circulating glucose in healthy 
individuals. High energy intake, including a high fat or high glucose diet, has been shown to be involved 
in dysregulation of glucose homoeostasis. This impairment, therefore, increase circulating insulin in 
response to hyperglycaemia associated with increase insulin resistance (Pang, et al., 2016;Zhang, et al., 
2015). Green tea extract and some of its active compounds have been reported to have reversible effects 
on high levels of insulin due to high glucose level (Moreno, et al., 2014;Nomura, et al., 2008;Qin, et al., 
2010). In the present study, the levels of insulin in response to DGTE, EGCG, and GTE in mice 
supplemented without and with a high glucose diet were determined. The results were fascinating, as it 
appears that EGCG caused a marked and significant increase in insulin level in mice fed a normal or 
glucose-rich diet, whilst GTE promoted a similar effect on insulin levels in mice that received a high 
glucose diet only (Figure 4.14). These results were accompanied by significant reduction of FBG in 
mice that received only DGTE and EGCG with glucose. These findings are in part supported by the 
study of Sundaram, et al. (2013), who identified that green tea could increase the level of circulating 
insulin in diabetic and high-calorie diet fed rats. Another study by Wolfram, et al. (2006) showed that 
administration of EGCG to db/db mice and diabetic rats for two and ten weeks respectively increased 
levels of insulin compared to diabetic control. Based on these results together, the study suggests that 
selected green tea extracts act as non-physiologically insulinotropic agents and could activate beta-cells 
to secrete high levels of insulin, however further studies are required to determine the role of green tea 
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on pancreatic beta-cell and glucose stimulated insulin secretion. This finding is important, as factors that 
can boost insulin secretion are of interest when considered in the context of the increasing levels of 
insulin resistance seen in many populations.  
 
HOMA is reliable, sensitive, and inexpensive method developed by Matthews which used to 
determin insulin resistance, sensitivity, and beta cell function in human based on the levels of insulin 
and glucose in fasting condition. Limited study validated this model to use in the rodent (Antunes, et 
al., 2016), however still limited due to the metabolic differences and more studies in this regards is 
needed to validate use in rodents. In this study, the effect of green tea extracts on insulin resistance, 
sensitivity, and beta cell function was investigated by calculating HOMA-IR, B, and S. Recent results 
of published studies identified the ability of green tea compounds to ameliorate insulin resistance, 
increase beta-cell function, and increase insulin sensitivity (Gan, et al., 2015;Jang, et al., 2013a), and 
therefore inagreement with current study result. Data from the present study suggests that EGCG 
significantly increased insulin resistance concomitant with increased pancreatic beta-cell function in 
mice fed a normal diet (Figure 4.15 and Figure 4.16 A), as insulin increased but blood glucose did not 
decrease equally. This effect of EGCG is, however, consistent with the result of Santana, et al. (2015) 
who found that Swiss mice exhibited insulin resistance when supplemented with EGCG compounds. 
This result suggests that EGCG is possibly interfering with the traditional glucoregulatory role of insulin 
under these conditions. Furthermore, all treatments did not change HOMA-IR, HOMA-B, and HOMA-
S in mice fed a glucose-rich diet (Figure 4.15, Figure 4.16, and Figure 4.17 B). Why the present study 
saw such a marked response in insulin secretion to EGCG, and therefore why the HOMA measures were 
so altered, is difficult to explain. It is clear that EGCG is insulinotropic agent, however, when taking 
this into account, it still does not explain such a marked increase with no change in glucose levels. This 
observation suggests that the animals under these conditions were insulin resistant, which contradicts 
the other published findings above. This could be due to insensitivity of HOMA in the mice as it used 
in human only, or insulin resistance is developed due to increase adipose depots mass which could 
secreted FFA and inflammatory cytokines and impaired insulin signalling. It would be interesting to 
assess the role of EGCG in pancreatic islet insulin secretion to better establish if this effect is irrespective 
of glucose levels. 
 
Alteration of lipid metabolism including TC, TG, HDL, and LDL in response to excess energy intake 
has been seen in several studies (Gan, et al., 2015;Zhang, et al., 2015). These alterations can be improved 
in response to green tea (Jeong, et al., 2012;Qin, et al., 2010;Santana, et al., 2015). The effect of DGTE, 
EGCG, and GTE on lipid metabolism were, therefore, investigated in mice fed a normal or glucose rich 
diet in the present study. After 28 days, only DGTE significantly reduced TC concentration in mice fed 
a normal diet (Figure 4.18 A). All green tea extracts significantly decreased TC levels in mice 
supplemented with a glucose diet (Figure 4.18 B). This result is consistent with most studies which have 
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shown green tea, and its active compounds can decrease the high level of TC in diabetic and high fat 
fed animal models (Bose, et al., 2008;Chen, et al., 2011;Santana, et al., 2015).This impact has been 
studied in normal, diabetic, and high energy intake animal models. however, no effect of green tea 
compounds on TC was seen in several studies including Richard, et al. (2009) in C57Bl/6 mice, Snoussi, 
et al. (2014) in normal rats, and Sugiura, et al. (2012) in mice treated for 30 days. Western lifestyle, 
liver dysfunction due to alcoholic addiction, and diabetes are risk factors of cardiovascular diseases due 
to high levels of TC. However, the present study result showed the ability of selected green tea extracts 
to reduce circulating TC levels. Therefore, regular drinking of green tea might provide protection from 
cardiovascular diseases through controlling circulating TC levels. 
 
Additionally, the levels of TG in the present study were significantly increased when mice received 
DGTE and EGCG alone, and EGCG with a high glucose diet (Figure 4.19). This result was accompanied 
by increases in SAT and VAT mass (Figure 4.7 and Figure 4.8), with no significant change in SREBP1c, 
PPARγ, and FASN mRNA expression (Table 4.3). in addition, decreased C/EBPα mRNA expression in 
response to DGTE and GTE in mice fed a glucose-rich diet, downregulation of LPL in mice fed a normal 
diet in response to all treatments (Table 4.3). Concomitant with significant downregulated FABP4 in all 
groups in response to all treatments (Table 4.3). These unexpected findings are inconsistent with many 
studies which have identified that green tea extracts can produce significant decreases in TG level in 
diabetic or high calorie fed animal models (Hininger-Favier, et al., 2009;Qin, et al., 2010;Roghani and 
Baluchnejadmojarad, 2010;Wu, et al., 2004a). This decrease in TG and inhibition of lipolysis were 
reported to be mediated through regulation expression of adipogenic and lipolytic genes, including 
downregulated PPARγ, SREBP1c, FAS, C/EBPα, FABP4, and LPL (Lee, et al., 2013;Lee, et al., 
2009b). Several studies have reported no effect of green tea extract on TG levels (Snoussi, et al., 
2014;Sugiura, et al., 2012;Tang, et al., 2013). However, supplemention of EGCG to rats fed a high-fat 
diet caused significant increase in TG level (Chen, et al., 2009). Alteration of lipid metabolism 
transcriptional factors like FABP4, SREBP1c, PPARγ, C/EBPα, FASN, and LPL are distinguishing 
markers of obesity, insulin resistance, and T2D (Guilherme, et al., 2008;Lee, et al., 2009b).  Expression 
of adipogenic factors can increase the level of TG which is then hydrolysed by the activity of LPL to 
release FFA that are transported in the circulation by FABP4 (Furuhashi, et al., 2014;Wang and Eckel, 
2009). These data collectively highlight the lack of a clear picture regarding green tea and TG. As TG 
is a significant cardiovascular risk factor, it is clearly important to identify factors that can reduce or 
increase TG, so that the public can be better informed. However, despite the current research provides 
evidence to prevent increase circulating FFA, more research in this field is required for a clearer view 
regarding this effect of green tea. Insignificant expression of some of glucose and lipid metabolism 
genes in the mice adipose tissue is could be nonspecific primer binding (Figure 8.28 to Figure 8.34), or 
methodological error due to insufficient independent experiment which need to be considered in future 
study. 
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In addition to previous results of TC and TG, the levels of HDL and cLDL were measured with no 
significant differences seen in all mice supplemented with green tea extracts in terms of HDL levels 
(Figure 4.20). This result is in disagreement with results that have shown green tea compounds can 
increase the level of HDL in diabetic animals or those with excess energy intake (Jeong, et al., 
2012;Roghani and Baluchnejadmojarad, 2010). However, no effect has also been observed as reported 
by Moreno, et al. (2014), Santana, et al. (2015), and Snoussi, et al. (2014) which is consistent with the 
present study result. Furthermore, DGTE and EGCG treatments significantly decreased the level of 
cLDL in mice fed a normal diet, whilst all green tea treatments did reduce the level of cLDL in mice fed 
a glucose-rich diet (Figure 4.21). This result is consistent with studies that showed green tea can reduce 
the LDL which is increased in diabetic and high energy diet fed animals (Qin, et al., 2010;Roghani and 
Baluchnejadmojarad, 2010). However, no effect of green tea on the level of LDL was reported by a 
study of. As LDL is a key modifiable mediator of cardiovascular risk, these data are of particular interest, 
as the current strategies clinically focus on drugs like statins which have significant side effect profiles 
(Golomb and Evans, 2008) so any natural or food based remedies are of interest clinically.  
 
The present study attempted to provide a mechanism for some of the physiological changes seen in 
green tea-treated mice by investigating the gene expression of the main metabolic genes in tissues taken 
from mice. Maintaining the normal levels of metabolic mRNA in the main sites of glucose metabolism 
including liver, skeletal muscles, and adipose tissue are essential to regulate glucose homoeostasis (Han, 
et al., 2016;Rui, 2014;Saltiel and Kahn, 2001). Green tea extract has been shown to have regulatory 
effects on several genes in relation to glucose metabolism in the liver (Yasui, et al., 2011), adipocytes 
(Chan, et al., 2011), and skeletal muscle (Ueda, et al., 2008). The result of the present study showed no 
significant differences between treatments and control in the expression of glucose metabolism genes in 
the liver, except PEPCK, which was significantly downregulated in EGCG fed mice that received a high 
glucose diet (Table 4.1). This result is associated with decreased FBG in response to selected green tea 
compounds in mice supplemented with glucose (Figure 4.13 B). Green tea has ability to maintain 
glucoregulatory gene expression in mice liver including suppressed G6Pase and PEPCK gene 
expression, and therefore inhibits glucose output (Collins, et al., 2007;Waltner-Law, et al., 
2002;Wolfram, et al., 2006). In addition, increases Glut2 expression and therefore regulate glucose 
uptake (Cao, et al., 2007). Based on these results together with the published study results, the present 
study suggests that selected green tea compounds could inhibit hepatic glucose production and is 
partially involved in the glucose regulation process. As the current study data showed levels of mRNA 
expression without considering levels of protein activity (due to cost and time limitations), a further 
study is required to measure protein expression alongside mRNA. The insignificant expression of the 
most of glucose metabolism genes in the liver is might be unspecific primer binding (Figure 8.28 to 
Figure 8.34). Second reason could be methodological error and more independent experiment is required 
to verify this insignificant expression, or mRNA did not expressed rather protein expression. 
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Similarly, no significant differences in glucose metabolism genes expression were recorded in 
skeletal muscle, except EGCG and GTE-mediated, which showed significant downregulation of PDK4 
in mice supplemented with a glucose diet (Table 4.2). This result is accompanied by a decrease in the 
level of FBG (Figure 4.13 B). These data are broadly inconsistent with the results of Cao, et al. (2007) 
and Qin, et al. (2010) who identified that green tea extract involves regulation of glucose metabolism in 
muscles through increasing expression of Glut4, Gys1, and PGC1α mRNA. As the main role of a PDK4 
transcriptional factor is regulation of pyruvate dehydrogenase complex (PDC) and utilisation of glucose, 
increased expression of PDK4 causes decreased PDC activity and impaired glucose utilisation, which 
can be seen in insulin resistance and diabetic conditions (Kim, et al., 2006b;Lee, 2014). The present 
study, therefore, suggests that inhibition PDK4 could partially involve regulation of glucose metabolism 
and modulate many disorders related to that. The insignificant expression of the most of glucose 
metabolism genes in the mice skeletal muscle is could be unspecific primer binding (Figure 8.28 to 
Figure 8.34), or insufficient independent experiment, or mRNA was not expression rather protein 
expression.  
 
In conclusion, a high glucose diet intake could induce dysregulation of some glucose and lipid 
metabolism markers including elevated levels of FBG and fasting insulin, and induce insulin resistance 
concomitant with a reduction in functional beta-cells being recorded. Furthermore, glucose 
supplementation might disturbance of lipid metabolism parameters, increased of SAT mass, and 
alteration of feeding behaviour. Green tea, including DGTE, EGCG, and GTE, could regulate many of 
these impairment parameters. Selected extracts improved the impaired FBG in mice fed glucose diet. 
Additionally, these extracts might be improved some lipid markers including TC and cLDL, however 
triglyceride levels were increased alongside an increase of fat pad mass (SAT, VAT, and BAT), and 
suppressed lipolysis through decreasing LPL gene only in normal mice. Surprisingly, some of these 
extracts increased insulin level without affecting level of glucose during GTT. Total body weight and 
weight gain were unchanged even with increased fat pad weight, which suggests there is no effect of 
green tea on weight, however decrease weight gain was seen in normal mice in response to selected 
extract which suggested that these extract could managed weight gain in individuals that not regularly 
consumed glucose-rich diet. As a result, green tea could potentially assist in the maintenance of normal 
glucose homoeostasis through regulating glucose and lipid metabolism. Therefore, regular consumption 
of green tea could help people with existing metabolic disorders to ameliorate impaired glucose and 
lipid metabolism. However, further research is required, particularly to elucidate the signalling pathway 
of green tea effects in different conditions. 
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5.1 Introduction 
All tissues in the body normally have a very tightly controlled balance between cellular proliferation 
and programmed cell death to regulate tissue structure and function (Guo and Hay, 1999). This normal, 
dynamic process of tissue homoeostasis is controlled by several key endocrine and paracrine factors 
(Medh and Thompson, 2000). Defects in these processes can lead to altered rates of cellular proliferation 
and/or apoptosis and can lead to serious pathological disorders including various types of cancer, 
autoimmune diseases, neurodegenerative diseases, and ischemic deterioration (Elmore, 2007).  
Uncontrolled cellular proliferation accompanied with the improper decrease of cellular deletion can 
eventually lead to the development of cancer, a  leading cause of death globally (WHO, 2014b).   
 
All types of cancer including breast cancer (BC) exhibit the characteristic hallmarks of altered 
metabolism and migration. BC cells acquire an ‘aggressive’ phenotype and can disseminate to other 
organs through a process called metastasis, which begins by the creation of new blood vessels through 
angiogenic processes, and then the cells undergo local migratory and systemic invasion, and finally 
specific organ cloning (Kozlowski, et al., 2015).  Another hallmark of cancerous cells is an alteration of 
cellular glucose metabolism towards a high rate of aerobic glycolysis. This alteration is to compensate 
for the high energy demand for rapid proliferation and survival under the hypoxic condition and is 
facilitated through consumption of high amounts of glucose concomitant with increased lactate 
production (Li, et al., 2011a). This metabolic process is called the Warburg phenomenon (Warburg, et 
al., 1924;Warburg, et al., 1927). Activation of Cori cycle in cancer is another process provides glucose 
as a source of energy required for proliferation and survival of cancer cells (Goodwin, et al., 2014). This 
process is generate energy through converting lactate to glucose in the liver (Tisdale, 2009). 
 
Several studies revealed that green tea or its abundant active compounds might have some anti-
cancerous effects in a variety of cancer types, including BC. These anti-cancerous effects have reported 
being mediated via reducing cell viability, activating apoptosis (Hsuuw and Chan, 2007;Thangapazham, 
et al., 2007) . In addition, suppressing cell growth and promoting cell cycle arrest (Adhami, et al., 
2003;Albrecht, et al., 2008;Baliga, et al., 2005;Carvalho, et al., 2010;Thyagarajan, et al., 2007). 
Furthermore, green tea active compounds are showed to have an inhibitory effect on cancer metastasis 
including BC (Baliga, et al., 2005;Farabegoli, et al., 2011;Kushima, et al., 2009). Several molecular 
pathways thought to be involved in green tea mediated anti-cancer and anti-metastasis. These effects 
including targeting cell signalling and metabolic enzymes like PI3K/Akt, MAPK, JAK/STAT, Wnt, 
Ras/Raf/MAPK, AP-1, Notch, COX, and NFκB (Shankar, et al., 2007;Singh, et al., 2011). 
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The aims of the research described in this chapter are 
 
• To identify the effect of green tea active compounds including EGCG, EC, ECG, 
myricetin, quercetin and a combination of (EGCG, EC, and ECG) on BC cell viability and 
apoptosis. 
• To explore the role of signalling pathways including Akt and AMPK in the effect of green 
tea compounds on BC cell viability and apoptosis. 
• To investigate the relationship between the effects of green tea compounds on BC cell 
viability via apoptosis and the effect of these compounds on BC cell glucose metabolism. 
• To determine the anti-migratory effect of these green tea compounds on BC cells. 
 
 
5.2 Materials and methods 
All materials and methods related to this chapter were previously mentioned in detail in chapter two. 
The effect of active compounds of green tea extract on cell viability of MCF7 and MDA-MB-231 was 
performed using two separate reagents and methods including PrestoBlue® and Neutral red to confirm 
the results. Furthermore, the role of additional of selective Akt and AMPK inhibitors, and sodium 
pyruvate on BC cell viability and glucose metabolism was investigated using PrestoBlue® cell viability 
assy. Induce apoptosis was determined by measuring the level of caspase 3/7 activation, and qPCR was 
used to measure the level of some apoptotic and pro-apoptotic gene expression. In addition, the effect 
of green tea compounds on glucose metabolism was explored by measuring amount of glucose uptake 
using fluorescent glucose analogue (2-NBDG) and amount of lactate release using fluorimetric assay 
kit. Cellular migration of both cell line in response to green tea compounds was investigated using 
classical microscopic imaging wound healling assy and CellIQ. The role of Akt and AMPK signalling 
in BC treated with green tea compounds was investigated by measuring the Phosphor-specific 
expression of Akt and AMPK using Western blotting. 
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5.3 Results  
5.3.1  Selected green tea compounds reduced MCF7 cell viability measured using 
PrestoBlue® 
The effect of active compounds of green tea on cell viability of MCF7 cells was initially investigated 
using PrestoBlue®, a resazurin based chemical marker of cell viability. MCF7 cells were treated with 0, 
1, 10, 50, 100, and 150µM EGCG, EC, ECG, a combination of these compounds, myricetin, and 
quercetin, and 30µM etoposide chemotherapy drug (positive control) for 24, 48, and 72 hours, followed 
by measuring cell viability. The result shows that EGCG, combination, and quercetin significantly 
decreased MCF7 cell viability compared to control. The decreases were: 12.54%±6.27% (p<0.0001), 
28%±8.2% (p<0.0001), 17.44%±2.33% (p<0.0001) for 100 and 150µM EGCG, and 150µM quercetin 
after 24h respectively (Figure 5.1). After 48h, 100 and 150µM EGCG and combination in addition to 
50, 100, and 150µM quercetin significantly decreased viability, with reductions of 16.24%±3.46% 
(p=0.0014), 18.21%±4% (p<0.0001), 14.22%±1.65% (p=0.0157), 15.86%±2.52% (p=0.0023), 
19%±6% (p<0.0001), 35.18%±13.2% (p<0.0001), and 30.17%±10.74% (p<0.0001) respectively 
(Figure 5.2). The recorded decreases in cell viability after 72h treatment with the same effective 
compounds and doses after 48h incubation were: 33%±7.75% (p<0.0001), 28.57%±6.68% (p<0.0001), 
23.95%±10.75% (p<0.0001), 20.93%±2% (p<0.0001), 15.4%±0.66% (p=0.0286), 18.72%±1.42% 
(p=0.0009), and 34.67%±13.25% (p<0.0001) respectively (Figure 5.3). 
5.3.2 Selected green tea compounds reduced MDA-MB-231 cell viability measured 
using PrestoBlue® 
The impact of green tea active compounds on cell viability of MDA-MB-231 cells was assessed after 
exposed cultured cells to various concentrations of EGCG, EC, ECG, combination of these compounds, 
myricetin, quercetin, and 30µM etoposide chemotherapy drug (positive control)  for 24, 48, and 72h 
using PrestoBlue® cell viability reagent. EGCG, combination, and quercetin caused significant 
decreases in MDA-MB-231 cell viability compared to control. 100 and 150µM EGCG and combination 
of catechins in addition to 150µM quercetin induced significant reductions in viable cells after 24h, and 
these decreases were: 18%±6.76% (p<0.0001), 21.7%±0.94% (p<0.0001), 11.78%±4.33% (p<0.0001), 
13.87%±0.62% (p<0.0001), and 14%±2.3% (p<0.0001) respectively (Figure 5.4). Decreases in cell 
viability were observed after 48h treatment and the recorded percent were: 38.93%±10.58% (p<0.0001), 
34.7%±1% (p<0.0001), 20.67%±4.65% (p<0.0001), 30.6%±0.68% (p<0.0001), 35.19%±13.19% 
(p<0.0001), and 14%±2.3% (p<0.0001) for 100 and 150µM of EGCG, combination, and quercetin 
respectively (Figure 5.5). EGCG and combination at 50, 100, 150µM, in addition to 100 and 150µM 
quercetin reduced cell viability by 16.6%±2% (p=0.0112), 19.14%±5.43% (p=0.0007), 31.57%±2.2% 
(p<0.0001), 16.9%±2.17% (p=0.0082), 19%±2% (p=0.0008), 24.8%±4.87% (p<0.0001), 
18.63%±6.34% (p=0.0016), and 30.67%±9.4% (p<0.0001) respectively after 72h (Figure 5.6). 
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Figure 5.1 Selected green tea compounds decrease MCF7 cell viability after 24h intervention. 
MCF cells were seeded in 96 well plate at density of 5000/well, and incubated in standard condition 
for 24h. Cells were exposed to green tea compounds for 24h, and cell viability was investigated using 
PrestoBlue®. EGCG at 100 and 150µM reduced viable cell compared to control, and 150µM quercetin 
decreased viable cell compared to DMSO. Data presented mean ± SEM, ****p<0.0001, n=3. 
 
Figure 5.2 Selected green tea compounds decrease MCF7 cell viability after 48h intervention. 
MCF cells were seeded in 96 well plate at density of 5000/well, and incubated in standard condition 
for 24h. Cells were exposed to green tea compounds for 48h, and cell viability was investigated using 
PrestoBlue®. EGCG and catechins combination at 100 and 150µM reduced viable cell compared to 
control, and 50, 100, and 150µM quercetin decreased viable cell compared to DMSO. Data presented 
mean ± SEM, *p<0.05, **p<0.01, ****p<0.0001, n=3. 
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Figure 5.3 Selected green tea compounds decrease MCF7 cell viability after 72h intervention. 
MCF cells were seeded in 96 well plate at density of 5000/well, and incubated in standard condition 
for 24h. Cells were exposed to green tea compounds for 72h, and cell viability was investigated using 
PrestoBlue®. EGCG and catechins combination at 100 and 150µM reduced viable cell compared to 
control, and 50, 100, and 150µM quercetin decreased viable cell compared to DMSO. Data presented 
mean ± SEM, *p<0.05, ***p<0.001, ****p<0.0001, n=3. 
 
Figure 5.4 Selected green tea compounds decrease MDA-MB-231 cell viability after 24h 
intervention. 
MDA-MB-231 cells were seeded in 96 well plate at density of 5000/well, and incubated in standard 
condition for 24h. Cells were exposed to green tea compounds for 24h, and cell viability was 
investigated using PrestoBlue®. EGCG and catechins combination at 100 and 150µM reduced viable 
cell compared to control, and 150µM quercetin decreased viable cell compared to DMSO. Data 
presented mean ± SEM, ****p<0.0001, n=3. 
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Figure 5.5 Selected green tea compounds decrease MDA-MB-231 cell viability after 48h 
intervention. 
MDA-MB-231 cells were seeded in 96 well plate at density of 5000/well, and incubated in standard 
condition for 24h. Cells were exposed to green tea compounds for 48h, and cell viability was 
investigated using PrestoBlue®. EGCG, catechins combination and quercetin at 100 and 150µM 
significantly decreased viable cell compared to control and DMSO. Data presented mean ± SEM, 
****p<0.0001, n=3. 
 
Figure 5.6 Selected green tea compounds decrease MDA-MB-231 cell viability after 72h 
intervention. 
MDA-MB-231 cells were seeded in 96 well plate at density of 5000/well, and incubated in standard 
condition for 24h. Cells were exposed to green tea compounds for 72h, and cell viability was 
investigated using PrestoBlue®. EGCG and catechins combination at 50, 100 and 150µM reduced viable 
cell compared to control, and 100 and 150µM quercetin decreased viable cell compared to DMSO. Data 
presented mean ± SEM, *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001, n=3. 
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5.3.3 Selected green tea compounds decreased MCF7 cell viability measured using 
neutral red 
To confirm the effect of selected ingredients of green tea on MCF7 cell viability that were obtained 
previously using the PrestoBlue® assay, the experiment was repeated using neutral red reagent. Cells 
were treated with green tea compounds at concentrations and incubation times that previously showed 
significant decreases in cells viability. Like previous results, MCF7 cells exhibited a significant 
reduction in cell viability when treated with EGCG, combination, and quercetin (Figure 5.7 to Figure 
5.9). The decreases after 24h of 100 and 150µM EGCG and 150µM quercetin were: 41.9%±13.4% 
(p=0.0010), 45%±17.7% (p=0.0004), and 51.4%±18.5% (p<0.0001) compared to control respectively. 
Whereas the recorded decreases after 48h of 100 and 150µM EGCG and catechins combination, and 50, 
100, 150µM quercetin were: 36%±10.2% (p=0.0345), 54.8%±22.6% (p<0.0001) and 35.4%±13.3% 
(p=0.0411), 44.3%±13.9% (p=0.0030), and 41%±14% (p=0.0091), 49.3%±17.1% (p=0.0006), and 
60.5%±24.7% (p<0.0001) respectively. The decreases in cell viability for the same compounds and 
concentration at 72h were: 33.4%±3.5% (p=0.0441), 44.25%±12.5% (p=0.0014) and 39.1%±15.6% 
(p=0.0079), 38.9%±13.2% (p=0.0085), and 34.6%±13.8% (p=0.0299), 35%±12.3% (p=0.0241), and 
57%±22.6% (p<0.0001) respectively. 
 
5.3.4 Selected green tea compounds decreased MDA-MB-231 cell viability measured 
using neutral red 
 MDA-MB-231 cell viability was investigated using neutral red reagent to confirm the results 
displayed previously when PrestoBlue® cell viability reagent was used. Cells were exposed to green tea 
compounds that previously caused significant reductions in cell viability for the same incubation periods 
of 24, 48, and 72h. Results confirmed that EGCG, combination, and quercetin induced significant 
decreases in cell viability (Figure 5.10 to Figure 5.12). The decreases in cell viability in response to 100 
and 150µM EGCG and catechins combination, and 150µM quercetin after 24h were: 46.7%±12.6% 
(p<0.0001), 69.2%±21.4% (p<0.0001) and 45%±13.4% (p<0.0001), 44.4%±11.9% (p<0.0001), and 
55.2%±15.5% (p<0.0001) respectively. Whereas, 100 and 150µM EGCG, catechins combination, and 
quercetin induced 65.8%±13.8% (p<0.0001), 68.3%±12.3% (p<0.0001) and 37.8%±14.2% (p=0.0007), 
53.4%±14.6% (p<0.0001), and 52.8%±18.6% (p<0.0001), and 62.2%±15.5% (p<0.0001) decreases in 
viable cells after 48h incubation respectively. After 72h 50, 100, and 150µM EGCG and catechins 
combination, in addition to 100 and 150µM quercetin caused reductions in cell viability of 32.9%±10% 
(p=0.0242), 65.4%±13.3% (p<0.0001),  64%±17.8% (p<0.0001) and 31.5%±6.7% (p=0.0375), 
37.4%±8.4% (p=0.0051), 58.4%±26.6% (p<0.0001) and 40.5%±7.5% (p=0.0032), and 53.9%±11.5% 
(p<0.0001) respectively.   
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Figure 5.7 Selected green tea compounds reduce MCF7 cell viability after 24h intervention. 
MCF7 cells were seeded in 96 well plate at density of 5000/well, and incubated in standard condition 
for 24h. Cells were exposed to green tea compounds for 24h, and cell viability was investigated using 
Neutral red. 100 and 150µM EGCG reduced viable cell compared to control, and 150µM quercetin 
reduced viable cell compared to DMSO. Data presented mean ± SEM, ***p<0.001, and ****p<0.0001, 
n=3. 
 
Figure 5.8 Selected green tea compounds reduce MCF7 cell viability after 48h intervention. 
MCF7 cells were seeded in 96 well plate at density of 5000/well, and incubated in standard condition 
for 24h. Cells were exposed to green tea compounds for 48h, and cell viability was investigated using 
Neutral red. 100 and 150µM EGCG and catechins combination reduced viable cell compared to control, 
and 50, 100, and 150µM quercetin reduced viable cell compared to DMSO. Data presented mean ± 
SEM, *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001, n=3. 
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Figure 5.9 Selected green tea compounds reduce MCF7 cell viability after 72h intervention. 
MCF7 cells were seeded in 96 well plate at density of 5000/well, and incubated in standard condition 
for 24h. Cells were exposed to green tea compounds for 72h, and cell viability was investigated using 
Neutral red. 100 and 150µM EGCG and catechins combination reduced viable cell compared to control, 
and 50, 100, and 150µM quercetin reduced viable cell compared to DMSO. Data presented mean ± 
SEM, *p<0.05, **p<0.01, and ****p<0.0001, n=3. 
 
Figure 5.10 Selected green tea compounds decrease MDA-MB-231 cell viability after 24h 
intervention. 
MDA-MB-231 cells were seeded in 96 well plate at density of 5000/well, and incubated in standard 
condition for 24h. Cells were exposed to green tea compounds for 24h, and cell viability was 
investigated using Neutral red. 100 and 150µM EGCG and catechins combination reduced viable cell 
compared to control, and 150µM quercetin reduced viable cell compared to DMSO. Data presented 
mean ± SEM, ****p<0.0001, n=3. 
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Figure 5.11 Selected green tea compounds decrease MDA-MB-231 cell viability after 48h 
intervention. 
MDA-MB-231 cells were seeded in 96 well plate at density of 5000/well, and incubated in standard 
condition for 24h. Cells were exposed to green tea compounds for 48h, and cell viability was 
investigated using Neutral red. 100 and 150µM EGCG, catechins combination, and quercetin 
significantly reduced viable cell compared to control and DMSO. Data presented mean ± SEM, 
***p<0.001, ****p<0.0001, n=3. 
 
Figure 5.12 Selected green tea compounds decrease MDA-MB-231 cell viability after 72h 
intervention. 
MDA-MB-231 cells were seeded in 96 well plate at density of 5000/well, and incubated in standard 
condition for 24h. Cells were exposed to green tea compounds for 72h, and cell viability was 
investigated using Neutral red. 50, 100 and 150µM EGCG and catechins combination reduced viable 
cell compared to control, and 100 and 150µM quercetin reduced viable cell compared to DMSO. Data 
presented mean ± SEM, *p<0.05, **p<0.01, ****p<0.0001, n=3. 
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5.3.5 Selected compounds of green tea does not alter BC cell viability after 6h 
 To identify the early effect of selected green tea compounds on cell viability, MCF7 and MDA-MB-
231 cells were exposed to selected green tea compounds for 6h. PrestoBlue® reagent was used to assess 
cells viability. No major changes in cell viability were recorded after 6h treatment in both MCF7 and 
MDA-MB-231 cell lines (Figure 5.13). 
 
 
Figure 5.13 Selected compounds of green tea do not alter BC cell viability after 6h intervention. 
BC cells were seeded in 96 well plate at density of 5000/well, and incubated in standard condition 
for 24h. Cells were exposed to selected green tea compounds for 6h, and cell viability was investigated 
using PrestoBlue®. (A) Selected green tea compounds did not change MCF7cell viability compared to 
control. (B) Selected green tea compounds did not change MDA-MB-231cell viability compared to 
control. Data presented mean ± SEM, n=3. 
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5.3.6 Akt inhibition further reduced MCF7 cell viability alongside green tea compounds 
The role of Akt was investigated on decreased MCF7 cell viability as a result of supplementation 
with selected compounds of green tea. Cells were co-incubated with 10µM of 10-[4'-(N, N-
Diethylamino)butyl]-2-chlorophenoxazine hydrochloride (Akt selective inhibitor molecule) in addition 
to 100 and 150µM EGCG and 150µM quercetin for 24h, cell viability was assessed using PrestoBlue® 
reagent. Results showed that MCF7 exhibited significant decreases in viable cells by 61.2%±3.2% 
(p<0.0001) and 89.8%±14.6% (p<0.0001), and 23.1%±7.3% (p<0.0001) respectively in response to the 
green tea compounds mentioned above. Akt inhibition showed further significant decreases in cell 
viability by 89.4%±22.5% (p<0.0001) and 39%±8.1% (p<0.0001) in cells supplemented with 100µM 
EGCG and 150µM quercetin respectively, compared to cells treated with green tea only (Figure 5.14).  
 
5.3.7 AMPK inhibition further reduced MCF7 cell viability alongside green tea 
compounds  
The role of AMPK on reduced MCF7 cell viability in response to selected compounds of green tea 
was explored by co-incubating cells with Dorsomorphin dihydrochloride (AMPK selective inhibitor 
molecule) alongside green tea treatments for 24h. Green tea compounds mentioned above caused 
significantly reduced cell viability by 17.4%±0.6% (p<0.0001) and 61.1%±4.1% (p<0.0001), and 
20.5%±0.8% (p<0.0001) respectively. AMPK inhibition caused an even greater significant reduction of 
viable cells by 13.8%±1.5% (p<0.0001) and 34.7%±2.9% (p<0.0001) respectively in cells incubated 
with 100µM EGCG and 150µM quercetin, compared to green tea treatments only (Figure 5.15).  
 
5.3.8 Sodium pyruvate suppressed reduced MCF7 cell viability induced by green tea 
compounds 
The effect of sodium pyruvate supplementation on reduced MCF7 cell viability in response to 
selected compounds of green tea was investigated by co-incubating cells with 1Mm sodium pyruvate 
alongside green tea treatments for 24h. Selected green tea compounds mentioned above caused 
35.9%±12.1% (p<0.0001) and 47.4%±12% (p<0.0.0001), and 20%±1.8% (p=0.0015) decreases in cell 
viability respectively. These decreases were significantly suppressed by 53.1.4%±0.3% (p<0.0001), 
88.3%±0.6% (p<0.0001), and 22.9%±0.61% (p<0.0001) respectively in response to supplement sodium 
pyruvate compared to green tea treatments (Figure 5.16).   
 
5.3.9 Akt inhibition further reduced MDA-MB-231 cell viability alongside green tea 
compounds 
The role of Akt was assessed on reduced MDA-MB-231 cell viability when exposed to selected green 
tea compounds. Cells were co-cultured with Akt selective inhibitor alongside 100 and 150µM of EGCG 
and combination of catechins, and 150µM quercetin. Cell viability was examined using 
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PrestoBlue® reagent. Cells exhibited a significant reduction in cell viability in response to these selected 
green tea compounds. Supplementing Akt inhibitor concomitant with 150µM EGCG and quercetin 
significantly reduced cell viability by 16.4%±4% (p<0.0001) and 35.1%±2.2% (p<0.0001) respectively 
compared to green tea treatments only (Figure 5.17). 
 
5.3.10 AMPK inhibition further reduced MDA-MB-231 cell viability alongside green tea 
compounds  
An AMPK selective inhibitor was supplemented to cells treated with selected green tea compounds 
mentioned above for 24h to identify the role of AMPK on reduced cell viability in response to green tea 
compounds. Co-incubating the cells with AMPK inhibitor alongside 150µM combination catechins and 
quercetin caused 13.7%±0.6% (p=0.0216) and 34.2%±7% (p<0.0001) further reduction in cell viability 
compared to green tea treatments only (Figure 5.18). 
 
5.3.11 Sodium pyruvate suppressed reduced MDA-MB-231 cell viability induced by 
green tea compounds 
The role of sodium pyruvate supplementation on reduced cell viability in response to green tea was 
investigated by co-incubating cells with sodium pyruvate combined with selected green tea compounds 
for 24h. Supplementing 1mM of sodium pyruvate was enough to counter the effect of 100 and 150µM 
EGCG and combination catechins, and 150µM quercetin on cell viability. Sodium pyruvate promoted 
significant increased viable cells by 24.8%±0.8% (p<0.0001), 27.8%±0.5% (p<0.0001) and 
14.9%±0.6% (p<0.0001), 18.7%±0.9% (p<0.0001), and 16%±0.55% (p<0.0001) respectively compared 
to cells treated with green tea compounds only (Figure 5.19). 
 
5.3.12 Impact of green tea compounds on phosphorylation of Akt and AMPK 
The impact of green tea compounds on Akt and AMPK activity in the BC cell lines was investigated. 
Phosphor-specific Western blotting was performed in response to active compounds of green tea that 
appeared to show significant effects based on previously obtained results, and the expression levels of 
pAkt and pAMPK proteins was determined. Unfortunately, due to budget and time limitations, it was 
not possible to run three independent experiments, and therefore, no statistical test could reliably be 
applied. The data qualitatively, however, suggests that there were no significant differences in pAkt and 
pAMPK between green tea compound treatments and control (Figure 5.20 and Figure 5.21), and these 
data cannot be used to draw firm conclusions, and more independent research is therefore required. 
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Figure 5.14 Akt inhibitor increases reduced MCF7 cell viability by green tea compounds. 
MCF7 cells were seeded in 96 well plate at density of 5000/well. Cells were exposed to selected 
green tea compounds in presence and absence 10µM of Akt inhibitor for 24h, and cell viability was 
measured using PrestoBlue®. Green tea compound reduced viable cell compared to control, and Akt 
inhibition selectively further decreased viable cell compared to green tea compounds. Data presented 
mean ± SEM, ****p<0.0001, n=3. 
 
Figure 5.15 AMPK inhibitor increases reduced MCF7 cell viability by green tea compounds. 
MCF7 cells were seeded in 96 well plate at density of 5000/well. Cells were exposed to selected 
green tea compounds in presence and absence 10µM of AMPK inhibitor for 24h, and cell viability was 
measured using PrestoBlue®. Green tea compound reduced viable cell compared to control, and AMPK 
inhibition selectively further decreased viable cell compared to green tea compounds. Data presented 
mean ± SEM, ****p<0.0001, n=3. 
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Figure 5.16 Sodium pyruvate suppresses reduced MCF7 cell viability by green tea compounds.  
MCF7 cells were seeded in 96 well plate at density of 5000/well. Cells were exposed to selected 
green tea compounds in presence and absence 1mM of sodium pyruvate for 24h, and cell viability was 
measured using PrestoBlue®. Green tea compound reduced viable cell compared to control, and sodium 
pyruvate increased viable cell compared to green tea compounds. Data presented mean ± SEM, 
**p<0.01****p<0.0001, n=3. 
 
Figure 5.17 Akt inhibitor increases reduced MDA-MB-231 cell viability by green tea compounds. 
MDA-MB-231 cells were seeded in 96 well plate at density of 5000/well. Cells were exposed to 
selected green tea compounds in presence and absence 10µM of Akt inhibitor for 24h, and cell viability 
was measured using PrestoBlue®. Green tea compound reduced viable cell compared to control, and Akt 
inhibition selectively further decreased viable cell compared to green tea compounds. Data presented 
mean ± SEM, *p<0.05. **p<0.01, and ****p<0.00001, n=3. 
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Figure 5.18 AMPK inhibitor increases reduced MDA-MB-231 cell viability by green tea. 
MCF7 cells (5000/well) of 96 well plate were exposed to green tea compounds with AMPK inhibitor 
for 24h, and cell viability was measured. AMPK inhibition selectively further decreased viable cell 
compared to green tea compounds. Data presented mean ± SEM, *p<0.05, **p<0.01, ***p<0.001, and 
****p<0.0001, n=3. 
 
Figure 5.19 Sodium Pyruvate suppresses reduced MDA-MB-231 cell viability by green tea.  
MDA-MB-231 cells (5000/well) of 96 well plate were exposed to green tea compounds with sodium 
pyruvate for 24h, and cell viability was measured. Sodium pyruvate increased viable cell compared to 
green tea compounds. Data presented mean ± SEM, ***p<0.001 and ****p<0.0001, n=3. 
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Figure 5.20 Effect of selected green tea compounds on pAkt & pAMPK expression in MCF7 cell. 
MCF7 cells were seeded in 6 well plate, and incubated in standard conditions until completed 
confluency. The cells were serum starved for 2h, and then were treated with 100µM of EGCG and 
quercetin for 15 and 30 minutes. Total protein was isolated and quantified, and phosphor western 
blotting was performed to identify the leves of pAkt and pAMPK. (A). Total Akt, total AMPK, pAkt, 
and pAMPK Bands expressed in MCF7 represented one experiment. (B). analysed data of pAkt 
expression. (C). Analysed data of pAMPK expression. The data displayed as a % of control which 
normalised to total Akt or AMPK expression. Bands intensity were quantified using Image J software. 
Data presented as n=2. 
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Figure 5.21 Effect of selected green tea compounds on pAkt & pAMPK expression in MDA-MB-
231 cell. 
MDA-MB-231 cells were seeded in 6 well plate, and incubated in standard conditions until 
completed confluency. The cells were serum starved for 2h, and then were treated with 100µM of 
EGCG, GTC, and quercetin for 15 and 30 minutes. Total protein was isolated and quantified, and 
phosphor western blotting was performed to identify the leves of pAkt and pAMPK. (A). Total Akt, 
total AMPK, pAkt, and pAMPK Bands expressed in MDA-MB-231 cell represented one experiment. 
(B). analysed data of pAkt expression. (C). Analysed data of pAMPK expression. The data displayed as 
a % of control which normalised to total Akt or AMPK expression. Bands intensity were quantified 
using Image J software. Data presented as n=2.  
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5.3.13 Selected green tea compounds induced apoptosis in BC cell lines 
As previous results have indicated, cell viability was reduced after exposure to green tea compounds. 
The effect of these compounds on the levels of cellular apoptosis was investigated in MCF7 and MDA-
MB-231 cells. Cells were exposed to previous effective concentrations of green tea compounds and 
supplemented with or without sodium pyruvate substrate to identify its role in apoptosis. Induction of 
apoptosis was measured through activation of caspase 3/7. The results show that EGCG at 100 and 
150µM, and 150µM quercetin significantly induced apoptosis in MCF7 cells after just 24h incubation 
compared to control (Figure 5.22 A). The increases in caspase 3/7 activity were 36.55%±1.5% 
(p=0.0009), 38.40%±2.8% (p=0.0004), 32.11%±3.34% (p=0.0055) respectively. Co-incubating 1mM 
sodium pyruvate alongside green tea compounds had no significant effect on green tea compounds-
induced increases in apoptosis by activation of caspase 3/7. Similarly, EGCG and a combination of 
catechins at 100 and 150µM, and quercetin at 150µM significantly promoted apoptosis in MDA-MB-
231 cells compared to control after 24h treatment (Figure 5.22 B). The data showed increases in caspase 
3/7 of 79.87%±3.6% (p=0.0080), 93.35%±5.33% (p=0.0007), 76.77%±8% (p=0.0132), 76.05%±9.22% 
(p=0.0147), and 86.36%±11.66% (p=0.0026) respectively. Like MCF7 cells, the addition of sodium 
pyruvate had no significant effect on activation of caspase 3/7 compared to cells treated with green tea 
active ingredients only.  
 
5.3.14 Effect of selected compounds of green tea on BC cell apoptotic gene expression 
The impact of active ingredients of green tea that induced apoptosis previously on the expression of 
some pro-apoptotic and anti-apoptotic gene expression in MCF7 and MDA-MB-231 were assessed by 
using qRT-PCR. These apoptosis regulatory genes are Bcl2, Bax, P53 and Myc. The obtained Ct values 
of targeting genes were normalised using endogenous reference hYWHAZ gene followed by using 
equation 2-∆∆Ct to estimate relative gene expression in control and treatment cells. In MCF7, the results 
showed that EGCG and quercetin did not alter expression of Bcl2, Myc, and P53 (Table 5.1) compared 
to control. Whereas, EGCG only significantly upregulated Bax gene expression by 0.7 fold (p=0.0335) 
compared to control (Table 5.1). Different effects of some active compounds of green tea on the 
apoptotic gene in MDA-MB-231 cells were displayed. Quercetin significantly upregulated Bcl2 
expression by 2.9 fold (p=0.0096) compared to control, with no effect of EGCG and GTC (p=0.9863 
and >0.9999) (Table 5.2). Significant upregulation of Bax expression was mediated by EGCG and 
quercetin by 1.75 (p=0.0417), and 1.9 (p=0.0165) fold more than control (Table 5.2). Furthermore, these 
selected compounds of green tea did not change the expression level of Myc, whereas only quercetin 
significantly upregulated P53 expression by 0.96 (p=0.0343) fold more than control (Table 5.2). 
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Figure 5.22 Selected green tea compounds induce apoptosis in BC cell. 
BC cells were seeded in 96 well plate at density of 5000/well. Cells were exposed to selected green 
tea compounds in presence and absence 1mM of sodium pyruvate for 24h. Apoptosis was investigated 
by exposing cells to CellEvent® Caspase 3/7 ready Probes® to measure activation of caspase 3/7 for 1h. 
(A) MCF7 cells exhibited a significant increase in apoptosis in response to green tea compounds 
compared to control, with no effect of addition sodium pyruvate. (B) MDA-MB-231 cells exhibited a 
significant increase in apoptosis in respond to green tea compounds compared to control, and sodium 
pyruvate did not alter apoptosis. Data presented mean ± SEM, *p<0.05, **p<0.01, and ***p<0.001, 
n=3. 
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Table 5.1 Effect of green tea compounds on some pro and anti-apoptotic mRNA expression in 
MCF7 cell. 
MCF7 cells were seeded into 12 well plate, and incubated in standard condition until completed 
confluency. Cells were serum starved for 2h and then were treated with 100µM of EGCG and quercetin 
for 24h. RNA was isolated and reverse transcriptased, followed by quantifing amplification of some pro 
and anti-apoptotic mRNA by using qPCR. No significant differences between green tea treatments and 
control of all tested genes were seen except EGCG significantly upregulated Bax mRNA leve compared 
to control. Data displayed as relative fold of gene expression which normalised to housekeeping gene. 
The data presented mean ± SEM, n=3. 
 
mRNA Treatment ↑↓ Fold of control P value 
Bcl2 EGCG 1.62 ± 0.7712 0.7725 
Quercetin 0.7542 ± 0.1996 0.9534 
Bax EGCG 1.714 ± 0.06678 0.0335* 
Quercetin 1.106 ± 0.1002 0.9722 
P53 EGCG 1.433 ± 0.4236 0.6833 
Quercetin 0.7992 ± 0.1272 0.9111 
Myc EGCG 2.63 ± 0.8306 0.1350 
Quercetin 1.315 ± 0.3704 0.9606 
 
Table 5.2 Effect of green tea compounds on some pro and anti-apoptotic mRNA expression in 
MDA-MB-231 cell. 
MDA-MB-231 cells were seeded into 12 well plate, and incubated in standard condition until 
completed confluency. Cells were serum starved for 2h and then were treated with 100µM of EGCG, 
GTC, and quercetin for 24h. RNA was isolated and reverse transcriptased, followed by quantifing 
amplification of some pro and anti-apoptotic mRNA by using qPCR. No significant differences between 
green tea treatments and control of Myc mRNA was seen. Quercetin significantly upregulated Bcl2, 
Bax, and P53 mRNA compared to control. Whereas, EGCG significantly upregulated Bax mRNA 
compared to control. Data displayed as relative fold of gene expression which normalised to 
housekeeping gene. The data presented mean ± SEM, n=3. 
 
mRNA Treatment ↑↓ Fold of control P value 
 
Bcl2 
EGCG 1.411 ± 0.3615 0.9863 
GTC 0.9905 ± 0.2471 >0.9999 
Quercetin 3.938 ± 0.9092 0.0096** 
 
Bax 
EGCG 2.753 ± 0.38 0.0417* 
GTC 1.606 ± 0.2781 0.8711 
Quercetin 2.907 ± 0.3345 0.0165* 
 
P53 
EGCG 0.949 ± 0.08675 0.9979 
GTC 1.079 ± 0.1522 0.9997 
Quercetin 1.966 ± 0.2795 0.0343* 
 
Myc 
EGCG 1.482 ± 0.1633 0.4537 
GTC 1.609 ± 0.1385 0.2303 
Quercetin 1.233 ± 0.1458 0.8714 
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5.3.15 Selected green tea compounds decreased BC cell lactate production after 24h 
The impact of active compounds of green tea on glycolysis in BC cells was investigated by expossing 
MCF7 and MDA-MB-231 cells to previous effective concentrations of green tea compounds for 24h. 
The amount of lactate produced from control and green tea-treated cells was measured. EGCG at 100 
and 150µM, and quercetin at 150µM, significantly decreased lactate release from MCF7 cells compared 
to control (Figure 5.23 A). The decreases in lactate were: 50%±20.84% (p=0.0073), 52.7%±16.6% 
(p=0.0019), and 34.44%±16% (p=0.0441) respectively. Furthermore, MDA-MB-231 cells also 
exhibited a significant decrease in lactate production when treated with 100 and 150µM of EGCG and 
combination of catechins, in addition to 150µM of quercetin compared to control (Figure 5.23 B). The 
reductions in lactate were: 56.9%±12.16% (p<0.0001), 45.3%±2% (p=0.0003), 40.8%±17.8% 
(p=0.0014), 48%±19.2% (p=0.0001), and 38.6%±4.26% (p=0.0026) respectively.  
 
5.3.16 Sodium pyruvate suppressed green tea reduced BC cell lactate production after 
24h 
To study the role of sodium pyruvate substrate on green tea mediated lactate reduction, MCF7 and 
MDA-MB-231 cells were treated with 150µM of selected green tea compounds that promoted 
significant decreases in lactate production in presence and absence of 1mM sodium pyruvate. The results 
showed EGCG and quercetin significantly decreased MCF7 lactate production by 65.3%±3.6% 
(p<0.0001) and 54.8%±5.2% (P<0.0001) respectively compared to control. Whereas, the addition of 
sodium pyruvate significantly restored lactate release by 122%±1.9% (p<0.0001), and 33.3%±6.8% 
(p=0.0486) respectively compared to cells treated with green tea compounds (Figure 5.24 A). Like 
MCF7, EGCG, a combination of catechins, and quercetin significantly reduced of lactate in media by 
39.4%±3.3% (p<0.0001), 26.7%±3.7% (p=0.0001), and 36.9%±3.9% (p<0.0001) respectively 
compared to control. Supplementing cells with sodium pyruvate alongside green tea compounds 
significantly increased lactate by 32.55%±2% (p=0.0031), 22.53%±2% (p=0.0147), and 27.6%±6.84% 
(p=0.0118) respectively compared to cells treated with green tea compounds (Figure 5.24 B).   
 
5.3.17 Selected compounds of green tea decreased BC cell lactate production after 6h. 
In order to establish whether the changes in glucose homoeostasis/glycolysis occur before or after 
changes in cell viability, the early effects of green tea active compounds on BC cell glycolysis were 
investigated by measuring the amount of lactate release from cells after just 6h. MCF7 and MDA-MB-
231 cell lines were treated with EGCG and quercetin for 6h only. As early as 6h incubation, EGCG and 
quercetin promoted significant reductions in lactate release from treated MCF7 compared to control 
(Figure 5.25 A). Percentage decreases were: 10.66%±3.36% (p=0.0462) and 10.2%±0.54% (p=0.0487) 
respectively. Similarly, both EGCG and quercetin mediated significant reduced amounts of lactate in 
MDA-MB-231 cells after just 6h treatment with decreases of 11.43%±2.6% (p=0.0015) and 
7.44%±0.4% (p=0.0143) respectively (Figure 5.25 B). 
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5.3.18 Sodium pyruvate does not alter green tea reduced BC lactate production after 6h 
MCF7 and MDA-MB-231 cells were treated with high concentrations of EGCG and quercetin with 
and without sodium pyruvate for 6h to identify the early effect on decreased lactate production mediated 
by green tea compounds. EGCG and quercetin caused significant decreases in MCF7 lactate production 
by 20.88%±2.11% (p=0.0040) and 23%±4.35% (p=0.0044) compared to control without any significant 
effect of sodium pyruvate to alter these reductions (Figure 5.26 A). Similarly, EGCG and quercetin 
mediated significant reductions in lactate release in MDA-MB-231 cells with 11.43%±2.6% (P=0.0015) 
and 7.44%±0.4% (P=0.0143) decreases being recorded respectively. These significant decreases in 
lactate production were unaffected by supplementing sodium pyruvate substrate (Figure 5.26 B). 
 
5.3.19 Selected compounds of green tea decreased 2-NBDG uptake in BC cells  
Previous results in the present study indicate that active compounds in green tea have the ability to 
decrease lactate release from BC cell earlier without affected viable cell. The effect of green tea active 
ingredients on BC cell glucose uptake were determined in MCF7 and MDA-MB-231 cells post exposure 
to previous effective compounds of green tea. Cellular glucose uptake was measured using a fluorescent 
glucose analogue after 4h treatment. Measuring direct cellular glucose uptake using 2-NBDG is 
accurate, valid and widely used method than measuring amount of glucose remain in the media, as the 
previous research in this study did (Nowis, et al., 2014). The results showed that 100 and 150µM EGCG 
and 150µM quercetin significantly reduced 2-NBDG uptake in MCF7 cells compared to control (Figure 
5.27 A) with decreases of 19.67%±5.4% (p<0.0001), 15.57%±3.62% (p=0.0018), and 13.34%±2% 
(p=0.0095) respectively being recorded. A similar effect of green tea compounds on glucose uptake in 
MDA-MB-231 cells was seen, with EGCG and combination compounds at 100 and 150µM in addition 
to quercetin at 150µM significantly decreases in glucose uptake compared to control (Figure 5.27 B). 
The recorded decreases in 2-NBDG uptake were: 20.44%±6.2% (p=0.0072), 24.25%±4.4% (p=0.0008), 
20.99%±2% (p=0.0053), 22.97%±5.58% (p=0.0017), and 21.80%±6.3% (p=0.0033) respectively. 
 
5.3.20 Akt and AMPK inhibition unaltered green tea compounds-induced decrease BC 
cell 2-NBDG uptake  
The role of Akt and AMPK signalling pathways on glucose uptake was determined through 
supplementing small molecule inhibitors alongside green tea compounds for 4 and 8h incubations in 
both MCF7 and MDA-MB-231 cells. Supplementation of Akt or AMPK inhibitor alongside green tea 
compounds to MCF7 cells did not significantly alter 2-NBDG uptake compared to significant decreases 
that were promoted by green tea compounds after 4h treatment (Figure 5.28 A). Similarly, MDA-MB-
231 cells exposed to Akt or AMPK inhibitor alongside selected green tea compounds did not respond 
differently regarding 2-NBDG uptake compared to green tea compounds alone after 4h incubation 
(Figure 5.28 B). Furthermore, no differences were observed in 2-NBDG uptake after 8h of co-incubated 
cell with Akt or AMPK inhibitor alongside selected green tea compounds in both cell lines (Figure 5.29). 
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Figure 5.23 Selected green tea compounds decrease BC cell lactate production after 24h 
intervention. 
BC cells were seeded into 24 well plate at density of 3x104, and incubated in standard condition for 
24h. Cells were then exposed to selected green tea compounds for 24h. Culture media were collected, 
deproteinsed, and the level of lactate was measured using fluorimetric L-Lactate assay. (A) MCF7 cells 
showed significantly decreased in lactate level in response to EGCG and quercetin compared to control. 
(B) MDA-MB-231 cells showed significantly reduced lactate level in response to EGCG, GTC, and 
quercetin compared to control and DMSO. Data presented mean ± SEM, *p<0.05, **p<0.01, 
***p<0.001, and ****p<0.0001, n=3. 
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Figure 5.24 Sodium pyruvate suppresses green tea reduced BC cell lactate release after 24h 
intervention. 
BC cells were seeded into 24 well plate at density of 3x104, and incubated in standard condition for 
24h. Cells were then exposed to selected green tea compounds in presence and absence 1mM sodium 
pyruvate for 24h. Culture media were collected, deproteinsed, and the level of lactate was measured 
using fluorimetric L-Lactate assay. (A) Supplementation of sodium pyruvate significantly increased 
MCF7 cells lactate production compared to green tea compounds. (B) Supplementation of sodium 
pyruvate significantly increased MDA-MB-231 cells lactate production compared to green tea 
compounds. Data presented mean ± SEM, *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001, n=3. 
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Figure 5.25 Selected green tea compounds reduce BC cell lactate production after 6h intervention. 
The early effects of selected green tea compounds on BC cell glycolysis were investigated. Cells 
were seeded into 24 well plate at density of 3x104, and incubated in standard condition for 24h. Cells 
were then exposed to selected green tea compounds for 6h. Culture media were collected, deproteinsed, 
and the level of lactate was measured using fluorimetric L-Lactate assay.  (A) MCF7 cells showed a 
significant decrease of lactate level in respond to EGCG and quercetin compared to control and DMSO 
(B) MDA-MB-231 cells showed significant reduce of lactate level in response to EGCG and quercetin 
compared to control and DMSO. Data presented mean ± SEM, *p<0.05, **p<0.01, n=3. 
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Figure 5.26 Sodium pyruvate does not alter BC cell lactate release after 6h intervention. 
BC cells were seeded into 24 well plate at density of 3x104, and incubated in standard condition for 
24h. Cells were then exposed to selected green tea compounds in presence and absence 1mM sodium 
pyruvate for 6h. Culture media were collected, deproteinsed, and the level of lactate was measured using 
fluorimetric L-Lactate assay. (A) Supplementation of sodium pyruvate did not alter MCF7 cell lactate 
level compared to green tea compounds. (B) Supplementation of sodium pyruvate did not alter MDA-
MB-231 cell lactate level compared to green tea compounds. Data presented mean ± SEM, *p<0.05, 
and **p<0.01, n=3. 
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Figure 5.27 Selected compounds of green tea reduce BC cell 2-NBDG uptake. 
BC cells were seeded into 96 well plate at density of 104, and incubated in standard condition for 
24h. Cells were then treated with selected green tea compounds in low glucose media containing 100µM 
2-NBDG for 4h, and amount of fluorescent 2-NBDG uptake was quantified. (A) MCF7 cells showed 
significantly decreased of 2-NBDG uptake in response to EGCG and quercetin compared to control. (B) 
MDA-MB-231 cells showed significant decreased of 2-NBDG uptake in response to EGCG, a 
combination of catechins, and quercetin compared to control.  Data presented mean ± SEM, **p<0.01, 
***p<0.001, and ****p<0.0001, n=3.  
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Figure 5.28 Akt and AMPK inhibitors do not alter green tea reduced BC 2-NBDG uptake after 
4h intervention. 
BC cells were seeded into 96 well plate at density of 104, and incubated in standard condition for 
24h. Cells were then treated with selected green tea compounds in low glucose media containing 100µM 
2-NBDG for 4h in presence and absence 10µM of Akt or AMPK inhibitors, and amount of fluorescent 
2-NBDG uptake was quantified. (A) Akt or AMPK inhibition did not alter MCF7 cell 2-NBDG uptake 
compared to green tea compounds. (B) Akt or AMPK inhibition did not alter MDA-MB-231 2-NBDG 
uptake compared to green tea compounds. Data presented mean ± SEM, *p<0.05, **p<0.01, 
***p<0.001, and ****p<0.0001, n=3. 
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Figure 5.29 Akt and AMPK inhibitors do not alter green tea reduced BC 2-NBDG uptake after 
8h intervention. 
BC cells were seeded into 96 well plate at density of 104, and incubated in standard condition for 
24h. Cells were then treated with selected green tea compounds in low glucose media containing 100µM 
2-NBDG for 8h in presence and absence 10µM of Akt or AMPK inhibitors, and amount of fluorescent 
2-NBDG uptake was quantified. (A) Akt or AMPK inhibition did not alter MCF7 cell 2-NBDG uptake 
compared to green tea compounds. (B) Akt or AMPK inhibition did not alter MDA-MB-231 2-NBDG 
uptake compared to green tea compounds. Data presented mean ± SEM, ****p<0.0001, n=3. 
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5.3.21 Selected compounds of green tea reduced MCF7 cellular migration  
The effect of green tea compounds on the cellular migration of BC cell was explored by using two 
methods based on wound healing to close an artificial scratch. The wound healing assay (scratch) has 
been widely used to study cellular migration of various type of cancer and drugs screening in vitro. This 
assay is either using microscope for imaging (Arif, 2014;Liu, et al., 2015) and/or live cell automated 
imaging (CellIQ™) (Arif, 2014;Isherwood, et al., 2011). Artificial scratches were made and the cells 
treated with 50µM of EGCG and quercetin. Images were captured using (inverted microscope, Figure 
5.30) and automated live imaging (CellIQ™, Figure 5.31) at time 0 and 24h. The data were collected, 
and cellular migration was calculated as a percentage of wound closure, as detailed in chapter two. The 
results of microscopic imaging of the wound healing assay showed that EGCG and quercetin 
significantly reduced MCF7 cellular migration after 24h (Figure 5.32 A). The percentage decreases in 
wound closure were: 46.71%±6.2% (p=0.0001) and 58.87%±13.32% (p=0.0003) compared to control. 
Similar results were recorded on the measurement of cellular migration in MCF7 cells using the 
automated cell live imaging system (CellIQ™). Cells exhibited significant decreases of wound closure 
after 24h treated with EGCG and quercetin compared to control (Figure 5.32 B). Reductions in migration 
of 28.33%±3.75% (p=0.0001) and 28.82%±6.25% (p=0.0003) respectively were recorded.  
 
5.3.22 Selected compounds of green tea reduced MDA-MB-231 cellular migration 
Similar to MCF7, the effect of selected compounds of green tea were examined on MDA-MB-231 
cellular migration using a standard wound healing assay, and an automated cell lives imaging system 
(CellIQ™). The artificial scratch was made and the cells treated with 50µM of EGCG, GTC, and 
quercetin. Images were captured using an inverted microscope (Figure 5.33) and automated live imaging 
CellIQ™ (Figure 5.34) at time 0 and 24h. The collected data were analysed, and cellular migration was 
calculated as a percent of wound closure as mentioned in detail in chapter two. The microscopic imaging 
analysis results showed that EGCG and quercetin significantly decreased wound closure by 40.56% 
±13.63% (p=0.0076) and 55.70%±15.44% (p<0.0001) compared to control (Figure 5.35 A). The 
combination of catechins did not significantly alter wound closure (reduction of 29%±11.20%, 
p=0.1024) compared to control. Like the microscopic imaging result, the CellIQ™ analysed imaging 
showed that EGCG and quercetin caused significant decreases in the cellular migration of MDA-MB-
231 by 34.37%±11% (p=0.0040) and 52.86%±8.61% (p=0.0003) respectively compared to control 
without significant effect of combination catechins (Figure 5.35 B).  
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Figure 5.30 Effect of selected green tea compounds on MCF7 cell migration (microscope images).  
MCF7 cells were seeded into 24 well plate, and incubated in standard condition until completely 
confluency. Cells were then exposed to 5µg of mitomycin C in serum free media for 2h to inhibit cellular 
proliferation. Cross artificial scratch was made, and the cells were then washed with HBSS and treated 
with 50µM of EGCG and quercetin for 24h. Images at day 0 and 24h were captured by using Leica 
DMI4000 B inversion microscope at 100x magnification and analysed using TScratch software (CSE 
Lab, ETH, Zurich), the images are representative sample of n=3 shown.       
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Figure 5.31 Effect of selected green tea compounds on MCF7 cell migration (CellIQ®) images.  
MCF7 cells were seeded into 24 well plate, and incubated in standard condition until completely 
confluency. Cells were then exposed to 5µg of mitomycin C in serum free media for 2h to inhibit cellular 
proliferation. Longitudinal artificial scratch was made, and the cells were then washed with HBSS and 
treated with 50µM of EGCG and quercetin for 24h. Two interested area of each well were chosen, and 
images at day 0 and 24h were captured by automated live cell imaging system (CellIQ®) and analysed 
using CellIQ® software, the images are representative sample of n=3 shown.       
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Figure 5.32 Selected compounds of green tea reduce MCF7 cell migration. 
MCF7 cells were seeded into 24 well plate, and incubated in standard condition until completely 
confluency. Cells were then exposed to 5µg of mitomycin C in serum free media for 2h to inhibit cellular 
proliferation. Artificial scratch was made, and the cells were then washed with HBSS and treated with 
50µM of EGCG and quercetin for 24h. Cellular migration was monitored, and calculated as a % of 
wound closure. (A) Microscope images wound healing analysis of MCF7 cells. (B) CellIQ® images 
wound healing analysis of MCF7 cells. Both results showed significantly decreased of wound closure 
in response to EGCG and quercetin after 24h compared to control. Microscopic data analysed using 
TScratch software (CSE Lab, ETH, Zurich) and CellIQ® data analysed using CellIQ® software. Data 
presented mean ± SEM, ***p<0.001, n=3.     
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Figure 5.33 Effect of selected green tea compounds on MDA-MB-231 cell migration (microscope 
images).  
MDA-MB-231 cells were seeded into 24 well plate, and incubated in standard condition until 
completely confluency. Cells were then exposed to 5µg of mitomycin C in serum free media for 2h to 
inhibit cellular proliferation. Cross artificial scratch was made, and the cells were then washed with 
HBSS and treated with 50µM of EGCG, GTC, and quercetin for 24h. Images at day 0 and 24h were 
captured by using Leica DMI4000 B inversion microscope at 100x magnification and analysed using 
TScratch software (CSE Lab, ETH, Zurich), the images are representative sample of n=3 shown.  
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Figure 5.34 Effect of selected green tea compounds on MDA-MB-231 cell migration (CellIQ®) 
images.  
MDA-MB-231 cells were seeded into 24 well plate, and incubated in standard condition until 
completely confluency. Cells were then exposed to 5µg of mitomycin C in serum free media for 2h to 
inhibit cellular proliferation. Longitudinal artificial scratch was made, and the cells were then washed 
with HBSS and treated with 50µM of EGCG and quercetin for 24h. Two interested area of each well 
were chosen, and images at day 0 and 24h were captured by automated live cell imaging system 
(CellIQ®) and analysed using CellIQ® software, the images are representative sample of n=3 shown.  
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Figure 5.35 Selected compounds of green tea reduce MDA-MB-231 cell migration. 
MDA-MB-231 cells were seeded into 24 well plate, and incubated in standard condition until 
completely confluency. Cells were then exposed to 5µg of mitomycin C in serum free media for 2h to 
inhibit cellular proliferation. Artificial scratch was made, and the cells were then washed with HBSS 
and treated with 50µM of EGCG, GTC, and quercetin for 24h. Cellular migration was monitored, and 
calculated as a % of wound closure. (A) Microscope images wound healing analysis of MDA-MB-231 
cells. (B) CellIQ® images wound healing analysis of MDA-MB-231 cells. Both results showed 
significant decreased of wound closure in response to EGCG and quercetin but not GTC after 24h 
compared to control. Microscopic data analysed using TScratch software (CSE Lab, ETH, Zurich) and 
CellIQ® data analysed using CellIQ® software. Data presented mean ± SEM, **p<0.01, ***p<0.001, and 
****p<0.0001, n=3.     
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5.4 Discussion 
The broad aim of this chapter is to investigate the effect of several individual compounds of green 
tea at set time points, and concentrations on BC cell biology. Initially, experiments determined the ability 
of these compounds to promote cytotoxic effects to reduce cell viability and induce apoptosis. Secondly, 
as metastasis is the major factor that is responsible for increasing mortality, the effect of these 
compounds on BC cellular migration was also explored to reduce the risk of death due to metastasis. 
Linking all these together with abnormal glucose metabolism in BC cells, a key purpose of this chapter 
is to investigate the role of green tea compounds on BC glucose metabolism. As a result of considering 
this approach, targeting BC glucose metabolism by natural compounds is the main purpose of the 
research described in this chapter.      
 
The effect of several compounds and concentrations of green tea on BC cell viability and activity of 
caspase 3/7 (apoptosis) was investigated. The results showed that EGCG, a combination of catechins, 
and quercetin significantly decreased cell viability in MCF7 (Figure 5.1 to Figure 5.6), and in MDA-
MB-231 (Figure 5.7 to Figure 5.12). The present study focussed on the role of glucose metabolism in 
BC biology in response to green tea, the data presented here shows that some green tea compounds 
decrease cell viability in BC cells; as would be expected from previously published findings. Green tea 
catechins caused cell cycle arrest and significantly decreased cell viability in different cell lines (Chen, 
et al., 2014;Geetha and Santhy, 2013;Liang, et al., 1999;Thangapazham, et al., 2007;Wang, et al., 
2010b).  In line with a wealth of previously published data, this gives a clear indication that the 
compounds found in green tea exhibit potent cytotoxic effect on BC. This result is substantiated by 
clinical studies that have shown consumption of green tea can reduce cancer risk or improve prognosis 
(Wu and Butler, 2011). Therefore, the potential development of new chemotherapeutic agents from 
green tea exists and needs further exploration. 
 
Additionally, the present study measured apoptosis in MCF7 and MDA-MB-231 cells exposed to 
selected green tea compounds. As a reduction of BC cell viability by selected compounds of green tea, 
these compounds could stimulate cancer cells to undergo apoptosis as measured by caspase 3/7 
activation. The result showed increased caspase 3/7 activity by EGCG and quercetin in MCF7 cells, 
whilst increases in caspase 3/7 activity was observed in MDA-MB-231 in response to EGCG, GTC, and 
quercetin (Figure 5.22). This activation of caspase 3/7 was associated with alteration of some pro-
apoptotic and anti-apoptotic gene expression in both cell lines in response to these compounds. Among 
all genes explored MCF7 cells exhibited increased Bax expression responding to EGCG only (Table 
5.1), and quercetin upregulated Bcl2 and P53 expression in MDA-MB-231 cells, concomitant with 
increased expression of Bax by EGCG and quercetin (Table 5.2). The strategy of chemotherapeutic 
drugs is based on induction of apoptosis in cancer cells through two distinct pathways which are intrinsic 
(mitochondrial) and extrinsic (death receptor) (Debatin, 2004;Mukhtar, et al., 2012). However, most 
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chemotherapeutic drugs have been used to promote their final effect through caspase activation 
(Debatin, 2004). Studies by Duo, et al. (2012) and Hsuuw and Chan (2007) showed that EGCG and 
quercetin induce apoptosis in MCF7 cells through activation of caspase 3/9 and with an increase in 
Bax/Bcl2 ratio. This effect was displayed in MDA-MB-468 cells exposed to EGCG (Roy, et al., 2005). 
Interestingly, a study by Katunuma, et al. (2006) reported that green tea and its catechins compound 
suppressed apoptosis in Hela cells through downregulation of caspase 2/ 3/7 activity; although this study 
seems to be almost unique in suggesting this effect. MCF7 cells lack caspase 3 (Jänicke, et al., 1998). 
Thus apoptotic results of the present study in MCF7 cells responding to green tea compounds refers to 
caspase 7 activation (Liang, et al., 2001) and an increase in Bax expression. The data from the present 
study indicates that the decreases in cell viability seen are likely due to increase cellular apoptosis and 
this fits with previously published findings. However, few studies have investigated the effect of green 
tea polyphenol, EGCG, and quercetin on cell viability and apoptosis in BC and most studies have used 
MCF7, with studies in MDA-MB-231 and MDA-MB-468 being even scarcer. These studies have looked 
at Bax/Bcl2 ratio as an indicator for apoptosis after 48h focusing on low concentrations of treatments. 
The current study used MCF7 and MDA-MB-231 cells, which exhibited a significant decrease in cell 
viability in response to high concentrations of EGCG, quercetin, and a combination of catechins just 
after 24h. These compounds also induced apoptosis just after 24h, mostly through caspase 3/7 activity, 
in conjugation with upregulated Bax by EGCG only. Therefore, from these results, the present study 
suggests that these compounds could promote their effect in a complex way and further investigation of 
this complexity is required.  More detailed investigation of the mechanisms is warranted, including 
protein-based (e.g. Western blotting) analysis of markers of apoptosis. 
 
While there exists evidence of the anti-cancerous effects of green tea, few studies have focussed on 
the role of glucose metabolism in this process. As the cancer cell exhibits alteration of glucose 
metabolism, targeting this aspect could provide spectacular therapeutic promise (Chaneton, 2014). 
Therefore, the present study assessed metabolic markers including glucose uptake and lactate release, 
and the role of Akt and AMPK in glucose uptake in MCF7 and MDA-MB-231 cells, in response to 
effective compounds of green tea. The results show selected green tea compounds significantly reduced 
lactate production in both cell lines after 24h treatment (Figure 5.23), suggesting that they are 
successfully interfering with glucose metabolism. The addition of sodium pyruvate restored lactate 
release compared to cells treated with green tea compounds only (Figure 5.24), which suggests this 
process can be manipulated by adding lactate precursor. As 24h treatment of green tea compounds 
caused a significant fall in cell viability previously, these decreases in lactate could be due to decreased 
cell viability. To further clarify this, analysis after 6h was performed. Selected green tea compounds 
significantly decreased MCF7 and MDA-MB-231 cell lactate production after just 6h of treatment 
(Figure 5.25), suggesting a rapid decline in glycolysis. This result was not associated with any reduction 
in cell viability (Figure 5.13), and any effect of supplementing sodium pyruvate (Figure 5.26), which 
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suggests that this change is not due to cell death. Overall, this result suggests that EGCG, quercetin, and 
combination of catechins modulate BC glycolysis which finally reduced lactate production. Several 
natural occurring compounds have been shown to have chemopreventive effects through targeting 
metabolic events of cancer cells (Dihal, et al., 2008;Jung, et al., 2013). However, few studies have 
identified the metabolic effect of green tea compounds as anti-cancer therapy. Thus more quantitative 
and qualitative research is required to elucidate the exact metabolic role of green tea compounds on 
cancer cells (Lu, et al., 2015;Zhang, et al., 2011). Limited studies have explored the metabolic effect of 
green tea on BC.  Those that have reported inhibition lactate production in response to EGCG and 
quercetin after 4h (Moreira, et al., 2013) and 24h (Xintaropoulou, et al., 2015). These studies were 
associated with significant reductions in cell viability which can reduce lactate production. The present 
study showed that these compounds reduced lactate production in BC cells after 6h without a reduction 
in cell viability. Interestingly, after 24h treatment, in addition to these compounds, GTC also decreased 
lactate production in MDA-MB-231 cells. However, this was associated with a decrease in cell viability. 
As these results are exclusively due to selected compounds of green tea, exploring the effect of more 
compounds individually and together is required for short and long term incubation to investigate all 
markers related to glucose metabolism and apoptosis.   
 
The reduction in lactate production could either be due to reduced glucose metabolism or reduced 
glucose uptake into the cells. The results presented here suggest that green tea compounds significantly 
suppress glucose uptake in both cell lines (Figure 5.27) and therefore this would appear to be the likely 
mechanism by which glycolysis is being reduced. By inhibiting the availability of glucose to the cell 
through blocking its uptake, glycolysis is reduced and therefore the cell has less ATP available to it. 
This hypothesis is supported by the data presented here; that showed supplementing green tea 
compounds with pyruvate could block some of the reduction in cell death previously induced by the 
green tea compounds alone. Further research is needed to elucidate the mechanism of reduced glucose 
uptake under these conditions. However, it is likely that the active ingredients in green tea may be 
suppressing expression or trafficking of Gluts, as has been previously reported (Lu, et al., 2015;Moreira, 
et al., 2013;Xintaropoulou, et al., 2015). As expected, EGCG and quercetin significantly prevent MCF7 
and MDA-MB-231 cells uptake of glucose, however this suppression in glucose uptake was induced 
just after 4h incubation, and for the first time combination of catechins (GTC) induced inhibition of 
MDA-MB-231 glucose uptake. Four hours is considered an early time point, however reducing the time 
of incubation and looking for glucose uptake, and expression of markers of glucose trafficking and 
metabolism would be an excellent study to clarify the relationship between green tea compounds and 
glucose uptake and metabolism in BC cells. Collectively, these data suggest that green tea contains 
compounds that can effectively target glucose metabolism in BC cells by direct targeting cellular glucose 
uptake and glycolytic activity.   
210 
 
PI3K/Akt is a critical pathway to regulate cellular proliferation, differentiation, growth, survival, and 
metabolism (Fresno Vara, et al., 2004). Accumulating evidence shows that this pathway is involved in 
the initiation of many pathological conditions including cancer. Accordingly, cancer cells have exhibited 
the high activity of PI3K/Akt to maintain cellular proliferation and survival (Cantley, 2002;Crowell, et 
al., 2007;Hidalgo and Rowinsky, 2000;Itoh, et al., 2002). The present study investigated this role of Akt 
in green tea active compound mediated changes in cell viability and apoptosis in BC cells through 
inhibition Akt, and measurement of phosphorylation levels of Akt, in response to green tea compounds. 
The results showed that inhibition of Akt caused significant further decreases of MCF7 and MDA-MB-
231 cell viability (Figure 5.14 and Figure 5.17). Furthermore, due to limited phosphor-specific Western 
blotting performed in the present study, it is difficult to suggest the activition of Akt (Figure 5.20 and 
Figure 5.21). As both time and resources prohibited repeats these experiments, sufficient time to be able 
to perform statistical analyses to draw any solid conclusions is difficult. Recently, the anti-cancer effect 
of green tea polyphenol and/or EGCG has been shown to be mediated through inhibition of PI3K/Akt 
pathway in human bladder cancer cells (Qin, et al., 2012). Furthermore, in ovarian cancer cells (Spinella, 
et al., 2006), prostate cancer cells (Siddiqui, et al., 2004), and HeLa and HepG2 cells (Zhang, et al., 
2006). Therefore, this study presented, for the first time, data regarding inhibition of Akt alongside 
selected compounds of green tea that caused more decreases in cell viability in BC cells. However 
repeated experiments related to pAkt expression are required.  Based on previously published data and 
the results of the present study, it is reasonable to suggest that EGCG and quercetin may interact with 
the PI3K/Akt pathways to exert their cytotoxic effect in BC cells. This result is the first data presented 
in BC which suggests targeting PI3K/Akt signalling pathway in cancer conditions by natural compounds 
like green tea may provide a therapeutic solution for different types of tumour. 
 
AMPK is a conservative energy sensor that has a critical role in the regulation of cellular energy 
homoeostasis, and believed to be involved in many diseases, including tumour progression (Hardie, 
2013). As such, activation of AMPK can switch anabolic processes to catabolic, which inhibits cellular 
proliferation and cell cycle progression, and induces apoptosis of cancer cells (Andrade and de Carvalho, 
2014;Kim and He, 2013;Li, et al., 2014). Therefore, neoplastic cells express a low AMPK expression 
(El-Masry, et al., 2012;Hadad, et al., 2008;Huang, et al., 2008;Kuhajda, 2008). The present study 
investigated the role of AMPK in reduced BC cell viability by selected compounds of green tea. The 
study showed that inhibiting AMPK had an additive effect to the cytotoxic effects of green tea 
compounds in MCF7 and MDA-MB-231 cells (Figure 5.15 and Figure 5.18). The limited Western 
blotting analysis seemed to suggest that more independent experiments are required, as the experiment 
was only run twice, and therefore, it is not possible to draw a solid conclusion from these observations. 
(Figure 5.20 and Figure 5.21). Green tea compounds have shown anti-cancer effects through activation 
of the AMPK pathway in MDA-MB-231 cells (Chen, et al., 2012), HT-29 cells (Hwang, et al., 
2007;Kim, et al., 2010), and HeLa cells (Jung, et al., 2010). As the main role of AMPK is maintaining 
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ATP levels required for cellular growth, proliferation and survival of cancer cells. This role casts doubt 
on previous studies that reported anti-cancer effect of green tea compounds through activation of AMPK 
(Bonini and Gantner, 2013;Chhipa, et al., 2010;Frigo, et al., 2011;Jang, et al., 2011;Jeon and Hay, 
2012;Park, et al., 2009). Due to the role of AMPK, the cancer cells therefore expressed activation level 
of AMPK (Laderoute, et al., 2014). The data presented here is unique in that it shows inhibition of 
AMPK alongside green tea compounds caused further reduction in BC cell viability, which suggests 
these compounds of green tea inhibit the activity of AMPK. However, this activity was not confirmed 
by Western blotting as it was conducted on two occasions only. This was not statistically reasonable, 
repetition of pAMPK expression in response to green tea compounds is therefore required.      
 
The migration of cancer cell from the original site to the various organs occurs through a multi-step 
process initiated by local invasion, angiogenesis, systemic invasion, and colonisation of target organs 
(Fidler, 2003;Friedl and Alexander, 2011;Gupta and Massague, 2006;Kozlowski, et al., 2015). The 
present study investigated the anti-migration effect of EGCG, quercetin, and the combination of 
catechins on MCF7 and MDA-MB-231 cells using microscopic and an automated imaging system 
(CellIQ®). The results showed EGCG and quercetin significantly delayed wound closure in BC cells 
(Figure 5.32 and Figure 5.35). Green tea compounds have been identified as anti-migratory compounds 
in oral cancer cells (Lai, et al., 2013), colorectal cancer cells (Maruyama, et al., 2014), prostate and 
cervical cancer cells (Senthilkumar, et al., 2011;Sharma, et al., 2012), lung cancer cells (Takahashi, et 
al., 2014), and BC cells (Bigelow and Cardelli, 2006;Ho, et al., 2013;Tao, et al., 2015). Exploring the 
effect of green tea compounds on the cellular migration of BC cell in this study is essential, as BC cell 
invasion and migration are often responsible for the high female mortality rate. The result of this study 
is consistent with previously published results. However, the data presented here is more reliable; firstly 
two methods were used and secondly the interference of cellular proliferation was inhibited to prevent 
erroneous result. Therefore, these results suggest that alongside the antiproliferative and proapoptotic 
effects of green tea compounds there exists a potential anti-migratory property mediated by an inhibitory 
effect on cell migration. However, signalling pathways of this effect in BC need to be elucidated. 
 
To conclude, some compounds of green tea, particularly EGCG, GTC, and quercetin show promising 
chemotherapeutic effects against two different BC cell lines. These compounds decreased cell viability 
and induced apoptosis, whilst also regulating cell migration. The cytotoxic effect of these green tea 
compounds could mediated through inhibition PI3K and interestingly AMPK which is unlike any other 
previous published findings. Furthermore, these effects of selected green tea compounds are likely 
mediated by the impact of these compounds on cellular glucose metabolism that includes decreased 
glucose uptake, and therefore, modulation of glycolysis due to glucose shortage. Thus, these compounds 
of green tea could be a therapeutic agent for various types of cancer including BC, but further work is 
needed to clarify the precise mechanisms involved.   
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6.1 Discussion 
The research questions upon which this project was based encompassed the concept that green tea, 
and therefore its constituent phytochemicals, may be able to regulate how the body handles glucose at a 
cellular level. Glucose homoeostasis is normally tightly regulated by hormones such as insulin and 
glucagon, but as modern lifestyles increasingly promote dysregulation of glucose homoeostasis, 
identifying factors that can restore or protect this loss of function is important. Globally, consumption 
of green tea is increasing as new geographical areas become aware of its potential benefits. These 
advantages are often suggested to include eliminating a wide variety of diseases and disorders (Chacko, 
et al., 2010), due to the numerous phenolic compounds contained therein, including catechins and more 
specifically to its most abundant active compound EGCG (Abdel-Rahman, et al., 2011). There are some 
physiological and pathological states that glucose has a role in, but the present study focusses on 
metabolic cell and cancer cell glucose homoeostasis. One of the potential beneficial properties of green 
tea is modulating impaired glucose homoeostasis and therefore potentially pre-diabetes and T2D (Babu, 
et al., 2013;Roghani and Baluchnejadmojarad, 2010). Another potential beneficial effect of green tea is 
promoting cytotoxic effects and, therefore, possible anti-cancerous actions (Adhami, et al., 2003;Baliga, 
et al., 2005). Therefore, the present thesis focused on the regulation of glucose homoeostasis and 
metabolism in metabolic cells, mice fed a glucose-rich diet and BC cells. Furthermore, this thesis looked 
at the mechanism of how green tea compounds act to regulate glucose metabolism in various conditions 
encompassing three different cellular metabolisms.  
 
Based on the initial aim of the present study, which included determination of glucoregulatory effect 
of several active compounds in green tea in vitro, the effect of green tea compounds to regulate glucose 
and lipid metabolism was investigated on insulin-sensitive cell lines including C2C12, 3T3-L1, and 
AML12 cells. The results showed that selected compounds of green tea potently and selectively regulate 
glucose uptake in these insulin-sensitive cell lines (Figure 3.3 to Figure 3.11, and Figure 3.24 to Figure 
3.26). These results are in agreement with previously published work which showed green tea 
compounds increase glucose uptake in human hepatoma (HepG2) cells (Cordero-Herrera, et al., 2014). 
In addition to, 3T3-L1 cells (Ueda, et al., 2010;Yan, et al., 2012), and C2C12 and L6 cells (Deng, et al., 
2012;Zhang, et al., 2010). These studies reported that these effects were mediated through modulation 
of Glut2 and Glut4 translocation. Expression of Glut2 and Glut4 mRNA in this study were not affected 
by exposure to green tea compounds (Table 3.1, Table 3.2, and Table 3.3), and without measuring 
protein expression or translocation, the present data set is therefore partially inconsistent with previously 
published results. Thus, specific immunohistochemical and phosphor-western bolting of translocation 
and phosphorylation levels of Gluts are required in future studies. As the data presented here shows, 
specific green tea compounds increased glucose uptake differently in insulin-sensitive cell lines. 
Therefore, the study suggests that green tea compounds selectively promote their effects to regulate 
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levels of glucose according to cell type. Although a combination of experimental compounds induced 
effect in AML12 cells, whole green tea extract needs to be assessed in these cell lines by variation of 
concentration and incubation time.  
 
As a part of exploring signalling pathways of the previously described effects of selected green tea 
compounds, Akt and AMPK regulators of glucose metabolism were separately inhibited alongside green 
tea compounds that increased glucose uptake. As selected green tea compounds increased glucose 
uptake, these increases were significantly suppressed by inhibiting of AMPK in C2C12 cells, and Akt 
in 3T3-L1 and AML12 cells (Figure 3.12 to Figure 3.23, and Figure 3.27 to Figure 3.29). Based on these 
results, phosphor-specific Western blotting was performed, but the results were limited as the 
independent experiment was only carried out on two occasions due to time and budget limitations 
(Figure 3.35 to Figure 3.37), and thus can only be qualitatively considered and firm conclusions cannot 
be made. This work, therefore, needs further independent experiments to be considered. In this regard, 
several studies reported different suggestions based on their final results, and have shown that the green 
tea compounds regulated glucose metabolism in insulin-sensitive cells by activation of AMPK pathway 
(Ding, et al., 2012;Li, et al., 2011b;Murase, et al., 2009).  Few studies, however, have reported 
glucoregulatory effect of green tea compounds in these cells through activation of PI3K/Akt pathway 
(Jung, et al., 2008;Ueda, et al., 2010). The results of these previous studies are based on increased 
expression of pAkt or pAMPK protein in response to green tea compounds. As above studies did not 
use AML12 cell and the present study built conclusions based on Akt or AMPK inhibition experiments 
only, the current study results are not completely in agreement with previous study results. Based on all 
findings together, the present data suggest that selected green tea compounds mediate their effect on 
insulin-sensitive cells through triggering different pathways in different cell types. With respect to whole 
green tea extract, which was not assessed in this study, specific research is needed to determine the role 
of this extract on regulation glucose homoeostasis in these metabolic cells and the molecular mechanism 
of this role.        
 
The levels of glycogen, glycogenic and gluconeogenic transcriptional factors Gsy1, G6Pase and 
PEPCK were assessed in AML12 cell that previously showed significant glucose uptake in response to 
selected green tea compounds. Whilst some compounds at specific concentrations and incubation times 
increased glycogen content (Figure 3.30 and Figure 3.31), none of these selected green tea compounds 
altered glycogen synthase (Gys1) gene expression, and glucose production (G6Pase and PEPCK) gene 
(Table 3.3). These results are inconsistent with almost all published study results that identified EGCG 
and green tea extract can increase the level of glycogen and decreased hepatic glucose production 
through the activation of GS gene and suppressed activity of G6Pase and PEPCK gene and enzymes 
(Collins, et al., 2007;Kim, et al., 2013;Sundaram, et al., 2013;Yasui, et al., 2011).  Although, the present 
study data showed the ability of quercetin and ECG to elevate the level of glycogen, which has not been 
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demonstrated before in AML12 cells, and both EGCG and green tea extract were not considered in these 
experiments.  These unexpected results are possibly due to increase cellular glucose oxidation, which 
prevents glycogen synthesis, as the cells consume more glucose in response to green tea compounds, 
and some of this glucose undergoes oxidation which was not investigated in this study.  Furthermore, 
this result might be due to insensitive of the kit used to measure glycogen, and therefore need to consider 
kit sensitivity in future study. Secondly, poor primer performance might be the reason behind the lack 
of changes in gene expression seen or methodological error and more independent experiments are 
required to clarify that. Whilst previous studies have looked at phosphorylation status of protein or 
enzyme activity in addition to gene expression. The present study measured the mRNA expression only, 
and a clear indication of the gene product levels or activity was not achievable. Investigating protein 
phosphorylation is a terrific tool that can show the amount of activation of a signalling molecule.  This 
measurment would have benefited the present study, but due to a neumerous of compounds and cell 
lines, and multi-targeting of interesting protein, this was not done due to the prohibitive cost. Another 
reason that could be responsible for all unexpected presented data is using AML12 cell lines which have 
not used before, and this cell might be less responsive to regulated glucose metabolism than any other 
cell line like the HepG2 cell line, which was employed in previous studies.      
 
As the adipose tissue plays a key role in glucose regulation and previously selected green tea 
compounds increased cellular glucose uptake in 3T3-L1 cells, estimation of the amount of triglyceride, 
the level of glycerol release, and expression level of lipogenesis and lipolysis gene were determined. 
Analysis showed that selected green tea compounds suppressed triglyceride synthesis and reduced levels 
of glycerol release (Figure 3.33 and Figure 3.34), without affected adipogenic and lipolytic gene 
expression (Table 3.2). Most of these results are consistent with previous study results that have shown 
green tea and EGCG suppresses lipid accumulation and inhibit 3T3-L1 cell differentiation (Hwang, et 
al., 2005;Lao, et al., 2015;Lee, et al., 2009a). This effect occurs through downregulating C/EBPα, 
SREBP-1c and PPARγ transcription factors, and inhibit lipolysis by reducing glycerol release (Chan, 
2009;Kim, 2014;Lao, et al., 2015). However the data presented here shows in addition to EGCG, both 
EC and ECG significantly reduced triglyceride and glycerol levels. Nonetheless, previous studies built 
their results using only primary pre-adipocyte, whereas the present data was obtained using mature 
adipocytes as the lipid droplets had already formed. Since mature adipose tissue that contains 
triglyceride being anatomically and physiologically present in the human body, the present results are 
more relevant to the physiological function of adipose tissue as it exhibits various levels of lipogenesis 
and lipolysis.  Therefore, the study suggests that selected green tea compounds mimicked the effects of 
insulin in adipocyte, although investigation of lipogenic and lipolytic genes expression did not provide 
any marked changes and therefore further research is required to clarify this. The latter result could be 
due to insufficient independent experiments, poor primer performance, incorrect time point selection or 
simply that the transcriptional levels of these genes are not altered, but rather that there are 
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translational/post-translational events. It would be particularly interesting to co-incubate insulin with 
green tea compounds to see if any potentiation or inhibition of insulin occurs. As high NEFA release 
due to active lipolysis triggers impairment of normal glucose metabolism pathways, and can, therefore, 
induce insulin resistance, and finally develop T2D. Therefore, downregulating lipolysis in diabetic 
patients using green tea compounds could help to counter the effect of excessive released of NEFA.        
 
Many people spend most of their time at work and therefore have limited time to prepare their meals. 
In addition to that, availability and low cost of fast food, therefore, makes their life easy as they regularly 
consume this type of food and accordingly consume a hypercaloric diet as standard. As part of the 
common modern lifestyle, this behaviour is also often associated with lack of physical activity (Kuneš, 
2014). Thus, taking all these factors into account, some disorders and diseases related to glucose 
metabolism can emerge such as obesity, insulin resistance, T2D, and their complications. A number of 
studies have reported beneficial effects of consumption of green tea, or its active compounds, including 
anti-obesity and anti-diabetes properties (Iso, et al., 2006;Wu, et al., 2003). Furthermore, regulation of 
glucose and lipid metabolism (Babu, et al., 2013;Roghani and Baluchnejadmojarad, 2010). Thus, 
linking to the previous work, the present study aimed to explore the effect of green tea extracts on 
regulation of glucose and lipid metabolism in vivo. This experiment used a mouse model, supplementing 
with or without a glucose rich diet (as a part of western diet) to attempt to extend the in vitro results 
from chapter 3. This study used three different extracts to determine their effect. Firstly, and in contrast 
to previous work which does not investigate the effect of whole green tea compounds, this study used 
purified DGTE and commercial GTE in a form that is available for purchase over the internet.  Secondly, 
like previous studies, the effective and abundant compound EGCG was also used. The original design 
of this study was to use all compounds previously tested in addition to whole green tea extract. However, 
only a limited range of extracts was used. This limitation was due to some compounds such as EC and 
ECG being too expensive, and the study budget was limited. Other compounds like myricetin and 
quercetin are easily dissolved in DMSO but came out of solution when placed in water and therefore 
had to be excluded from this study, as they could not be administered in the drinking supply. This issue 
occurred on the first morning of the test so last minute adjustments had to be made to ensure the 
experiment could continue. Furthermore, the study was designed to investigate the effect of these 
extracts on mice just for 28 days. This limited time was again due to cost, as 28 days was felt to be 
enough to have an effect on mice physiologically. Secondly, the number of mice used in this study was 
48. Therefore, it was very hard to run the experiments using all mice together. Thus the mice were 
separated into four groups used in four weeks, which finally extended the experiments one month more 
than the original design, which extended overall time, and cost of care (such as food costs), which in 
turn affected the study budget and thus longer treatments could not be used.      
 
217 
 
Glucose data generated during GTT, including gAUC and glucose clearance (Figure 4.11 and Figure 
4.12), reported here in addition to Glut2 and Glut4 mRNA activity in liver and skeletal muscle (Table 
3.1 and Table 3.3), showed no significant changes in response to green tea treatments. Whilst, 
impairment of FBG due to exposure to a calorie rich diet was significantly improved by DGTE and 
EGCG (Figure 4.13). This result was associated with decreased Glut4 expression in adipose tissue 
(Table 3.2). However, PEPCK mRNA was reduced by EGCG (Table 3.1). Most of these results are 
contradictory with the results of many studies in this field which have revealed several green tea 
compounds can reduce gAUC (Gan, et al., 2015;Santamarina, et al., 2015). In addition, reduce glucose 
clearance time thereby improving glucose tolerance associated with reduced FBG and increased activity 
of Glut2 and Glut4 (Ortsater, et al., 2012;Snoussi, et al., 2014;Tang, et al., 2013). As the FBG is the 
main physiological indicator of the proper level of circulating glucose, high FBG indicates pre-diabetic 
or diabetic conditions. Glucose rich diet exposure did increase FBG and this impaired glucose uptake 
and increased glucose output. Although the effects of green tea extracts appear above, data reported here 
is only related to mRNA expression, so further studies to investigate protein expression of Glut2, Glut4, 
PEPCK, and G6Pase are needed to draw clear conclusions. DGTE or EGCG might, therefore, help pre-
diabetic and diabetic people to maintain FBG levels and inhibit glucose production. Several explanations 
of differences in GTT results are raised; the relatively short time of treatment (28 days), the low 
concentration of extracts used (these concentrations were derived from previously published literature) 
and the route of administration, as the study here administered treatments by the rarely used method of 
inclusion in drinking water. This latter fact meant that various concentrations could theoretically be 
taken by different mice within a group, based on individual drinking behaviour, which can affect the 
results. Instead of this, ideally treatment can be given by oral gavage on one time/day. However, this is 
very hard to do as the number of mice and treatments used are numerous, but it is not impossible if all 
divided but again this takes time and is associated with increased costs.  
 
The level of fasting insulin was measured as it is proportional to the level of FBG. Interestingly, the 
level of fasting insulin was elevated in response to EGCG or both EGCG and GTE in mice fed normal 
or glucose rich diets respectively (Figure 4.14).Only this effect in mice fed a normal diet was associated 
with high values of HOMA-IR and HOMA-B (Figure 4.15 and Figure 4.16). These results are unique 
but contradict with several published studies that have reported green tea, and EGCG are able to reduce 
high levels of insulin in rats and mice fed excess energy diets (Moreno, et al., 2014;Qin, et al., 2010). 
An increase in insulin level have been observed in diabetic rats in response to green tea extracts 
(Sundaram, et al., 2013) and therefore was in agreement with the present results. Furthermore, EGCG 
reduced insulin resistance, increased insulin sensitivity and beta-cell function in mice fed a high-enery 
diet (Gan, et al., 2015) which contradicts with the present study result. Therefore, the present study 
suggests that the selected green tea extracts stimulate insulin secretion independently despite glucose 
level, this could be due to the stimulating effect of green tea on pancreatic beta-cell biogenesis and 
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increase insulin secretion. Increased HOMA-IR and B in response to EGCG is likely due to high levels 
of insulin secreted, which indicates high activity of pancreatic beta-cells. HOMA-IR is not the best way 
to measure insulin resistance in mice, as it developed and validated to measure insulin sensitivity in 
human (Chang, et al., 2006). Indeed there are other methods of calculating resistance such as QUICKI 
(Gutch, et al., 2015) or the gold standard (glucose clamp) (Gutch, et al., 2015). Therefore a specific 
study is required to investigate the role of these green tea compounds on insulin secretion, action and 
biogenesis of beta cell in vitro. The data presented here, however, does not clearly provide a specific 
solution to diabetic patients that exhibit markers of insulin resistance but could be potentially involved. 
A study on diabetic mouse models or human volunteer is therefore needed to clarify the potential effect 
of drinking green tea by diabetic patients.        
    
Several formulations of green tea have been advertised and used globally to control body weight and 
weight loss based on recently accumulated evidence of usage (Kozuma, et al., 2005;Wang, et al., 2010a). 
The results of the present study showed no effect of these compounds on body weight after 28 days, but 
the collective weight gain in mice fed a normal diet was decreased only in response to DGTE and EGCG 
(Figure 4.2). This result is inconsistent with most studies that have determined green tea, and EGCG can 
reduce body mass, and weight gain in mice and rats fed a high fat and normal diet (Bose, et al., 
2008;Snoussi, et al., 2014).  Therefore, the present study suggests that the selected green tea extracts 
could be potentially involved in reducing weight and weight gain when drinking is accompanied by 
calorie restriction. As regular ingestion of a glucose-rich diet can increase body weight and induce 
obesity, green tea cannot likely counter this effect as long as this behaviour exists. The results observed 
here could due to the time limit of 28 days not being enough to make differences, even in mice fed a 
normal diet. The second reason, as mentioned before, might be due to low concentrations of treatments 
associated with differences in drinking behaviour as a route of dependent administration.  Decreased 
weight gain in mice fed a normal diet in response to selected compounds of green tea could be due to 
reduced appetite, which decreased food and water intake. Overall, these extracts could be used as anti-
obesity agents, but not alone, and should be associated with physical activity and calorie restriction. 
Some studies would be required with several modifications in green tea concentration, route of 
administration and period of treatments to identify any real effect; this was not considered in the present 
study due to limited funding.     
 
In addition to measurement of body mass and weight gain, metabolic tissue mass including liver, 
skeletal muscle, SAT, VAT, and BAT were measured. The result of liver and skeletal muscle mass in 
response to green tea extracts showed that only EGCG fed a normal diet increased liver mass (Figure 
4.5 and Figure 4.6). Interestingly SAT pad was significantly increased in response to DGTE and EGCG 
in mice fed a normal diet, whilst DGTE and GTE were elevated in SAT mass of mice fed a glucose-rich 
diet (Figure 4.7). Noticeably, these results were associated with significantly increased VAT mass 
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(Figure 4.8). Astonishingly, all of these results were accompanied by significantly increased BAT mass 
(Figure 4.9). As increases in fat pad mass were seen without overall changes in body weight, this 
suggests a significant change in body composition. However, almost all previously published studies 
showed that green tea compounds reduced body mass and weight gain associated with reducing fat pad 
mass (Bose, et al., 2008;Chen, et al., 2009;Chen, et al., 2011;Li, et al., 2006b). The results presented 
here conflict with the results of these studies, which makes it unique data as body weight did not change 
with increases in fat mass in response to selected green tea extracts. Despite the views that considered 
increasing peripheral adipose tissue fat (SAT) might or might not be implicated in a number of diseases 
pathogenesis, an increase of SAT and VAT mass can systemically contribution in several metabolic 
disorders and diseases like obesity, T2D and cardiovascular disease (CVD). Some of these fat pads could 
provide a protective effect as the normal physiological function is to store nutrients. The data presented 
in this study could reflect to this protective effect as the BAT mass was also increased. These increases 
in SAT and VAT mass could be due to the adipocyte hypertrophy and/or storage of more energy as 
triglyceride without affected physiological function. Whereas, the reason that could be responsible for 
increasing BAT mass is the ability of green tea to stimulate BAT growth (proliferation and 
differentiation) through activating adipogenesis to maintain thermogenesis (Cypess and Kahn, 
2010;Dulloo, 2013;Dulloo, et al., 2000). The results presented here are difficult to explain clearly, 
therefore, ideally further experiments to clarify how these compounds might regulate fat pad mass and 
how this might relate to metabolic rate are required.  
 
Following previous study results, the effect of green tea extracts on circulating levels of TC, TG, 
HDL, and LDL were investigated. All green tea extracts reduced TC, and cLDL levels in mice fed a 
high glucose diet, whilst mice fed a normal diet exhibited a significantly decreased the level of TC by 
EGCG and cLDL level in response to DGTE and EGCG (Figure 4.18 and Figure 4.21). Interestingly, 
the level of circulating TG was increased in mice fed a glucose-rich diet alongside EGCG, while DGTE 
and EGCG elevated TG levels in mice fed a normal diet (Figure 4.19). These results were accompanied 
with down regulation of FABP4 in all mice and only LPL mRNA expression in mice fed a normal diet 
(Table 3.2). These results are partially consistent with a number of published study results that have 
shown some green tea compounds can regulate lipid metabolism through reducing the level of TC (Bose, 
et al., 2008;Snoussi, et al., 2014), and increasing the level of HDL (Jeong, et al., 2012). Furthermore, 
reducing the levels of TG and LDL (Qin, et al., 2010;Roghani and Baluchnejadmojarad, 2010). These 
regulations of lipid metabolism occurred through regulating the adipogenic and lipolytic transcriptional 
factors, including downregulated PPARγ, SREBP1c, C/EBPα, FAS, FABP4, and LPL (Lee, et al., 
2013;Lee, et al., 2009b). Based on the results of all previous studies, the present study showed the ability 
of some green tea compounds to regulate the levels of TC and cLDL, in normal and glucose fed mice 
just after 28 days using different low concentrations. The unexpected and interesting result was related 
to the high level of circulating TG, which may reflect to the increase in SAT and VAT mass. As the 
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high level of TG is a risk factor for CVD and can be hydrolysed to increase the level of NEFA, all green 
tea extracts inhibited transcriptional factor FABP4, which is responsible for transporting NEFA. This 
effect, therefore, reduces the level of circulating NEFA; thought to be involved in many pathogenesis 
processes. Data presented here is promising and suggestive that the consumption of these green tea 
extracts could improve impairment in lipid metabolism in obese and diabetic conditions. However, the 
increased TG level in response to selected green tea extract might be due to excessive storing of TG due 
to continuous glucose uptake, which could impair metabolism and therefore increase the level of 
circulating TG. Modulation of this impairment by green tea requires more time than was available in 
this study to promote this recovery effect and decrease the level of circulating TG.      
 
Dysregulation of glucose and lipid metabolism can increase obesity and eventually T2D, which 
robustly correlated with initiation of cancer including BC through several mechanisms (Gallagher and 
LeRoith, 2015;Lipscombe, et al., 2015). As BC is markedly involved in the female death, and a number 
of side effects are reported when using chemotherapeutic drugs, looking for authentic natural 
compounds that possess chemotherapeutic property is important. Green tea has been reported previously 
to have potential anti-cancerous properties (Chen, et al., 2012;Hsuuw and Chan, 2007;Moreira, et al., 
2013).  In line with previous literature, the present study was designed to identify the effect of several 
active compounds of green tea on BC using an MCF7 and MDA-MB-231 cell line model with a focus 
on glucose metabolism. 
 
The initial results of this study showed decreased cell viability in both cell lines in response to EGCG, 
a combination of catechins, and quercetin (Figure 5.1 to Figure 5.12). This result seemingly appeared 
due to increased activation of caspase 3/7 which triggered apoptosis process (Figure 5.22). Induction of 
apoptosis in different cancer cell lines in response to several compounds of green tea have been reported. 
However, the signalling pathway of this effect still needs to be elucidated (Alshatwi, 2010;Roy, et al., 
2005). The results presented here are partially different from some previously published results (Duo, 
et al., 2012;Hsuuw and Chan, 2007), as some green tea compounds that have not been shown before to 
induce apoptosis in MDA-MB-231 cells through the activation of caspase 3/7 after just 24h. Reduced 
cell viability could refer to the status of pro-apoptotic and apoptotic factors which was not verified, as 
only mRNA level was measured, therefore ideal measurement of protein activity is required for 
clarification (which was not considered in this study due to cost). Here it seems that the apoptosis in 
MCF7 was induced by activation of caspase 3/7, since caspase 3 is not exist in the cell (Liang, et al., 
2001). Thus caspase 7 could be responsible for this effect. The study, therefore suggests that high 
concentrations of selected green tea compounds could potentially treat cancer conditions that are not 
responding favourably to chemotherapy. In addition, could be synergistically uses with chemotherapy 
drug to treat chemotherapy resistance cancer conditions, however in vivo studies are needed to 
investigate and validate these findings. 
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With regards to signalling mechanisms, the role of PI3K/Akt and LKB1/AMPK pathways on 
decreased BC cell viability by green tea compounds were considered. Inhibition of either Akt or AMPK 
alongside selected green tea compounds caused further reduction in cell viability of BC cell lines, which 
was restored by supplementing sodium pyruvate (Figure 5.14 to Figure 5.19). A number of studies have 
revealed that some green tea compounds suppress PI3K/Akt pathways to promote their anti-cancer effect 
(Qin, et al., 2012;Singh, et al., 2011;Spinella, et al., 2006) which is consistent with the data presented. 
However, Western blotting analysis of pAkt or pAMPK expression in response to selected green tea 
compounds was not able to support this finding, as the experiment was repeated on only two occasions 
and does not allow clear conclusions to be drawn. Although the present study suggests that the green tea 
compounds could exert their effect on BC cells through inhibiting Akt signalling, further experiments 
are needed to focus on expression/activation levels of pAkt to validate this theory. Green tea is believed 
to be an adequate AMPK activator to mediate anti-cancer effects (Hwang, et al., 2007;Kim, et al., 2010) 
which is in conflict with the data presented here. With respect to this, activation of AMPK could be 
involved in cancer initiation and progression, which reflected to the main function of AMPK to maintain 
the level of ATP, that required for cellular proliferation and survival (Bonini and Gantner, 2013;Frigo, 
et al., 2011). As cancer cells are adapted to metabolic stress, the activation level of AMPK exists in 
cancer cells to maintain proliferation and survival (Laderoute, et al., 2014;Rios, et al., 2014). This result 
is in agreement with data presented here regarding inhibition of AMPK which induced a decrease in cell 
viability regardless of the protein phosphorylation result mentioned above. The current study, therefore, 
shows conflicting data in this area. However, further study is needed to support these findings. Take all 
of these conclusions into account, selected green tea compounds could potentially exert anti-cancerous 
effects by targeting cellular proliferation and survival signalling. Interestingly they could regulate both 
Akt and AMPK, although a study linking these data with protein activation could provide clearer 
evidence of the signalling pathway of green tea compounds.  
  
The cancer cells modify glucose metabolism to provide the energy required for rapid growth, 
proliferation, and invasive properties. Therefore, the effect of green tea compounds on this aspect in BC 
was explored. The results show that 24h or 6h exposure of BC cells to selected green tea compounds 
reduced lactate production (Figure 5.23 and Figure 5.25). As a reduction of cell viability was seen after 
24h, this effect could be due to decreased cell numbers. Acute exposure is however considered the proper 
effect as cell viability was unaffected. These decreases in lactate production were accompanied by 
reduced glucose uptake (Figure 5.27).  These results are in agreement with all of the studies that have 
shown green tea compounds can reduce cancer cell glucose uptake and glycolysis including the study 
of Xintaropoulou, et al. (2015) in breast and ovarian cancer cell lines, the study of Lu, et al. (2015) in 
pancreatic adenocarcinoma MIA PaCa-2 cells. In addition to the study of Moreira, et al. (2013) in MCF7 
and MDA-MB-231 cell lines . Collectively, these results suggest that some active compounds of green 
tea successfully interfered with BC metabolism and exert their effect through decreasing glucose uptake, 
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thereafter reducing glycolysis. The acute result in this study is unique as the selected green tea 
compounds modified cellular glucose metabolism without affected cell viability. In addition, the 
combination of green tea compounds for the first time successfully altered MDA-MB-231 cell 
metabolism after 24h, but unfortunately this was associated with reduce cell viability. Although the 
current study did not investigate the full BC glucose metabolism modification process in response to 
selected green tea compounds, several future studies should be considered in this aspect in gathering 
details from glucose uptake to production of lactate to establish a clear signalling network. 
 
Cancer cell migration is considered a significant predictor of poor prognosis, therefore, inhibition of 
migratory behaviour of cancerous cells is a substantial tool to provide a better prognosis. The present 
study investigated the impact of selected green tea compounds on BC migration, and both cell lines 
reduced their migratory behaviour in response to selected green tea compounds (Figure 5.32 and Figure 
5.35). This result was expected, however, in some areas was different from the results of published 
studies in this field (Ho, et al., 2013;Tao, et al., 2015). The current study used two separate scratched 
assay methods to confirm the results, in addition to considering cellular proliferation, which was 
inhibited using mitomycin c. Although the data presented in this study is promising, clarification of the 
mechanism of this effect was not explored due to the cost, and therefore future specific studies to identify 
the mechanisms of potential anti-metastatic effects of selected green tea compounds is required. 
Collectively, this study suggests that early consumption of effective green tea compounds could 
potentially improve cancer prognosis by inhibiting cellular migration.  
 
In the present study, several limitations were presented which were likely to have affect on the results 
and should be considered for future research. Most of these constraints arose from funding and lack of 
time. The results showed the level of gene expression related to glucose and lipid metabolism and pro 
and anti-apoptotic in response to green tea compounds, but protein expression/activity was therefore not 
determined, which is important because the level of mRNA is not always indicative of protein expression 
or activity. Secondly, Gluts translocation in response to green tea compounds that increased glucose 
uptake in insulin-sensitive cell, and reduced BC cell glucose uptake were not assessed in this study due 
to the cost. It could have been done, however, using fluorescent immunocytochemistry, which would 
have provided images that could allow identification of the position of Gluts in the cell. Several methods 
could be used to detect Gluts translocation, the first method is using flow cytometry to quantify the level 
of Gluts translocation using specific Gluts antibody tagged with fluorophore dye which bind with the 
Gluts after translocation to the plasma membrane, or visualised using fluorescent microscope. Another 
method is to transfect cells with lipofectamine which is the Gluts-4-eGFP fluorescence plasmid, and the 
latter translocation is then visualised using laser-scanning confocal microscope. Furthermore, the study 
identified the phosphorylation level of Akt or AMPK in response to selected green tea compounds. 
Unfortunately, no conclusion can be drawn as the experiment was repeated only twice, as previously 
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mentioned in the results. This limited meaurement was mostly due to the study budget. In addition, 
identifying the phosphorylation level of downstream signalling proteins that are directly regulated by 
both Akt and AMPK in response to selected green tea compounds is needed to draw accurate 
conclusions; it was not considered in the scope of the present study. The other constraint to this research 
was using high glucose drinking solution instead of a high-fat diet, which again was due to costs as high-
fat chow cost £700 per week and was not allocated in the study budget. Furthermore, the low volumes 
of blood obtained from the tail of mice during GTT was another limitation of the study which only 
allowed low levels of glucose to be measured, and therefore the research had to exclude measurement 
of insulin during GTT test and the levels of circulating TC, TG, HDL, and cLDL at the base line before 
treatments apply. The main reason for this was the route of obtaining blood described in animal 
licensing, which is allow to obtained blood only from the tail of mice. Instead, many other methods and 
sites could be used to collect blood from mice, these are from orbital sinus (periorbital, posterior orbital, 
venous plexus) and cardiac puncture, however the single sample only collected in these both collection 
sites, with cardiac puncture used only at the end of experiment. As the research required many samples 
based on the test employ in this study, therefore, tail vein surgical cannulation could be used or surgical 
cannulation of femoral artery or vein, carotid artery, and jugular vein.  
 
6.2 Future studies 
This study has added to the existing knowledge in the field and has helped to emphasise the 
beneficial effects of green tea compounds on glucose and lipid metabolism metabolism and their ability 
to target cancer cells. Future studies are required to take forward the interesting data reported here to 
clarify some of the contradictory or controversial findings. Ideally, these studies would be in human 
volunteers. 
 
In vitro studies suing human insulin-sensitive primary cell lines to better identify the signalling 
pathways of green tea extracts would be beneficial. These studies should measure gene and protein 
activity markers related to glucose and lipid metabolism in these cell lines. These studies are focusing 
on the effect of green tea extracts on the main glucose regulation pathways PI3K/Akt and AMPK and 
their up regulators (extracellular growth factors could stimulate cell membrane receptor tyrosine kinases 
(RTKs), G-protein-coupled receptors (GPCRs), and cytokine receptors, as well as ROS, ATP, and 
calcium level could involve in activation of LKB1, CaMKK, and TAK1.  In addition to, downstream 
signalling including G6Pase, PEPCK, C/EBPα, PPARγ, SREBP1c, FASN, GS, FABP4, Gluts, PDK4, 
and more. Furthermore, explore the glucoregulatory effect of decaffeinated green tea extract, 
commercial green tea extract, and caffeine on these cells to identify the potential effective compounds 
or extracts. These studies would be valuable research to confirm the mechanism of these compounds 
so that their actions can be better formulated as therapeutic agents.  
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Several in vivo studies to explore the proper effect of various extracts and/or active compounds of 
green tea would be a beneficial next step. Primarily, further clarification of the effects of green tea on 
impaired glucose and lipid metabolism in individuals with pre-diabetes or T2D. The studies could 
include inclusion of various extracts, formulation (liquid, capsule or caplet, tablet), and oral daily doses 
during short or long duration. Secondly a more comprehensive study of the effects of green tea on body 
weight in obese and diabetic subjects. These studies could include other measurements of glucose 
homoeostasis, such as measuring HbA1c or fructosamine in addition to assessing the levels of fasting 
glucose and insulin, as well as OGTT at the base line and at the end of experiments. Furthermore, 
measuring body weight, weight gain, body adiposity, and fat free mass in response to these green tea 
extracts. Moreover, measurement cytokines leptin/adiponectin index, as well as pro and inti-
inflammatory biomarkers like chemokine ligand 2 (CCL2), interferon gamma-induced protein 
10 (CXCL10), TNFα, IL-6, IL-10, IL-1Ra, and C-reactive protein (CRP).  To extent the research, 
inclusion of green tea could associate with calorie restriction and/or easy to moderate excise to identify 
the effect of each of these factors alone or agonist effect to regulate glucose and lipid metabolism.  
Aligned to this, further study of lipid profiles and cardiovascular risk levels of TC, TG, HDL, and LDL 
before and after treatments would be fascinating. Furthermore, identifying the main signalling pathways 
of the effect of green tea compounds in vivo by focusing on key genes and proteins to confirm the in 
vitro studies would provide interesting data. Examination of several concentrations, compounds and 
extracts, route of administration (orally or injection), and several different time periods of treatment 
could comprehensively assess the proper effects and therefore provide a clearer view regarding the 
regulation of glucose and lipid metabolism, as well as weight loss in overweight, obese, pre-diabetic, 
and T2D individuals. 
 
Future studies could also assess the role of green tea in animal models of BC, using a nude mouse 
system, cancer cells could be injected into the tail vein of mice with and without green tea, or cancer 
cells injected before treatment until cancer formation is confirmed. Various extracts and doses could IV 
administration for short and long duration, and then the effect of these extract on formed tumour was 
measured. The measurement including histological study, in addition to size and metastasis properties, 
as well as radioactive glucose uptake activity. Furthermore, measurement pro and anti-apoptotic gene 
and protein activity using qPCR and western blotting, these including Bcl2, Bax, P53, and Myc, in 
addition to caspase 3, 7, and 9. This experiment would give physiologically relevant data regarding the 
anti-cancerous effects of green tea compounds. Moreover, identify specific changes in the glycolytic 
activity of BC cells treated with green tea using the seahorse technique that measures the level of oxygen 
consumption and PH level in surrounding environment would also be a logical next step in future 
studies. As the present study only showed the effect of purified compounds of green tea on BC cell lines, 
examination of whole green tea extracts is therefore required to identify the exact effect of this extract. 
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6.3 Conclusions  
The current study identified several interesting findings which potentially could be used as a basis 
for future research. The research observations presented in this study showed that selected compounds 
of green tea regulated glucose and lipid metabolism in insulin-sensitive cell lines through stimulating 
cellular glucose uptake, maintaining metabolism, and reducing glycolysis and lipolysis in vitro. These 
effects could be mediated either through activation of PI3/Akt or AMPK signalling pathways, however 
further research on this approach is required to confirm the signalling pathway of the effect of these 
selected green tea compounds.  
 
The in vivo study presented in this thesis confirmed that consuming of a glucose rich diet might cause 
deterioration of several markers of glucose and lipid metabolism, which in turn promoted impairment 
of glucose homoeostasis including glucose and lipid metabolism; a distinguished marker of obesity and 
T2D. Green tea extracts including DGTE, EGCG, and GTE showed the ability to modulate impaired of 
glucose homoeostasis by improving most impaired markers related to glucose and lipid metabolism. 
This effect was concomitant with interesting increases in adipose depots mass and circulating 
triglyceride. However, these effects were associated with reduced NEFA release through inhibiting 
lipolysis. As these extracts are used widely for weight loss, the results presented in this study suggest 
that these extracts did not affect body weight after four weeks of treatments, although this was a 
relatively short period.  
 
In vitro data also showed that selected green tea compounds, especially EGCG and quercetin, possess 
cytotoxic effects against BC cell through stimulating apoptosis and decreasing viable cells. These effects 
could be mediated through inhibiting PI3K/Akt and partially or completely suppressing LBK1/AMPK 
activation. This effect is likely due to altered cellular glucose metabolism which forces the cells to 
change their glucose metabolism behaviour by decreasing glucose uptake and lactate production. 
However, this pathway needs to be further elucidated as it is not completely validated. The study also 
observed that these green tea compounds could inhibit cellular migration, and therefore could be 
potential anti-metastatic agents.   
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8.1 Appendix 1; Amplification and disassociation curves of glucose and lipid 
metabolism gene expression in insulin-sensitive cell lines 
8.1.1 Amplification and disassociation curves of glucose metabolism gene expression 
in C2C12 cells 
 
Figure 8.1 C2C12 SYBR® Green Rt. PCR analysis of actin gene expression.  
Actin gene expression was determined in C2C12 cDNA samples. (A) Amplification curves displayed 
the mean Ct value of actin was 22.020. (B) Dissociation curve showed one peak which dissociated 
approximately at 87ᵒC suggestion excellent primer specificity, n=3. 
 
 
 
 
 
Figure 8.2 C2C12 SYBR® Green Rt. PCR analysis of IR gene expression. 
Insulin receptor gene expression was determined in control and treated C2C12 cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of IR gene was 29.845. (B) Dissociation curve 
showed one peak which dissociated approximately at 83ᵒC suggestion excellent primer specificity, n=3. 
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Figure 8.3 C2C12 SYBR® Green Rt. PCR analysis of HK1 gene expression. 
HK1 gene expression was determined in control and treated C2C12 cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of HK1 gene was 30.426. (B) Dissociation curve 
showed one peak which dissociated approximately at 81ᵒC suggesting excellent primer specificity, n=3. 
 
 
 
 
 
 
 
 
 
Figure 8.4 C2C12 SYBR® Green Rt. PCR analysis of Glut4 gene expression 
Glut4 gene expression was determined in control and treated C2C12 cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of Glut4 gene was 28.454. (B) Dissociation curve 
showed one peak which dissociated approximately at 85ᵒC suggesting excellent primer specificity, n=3. 
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Figure 8.5 C2C12 SYBR® Green Rt. PCR analysis of PDK4 gene expression. 
PDK4 gene expression was determined in control and treated C2C12 cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of PDK4 gene was 30.277. (B) Dissociation 
curve showed one peak which dissociated approximately at 83ᵒC suggestion excellent primer specificity, 
n=3. 
 
 
 
 
 
 
 
 
 
 
Figure 8.6 C2C12 SYBR® Green Rt. PCR analysis of PGC1α gene expression. 
PGC1α gene expression was determined in control and treated C2C12 cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of PGC1α gene was 26.991. (B) Dissociation 
curve showed one peak with minor shouldering which dissociated approximately at 83ᵒC suggestion 
very good primer specificity, n=3. 
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Figure 8.7 C2C12 SYBR® Green Rt. PCR analysis of Gys1 gene expression. 
Gys1 gene expression was determined in control and treated C2C12 cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of Gys1 gene was 31.999. (B) Dissociation curve 
showed two peaks which dissociated at two temperatures suggestion some nonspecific primer binding, 
n=3. 
 
 
8.1.2 Amplification and disassociation curves of glucose and lipid metabolism gene 
expression in 3T3L1 cells 
 
 
 
 
Figure 8.8 3T3-L1 SYBR® Green Rt. PCR analysis of actin gene expression.  
Actin gene expression was determined in 3T3-L1 cDNA samples. (A) Amplification curves 
displayed the mean Ct value of actin was 27.674. (B) Dissociation curve showed one peak which 
dissociated approximately at 86.5ᵒC suggesting excellent primer specificity, n=3. 
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Figure 8.9 3T3-L1 SYBR® Green Rt. PCR analysis of IR gene expression. 
IR gene expression was determined in control and treated 3T3-L1 cDNA samples. (A) Amplification 
curves displayed that the mean Ct value of IR gene was 27.897. (B) Dissociation curve showed one peak 
which dissociated approximately at 83ᵒC suggesting excellent primer specificity, n=3. 
 
 
 
 
 
 
 
 
 
Figure 8.10 3T3-L1 SYBR® Green Rt. PCR analysis of HK1 gene expression. 
HK1 gene expression was determined in control and treated 3T3-L1 cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of HK1 gene was 32.331. (B) Dissociation curve 
showed multiple peaks which dissociated at different temperatures suggestion poor specificity of primer 
binding. n=3. 
 
 
254 
 
 
 
Figure 8.11 3T3-L1 SYBR® Green Rt. PCR analysis of Glut4 gene expression. 
Glut4 gene expression was determined in control and treated 3T3-L1 cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of Glut4 gene was 25.339. (B) Dissociation curve 
showed one peak which dissociated approximately at 85.5ᵒC suggesting excellent primer specificity, 
n=3. 
 
 
 
 
 
 
 
 
 
Figure 8.12 3T3-L1 SYBR® Green Rt. PCR analysis of C/EBPα gene expression. 
C/EBPα gene expression was determined in control and treated 3T3-L1 cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of C/EBPα gene was 29.886. (B) Dissociation 
curve showed one peak which dissociated approximately at 86ᵒC suggesting excellent primer specificity, 
n=3. 
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Figure 8.13 3T3-L1 SYBR® Green Rt. PCR analysis of LPL gene expression. 
LPL gene expression was determined in control and treated 3T3-L1 cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of LPL gene was 21.443. (B) Dissociation curve 
showed one peak which dissociated approximately at 85.75ᵒC suggesting excellent primer specificity, 
n=3. 
 
 
 
 
 
 
 
 
 
 
Figure 8.14 3T3-L1 SYBR® Green Rt. PCR analysis of FASN gene expression. 
FASN gene expression was determined in control and treated 3T3-L1 cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of FASN gene was 32.6. (B) Dissociation curve 
showed one peak which dissociated approximately at 86ᵒC suggestion mixed primer specificity, n=3. 
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Figure 8.15 3T3-L1 SYBR® Green Rt. PCR analysis of FABP4 gene expression. 
FABP4 gene expression was determined in control and treated 3T3-L1 cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of FABP4 gene was 20.007. (B) Dissociation 
curve showed one peak which dissociated approximately at 83ᵒC suggesting excellent primer specificity, 
n=3. 
 
 
 
 
 
 
 
 
 
 
Figure 8.16 3T3-L1 SYBR® Green Rt. PCR analysis of SREBP1c gene expression. 
SREBP1c gene expression was determined in control and treated 3T3-L1 cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of SREBP1c gene was 33.265. (B) Dissociation 
curve showed one peak with shouldering which dissociated approximately at 89.5ᵒC suggesting poor 
primer specificity, n=3. 
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Figure 8.17 3T3-L1 SYBR® Green Rt. PCR analysis of PPARγ gene expression. 
PPARγ gene expression was determined in control and treated 3T3-L1 cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of PPARγ gene was 31.038. (B) Dissociation 
curve showed one peak which dissociated approximately at 86ᵒC suggestion adequate primer specificity, 
n=3. 
 
 
8.1.3 Amplification and disassociation curves of glucose metabolism gene expression 
in AML12 cells 
 
 
 
 
Figure 8.18AML12 SYBR® Green Rt. PCR analysis of actin gene expression. 
Actin gene expression was determined in control and treated AML12 cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of actin gene was 19.008. (B) Dissociation curve 
showed one peak which dissociated approximately at 87ᵒC suggesting excellent primer specificity, n=3. 
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Figure 8.19 AML12 SYBR® Green Rt. PCR analysis of IR gene expression. 
IR gene expression was determined in control and treated AML12 cDNA samples. (A) Amplification 
curves displayed that the mean Ct value of IR gene was 29.127. (B) Dissociation curve showed one peak 
which dissociated approximately at 83ᵒC suggesting excellent primer specificity, n=3. 
 
 
 
 
 
 
 
 
 
 
Figure 8.20 AML12 SYBR® Green Rt. PCR analysis of HK1 gene expression. 
HK1 gene expression was determined in control and treated AML12 cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of HK1 gene was 29.603. (B) Dissociation curve 
showed one peak which dissociated approximately at 81ᵒC suggesting excellent primer specificity, n=3. 
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Figure 8.21  AML12 SYBR® Green Rt. PCR analysis of Glut2 gene expression. 
Glut2 gene expression was determined in control and treated AML12 cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of Glut2 gene was 30.88. (B) Dissociation curve 
showed one peak with minor shouldering which dissociated approximately at 83ᵒC suggestion good 
primer specificity, n=3. 
 
 
 
 
 
 
 
 
 
 
Figure 8.22 AML12 SYBR® Green Rt. PCR analysis of Gys1 gene expression. 
Gys1 gene expression was determined in control and treated AML12 cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of Gys1 gene was 30.391. (B) Dissociation curve 
showed two peaks which dissociated at different temperatures suggestion nonspecific primer binding, 
n=3. 
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Figure 8.23 AML12 SYBR® Green Rt. PCR analysis of G6Pase gene expression. 
G6Pase gene expression was determined in control and treated AML12 cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of G6Pase gene was 33.4. (B) Dissociation curve 
showed multiple peaks which dissociated at different temperatures suggestion nonspecific primer 
binding, n=3. 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.24 AML12 SYBR® Green Rt. PCR analysis of PEPCK gene expression. 
PEPCK gene expression was determined in control and treated AML12 cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of PEPCK gene was 28.490. (B) Dissociation 
curve showed multiple peaks which dissociated at different temperatures suggestion nonspecific primer 
binding, n=3. 
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Figure 8.25 AML12 SYBR® Green Rt. PCR analysis of CPT1α gene expression. 
CPT1α gene expression was determined in control and treated AML12 cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of CPT1α gene was 29.327. (B) Dissociation 
curve showed one peak which dissociated approximately at 83.5ᵒC suggesting excellent primer 
specificity, n=3. 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.26 AML12 SYBR® Green Rt. PCR analysis of ACSL gene expression. 
ACSL gene expression was determined in control and treated AML12 cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of ACSL gene was 28.400. (B) Dissociation 
curve showed one peak which dissociated approximately at 86ᵒC suggesting excellent primer specificity, 
n=3. 
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8.2 Appendix 2; Amplification and disassociation curves of glucose and lipid 
metabolism gene expression in mice insulin-sensitive tissues 
8.2.1 Amplification and disassociation curves of glucose metabolism gene expression 
in mice liver 
   
 
Figure 8.27 Liver SYBR® Green Rt. PCR analysis of actin gene expression. 
Actin gene expression was determined in treated and control mice liver cDNA samples. (A) 
Amplification curves displayed the mean Ct value of actin was 23.16. (B) Dissociation curve showed 
one peak which dissociated approximately at 85°C suggestion excellent primer specificity, n=3. 
  
 
 
Figure 8.28 Liver SYBR® Green Rt. PCR analysis of IR gene expression. 
Insulin receptor gene expression was determined in treated and control mice liver cDNA samples. 
(A) Amplification curves displayed that the mean Ct value of IR gene was 27.08. (B) Dissociation curve 
showed one peak which dissociated approximately at 83°C suggestion excellent primer specificity, n=3. 
A B 
A B 
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Figure 8.29 Liver SYBR® Green Rt. PCR analysis of Glut2 gene expression. 
Glut2 gene expression was determined in treated and control mice liver cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of Glut2 gene was 23.987. (B) Dissociation curve 
showed one peak which dissociated approximately at 83°C suggestion good primer specificity, n=3. 
 
 
 
 
 
  
 
 
Figure 8.30 Liver SYBR® Green Rt. PCR analysis of Gys1 gene expression. 
Gsy1 gene expression was determined in treated and control mice liver cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of Gys1 gene was 30.2. (B) Dissociation curve 
showed more than one peak which dissociated approximately at different temperatures which suggestion 
nonspecific primer binding, n=3. 
 
A B 
A B 
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Figure 8.31 Liver SYBR® Green Rt. PCR analysis of G6Pase gene expression. 
G6Pase gene expression was determined in treated and control mice liver cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of G6Pase gene was 24.892. (B) Dissociation 
curve showed one peak which dissociated approximately at 85°C suggestion excellent primer 
specificity, n=3. 
 
 
 
 
 
  
 
Figure 8.32 Liver SYBR® Green Rt. PCR analysis of PEPCK gene expression. 
PEPCK gene expression was determined in treated and control mice liver cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of PEPCK gene was 24.454. (B) Dissociation 
curve showed one major peak which dissociated approximately at 88°C suggestion acceptable primer 
specificity, n=3. 
 
A B 
A B 
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Figure 8.33 Liver SYBR® Green Rt. PCR analysis of CPT1α gene expression. 
CPT1α gene expression was determined in treated and control mice liver cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of CPT1α gene was 23.461. (B) Dissociation 
curve showed one peak which dissociated approximately at 85°C suggestion excellent primer 
specificity, n=3. 
 
 
 
 
 
 
  
 
Figure 8.34 Liver SYBR® Green Rt. PCR analysis of FASN gene expression. 
FASN gene expression was determined in treated and control mice liver cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of FASN gene was 25.231. (B) Dissociation 
curve showed one peak which dissociated approximately at 87°C suggestion excellent primer 
specificity, n=3. 
A B 
A B 
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8.2.2 Amplification and disassociation curves of glucose metabolism gene expression 
in mice skeletal muscle 
  
 
Figure 8.35 Skeletal muscle SYBR® Green Rt. PCR analysis of actin gene expression. 
Actin gene expression was determined in treated and control mice skeletal muscle cDNA samples. 
(A) Amplification curves displayed the mean Ct value of actin was 21.786. (B) Dissociation curve 
showed one peak which dissociated approximately at 85°C suggestion excellent primer specificity, n=3. 
 
 
  
 
Figure 8.36 Skeletal muscle SYBR® Green Rt. PCR analysis of IR gene expression. 
Insulin receptor gene expression was determined in treated and control mice skeletal muscle cDNA 
samples. (A) Amplification curves displayed that the mean Ct value of IR gene was 26.202. (B) 
Dissociation curve showed one peak which dissociated approximately at 83°C suggestion excellent 
primer specificity, n=3. 
A B 
A B 
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Figure 8.37 Skeletal muscle SYBR® Green Rt. PCR analysis of Glut4 gene expression. 
Glut4 gene expression was determined in treated and control mice skeletal muscle cDNA samples. 
(A) Amplification curves displayed that the mean Ct value of Glut4 gene was 19.272. (B) Dissociation 
curve showed one peak which dissociated approximately at 86°C suggestion excellent primer 
specificity, n=3. 
 
 
 
 
 
 
  
 
Figure 8.38 Skeletal muscle SYBR® Green Rt. PCR analysis of Gys1 gene expression. 
Gsy1 gene expression was determined in treated and control mice skeletal muscle cDNA samples. 
(A) Amplification curves displayed that the mean Ct value of Gys1 gene was 24.793. (B) Dissociation 
curve showed one peak which dissociated approximately at 86.5°C suggestion excellent primer 
specificity, n=3. 
A B 
A B 
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Figure 8.39 Skeletal muscle SYBR® Green Rt. PCR analysis of PDK4 gene expression. 
PDK4 gene expression was determined in treated and control mice skeletal muscle cDNA samples. 
(A) Amplification curves displayed that the mean Ct value of PDK4 gene was 22.346. (B) Dissociation 
curve showed one peak which dissociated approximately at 83.5°C suggestion excellent primer 
specificity, n=3. 
 
 
 
 
 
 
  
 
Figure 8.40 Skeletal muscle SYBR® Green Rt. PCR analysis of PGC1α gene expression. 
PGC1α gene expression was determined in treated and control mice liver cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of PGC1α gene was 25.771. (B) Dissociation 
curve showed more than one peak which dissociated approximately at different temperatures which 
suggestion nonspecific primer binding, n=3. 
A B 
A B 
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8.2.3 Amplification and disassociation curves of glucose and lipid metabolism gene 
expression in mice adipose tissue 
  
 
Figure 8.41 Adipose tissue SYBR® Green Rt. PCR analysis of Actin gene expression. 
Actin gene expression was determined in treated and control mice adipose tissue cDNA samples. (A) 
Amplification curves displayed the mean Ct value of actin was 25.611. (B) Dissociation curve showed 
one peak which dissociated approximately at 85°C suggestion excellent primer specificity, n=3. 
 
 
 
 
  
 
 
Figure 8.42 Adipose tissue SYBR® Green Rt. PCR analysis of IR gene expression. 
IR gene expression was determined in treated and control mice adipose tissue cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of IR gene was 30.739. (B) Dissociation curve 
showed one peak which dissociated approximately at 83°C suggestion excellent primer specificity, n=3. 
A B 
A B 
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Figure 8.43 Adipose tissue SYBR® Green Rt. PCR analysis of SREBP1c gene expression. 
SREBP1c gene expression was determined in treated and control mice adipose tissue cDNA samples. 
(A) Amplification curves displayed that the mean Ct value of SREBP1c gene was 33.002. (B) 
Dissociation curve showed more than one peak which dissociated approximately at different 
temperatures which suggestion nonspecific primer binding, n=3. 
 
 
 
 
 
 
  
 
Figure 8.44 Adipose tissue SYBR® Green Rt. PCR analysis of PPARγ gene expression. 
PPARγ gene expression was determined in treated and control mice adipose tissue cDNA samples. 
(A) Amplification curves displayed that the mean Ct value of PPARγ gene was 35.041. (B) Dissociation 
curve showed more than one peak which dissociated approximately at different temperatures which 
suggestion nonspecific primer binding, n=3. 
A B 
A B 
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Figure 8.45 Adipose tissue SYBR® Green Rt. PCR analysis of FASN gene expression. 
FASN gene expression was determined in treated and control mice adipose tissue cDNA samples. 
(A) Amplification curves displayed that the mean Ct value of FASN gene was 29.682. (B) Dissociation 
curve showed one peak which dissociated approximately at 86.5°C suggestion excellent primer 
specificity, n=3. 
 
 
 
 
 
 
  
 
Figure 8.46 Adipose tissue SYBR® Green Rt. PCR analysis of Glut4 gene expression. 
Glut4 gene expression was determined in treated and control mice adipose tissue cDNA samples. 
(A) Amplification curves displayed that the mean Ct value of Glut4 gene was 27.558. (B) Dissociation 
curve showed one peak which dissociated approximately at 85°C suggestion excellent primer 
specificity, n=3. 
A B 
A B 
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Figure 8.47 Adipose tissue SYBR® Green Rt. PCR analysis of C/EBPα gene expression. 
C/EBPα gene expression was determined in treated and control mice adipose tissue cDNA samples. 
(A) Amplification curves displayed that the mean Ct value of C/EBPα gene was 31.689. (B) Dissociation 
curve showed one peak which dissociated approximately at 86°C suggestion good primer specificity, 
n=3. 
 
 
 
 
 
 
  
 
Figure 8.48 Adipose tissue SYBR® Green Rt. PCR analysis of FABP4 gene expression. 
FABP4 gene expression was determined in treated and control mice adipose tissue cDNA samples. 
(A) Amplification curves displayed that the mean Ct value of FABP4 gene was 22.292. (B) Dissociation 
curve showed one peak which dissociated approximately at 82.5°C suggestion excellent primer 
specificity, n=3. 
A B 
A B 
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Figure 8.49 Adipose tissue SYBR® Green Rt. PCR analysis of LPL gene expression. 
LPL gene expression was determined in treated and control mice adipose tissue cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of LPL gene was 25.575. (B) Dissociation curve 
showed one peak which dissociated approximately at 84.5°C suggestion excellent primer specificity, 
n=3. 
 
 
8.3 Appendix 3; Amplification and disassociation curves of pro and anti-apoptotic 
gene expression in BC cells 
8.3.1 Amplification and disassociation curves of pro and anti-apoptotic gene 
expression in MCF7 cell 
 
Figure 8.50 MCF7 SYBR® Green Rt. PCR analysis of hYWHAZ gene expression.  
Housekeeping hYWHAZ gene expression was determined in treated MCF7 cell cDNA samples. (A) 
Amplification curves displayed the mean Ct value of actin was 23.44625. (B) Dissociation curve showed 
one peak which dissociated approximately at 82ᵒC suggestion excellent primer specificity, n=3. 
A B 
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Figure 8.51 MCF7 SYBR® Green Rt. PCR analysis of Bcl2 gene expression. 
Bcl2 gene expression was determined in treated MCF7 cell cDNA samples. (A) Amplification curves 
displayed that the mean Ct value of Bcl2 gene was 25.637. (B) Dissociation curve showed many peaks 
which dissociated at temperatures suggestion nonspecific primer binding, n=3. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.52 MCF7 SYBR® Green Rt. PCR analysis of Bax gene expression. 
Bax gene expression was determined in treated MCF7 cell cDNA samples. (A) Amplification curves 
displayed that the mean Ct value of Bax gene was 24.501. (B) Dissociation curve showed one peak 
which dissociated approximately at 87ᵒC suggestion excellent primer specificity, n=3. 
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Figure 8.53 MCF7 SYBR® Green Rt. PCR analysis of Myc gene expression. 
Myc gene expression was determined in treated MCF7 cell cDNA samples. (A) Amplification curves 
displayed that the mean Ct value of Myc gene was 29.895. (B) Dissociation curve showed one peak 
which dissociated approximately at 89ᵒC suggestion excellent primer specificity, n=3. 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.54 MCF7 SYBR® Green Rt. PCR analysis of P53 gene expression. 
P53 gene expression was determined in treated MCF7 cell cDNA samples. (A) Amplification curves 
displayed that the mean Ct value of P53 gene was 30.343. (B) Dissociation curve showed many peaks 
which dissociated at temperatures suggestion nonspecific primer binding, n=3. 
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8.3.2 Amplification and disassociation curves of pro and anti-apoptotic gene 
expression in MDA-MB-231 cell 
 
 
 
Figure 8.55 MDA-MB-231 SYBR® Green Rt. PCR analysis of hYWHAZ gene expression.  
Housekeeping hYWHAZ gene expression was determined in treated MDA-MB-231 cell cDNA 
samples. (A) Amplification curves displayed the mean Ct value of actin was 18.404. (B) Dissociation 
curve showed one peak which dissociated approximately at 81.5ᵒC suggestion excellent primer 
specificity, n=3. 
 
 
 
 
 
 
 
 
Figure 8.56 MDA-MB-231 SYBR® Green Rt. PCR analysis of Bcl2 gene expression. 
Bcl2 gene expression was determined in treated MDA-MB-231 cell cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of Bcl2 gene was 24.997. (B) Dissociation curve 
showed one peak which dissociated approximately at 87ᵒC suggestion adequate primer specificity, n=3. 
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Figure 8.57 MDA-MB-231 SYBR® Green Rt. PCR analysis of Bax gene expression. 
Bax gene expression was determined in treated MDA-MB-231 cell cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of Bax gene was 25.121. (B) Dissociation curve 
showed one peak which dissociated approximately at 87ᵒC suggestion excellent primer specificity, n=3. 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.58 MDA-MB-231 SYBR® Green Rt. PCR analysis of Myc gene expression. 
Myc gene expression was determined in treated MDA-MB-231 cell cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of Myc gene was 18.875. (B) Dissociation curve 
showed one peak which dissociated approximately at 85ᵒC suggestion excellent primer specificity, n=3. 
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Figure 8.59 MDA-MB-231 SYBR® Green Rt. PCR analysis of P53 gene expression. 
P53 gene expression was determined in treated MDA-MB-231 cell cDNA samples. (A) 
Amplification curves displayed that the mean Ct value of P53 gene was 26.254. (B) Dissociation curve 
showed one peak which dissociated approximately at 89ᵒC suggestion excellent primer specificity, n=3. 
 
 
 
